

Anxiety Disorders and Gender

Dan J. Stein
Bavi Vythilingum
Editors

 Springer

Anxiety Disorders and Gender

Dan J. Stein • Bavi Vythilingum
Editors

Anxiety Disorders and Gender

 Springer

Editors

Dan J. Stein
Department of Psychiatry
University of Cape Town and
Groote Schuur Hospital
Cape Town
South Africa

Bavi Vythilingum
Department of Psychiatry
University of Cape Town and
Groote Schuur Hospital
Cape Town
South Africa

ISBN 978-3-319-13059-0

ISBN 978-3-319-13060-6 (eBook)

DOI 10.1007/978-3-319-13060-6

Library of Congress Control Number: 2015942125

Springer Cham Heidelberg New York Dordrecht London

© Springer International Publishing Switzerland 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)

Foreword

Large epidemiologic studies have consistently found the anxiety disorder to be one of the most common psychiatric disorders in the world. Anxiety disorders have a negative impact on physical and mental health as well as on educational, social, and occupational functioning and overall quality of life. It has long been known that anxiety disorders are much more prevalent in women than men, but more recent work has also found differences in comorbidity, symptoms, and how these disorders affect each gender. As the term “sex” refers to biological aspects and “gender” refers to the psychological and social aspects of maleness or femaleness, it is appropriate to discuss these differences in anxiety disorders as “gender differences,” to acknowledge the biological and psychosocial components that are inherent in their etiology and persistence. What is not yet known is if there are gender differences in the psychobiology or treatment responses of the anxiety disorders and if these are found to exist, what clinical implications they may have.

This book, edited by two international authors on anxiety disorders (Dan Stein and Bavi Vythilingum), is a treasure trove of the collective wisdom of the leading anxiety disorder psychiatrists and psychologists from across the globe. Each chapter addresses the gender aspects of one of the anxiety and related disorders: general anxiety, panic, social anxiety, obsessive-compulsive and related disorders, trauma, and stress-related disorders. There are also summary chapters on anxiety disorders in women and men.

Genetics, neuroimaging, gonadal hormones, psychological diagnostic tests, clinical evaluation, pharmacology, and psychotherapy of each disorder are elegantly discussed. The essential role of cognitive behavioral therapy is emphasized, with modifications for specific diagnoses. Gender differences in phenomenology are illustrated, for example, women with obsessions are more likely to focus on contamination and cleaning, while men are more likely to focus on sexual and symmetry obsessions. Interestingly, these differences appear to be stable across cultures, suggesting that biological or cross-cultural gender roles may play a role. Gender differences are also illustrated for body dysmorphic disorder in which women are more likely to focus on facial and breast details, while men are more likely to be preoccupied by inadequate musculature. In terms of comorbidity by gender, women with obsessive-compulsive disorders are more likely to suffer from depression, while men are more likely to have a substance abuse disorder.

The importance of disorders in the perinatal period, including those – the majority – that are persistent disorders from earlier onset, and their implications for treatment and child development are given due prominence.

These examples and many others contribute to the compelling case for the study of gender differences in psychiatry to better understand and treat mental disorders with increased specificity. The need for gender-specific early intervention is gaining more prominence as the possibilities and implications for both genders become more apparent. The authors have made a critical advance in this work on gender differences in anxiety disorders. This valuable book will not only inform the reader of the most recent knowledge but also greatly assist them in the optimal care of all patients suffering from anxiety disorders.

Donna Stewart, CM, MD, FRCPC
University Professor and Inaugural Chair in Women's Health
Senior investigator, University Health Network,
University of Toronto, Toronto, ON, Canada

Helen Herman, MBBS, MD
Professor of Psychiatry and Director of Research
Orygen: The National Center of Excellence in Youth Mental Health
Centre for Youth Mental Health, The University of Melbourne
Parkville, Victoria, Australia

Contents

Generalized Anxiety Disorder	1
Katja Beesdo-Baum and Kevin Hilbert	
Panic Disorder	31
Borwin Bandelow and Katharina Domschke	
Social Anxiety Disorder	49
Franklin Schneier and Julia Goldmark	
Obsessive-Compulsive Disorder	69
Lauren S. Hallion, Laura E. Sockol, and Sabine Wilhelm	
Obsessive-Compulsive Related Disorders	89
Elsie Breet and Christine Lochner	
Trauma and Stressor-Related Disorders	113
Kate Walsh, Jennifer B. Wells, Briana Lurie, and Karestan C. Koenen	
Anxiety and Related Disorders in Women	137
Katherine Sevar, Bavi Vythilingum, and David Castle	
Anxiety and Related Disorders in Men	155
Jon E. Grant and Brian L. Odlaug	

Introduction

Anxiety disorders are the most prevalent of the psychiatric disorders, and therefore of particular interest to both the practising clinician and to the mental health policy-maker. In this volume we also often refer to the anxiety and related disorders, as the 5th edition of the *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)* (American Psychiatric Association 2013) has split the older category of anxiety disorders into anxiety disorders, obsessive-compulsive and related disorders, and trauma- and stressor-related disorders. The DSM-5 approach takes into account a growing evidence-base which suggests that there is both diagnostic validity and clinical utility in separating out these conditions, but the manual also lists these disorders directly adjacent to one another in order to emphasize their significant overlap (Stein et al. 2011).

The volume approaches these disorders through the important prisms of sex and gender. There is a growing appreciation in psychiatry and clinical psychology that sex and gender have important implications for diagnosis, for pathogenesis, and for management. Consider, for example, the finding that in countries with lower traditionality of female gender roles there is a narrowing of differences between men and women in prevalence of mental disorders (Seedat et al. 2009). Relatedly, there is also growing awareness of the complexity of sex and gender; these are constructs that entail biological, psychological, and sociocultural mechanisms.

Indeed, part of the interest of the current volume is that chapters necessarily cover a broad range of different disciplines in an effort to unpack sex and gender in relation to anxiety and related disorders. In this brief introduction, we wish to make a few key points about the relevant literature, in the hope that this will provide the reader a conceptual framework for the remainder of the volume. We cover in turn, some key advances at the intersection of sex/gender and the anxiety and related disorders, as well as a number of the important gaps that remain.

Key Advances

Several key advances have been made at the intersection of sex/gender and anxiety related disorders. In the realm of diagnosis and evaluation, both clinical and community studies have repeatedly emphasized important differences in the prevalence and presentation of anxiety and related disorders in women (Baxter et al. 2013).

Community studies demonstrate that anxiety and related disorders are more common in females throughout the world, with the onset of this difference occurring between pregnancy and menopause. At the same time, when it comes to treatment-seeking, the female predominance is not always apparent; social anxiety may for example be more likely to interfere with the professional and social lives of men than of women, accounting for a less skewed distribution of males in social anxiety disorder clinics. DSM-5 has taken particular care to document gender issues in each of its chapters.

A second important advance has been in the awareness that sex and gender-related variables impact on the pathogenesis of mental disorders. As above, such mechanisms may range from the biological to the cultural. Puberty, the menstrual cycle, pregnancy, and the menopause are important precipitants for onset, exacerbation, recurrence and relapse of a number of mental disorders, including several of the anxiety and related disorders. These events certainly involve complex changes in hormonal profiles, and in multiple downstream aspects of neurocircuitry and neurochemistry (McEwen 2014). It is also notable that girls demonstrate more internalizing coping styles and more anxiety than boys; suggesting the importance of developmental factors in contributing to the complex array of factors involved in pathogenesis of anxiety and related disorders (Altemus et al. 2014). At the same time it is important to emphasize that such differences are not absolute and, indeed, the magnitudes of such differences across gender is small.

A third important advance has been in awareness of the impact of sex and gender-related variables on the pharmacotherapy and psychotherapy of mental illness. There is increased understanding, for example, of pharmacodynamic and pharmacokinetic differences between males and females for a range of different medications. Lower doses of z-drugs, for example, may be required in females. Similarly, psychotherapy of anxiety and related disorders may well need to address gender-related issues. For example, in many places in the world, it may be relatively easier for a woman not to have to do exposure work around agoraphobic concerns; clinicians may need to be particularly encouraging of basic psychotherapy principles under such circumstances.

Key Gaps

At the same time that there have been important advances at the intersection of sex/gender and the anxiety and related disorders, it is also important to emphasize multiple gaps in our understanding.

First, despite the attention of community and clinical studies to sex differences in psychopathology, and despite the attention to gender in DSM-5, at the end of the day sex and gender have not impacted on diagnostic criteria for key serious mental disorders, nor for common mental disorders (American Psychiatric Association 2013). That said, perhaps this is not so much a deficit in understanding as a reasonable approach to enhance the diagnostic validity and clinical utility of the nosology. Thus, for example,

while it behoves the clinician to be aware of telescoping of symptoms in women with certain conditions (e.g. gambling disorder), this does not imply that women have such a distinct symptom profile that they warrant a different diagnostic criteria set.

Second, despite significant research in laboratory, clinical, and community settings on sex and gender-related factors in the pathogenesis of anxiety and related disorders, our knowledge base remains fragmentary. Indeed, it should be noted that for many differences between males and females, we remain uncertain whether these reflect biological or psychosocial mechanisms. While there are clearly differences in brain structure across the sexes, the mechanisms and implications behind such differences are far from clear, and reductionistic conclusions should be avoided. There is a definite need for longitudinal studies of sex and gender-related variables in relationship to psychopathology; this may shed great light on differences between males and females in years to come. There is also a need to focus not only on proximal (psychobiological) mechanisms but also on distal (evolutionary) mechanisms; for example, in women factors that promote reproductive success may also contribute to a range of health problems (Jasienska 2013).

Third, despite many advances in the prevention and treatment of anxiety and related disorders, it is remarkable how little is known about what can be done specifically to improve male or female clinical outcomes during the management of anxiety and related disorders. It is again possible that this reflects not so much a lack of knowledge about appropriate pharmacotherapy and psychotherapy of anxiety and related disorders, as the fact that the treatments provided are substantially similarly across gender. This is not to downplay the need and scope for much further development of this important area of investigation

Conclusion

In recent decades there has been growing awareness of sex and gender-related variables in both the basic and clinical context. During this time there has also been growing work on anxiety and related disorders, and a growing number of women have entered the professional workforce of psychiatry and clinical psychology. A volume on the intersection between sex/gender and anxiety-related disorders therefore seems very timely; the prism of sex and gender provides an important perspective on these prevalent and disabling disorders. This volume will cover a broad range of conditions, and will attempt to synthesize the state of the art knowledge in this area. In subsequent chapters leading authorities will address each of the major anxiety disorders, obsessive-compulsive and related disorders, and trauma- and stressor-related disorders.

At the same time, despite important advances it is remarkable that so much remains unknown. In the laboratory context, male rats have been a model organism for many years, and there is a real need to include female rats in experiments (Clayton and Collins 2014). In the clinical context, it is clear that women suffer much more than men from anxiety and related disorders, and while some of the

contributing factors to this phenomenon have been investigated, many others have not. Historically, psychiatry has at times had a patriarchal and condescending approach to women. Going forwards, it must take sex and gender issues with utmost seriousness. We hope that this volume makes one contribution, albeit relatively restricted, to this important goal.

Dan J. Stein and Bavi Vythilingum

References

- Altemus M et al (2014) Sex differences in anxiety and depression clinical perspectives. *Front Neuroendocrinol* 35(3):320–330
- American Psychiatric Association (2013) *Diagnostic and statistical manual of mental disorders*, 5th edn. Arlington: American Psychiatric Publishing Inc
- Baxter AJ et al (2013) Global prevalence of anxiety disorders: a systematic review and meta-regression. *Psychol Med* 43(5):897–910
- Clayton JA, Collins FS (2014) Policy: NIH to balance sex in cell and animal studies. *Nature* 509(7500):282–283
- Jasienska G (2013) *The fragile wisdom: an evolutionary view on women's biology and health*. Cambridge, MA: Harvard University Press
- McEwen BS (2014) Sex, stress and the brain: interactive actions of hormones on the developing and adult brain. *Climacteric* 17(S2):18–25
- Seedat S et al (2009) Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys 66(7):785–795
- Stein DJ et al (2011) Meta-structure issues for the DSM-5: how do anxiety disorders, obsessive-compulsive and related disorders, post-traumatic disorders, and dissociative disorders fit together? *Curr Psychiatry Rep* 13(4):248–250

Generalized Anxiety Disorder

Katja Beesdo-Baum and Kevin Hilbert

A 32-year old woman complains of permanent nervousness, irritability and inability to relax. She has been working as a nurse on an oncology unit since she returned from maternity leave with her now 2-year old son. During shifts, she has trouble concentrating on her work because of concerns relating to her son's wellbeing in day care. She has also fears about possible accidents or harm coming to him even when he is with his father or the grandparents. "What if he runs on the street and gets caught by a car? What if they have an accident when driving home from kindergarten?" She therefore checks her mobile phone frequently or calls to hear that everything is o.k. The time she is spending with her family is usually well organized and any special events such as going on a trip are planned with extensive lists in advance. Situations outside of her personal control such as a short-notice business trip of her husband usually lead to intense distress. Just recently, related to adverse experiences of dying patients at work, she also developed excessive worries about severe illnesses befalling her son, herself or her husband which could lead to destruction of her family.

K. Beesdo-Baum (✉) • K. Hilbert
Behavioral Epidemiology, Institute of Clinical Psychology and Psychotherapy,
Technische Universität Dresden, Chemnitz Str. 46, Dresden D-01187, Germany
e-mail: Katja.Beesdo-Baum@tu-dresden.de; Kevin.Hilbert@tu-dresden.de

According to the recently published fifth edition of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5; APA 2013), generalized anxiety disorder (GAD) is characterized by worry and anxiety about a range of events and situations occurring on the majority of days for a minimum of 6 months. Worry and anxiety are excessive, difficult to control and accompanied by several symptoms. These include restlessness, muscle tension, irritability, fatigue and difficulties in concentration or sleep. Among the situations and events worried about are mostly everyday matters such as financial affairs, family or health issues. The current diagnostic criteria have undergone no significant change from DSM-IV (APA 2000). Although the 11th Version of the *International Classification of Diseases* (ICD-11)¹ will possibly be more similar to GAD criteria in DSM-5 than the currently still employed ICD-10 (WHO 1993), it will likely still consider a broader symptom list (including gastrointestinal and autonomic arousal symptoms) and will not emphasize uncontrollability of anxiety and worry.

Epidemiology

Prevalence and Age of Onset

Generalized anxiety disorder is a common disorder in the general population with lifetime prevalence estimates ranging between 1.7 and 5 %, 12-month prevalence estimates being only slightly lower between 1.2 and 4.6 %; the point prevalence is 1–2 % (Lieb et al. 2005; Wittchen et al. 2011; Kessler et al. 2012; Beesdo et al. 2009b). The lifetime morbid risk as of age 75 has been estimated to be 9 % (Kessler et al. 2012). In primary medical care, GAD has a high point prevalence of about 4–8 % (Wittchen 2002; Munk-Jorgenson et al. 2006; Kroenke et al. 2007), accounting for about 8–9 % of all cases of mental disorders in this setting (Lieb et al. 2005; Wittchen 2002). Both in the general population and in primary medical care, females are overall approximately 1.5–2 times as likely as males to meet criteria for GAD, although the female preponderance for GAD may not emerge before mid-adolescence (Copeland et al. 2014) and increases with age (Beesdo-Baum and Knappe 2012). Lastly, GAD is very prevalent in specialist mental health care settings, with point prevalence rates over 10.0 % (Brown and Barlow 2002; Bobes et al. 2011).

The first onset of GAD may occur at any time from childhood to late adulthood. Compared to other anxiety disorders, the median age of onset in community-based samples is at 30 years relatively late (Kessler et al. 2012). The incidence sharply increases in adolescence (Burstein et al. 2013; Copeland et al. 2014; Beesdo et al. 2010b) after which new cases steadily emerge until old age (Kessler et al. 2012). An early onset, however, has been linked to a more severe progression of the disorder (Rubio and Lopez-Ibor 2007). Gender effects on the age of onset are not definite.

¹<http://apps.who.int/classifications/icd11/browse/f/en#/http%3a%2f%2fid.who.int%2fid%2fentity%2f1712535455>. Entered on March 25, 2014.

While there is some evidence for a slightly earlier age of onset in women (Steiner et al. 2005; Beesdo et al. 2009b) and the female preponderance in GAD diagnoses appears to arise at a very early age (Parker and Hadzi-Pavlovic 2004; Burstein et al. 2013; Beesdo-Baum and Knappe 2012), other studies did not report gender differences (e.g. Goncalves and Byrne 2012; McLean et al. 2011).

Course

The natural course of GAD in community samples can be described as waxing and waning (Wittchen et al. 2000; Angst et al. 2009; Beesdo 2006) and occurring in recurring episodes of several months or years (Kessler et al. 2005a; Burstein et al. 2013; Grant et al. 2005), with symptom-free intervals in about half of the cases (Angst et al. 2009). Nevertheless, individuals with GAD are affected by the condition in about 50–60 % of the years between first onset and last episode (Kessler et al. 2005a). Persistence is similar among those with shorter and longer episode durations indicating high recurrence among those with short episode durations. Even among adults with GAD indicating a maximum episode duration of only 6–11 months, episodes re-occurred in about 6.5 years; those with longer maximum episodes were affected within 10.4 years (Kessler et al. 2005a). The mean time in episode since first disorder onset in affected adolescents was 65 months (Burstein et al. 2013). A prolonged and chronic course of GAD occurs in clinical samples. In an 8-year naturalistic follow-up study of patients with GAD, spontaneous remissions may occur (men 56 %, women 46 %) but are mostly not persisting (relapses in 43 % of men and 36 % of women) (Yonkers et al. 2003). In primary care patients with GAD, the cumulative probability of full or partial recovery within 2 years was 39 and 54 %, respectively; roughly half of the fully remitted cases experienced a partial or full recurrence of symptoms (Rodriguez et al. 2006). There are no consistent indications that sex differences in course patterns of GAD symptomatology are significant either in clinical or primary care (Rodriguez et al. 2006; Yonkers et al. 2003) or in community samples (Angst et al. 2009). Of note, among those with a GAD diagnosis, syndromatic shifts are often observed suggesting that full diagnostic remission is rare on the long run (Angst et al. 2009; Rubio and Lopez-Ibor 2007; Beesdo 2006).

Comorbidity

As for virtually all other mental disorders, comorbidity is not unusual for GAD. Even in community samples, about 90 % of individuals with GAD are also affected by at least one other mental disorder either at the same time or at any other time during the life course (Kessler et al. 2002a, 2005b; Hoyer et al. 2002; Carter et al. 2001; Copeland et al. 2014). Conversely, GAD is often a comorbid condition in other mental disorders (de Graaf et al. 2003; Faravelli et al. 2004; Copeland et al. 2014). Overall, strongest associations are generally found for mood disorders as well as for

other anxiety disorders (particularly social anxiety disorder and panic disorder as well as separation anxiety disorder), while associations with substance use disorders and impulse-control disorders as well as childhood externalizing or behaviour disorders are lower and less consistent (e.g. Carter et al. 2001; Grant et al. 2005; Lee et al. 2009; Burstein et al. 2013; Copeland et al. 2014; Kessler et al. 2005a). In addition, some studies indicate associations with dependent and avoidant personality disorders as well as with somatoform disorders and pain conditions (Faravelli et al. 2004; Beesdo et al. 2009a, 2010a). Eating disorders (anorexia and bulimia nervosa) have been rarely examined in general population samples but there are also some indications that these disorders co-occur more frequently than expected by chance in individuals with GAD (Faravelli et al. 2004; Carter et al. 2001; Beesdo 2006). Studies on gender differences in comorbidity patterns are rare; yet the association between GAD and mood disorders appears to be particularly pronounced in females (Beesdo 2006).

Regarding the temporal order of onset, GAD may occur prior to, simultaneous or after the onset of any comorbid condition (Kessler et al. 2002a). With regard to any comorbid anxiety disorder (particularly specific phobia and social anxiety disorder), GAD is usually the secondary onset condition; however, GAD also significantly predicts the secondary onset of other anxiety disorders (Lee et al. 2009; Beesdo et al. 2010b). Mood disorders emerge often in the same year as GAD (in about 50 % of comorbid cases) (Kessler et al. 2002a), which challenges differential diagnosis (see below). Substance use disorders mostly occur secondary to the onset of GAD (Kessler et al. 2002a) and risk for secondary substance use disorders is particularly high in individuals with more prolonged GAD episodes (Lee et al. 2009), indicating that alcohol, nicotine or medications may be used to cope with chronic anxiety and worry.

Besides comorbid psychiatric disorders, somatic complaints such as chest pain, irritable bowel and chronic fatigue syndrome as well as medical illnesses (diabetes, hypertension, gastrointestinal and heart diseases) are associated with GAD (Sareen et al. 2005; Lieb et al. 2005). Generally, the presence of comorbid mental or physical disorders confers a greater level of disability in patients with GAD (Sareen et al. 2005).

Personal and Societal Costs

GAD is associated with significant personal burden for the patient as well as costs for the health care system and the society (Andlin-Sobocki and Wittchen 2005; Hoffman et al. 2008). Community studies show, for example, that up to one third of individuals suffering from GAD, even in the absence of depression, report days in the past month on which normal daily activities were limited or impossible to perform due to disorder symptoms; the average number of disability or sick days among these individuals ranged between 1.5 and 5.6 days (Kessler et al. 2002b). Of note, these impairments in role functioning were comparable to those observed in individuals affected by major depression. Similar findings emerged in primary

care studies (Wittchen et al. 2002). Such role impairments considerably reduce subjective health (Schonfeld et al. 1997), quality of life and general wellbeing in GAD patients (Bobes et al. 2011; Beesdo et al. 2009a; Stein and Heimberg 2004) and are mostly intensified if comorbid conditions are present (Beesdo et al. 2009a; Hoffman et al. 2008). Of note, childhood/adolescent GAD was recently shown to have a predictive role for adverse health, financial/educational and social functioning in young adulthood (Copeland et al. 2014). Few studies have investigated the effects of gender on personal burden of GAD, but no differences in quality of life between genders due to diagnosis have been detected so far (e.g. Bobes et al. 2011).

GAD also invokes considerable economic burden, not only because of direct health care costs associated with increased health care utilization and treatment (Berger et al. 2009b; Lieb et al. 2005; Wittchen et al. 2002; Greenberg et al. 1999), but also due to the indirect costs associated with role impairments at work (sick leaves, decreased productivity, early retirement etc.) (Greenberg et al. 1999; Andlin-Sobocki and Wittchen 2005; Hoffman et al. 2008; Gustavsson et al. 2011). In a recent study investigating health care cost per case due to mental disorders in Europe, the costs of GAD per case were higher as compared to other impairing anxiety disorders (obsessive-compulsive disorder, agoraphobia) and higher than the cost per case for major depression (Gustavsson et al. 2011). While treatment seeking seems to be lower in men than in women (see below), no studies have compared the consequences of these different amounts of treatment seeking between genders on health care costs or other markers of economic burden.

Psychobiology

Aetiology and Risk Factors of Generalized Anxiety Disorder

A number of different risk factors have been proposed for GAD, including genetics, personality, attachment style, stressful life events and dysfunctional coping styles. However, empirical evidence is not conclusive for all of these factors and is often incomplete or inconsistent. Additionally, some of the proposed risk factors seem to lack specificity and should rather be regarded as vulnerability for anxiety and anxiety disorders in general (Beesdo et al. 2009b). Here, we will focus on a selection of those factors that have been investigated most extensively.

The specific genetic basis of GAD is not well elucidated. Generally, twin studies revealed heritability estimates of 20–50 % (Giddens et al. 2011; Hettema et al. 2001, 2006; Kendler et al. 2011). This genetic basis of the disorder seems to be largely shared with personality traits such as neuroticism (Hettema et al. 2006) and with a range of other anxiety and mood disorders, which suggests that high comorbidity between these conditions can be partly attributed to genetic factors as well (Cerdeira et al. 2010). As a consequence, many of the candidate genes proposed for the development of GAD are also somewhat non-specific and associated with other mental disorders as well. This includes polymorphisms in the serotonin-transporter gene (5-HTTLPR; You et al. 2005), the brain-derived neurotrophic

factor (BDNF; Meng et al. 2011) gene, the monoamine oxidase A (MAO-A; Samochowiec et al. 2004; Tadic et al. 2003) gene and in the promoter region of the neuropeptide Y gene that hypothetically reduced resilience to high stress conditions and thereby increased vulnerability and prevalence for subsequent GAD diagnoses (Amstadter et al. 2010). Additionally, an association between a range of anxiety disorders including GAD and genes related to the circadian cycle has been reported (Sipila et al. 2010). The tryptophan hydroxylase (TPH) gene has been frequently investigated as candidate gene for GAD as well, but no differences between patients and healthy controls were found so far (Fehr et al. 2001; You et al. 2005). Given the differences in GAD prevalence between genders, a biological basis for these findings has been proposed (Altemus 2006), including possible genetic differences as well. However, population-based studies found no gender-specific effects in heritability or in the overall genetic basis of the disorder (Hettema et al. 2005). This is true for most candidate gene studies as well, with the notable exception of the MAO-A gene polymorphisms that were found to be relatively gender-specific, being related only or much stronger in women (Samochowiec et al. 2004; Tadic et al. 2003).

Regarding personality traits, research on risk factors for developing GAD has identified three factors, including partly overlapping constructs. Patients generally seem to be more often in a negative affective state and to experience these states for a longer period of time. As such, GAD is moderately associated with negative temperament and neuroticism and negatively correlated with positive temperament (Brown and Naragon-Gainey 2013; Gamez et al. 2007). Secondly, GAD is associated with a pattern of fear of the unknown or unfamiliar, and with interpretation of such situations as threatening and frequently resulting behaviours of avoiding such situations (Carleton 2012), including constructs such as harm avoidance (Rettew et al. 2006; Beesdo et al. 2010b), behavioural inhibition (Maack et al. 2012; Beesdo et al. 2010b) or intolerance of uncertainty (Read et al. 2013). But as these potential risk factors are mostly shared between a wide range of anxiety and other mental disorders, the specificity for GAD is not always clear. For instance, there is some evidence suggesting behavioural inhibition as being relatively specific for the disorder (Maack et al. 2012), while the opposite seems to be the case for intolerance of uncertainty (Boswell et al. 2013). Lastly, GAD seems to be related to increased attempts but reduced subjective success in attempting to control one's own life and emotion. In particular, GAD is negatively associated with perceived control over conditions of life, stressful events and emotional states (Brown and Naragon-Gainey 2013); however, increased inhibition of emotional processing in stressful situations actually increases worry severity (Price and Mohlman 2007). Research on gender differences in GAD related personality traits is sparse, but suggests that there are some differences between the sexes regarding personality traits, with women often scoring higher on negative affectivity and trait anxiety, and also seeming to be more intolerant of uncertainty while at the same time experiencing subjectively less control about life and events surrounding them (McLean and Anderson 2009). However, there are still relatively few data on gender differences in personality traits that are possibly of relevance to GAD (McLean and Anderson 2009).

There is a clear relationship between anxiety disorders in general and GAD in particular, and attachment style. Insecure or poor childhood attachment styles have been linked to GAD (Cassidy et al. 2009; Marganska et al. 2013). Additionally, the relationship between childhood attachment styles and future GAD symptoms seems to be mediated by inadequate emotion regulation strategies and competences (Marganska et al. 2013). First studies also pointed towards an interaction between attachment styles and gender, with the relationship between perceived attachment quality towards fathers and GAD symptoms being stronger in males than in females (van Eijck et al. 2012), while GAD patients in general reported more maternal rejection and role reversal than healthy persons (Cassidy et al. 2009). On a broader scale of parental or family risk factors, individuals with GAD also reported more childhood maltreatment (Moffitt et al. 2007); yet parental overprotection appears also to be a risk factor for the development of disorder (Beesdo et al. 2010b).

As with a wide range of mental disorders, stressful life events have been related to the development of GAD. For GAD, such events include separation events during childhood (Beesdo et al. 2010b), stress due to high psychological job demands during adulthood (Melchior et al. 2007) and events related to loss and danger over the whole course of the lifetime (Kendler et al. 2003). As a subset of all potentially stressful life events, trauma events have been related to GAD as well (Roemer et al. 1996), including past physical or sexual abuse (Safren et al. 2002), although such events are not specific for GAD. They do, however, increase the probability of additional comorbid anxiety disorders or depression (Safren et al. 2002). In addition to being connected to the onset of GAD, stressful life events also increase the risk of relapse in already GAD-diagnosed patients (Francis et al. 2012). Relapse probability here is mainly linked to the number of stressful events in the last 4 weeks. Additionally, some types of events seemed to be particularly symptom-inducing, including events related to health, death and family friends or household (Francis et al. 2012). So far, no influence of gender on the sensitivity to stressful life events has been reported (Kendler et al. 2003).

Specific coping styles, especially related to coping with aversive emotional arousal, also mark an important risk factor of GAD. Generally, in GAD patients, awareness of one's own emotions seems to be less than usual and more dysfunctional strategies of emotion regulation are used (Roemer et al. 2009). In the long term, the use of these dysfunctional strategies predicts a diagnosis of GAD (Tull et al. 2009). Many such inefficient strategies have been identified so far, among them self-blaming, catastrophizing and rumination (Legerstee et al. 2011) and clinically well-known dysfunctional strategies such as reassurance seeking (Cogle et al. 2012) and cognitive avoidance (Olatunji et al. 2010). The specificity of such maladaptive behaviour for GAD is somewhat less well investigated; however, rumination in particular seems to be characteristic for GAD compared to other anxiety disorders (Legerstee et al. 2011), although probably less specific when compared to depressive disorders. Matching these findings, worry and rumination have been found to mediate the association between cognitive avoidance and anxiety, with this mediating effect being attributed as one of the factors establishing the high

coherence between GAD and major depression (Dickson et al. 2012). Conversely, reassurance seeking has been shown to be an additional factor yielding possibly high specificity for GAD in comparison to depressive disorders (Cougle et al. 2012). However, reassurance seeking seems to be less specific when compared to other anxiety disorders (Cougle et al. 2012). Generally, most of the discussed dysfunctional emotion regulation strategies aim at inhibiting or avoiding processing of especially aversive emotions, while acceptance of emotions is less prevalent in these individuals (Roemer et al. 2009) and a negative association between emotion acceptance and processing and GAD symptom severity has been demonstrated (Price and Mohlman 2007). Besides a decreased disposition or willingness to endure negative emotional states, other variables may also influence these maladaptive coping styles: for example, some studies found a heightened level of emotions in GAD (Mennin et al. 2007, 2009).

Possible gender differences in dysfunctional emotion regulation strategies are currently still in question as findings are few and inconsistent. Some studies did not find any gender differences in the use of these strategies (e.g. Legerstee et al. 2011; Olatunji et al. 2010); while others conclude that some strategies such as cognitive avoidance or negative problem orientation (Robichaud et al. 2003) or even most such strategies are used more frequently by women than by men (Nolen-Hoeksema 2012). Additionally, there is preliminary data suggesting that men may actually benefit from some strategies usually classified as dysfunctional, especially emotion inhibition, while women in fact suffer from such strategies (Bardeen et al. 2013). Potentially, this finding that usually dysfunctional strategies of emotional regulation do not yield the same negative impact in men as in women might be a first hint on why GAD is more prevalent in females.

Psychological Models of Generalized Anxiety Disorder

Besides findings of selected risk factors and variables contributing to GAD, there are also some more elaborated psychological models of the disorder integrating different etiological and/or pathogenic aspects. Here, we will outline three of the more popular of these models: the Avoidance Model of Worry and GAD (Borkovec 1994, 2004), the Emotion Dysregulation Model (Mennin et al. 2002) and the Intolerance of Uncertainty Model (Dugas et al. 1998).

The central idea behind the Avoidance Model of Worry and GAD is that worry is a dysfunctional emotion regulation strategy that actually inhibits autonomic and somatic arousal and dampens aversive emotional states. Additionally, worry serves as a strategy to avoid exposure to topics that are even more important and more aversive (Borkovec and Roemer 1995). Possibly, the mechanism behind this dampening effect is a shift from anxiety-related autonomic system activating mental images to less activating, and more cognitively mediated, verbal thoughts about the problem (Behar et al. 2005; Borkovec and Inz 1990). Due to the large exclusion of the somatic and affective parts of fear and the concentration on cognitive processing, worry likewise seems to inhibit successful exposure to aversive emotions

including further processes such as habituation to feared stimuli and situations and extinction of maladaptive fear-stimulus connections (Stapinski et al. 2010). Given the initial decrease in negative affect and autonomic arousal, worry gets reinforced and is more likely to be used again in the future. From this perspective, worry is actually a strategy to avoid profoundly dealing with one's own emotions, giving the model its name. Additionally, many GAD patients believe worry to be actually helpful for avoiding negative consequences and therefore successful problem solving, which again increases the likelihood of worry being used again as emotion regulation strategy in the future (Behar et al. 2009). More recent further developments of the model suggest that individuals with GAD may be hypersensitive to boosts of negative emotions and therefore use worry to maintain a steady state of negative emotions that prevents increased changes in emotion in response to negative events (Llera and Newman 2014).

The idea of experienced hyperarousal when facing negative emotional states is also relevant for the Emotion Dysregulation Model. Here, a disposition to experience negative emotions earlier, faster and stronger than other people is enhanced by decreased abilities to access, identify or understand emotions in general, but also one's options to regulate one's own emotions (Mennin et al. 2005; McLaughlin et al. 2007; Salters-Pedneault et al. 2006). As patients also hold mainly negative beliefs about experiencing any emotion, they quickly attempt to minimize or control these negative affects, resulting in mostly dysfunctional emotion regulation or emotion expression strategies, including worrying (Behar et al. 2009). However, over time, dysfunctional regulation strategies may again increase the likelihood of negative emotions occurring (Mennin et al. 2005).

Worry as a dysfunctional strategy of emotion regulation is also present in the Intolerance of Uncertainty Model of GAD. Here, especially uncertain or ambiguous situations are interpreted as threatening, since these situations allow for the chance of negative consequences to occur. These consequences are considered unacceptable without regard to their actual likelihood (Carleton 2012). In attempting to cope with these aversive expectations, GAD patients again use worry as a strategy for emotion regulation or for preventing the feared consequence to occur at all (Behar et al. 2009). However, in the Uncertainty Model of GAD, worry leads to feelings of anxiety on an affective level, and poor problem orientation and cognitive avoidance on a cognitive and behavioural level (Dugas et al. 1998). Again, cognitive avoidance aims at reducing autonomic arousal coming from anxiety and worry, and together with poor problem orientation in turn affects future behaviour in uncertain situations and future worry.

(Neuro-)Biological Models of Generalized Anxiety Disorder

Research on the biological underpinnings of GAD is relatively sparse compared to other anxiety and mental disorders. Still, early reliable findings have emerged in the literature, especially regarding structural and functional alterations found in GAD patients. In comparison, even fewer hormonal and molecular findings are available

so far, although these may prove equally fruitful for expanding our knowledge on GAD aetiology.

On the level of brain areas involved in attentional control, emotional processing, cognitive avoidance and similar functions tied to the disorder, research up to now has focused on a relatively small group of structures, including the amygdala, anterior cingulate gyrus (ACC) and prefrontal cortex (PFC); the latter one especially in its dorsolateral and ventrolateral parts (Hilbert et al. 2014). Among these, the amygdala has been shown to exhibit increased volume (Etkin et al. 2009) and abnormal responding during tasks of attention, emotional perception and processing, or anticipation in GAD (Etkin and Schatzberg 2011; McClure et al. 2007; Nitschke et al. 2009). Additionally, the amygdala is supposedly related to the mediation and enhancement of autonomic hyperarousal (Macefield 2009). Therefore, amygdala abnormalities have been related particularly to the clinical symptoms of apprehensive expectations, feeling on edge or muscle tensions. PFC and ACC, on the other hand, are related to the processing, evaluation and (re-)appraisal of emotions, with especially the ventral parts of the PFC being closely tied to negative feelings. While structural findings are sparse in these regions, functional data on the prefrontal cortex indicated hyperactivation in GAD patients (Price et al. 2011; Strawn et al. 2012), while ACC findings are mixed (Etkin and Schatzberg 2011; McClure et al. 2007). Clinically, these findings have been related to excessive worries, difficulties in stopping worrying and maladaptive cognitive control strategies as cognitive avoidance. However, activation of both PFC and ACC have also been implicated in successful emotional processing, giving rise to the question of why these patterns of neural responding are unsuccessful in GAD patients. While a definite answer to this question has not yet been found, mounting evidence points towards additional perturbations on the level of brain circuitry. Supposedly indicating regulatory and inhibitory processes, there is structural and functional connectivity between the amygdala and the PFC and ACC in healthy persons, and this has been repeatedly found to be significantly decreased in GAD (Etkin et al. 2009; Etkin and Schatzberg 2011; Tromp et al. 2012). Possibly, this indicates failure to recruit both structures in an efficient way and marks the shift from functional cognitive strategies of emotion regulation to the dysfunctional set of strategies subsumed under worrying.

While some of these findings seemed to emerge consistently during recent years, many other results are still mixed and can only be interpreted with caution, even in these comparatively well-investigated regions. Generally, relatively few studies investigated neurofunctional and neurostructural alterations in GAD, using a relatively broad accumulation of methods, paradigms and samples. This results in only a few replications being available (especially compared to affective disorders as depression), and many findings should be regarded as preliminary. Additionally, structures such as the amygdala or ACC have been implicated in a wide range of anxiety and other mental disorders (e.g. Shin and Liberzon 2010), and with the current literature mostly lacking studies employing a comparative design including GAD and at least one other disorder group, the specificity of the above findings is still in question. Further, most neuroimaging studies investigating GAD so far have

used moderately to highly comorbid samples, often including subjects with other anxiety disorders or depression.

There is also some knowledge available on pathophysiological changes in hormone and neurotransmitter functioning in GAD, although the number of related studies is relatively limited. So far, these abnormalities seem to be most closely tied to serotonin, GABA and cortisol (e.g. Connor and Davidson 1998). For serotonin, reduced levels of the neurotransmitter probably due to increased reuptake have been reported (Brewerton et al. 1995). Reuptake might be chronically increased due to permanent stress (Tafet et al. 2001), and these abnormal serotonin levels have been related to the affective changes observed in GAD and accounting for a certain overlap with major depression. For GABA, being one of the most important inhibitory neurotransmitters, the functioning of the corresponding receptor sites may be reduced, as studies on the very similar benzodiazepine receptors have suggested (Connor and Davidson 1998). Possibly, this reduced GABAergic sensitivity is connected to the sympathetic hyperarousal observed in GAD, as it leads to the vagal system being not as efficient in inhibiting sympathetic arousal as in healthy controls (Thayer and Lane 2000). Data on cortisol is very mixed so far, with both increased and decreased cortisol levels being reported, allowing for no clear interpretation of the abnormalities found so far. As a working hypothesis to merge these conflicting results, an initial cortisol secretion increase followed by long-term decrease due to chronicity was proposed (Steudte et al. 2011). However, further data to support this promising notion are awaited. Most studies did not investigate gender differences for the hormones and neurotransmitters discussed here. When investigated (as for serotonin), no gender differences were detected (Hernandez et al. 2002; Park et al. 2010).

Diagnosis

Generalized anxiety disorder can be diagnosed according to the criteria outlined in the recently published *Diagnostic and Statistical Manual of Mental Disorders*, fifth edition (DSM-5; APA 2013) and the *International Classification of Diseases*, 10th edition (ICD-10; WHO 1993). Diagnoses are best made based on structured or standardized clinical interviews. These interviews usually allow for both classifications to be applied in the diagnostic process, considering that the DSM-IV/DSM-5 and the ICD-10 only partially overlap in diagnostic criteria specified for GAD: While both classifications name anxiety, worry and apprehension as the cardinal features of GAD, and as being present over at least 6 months, only the DSM-5 states that worry and anxiety must be excessive and difficult to control. Additionally, both systems require a number of further symptoms with DSM-5 focusing on symptoms of tension and hypervigilance (3 out of 6; 1 in children) while the ICD-10 requires 4 symptoms out of a broader symptom list that also includes autonomic arousal, gastrointestinal and other general and unspecific symptoms. A further major difference between classifications concerns clinically significant distress or impairment, which is only required in the DSM-5. In conclusion, the DSM-5 focuses more on

the psychological symptoms of anxiety, whereas the ICD-10 focuses more on the physiological symptoms of anxiety (Hoyer and Beesdo 2006). It is expected that ICD-11 will adopt some of the DSM-5 criteria (excessiveness, distress/impairment) so that definition of GAD will be more similar in both classification systems than is currently the case.

During the preparation of the DSM-5, it was proposed that the criterion on difficulty in control worrying be exchanged with a list of specified behavioural symptoms such as behavioural avoidance, safety behaviours or reassurance seeking (Andrews et al. 2009), and that this would make the diagnostic criteria for GAD more similar to other anxiety disorders that all include behavioural criteria, specifically avoidance. Recent research has shown that GAD patients use behavioural strategies in attempting to control their worries and that these behaviours are of clinical importance, as they can be used to predict the long-term outcome of psychotherapy (Beesdo-Baum et al. 2012a). However, the proposed changes were not implemented in the current edition of the DSM due to lack of further empirical data, particularly with regard to external validators (Starcevic et al. 2012). Nevertheless, these symptoms may be clinically useful in diagnosis and treatment of patients with GAD.

Differential Diagnosis

Differential diagnosis in GAD may be difficult but is of great importance, as the overlap of GAD with other mental disorder groups such as anxiety, mood or somatoform disorders is considerable and significantly aggravates the diagnostic process (Bener et al. 2013). Overall, there are five major domains that should be carefully evaluated during differential diagnosis: other anxiety disorders, particularly social anxiety disorder, obsessive-compulsive disorders, depressive disorders, somatic symptom and related disorders, particularly somatic symptom disorder and illness anxiety disorder, and somatic diseases. Somatic diseases, symptoms or the influence of other injuries, substances or medical conditions may cause physiological symptoms similar to those found in GAD, and may also cause subsequent worry and anxiety as well as rather unspecific symptoms such as sleep disturbances. To determine whether such symptoms should be attributed to somatic or physiological causes, a careful medical history and examination is warranted. If worries and anxiety are mostly related to health topics, but no or only minor somatic abnormalities have been detected, differential diagnosis should also feature illness anxiety disorder. Here, health topics are usually the only focus of anxiety or worrying, while in GAD other worry topics are present as well (APA 2013). Anxiety, worrying and rumination are also main features of social anxiety disorder and depressive disorder. However, in social anxiety disorder, anxiety and worries should mainly occur when experiencing or anticipating social situations in which evaluation by others is likely or possible, while anxiety and worry in GAD should be present regardless of social evaluation and mostly include not only worry topics that are related to social situations (APA 2013). Differentiating GAD and major depression is more difficult, as

both disorders do not only share frequent worrying or rumination, but also many accompanying physiological symptoms such as problems sleeping or concentrating (Hoyer and Beesdo-Baum 2011). However, rumination in major depression mostly focuses on past events and frequently features depressive notions of loss, failure and guilt; worry in GAD, in contrast, mostly focuses on future events and features more anxious ideas of danger or risk. Ascertaining past periods with only anxiety and worry but no depressed mood may also justify a separate diagnosis of GAD in patients presenting with symptoms of both anxiety and depression. Lastly, frequently re-occurring thoughts and images eliciting anxiety and worry are also present in obsessive-compulsive disorder, but are experienced as intrusive and unreasonable. Additionally, they tend to comprise a range of topics typically found in obsessive-compulsive disorder, such as infection, tidiness or violent or sexual images (Hoyer and Beesdo-Baum 2011).

Clinical Interviews for Diagnosis

There is a wide range of clinical interviews available for the diagnosis of generalized anxiety disorder, ranging from structured to fully standardized ones. These interviews are all based on the DSM-IV diagnostic criteria, but as no major changes occurred for GAD during the transition to the DSM-5, they are still applicable for DSM-5 GAD. Internationally, the most commonly used interviews are the Composite International Diagnostic Interview (CIDI; Robins et al. 1988; Kessler and Ustun 2004; WHO 1990), the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID; First et al. 1997), the Mini-International Neuropsychiatric Interview (M.I.N.I.; Sheehan et al. 1998) and the Anxiety Disorders Interview Schedule for DSM-IV (ADIS-C/P; Albano and Silverman 1996). Among these, the CIDI is the only fully standardized clinical interview, while all others of the above are structured interviews, giving both the interviewer and the patient more degrees of freedom during the assessment, however, also requiring clinically trained personnel to successfully administer the interview. Besides GAD, all of the above interviews can also be used to diagnose a range of other mental disorders, for example for differential diagnosis or assessment of comorbidity. Here, the CIDI and SCID are the most comprehensive interviews allowing for the broadest range of mental disorder; however, common comorbid diagnoses such as major depression or substance abuse and dependence are available in all of the above interviews. Regarding the available timeframe, the CIDI is the only interview allowing for a lifetime diagnosis of GAD, while all of the other interviews only address current episodes of the disorder. For the ADIS, however, there is a lifetime version available (ADIS-IV-L; Di Nardo et al. 1994). On the other hand, the CIDI is also the interview with the longest duration, while the MINI is usually the shortest.

There are also diagnostic interviews available for diagnosing GAD in children and adolescents, with the most prominent being the Kiddie Schedule for Affective Disorders – Present and Lifetime Version (K-SADS-PL; Kaufman et al. 1997). The K-SADS-PL is a semi-structured interview and suitable for children and adolescents

between 6 and 18 years of age. Like its adult counterparts, the K-SADS-PL covers a range of mental disorders, including GAD and its most common comorbidities, and allows for the diagnosis of current episodes and lifetimes diagnoses. Besides information provided by the child or adolescents itself, information provided by the parents and if available by school and other sources is considered.

Recognition in Primary Medical Care

Although GAD is a prevalent anxiety disorder and GAD patients are high utilizers of general health care resources, recognition rates are surprisingly low (Lieb et al. 2005; Wittchen et al. 2002). When confronted with a patient presenting GAD symptoms, only about two-thirds of all general practitioners recognized the presence of a mental disorder at all, and only one-third recognized GAD as the specific diagnosis (Munk-Jorgenson et al. 2006; Wittchen et al. 2002). Recognition is generally better when patients report anxiety among the reasons for consulting the general practitioner. However, it seems that GAD patients also struggle to identify their problems as they mainly describe physiological and unspecific psychological symptoms such as pain or difficulties sleeping (Allgulander 2012; Wittchen et al. 2002). Consequently, the number of patients seeking treatment in settings specialized on mental disorders is relatively low, especially when compared to patients consulting their general practitioner (Wittchen et al. 2002).

The presence of comorbid disorders has been found to both facilitate and aggravate the help-seeking and recognition of GAD (Bener et al. 2013; Vesga-Lopez et al. 2008; Wittchen et al. 2002, 2012). Empirically, studies so far have demonstrated that comorbid depression makes case recognition easier, possibly as it exacerbates GAD symptom severity (Bener et al. 2013) but does also increase diagnosis recognition significantly (Wittchen et al. 2002). Gender was not found to have a significant influence on recognition (Bystritsky et al. 2012; Munk-Jorgenson et al. 2006; Wittchen et al. 2002), although males were found to seek help – or more specifically treatment – less frequently than females (Vesga-Lopez et al. 2008; Manassis et al. 2004). Possibly, lower treatment seeking in men is one factor accounting for different prevalence estimates for GAD in men and women in primary care settings.

Evaluation

Standard measures for GAD symptom severity are typically self-report-questionnaires. Despite having been relevant for many aspects in the diagnostic process, for example, for supporting diagnosis or measuring progress during therapy, such measures are likely to gain further importance due to the DSM-5's emphasis on dimensional evaluation of disorders. During the development of DSM-5, a set of brief self-rating dimensional anxiety scales was developed for each of the anxiety

diagnoses including GAD. Good psychometric properties and classification performance were demonstrated for these scales in clinical and non-clinical studies (LeBeau et al. 2012; Beesdo-Baum et al. 2012b; Knappe et al. 2013, 2014), so that the scales are now available for researchers and clinicians for further use at www.psychiatry.org/dsm5.

Beyond these novel scales, there is a range of other, more traditional self-rated measures for GAD symptomatology, of which only the most widely used will be presented here, namely the Penn State Worry Questionnaire (PSWQ; Meyer et al. 1990), the Generalized Anxiety Disorder 7 (Spitzer et al. 2006), the Generalized Anxiety Questionnaire-IV (GAD-Q-IV; Newman et al. 2002), the Hospital Anxiety and Depression Scale (HADS; Zigmond and Snaith 1983) and the Screen for Child Anxiety Related Emotional Disorders Scale (SCARED; Birmaher et al. 1997). While the PSWQ, GAD-7 and GAD-Q-IV are specifically relevant for GAD, with the GAD-7 and the GAD-Q-IV screening for the current presence of the DSM-IV/DSM-5 criteria and the PSWQ focusing on the intensity, severity and subjective controllability of worry, both the HADS and SCARED cover a broader spectrum of mental disorders, including questions related to other anxiety disorders (for both HADS and SCARED) and depression (only for HADS). As a pure measure for symptom severity, the PSWQ is probably the most widely used instrument. For all of these questionnaires, reasonable to good psychometric properties have been reported, including good specificity and sensitivity (Birmaher et al. 1997; Bjelland et al. 2002; Brown et al. 1992; Newman et al. 2002; Spitzer et al. 2006; Kroenke et al. 2007).

The most widely used clinician-rated severity measure for GAD is the Hamilton Anxiety Rating Scale (Hamilton 1959) for which a structured interview guide is also available (GADSS; Shear et al. 2001). However, more novel clinician-based instruments consistent with the DSM criteria are available such as the Generalized Anxiety Disorder Severity Scale (GADSS; Shear et al. 2006) and the DSM-IV GAD severity scale (DGSS; Stein 2013). The latter assesses both symptom severity and symptom frequency.

Developmental Aspects

When diagnosing generalized anxiety disorder in children and adolescents, a careful evaluation of presenting symptoms is warranted, as verifying the diagnostic criteria of GAD in these patients often proves even more difficult than in adult GAD. In fact, the development of more sensitive diagnostic instruments and criteria has been identified as one of the major tasks for improving GAD recognition in children and adolescents (Beesdo et al. 2009b). The DSM-5 only specifies one difference in criteria for GAD in children versus adults: Only 1 and not 3 associated symptoms are required in children (APA, 2013). This developmental difference in GAD criteria has found empirical support (Burstein et al. 2013; Beesdo-Baum et al. 2011); yet there are further indications for a more developmentally sensitive diagnosis. Specifically, children may experience shorter but more frequent episodes (Beesdo

2006; Burstein et al. 2013). Children may also find it hard to reflect and report on distress and impairment so that a more flexible handling of this criterion or additional diagnostic information from other sources such as parents, close friends or teachers is advisable (Beesdo-Baum et al. 2011). Moreover, restlessness and muscle tension are relatively rare among affected children or young adolescents, while poor concentration and irritability are more common symptoms (Burstein et al. 2013; Beesdo 2006). Particularly in children it may advantageous to evaluate any anxiety or worry-related behaviours such as excessive reassurance seeking from caregivers or teachers (Andrews et al. 2010).

Geriatric Aspects

As in children and adolescents, diagnosing generalized anxiety disorder can be challenging in older adults. While some of these difficulties can be related to diagnostic criteria, there are also specific factors impacting the sensitivity and reliability of the diagnosis in the elderly, including a decreased willingness to provide information about symptoms of mental disorders and frequent combination and overlap of somatic and psychological symptoms (as reviewed in Kogan et al. 2000). Especially with regard to the latter point, it is again of high importance to use sufficiently sensitive and reliable diagnostic instruments for disorder recognition. However, as the current generation of interviews and scales has been developed mainly for use in adult populations, the psychometric properties of these instruments in older populations are often unclear and sometimes even questionable (for a review, see Alwahabi 2003). However, there are some initial studies that have systematically investigated the use of self-report measures in the elderly. So far, these studies cautiously recommend the use of either the HADS or the PSWQ for use in older adults (Alwahabi 2003; Hopko et al. 2000; Wetherell et al. 2007). Additionally, the use of multiple methods, possibly including also laboratory and physical examinations and other sources for information such as close relatives, has been recommended (Kogan et al. 2000).

Pharmacotherapy

Pharmacological treatment is the most common type of treatment in patients with GAD (Wittchen et al. 2002). Overall, about 60 % of recognized GAD patients in primary care are treated by their general practitioner, while only 20 % of patients are referred to specialized care (psychotherapist, psychiatrist). Unfortunately, overall treatment rates are considerably lower due to lack of recognition or failure to provide treatment despite diagnosis of the disorder (Wittchen et al. 2002). In a large community sample, only 14 % of all GAD cases reported to have seen a psychiatrist in the past year, where the proportion of cases receiving minimally adequate treatment is higher (51 %) than in the general medical care section (20 %) (Wang et al. 2005). While females were found to have overall higher rates for any treatment

utilization than males, they were less likely to receive mental health specialty treatment (Wang et al. 2005). Among primary care patients slightly more affected women than men use psychotropic medication (61 % compared to 54 %; Berger et al. 2009a). Comorbidity with depression was shown to increase the probability for receiving pharmacotherapy (Wittchen et al. 2002). When prescribing these drugs, possible gender differences in efficacy and side effects should always be considered, as the pharmacokinetics and pharmacodynamics may differ between men and women (Keers and Aitchison 2010).

Overall, a wide range of psychotropic drugs is available for GAD treatment (Baldwin et al. 2014), with the modern antidepressants being the first-line treatment choice, given the overall chronic-persistent nature of GAD and the respectively required long-term treatment. Selective serotonin reuptake inhibitors (SSRIs) as well as serotonin and noradrenaline reuptake inhibitors (SNRIs) have established efficacy (Baldwin et al. 2005, 2011). Commonly used SSRI that are licensed in many countries for GAD are paroxetine and escitalopram; common SNRIs are venlafaxine and duloxetine. Generally, both SSRIs and SNRIs anxiolytic efficacy is supported by a reasonable number of studies, and both SSRIs and SNRIs are usually tolerated well (Baldwin et al. 2005). The SSRI sertraline has also been reported as appropriate for children and adolescents (Rickels and Rynn 2001) (Walkup et al. 2008). As all these drugs are commonly used to treat depression, there may be an additional positive effect of this therapy in the frequent cases of comorbid GAD and depression (Durham 2004). Generally, there is little research on possible gender differences regarding efficacy or side effects for these drugs, although it was suggested that the female hormonal cycle might interact with serotonergic antidepressants (Martenyi et al. 2001). Some sparse research on gender-specific effects is available for specific serotonergic drugs: While men and women responded equally to sertraline, treatment response seems to be lower for women treated with fluoxetine but higher for women treated with venlafaxine (Pollack et al. 2003; Simon et al. 2006; Steiner et al. 2005). Additionally, according to Allgulander (2012), sertraline and fluoxetine are first choice treatments during pregnancy, while paroxetine has been reported as unsafe during pregnancy (Marks et al. 2008).

Besides SSRIs and SNRIs, tricyclic antidepressants (TCAs) are commonly used for GAD treatment. Here, efficacy is supported by studies as well, but side effects are more disruptive and more common (Baldwin et al. 2005). Therefore, the current recommendation regarding TCAs is to use these drugs only when SSRIs and SNRIs have not led to a sufficient improvement for the patient and other alternatives have been tested or are not available (Baldwin et al. 2014). As with SSRIs and SNRIs, patients with comorbid GAD and depression may also benefit from the antidepressant effect of the drug. However, TCAs should not be used in severe depression when there is a risk of suicide, as an overdose is considered highly toxic (Baldwin et al. 2014). While there are no studies investigating possible interactions between TCA medication and gender, studies on depression suggested interactions between the female hormonal cycle and TCA efficacy and tolerability, but again the possible implication for clinical practice have not been fully investigated (Hildebrandt et al. 2003; Kornstein et al. 2000).

For short-term treatment and rapid symptomatic relief in GAD, mostly benzodiazepines and also buspirone have been used. Both features established short-term efficacy, although buspirone seems to be somewhat less effective (Chessick et al. 2006). Both are usually well tolerated (Berger et al. 2011; Chessick et al. 2006). However, benzodiazepines pose a risk of dependency which is usually related to duration of drug intake (Baldwin et al. 2005; Durham 2004). No such risk is present for buspirone (Baldwin et al. 2005). However, buspirone has been reported to show dysphoric side effects (Durham 2004) and thus should not be used when comorbid depression is present. All in all, both benzodiazepines and buspirone should mainly be used for acute treatment, and possible adverse effects should be monitored closely, while long-term use of benzodiazepines should be avoided (Durham 2004).

There is also a wide range of other drugs that have been used for GAD, including anticonvulsants, antipsychotics or plant-based drugs. However, for most of these possible alternatives, few data are available regarding response and tolerability, including possibly severe side effects. Therefore, these drugs should be avoided if possible and first- or second-line treatments as outlined above should be used. If these fail to achieve the intended effect and one of these alternatives is prescribed, possible side effects should be monitored very closely.

One notable exception is pregabalin, an anticonvulsant recently available for GAD treatment (Allgulander 2012; Baldwin et al. 2011). Here, efficacy and tolerability have been demonstrated for GAD (Montgomery et al. 2008; Stein et al. 2008) and there may be an antidepressive effect as well (Stein et al. 2008). Until now, no study has reported gender differences in efficacy or tolerability for pregabalin.

Psychotherapy

In a large community sample, 17 % of the GAD cases reported to have seen a psychologist or other nonpsychiatrist mental health professional, including social worker or counselor in a mental health setting, or used a mental health hotline in the past year, with almost two thirds receiving minimally adequate treatment (Wang et al. 2005).

Psychotherapy, particularly cognitive-behavioural therapy (CBT), has proven efficacy in the treatment of GAD with large effect sizes (Mitte 2005; Hunot et al. 2007; Cuijpers et al. 2014). Improvements generally remain stable at follow-up and positive effects also occur on co-occurring symptoms such as depression (Cuijpers et al. 2014). However, given heterogeneity between study findings and the fact that on average only half of the treated patients fully remit from GAD through treatment, further research is necessary regarding both advancing disorder models and improving active treatment ingredients. Most studies have tested the effects of treatments containing multiple CBT intervention components such as applied relaxation, self-control desensitization, self-monitoring of worrying, stimulus control, cognitive restructuring and various forms of anxiety management (Hoyer and Gloster 2009). More complex CBT programmes, however, are not necessarily beneficial over narrower treatments such as pure behavioural therapy (Cuijpers et al. 2014), suggesting that identification of active treatment ingredients is essential.

Individual interventions with proven efficacy as stand-alone treatments are applied relaxation (Öst 1987) and massed worry exposure (Hoyer et al. 2009). Applied relaxation is a coping technique. Patients learn how to relax based on progressive muscle relaxation and to decrease the time to relaxation using several practice steps. Finally, they will be able to apply a short relaxation procedure whenever first signs of anxiety, worry or tension arise in order to reduce autonomic arousal and cope with the anxiety eliciting situations. Massed worry exposure attempts to target more directly the putative underlying core pathogenic mechanisms of the disorder (Hoyer and Beesdo-Baum 2012). Patients are exposed to emotions and cognitions that are avoided during episodes of worrying. For that purpose, an image script is generated for the most feared worry outcomes (e.g. “My son and husband die in a car accident”) and patients are confronted with this image until anxiety reactions decrease. More research is necessary on the effectiveness of specific interventions and possible add on components contributing to more favourable treatment outcomes. For example, there are indications that greater emphasis on interventions targeting dysfunctional GAD behaviours such as reassurance, avoidance and safety behaviours might be beneficial (Beesdo-Baum et al. 2012a). Very favourable effect sizes in more recently developed alternative treatment approaches employing mindfulness and acceptance based techniques (Roemer et al. 2008) can also be interpreted in this way. Further, more research is necessary regarding potential incremental beneficial effects of combined psychotherapy and pharmacotherapy as initial findings are inconsistent (Walkup et al. 2008; Crits-Christoph et al. 2011). Finally, considerably more work is needed regarding more personalized or tailored treatment based on patient characteristics. There are to date only few and inconsistent findings regarding predictors for treatment outcome in patients with GAD (Hoyer and Gloster 2009) suggesting heterogeneity in terms of best treatment choice. With few exceptions where females appear to have worse treatment outcomes than males (Manassis et al. 2004), gender does mostly not emerge as significant predictor (e.g. Payne et al. 2011).

Conclusion

Although gender differences have been consistently revealed for GAD in terms of prevalence, with women being more commonly affected than men, the causes for this difference remain largely unknown. Researchers have not consequently conducted separate analyses for males and females or explored the moderating or predictor role of gender. Given this background, focused re-analyses of available data and well-planned novel studies are necessary to unravel the causes of gender differences in GAD.

References

- Albano AM, Silverman WK (1996) Guide to the use of the anxiety disorders interview schedule for DSM-IV-child and parent versions. Oxford University Press, London
- Allgulander C (2012) Generalized anxiety disorder: a review of recent findings. *J Exp Clin Med* 4(2):88–91

- Altemus M (2006) Sex differences in depression and anxiety disorders: potential biological determinants. *Horm Behav* 50(4):534–538
- Alwahabi F (2003) Anxiety symptoms and generalized anxiety disorder in the elderly: a review. *Harv Rev Psychiatry* 11(4):180–193
- Amstadter AB, Koenen KC, Ruggiero KJ, Acierno R, Galea S, Kilpatrick DG et al (2010) Npy moderates the relation between hurricane exposure and generalized anxiety disorder in an epidemiologic sample of hurricane-exposed adults. *Depress Anxiety* 27(3):270–275
- Andlin-Sobocki P, Wittchen HU (2005) Cost of anxiety disorders in Europe. *Eur J Neurol* 12(Suppl 1):39–44
- Andrews G, Goldberg DP, Krueger RF, Carpenter WT, Hyman SE, Sachdev P et al (2009) Exploring the feasibility of a meta-structure for DSM-V and ICD-11: could it improve utility and validity? *Psychol Med* 39(12):1993–2000
- Andrews G, Hobbs MJ, Borkovec TD, Beesdo K, Craske MG, Heimberg RG et al (2010) Generalized worry disorder: a review of DSM-IV generalized anxiety disorder and options for DSM-V. *Depress Anxiety* 27:134–147
- Angst J, Gamma A, Baldwin DS, Ajdacic-Gross V, Rossler W (2009) The generalized anxiety spectrum: prevalence, onset, course and outcome. *Eur Arch Psychiatry Clin Neurosci* 259(1):37–45
- APA (2000) Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR), 4th edn. American Psychiatric Association, Washington, DC
- APA (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington
- Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT et al (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* 19(6):567–596
- Baldwin D, Woods R, Lawson R, Taylor D (2011) Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. *BMJ* 342. doi: <http://dx.doi.org/10.1136/bmj.d1199>
- Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA et al (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. *J Psychopharmacol*. doi: [10.1177/0269881114525674](https://doi.org/10.1177/0269881114525674)
- Bardeen JR, Stevens EN, Murdock KW, Lovejoy MC (2013) A preliminary investigation of sex differences in associations between emotion regulation difficulties and higher-order cognitive abilities. *Pers Individual Differences* 55(1):70–75
- Beesdo K (2006) Wie entstehen Generalisierte Ängste? Eine prospektiv-longitudinale, klinisch-epidemiologische Studie bei Jugendlichen und jungen Erwachsenen [The development of generalized anxiety. A prospective-longitudinal, clinicaledgepidemiologic study among adolescents and young adults]. TUD Press, Dresden
- Beesdo K, Hoyer J, Jacobi F, Low NCP, Höfler M, Wittchen HU (2009a) Association between generalized anxiety levels and pain in a community sample: evidence for diagnostic specificity. *J Anxiety Disord* 23:684–693
- Beesdo K, Knappe S, Pine DS (2009b) Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. *Psychiatr Clin North Am* 32(3):483–524
- Beesdo K, Jacobi F, Hoyer J, Low NCP, Höfler M, Wittchen HU (2010a) Pain associated with specific anxiety and depressive disorders in a nationally representative population sample. *Soc Psychiatry Psychiatr Epidemiol* 45(1):89–104
- Beesdo K, Pine DS, Lieb R, Wittchen HU (2010b) Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. *Arch Gen Psychiatry* 67(1):47–57
- Beesdo-Baum K, Knappe S (2012) Developmental epidemiology of anxiety disorders. *Child Adolesc Psychiatr Clin N Am* 21(3):457–478

- Beesdo-Baum K, Winkel S, Pine DS, Hoyer J, Höfler M, Lieb R et al (2011) The diagnostic threshold of generalized anxiety disorder in the community: a developmental perspective. *J Psychiatr Res* 45:962–972
- Beesdo-Baum K, Jenjahn E, Hofler M, Lueken U, Becker ES, Hoyer J (2012a) Avoidance, safety behavior, and reassurance seeking in generalized anxiety disorder. *Depress Anxiety* 29(11): 948–957
- Beesdo-Baum K, Klotsche J, Knappe S, Craske MG, LeBeau RT, Hoyer J et al (2012b) Psychometric properties of the dimensional anxiety scales for DSM-5 in an unselected sample of German treatment seeking patients. *Depress Anxiety* 29:1014–1024
- Behar E, Zuellig AR, Borkovec TD (2005) Thought and imaginal activity during worry and trauma recall. *Behav Ther* 36(2):157–168
- Behar E, DiMarco ID, Hekler EB, Mohlman J, Staples AM (2009) Current theoretical models of generalized anxiety disorder (GAD): conceptual review and treatment implications. *J Anxiety Disord* 23(8):1011–1023
- Bener A, Al-Kazaz M, Ftouni D, Al-Harthy M, Dafeeah EE (2013) Diagnostic overlap of depressive, anxiety, stress and somatoform disorders in primary care. *Asia-Pac Psychiatry* 5(1):E29–E38
- Berger A, Dukes E, Wittchen HU, Morlock R, Edelsberg J, Oster G (2009a) Patterns of healthcare utilization in patients with generalized anxiety disorder in general practice in Germany. *Eur J Psychiatry* 23(2):90–100
- Berger A, Mychaskiw M, Dukes E, Edelsberg J, Oster G (2009b) Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder. *BMC Geriatr* 9:31
- Berger A, Edelsberg J, Bollu V, Alvir JM, Dugar A, Joshi AV et al (2011) Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study. *BMC Psychiatry* 11:193
- Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J et al (1997) The screen for child anxiety related emotional disorders (SCARED): scale construction and psychometric characteristics. *J Am Acad Child Adolesc Psychiatry* 36(4):545–553
- Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the hospital anxiety and depression scale – an updated literature review. *J Psychosom Res* 52(2):69–77
- Bobes J, Caballero L, Vilardaga I, Rejas J (2011) Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement? *Ann Gen Psychiatry* 10:7
- Borkovec TD (1994) The nature, functions, and origins of worry. In: Davey G, Tallis F (eds) *Worrying: perspectives on theory assessment and treatment*. Wiley & Sons, Sussex, pp 5–33
- Borkovec TD, Inz J (1990) The nature of worry in generalized anxiety disorder – a predominance of thought activity. *Behav Res Ther* 28(2):153–158
- Borkovec TD, Roemer L (1995) Perceived functions of worry among generalized anxiety disorder subjects – distraction from more emotionally distressing topics. *J Behav Ther Exp Psychiatry* 26(1):25–30
- Borkovec TD, Alcaine OM, Behar E (2004) Avoidance theory of worry and generalized anxiety disorder. In: Heimberg R, Turk C, Mennin D (eds) *Generalized anxiety disorder: advances in research and practice*. Guilford Press, New York, pp 77–108
- Boswell JF, Thompson-Hollands J, Farchione TJ, Barlow DH (2013) Intolerance of uncertainty: a common factor in the treatment of emotional disorders. *J Clin Psychol* 69(6): 630–645
- Brewerton TD, Lydiard RB, Johnson MR, Ballenger JC, Fossey MD, Zealberg JJ et al (1995) CSF serotonin: diagnostic and seasonal differences. *Biol Psychiatry* 37(9):655–655
- Brown TA, Barlow DH (2002) Classification of anxiety and mood disorders. In: Barlow DH (ed) *Anxiety and its disorders*, 2nd edn. Guilford Press, New York, pp 292–329

- Brown TA, Naragon-Gainey K (2013) Evaluation of the unique and specific contributions of dimensions of the triple vulnerability model to the prediction of DSM-IV anxiety and mood disorder constructs. *Behav Ther* 44(2):277–292
- Brown TA, Antony MM, Barlow DH (1992) Psychometric properties of the penn state worry questionnaire in a clinical anxiety disorders sample. *Behav Res Ther* 30(1):33–37
- Burstein M, Beesdo-Baum K, He J-P, Merikangas KR (2013) Threshold and subthreshold generalized anxiety disorder among US adolescents: prevalence, sociodemographic and clinical characteristics. *Psychol Med*. doi:[10.1017/S0033291713002997](https://doi.org/10.1017/S0033291713002997)
- Bystritsky A, Hovav S, Sherbourne C, Stein MB, Rose RD, Campbell-Sills L et al (2012) Use of complementary and alternative medicine in a large sample of anxiety patients. *Psychosomatics* 53(3):266–272
- Carleton RN (2012) The intolerance of uncertainty construct in the context of anxiety disorders: theoretical and practical perspectives. *Expert Rev Neurother* 12(8):937–947
- Carter RM, Wittchen H-U, Pfister H, Kessler RC (2001) One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. *Depress Anxiety* 13:78–88
- Cassidy J, Lichtenstein-Phelps J, Sibrava NJ, Thomas CL Jr, Borkovec TD (2009) Generalized anxiety disorder: connections with self-reported attachment. *Behav Ther* 40(1):23–38
- Cerda M, Sagdeo A, Johnson J, Galea S (2010) Genetic and environmental influences on psychiatric comorbidity: a systematic review. *J Affect Disord* 126(1–2):14–38
- Chessick CA, Allen MH, Thase ME, Batista Miralha da Cunha AABC, Kapczinski FFK, Silva de Lima M, dos Santos Souza JJSS (2006) Azapirones for generalized anxiety disorder. *Cochrane Database Syst Rev* (3):CD006115
- Connor KM, Davidson JR (1998) Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. *Biol Psychiatry* 44(12):1286–1294
- Copeland WE, Angold A, Shanahan L, Costello EJ (2014) Longitudinal patterns of anxiety from childhood to adulthood: the great smoky mountains study. *J Am Acad Child Adolesc Psychiatry* 53(1):21–33
- Cougle JR, Fitch KE, Fincham FD, Riccardi CJ, Keough ME, Timpano KR (2012) Excessive reassurance seeking and anxiety pathology: tests of incremental associations and directionality. *J Anxiety Disord* 26(1):117–125
- Crits-Christoph P, Newman MG, Rickels K, Gallop R, Gibbons MBC, Hamilton JL et al (2011) Combined medication and cognitive therapy for generalized anxiety disorder. *J Anxiety Disord* 25(8):1087–1094
- Cuijpers P, Sibbrandij M, Koole S, Huibers M, Berking M, Andersson G (2014) Psychological treatment of generalized anxiety disorder: a meta-analysis. *Clin Psychol Rev* 34(2):130–140
- de Graaf R, Bijl R, Spijker J, Beekman ATF, Vollebergh WAM (2003) Temporal sequencing of lifetime mood disorders in relation to comorbid anxiety and substance use disorders. *Soc Psychiatry Psychiatr Epidemiol* 38:1–11
- Di Nardo PA, Brown TA, Barlow DH (1994) Anxiety disorders interview schedule for DSM-IV: lifetime version (ADIS-IV-L). Psychological Corporation, San Antonio
- Dickson KS, Ciesla JA, Reilly LC (2012) Rumination, worry, cognitive avoidance, and behavioral avoidance: examination of temporal effects. *Behav Ther* 43(3):629–640
- Dugas MJ, Gagnon F, Ladouceur R, Freeston MH (1998) Generalized anxiety disorder: a preliminary test of a conceptual model. *Behav Res Ther* 36(2):215–226
- Durham RC (2004) Treatment of generalized anxiety disorder. *Psychiatry* 3(4):30–34
- Etkin A, Schatzberg AF (2011) Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. *Am J Psychiatry* 168(9):968–978
- Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD (2009) Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. *Arch Gen Psychiatry* 66(12):1361–1372

- Faravelli C, Abrardi L, Bartolozzi D, Cecchi C, Cosci F, D'Adamo D et al (2004) The Sesto Fiorentino Study: background, methods and preliminary results. *Psychother Psychosom* 73:216–225
- Fehr C, Schleicher A, Szegedi A, Anghelescu I, Klawe C, Hiemke C et al (2001) Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. *Prog Neuropsychopharmacol Biol Psychiatry* 25(5):965–982
- First M, Spitzer R, Gibbon M, Williams J (1997) Structured clinical interview for DSM-IV. American Psychiatric Press, Washington, DC
- Francis JL, Moitra E, Dyck I, Keller MB (2012) The impact of stressful life events on relapse of generalized anxiety disorder. *Depress Anxiety* 29(5):386–391
- Gamez W, Watson D, Doebbeling BN (2007) Abnormal personality and the mood and anxiety disorders: implications for structural models of anxiety and depression. *J Anxiety Disord* 21(4):526–539
- Giddens JL, Xian H, Scherrer JF, Eisen SA, Potenza MN (2011) Shared genetic contributions to anxiety disorders and pathological gambling in a male population. *J Affect Disord* 132(3):406–412
- Goncalves DC, Byrne GJ (2012) Sooner or Later: Age at Onset of Generalized Anxiety Disorder in Older Adults. *Depress Anxiety* 29(1):39–46
- Grant BF, Hasin DS, Stinson FS, Dawson DA, Ruan WJ, Goldstein RB et al (2005) Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on alcohol and related conditions. *Psychol Med* 35(12):1747–1759
- Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR et al (1999) The economic burden of anxiety disorders in the 1990s. *J Clin Psychiatry* 60(7):427–435
- Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E et al (2011) Cost of disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* 21(10):718–779
- Hamilton M (1959) The assessment of anxiety-states by rating. *Br J Med Psychol* 32(1):50–55
- Hernandez E, Lastra S, Urbina M, Carreira I, Lima L (2002) Serotonin, 5-hydroxyindoleacetic acid and serotonin transporter in blood peripheral lymphocytes of patients with generalized anxiety disorder. *Int Immunopharmacol* 2(7):893–900
- Hettema JM, Neale MC, Kendler KS (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. *Am J Psychiatry* 158(10):1568–1578
- Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS (2005) The structure of genetic and environmental risk factors for anxiety disorders in men and women. *Arch Gen Psychiatry* 62(2):182–189
- Hettema JM, Neale MC, Myers JM, Prescott CA, Kendler KS (2006) A population-based twin study of the relationship between neuroticism and internalizing disorders. *Am J Psychiatry* 163(5):857–864
- Hilbert K, Lueken U, Beesdo-Baum K (2014) Neural structures, functioning and connectivity in generalized anxiety disorder and interaction with neuroendocrine systems: a systematic review. *J Affect Disord* 158:114–126
- Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Soerensen P (2003) Are gender differences important for the clinical effects of antidepressants? *Am J Psychiatry* 160(9):1643–1650
- Hoffman D, Dukes E, Wittchen H-U (2008) Human and economic burden of generalized anxiety disorder. *Depress Anxiety* 25(1):72–90
- Hopko DR, Bourland SL, Stanley MA, Beck JG, Novy DM, Averill PM et al (2000) Generalized anxiety disorder in older adults: examining the relation between clinician severity ratings and patient self-report measures. *Depress Anxiety* 12(4):217–225
- Hoyer J, Beesdo K (2006) Generalisierte Angststörung [Generalised anxiety disorder]. In: Wittchen HU, Hoyer J (eds) *Klinische Psychologie und Psychotherapie [Clinical psychology and psychotherapy]*. Springer Medizin Verlag, Heidelberg

- Hoyer J, Beesdo-Baum K (2011) Generalisierte Angststörung. [Generalized anxiety disorder]. In: Wittchen HU, Hoyer J (eds) *Klinische Psychologie und Psychotherapie*. [Textbook of clinical psychology and psychotherapy], 2nd edn. Springer, Heidelberg, pp 937–952
- Hoyer J, Beesdo-Baum K (2012) Prolonged imaginal exposure based on worry scenarios. In: Neudeck P, Wittchen H-U (eds) *Exposure therapy: rethinking the model – refining the method*. Springer, New York, pp 245–260
- Hoyer J, Gloster AT (2009) Psychotherapy for generalized anxiety disorder: don't worry, it works! *Psychiatr Clin North Am* 32:629–640
- Hoyer J, Becker E, Margraf J (2002) Generalized anxiety disorder and clinical worry episodes in young women. *Psychol Med* 32:1227–1237
- Hoyer J, Beesdo K, Gloster AT, Höfler M, Runge J, Becker ES (2009) Worry exposure versus applied relaxation in the treatment of generalized anxiety disorder. *Psychother Psychosom* 78:106–115
- Hunot V, Churchill R, Silva de Lima M, Teixeira V (2007) Psychological therapies for generalised anxiety disorder. *Cochrane Database Syst Rev* (1):CD001848. doi:10.1002/14651858.CD001848.pub4
- Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P et al (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry* 36(7):980–988
- Keers R, Aitchison KJ (2010) Gender differences in antidepressant drug response. *Int Rev Psychiatry* 22(5):485–500
- Kendler KS, Hetttema JM, Butera F, Gardner CO, Prescott CA (2003) Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety. *Arch Gen Psychiatry* 60(8):789–796
- Kendler KS, Myers JM, Maes HH, Keyes CLM (2011) The relationship between the genetic and environmental influences on common internalizing psychiatric disorders and mental well-being. *Behav Genet* 41(5):641–650
- Kessler RC, Ustun TB (2004) The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). *Int J Methods Psychiatr Res* 13(2):93–121
- Kessler RC, Andrade L, Bijl R, Offord D, Demler O, Stein DJ (2002a) The effects of co-morbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys. *Psychol Med* 32:1213–1225
- Kessler RC, Berglund PA, Dewit DJ, Ustun TB, Wang PS, Wittchen HU (2002b) Distinguishing generalized anxiety disorder from major depression: prevalence and impairment from current pure and comorbid disorders in the US and Ontario. *Int J Methods Psychiatr Res* 11(3):99–111
- Kessler RC, Brandenburg N, Lane M, Roy-Byrne P, Stang PD, Stein DJ et al (2005a) Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. *Psychol Med* 35(7):1073–1082
- Kessler RC, Chiu WT, Demler O, Walters EE (2005b) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 62:617–627
- Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *Int J Methods Psychiatr Res* 21(3):169–184
- Knappe S, Klotsche J, Strobel A, LeBeau RT, Craske MG, Wittchen H-U et al (2013) Dimensional anxiety scales for DSM-5: sensitivity to clinical severity. *Eur Psychiatry* 28:448–456
- Knappe S, Klotsche J, Heyde F, Hiob S, Hoyer J, Strobel A et al (2014) Test-retest reliability and sensitivity to change of the dimensional anxiety scales for DSM-5. *CNS Spectr* 19(3):256–267. doi:10.1017/S1092852913000710
- Kogan JN, Edelman BA, McKee DR (2000) Assessment of anxiety in older adults: current status. *J Anxiety Disord* 14(2):109–132

- Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI et al (2000) Gender differences in treatment response to sertraline versus imipramine in chronic depression. *Am J Psychiatry* 157(9):1445–1452
- Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Löwe B (2007) Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med* 146:317–325
- LeBeau RT, Glenn DE, Hanover LN, Beesdo-Baum K, Wittchen H-U, Craske MG (2012) A dimensional approach to measuring anxiety for DSM-5. *Int J Methods Psychiatr Res* 21(4):258–272
- Lee S, Tsang A, Ruscio AM, Haro JM, Stein DJ, Alonso J et al (2009) Implications of modifying the duration requirement of generalized anxiety disorder in developed and developing countries. *Psychol Med* 39(7):1163–1176
- Legerstee JS, Garnefski N, Verhulst FC, Utens EM (2011) Cognitive coping in anxiety-disordered adolescents. *J Adolesc* 34(2):319–326
- Lieb R, Becker E, Altamura C (2005) The epidemiology of generalized anxiety disorder in Europe. *Eur Neuropsychopharmacol* 15(4):445–452
- Llera SJ, Newman MG (2014) Rethinking the role of worry in generalized anxiety disorder: evidence supporting a model of emotional contrast avoidance. *Behav Ther* 45(3):283–299
- Maack DJ, Tull MT, Gratz KL (2012) Examining the incremental contribution of behavioral inhibition to generalized anxiety disorder relative to other axis I disorders and cognitive-emotional vulnerabilities. *J Anxiety Disord* 26(6):689–695
- Macefield VG (2009) Developments in autonomic research: a review of the latest literature. *Clin Auton Res* 19(4):193–196
- Manassis K, Avery D, Butalia S, Mendlowitz S (2004) Cognitive-behavioral therapy with childhood anxiety disorders: functioning in adolescence. *Depress Anxiety* 19(4):209–216
- Marganska A, Gallagher M, Miranda R (2013) Adult attachment, emotion dysregulation, and symptoms of depression and generalized anxiety disorder. *Am J Orthopsychiatry* 83(1):131–141
- Marks DM, Park MH, Ham BJ, Han C, Patkar AA, Masand PS et al (2008) Paroxetine: safety and tolerability issues. *Expert Opin Drug Saf* 7(6):783–794
- Martenyi F, Dossenbach M, Mraz K, Metcalfe S (2001) Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrine reuptake inhibition profile. *Eur Neuropsychopharmacol* 11(3):227–232
- McClure EB, Monk CS, Nelson EE, Parrish JM, Adler A, Blair RJ et al (2007) Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. *Arch Gen Psychiatry* 64(1):97–106
- McLaughlin KA, Mennin DS, Farach FJ (2007) The contributory role of worry in emotion generation and dysregulation in generalized anxiety disorder. *Behav Res Ther* 45(8):1735–1752
- McLean CP, Anderson ER (2009) Brave men and timid women? A review of the gender differences in fear and anxiety. *Clin Psychol Rev* 29(6):496–505
- McLean CP, Asnaani A, Litz BT, Hofmann SG (2011) Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. *J Psychiatr Res* 45(8):1027–1035
- Melchior M, Caspi A, Milne BJ, Danese A, Poulton R, Moffitt TE (2007) Work stress precipitates depression and anxiety in young, working women and men. *Psychol Med* 37(8):1119–1129
- Meng XF, Kou CG, Shi JP, Yu YQ, Huang YQ (2011) Susceptibility genes, social environmental risk factors and their interactions in internalizing disorders among mainland Chinese undergraduates. *J Affect Disord* 132(1–2):254–259
- Mennin DS, Heimberg RG, Turk CL, Fresco DM (2002) Applying an emotion regulation framework to integrative approaches to generalized anxiety disorder. *Clin Psychol Sci Pract* 9(1):85–90
- Mennin DS, Heimberg RG, Turk CL, Fresco DM (2005) Preliminary evidence for an emotion dysregulation model of generalized anxiety disorder. *Behav Res Ther* 43(10):1281–1310

- Mennin DS, Holaway RM, Fresco DM, Moore MT, Heimberg RG (2007) Delineating components of emotion and its dysregulation in anxiety and mood psychopathology. *Behav Ther* 38(3):284–302
- Mennin DS, McLaughlin KA, Flanagan TJ (2009) Emotion regulation deficits in generalized anxiety disorder, social anxiety disorder, and their co-occurrence. *J Anxiety Disord* 23(7): 866–871
- Meyer TJ, Miller ML, Metzger RL, Borkovec TD (1990) Development and validation of the Penn State Worry Questionnaire. *Behav Res Ther* 28(6):487–495
- Mitte K (2005) Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. *Psychol Bull* 131(5):785–795
- Moffitt TE, Caspi A, Harrington H, Milne BJ, Melchior M, Goldberg D et al (2007) Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32. *Psychol Med* 37(3):441–452
- Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F (2008) Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. *Br J Psychiatry* 193(5):389–394
- Munk-Jorgenson P, Allgulander C, Dahl AA, Foldager L, Holm M, Rasmussen I et al (2006) Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway and Sweden. *Psychiatr Serv* 57(12):1738–1744
- Newman MG, Zuellig AR, Kachin KE, Constantino MJ, Przeworski A, Erickson T et al (2002) Preliminary reliability and validity of the generalized anxiety disorder questionnaire – IV: a revised self-report diagnostic measure of generalized anxiety disorder. *Behav Ther* 33(2):215–233
- Nitschke JB, Sarinopoulos I, Oathes DJ, Johnstone T, Whalen PJ, Davidson RJ et al (2009) Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. *Am J Psychiatry* 166(3):302–310
- Nolen-Hoeksema S (2012) Emotion regulation and psychopathology: the role of gender. *Annu Rev Clin Psychol* 8:161–187
- Olatunji BO, Moretz MW, Zlomke KR (2010) Linking cognitive avoidance and GAD symptoms: the mediating role of fear of emotion. *Behav Res Ther* 48(5):435–441
- Öst L-G (1987) Applied relaxation: description of a coping technique and review of controlled studies. *Behav Res Ther* 25:397–409
- Park YM, Lee SH, Kim S, Bae SM (2010) The loudness dependence of the auditory evoked potential (LDAEP) in schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, and healthy controls. *Prog Neuropsychopharmacol Biol Psychiatry* 34(2):313–316
- Parker G, Hadzi-Pavlovic D (2004) Is the female preponderance in major depression secondary to a gender difference in specific anxiety disorders? *Psychol Med* 34(3):461–470
- Payne S, Bolton D, Perrin S (2011) A pilot investigation of cognitive therapy for generalized anxiety disorder in children aged 7–17 years. *Cogn Ther Res* 35(2):171–178
- Pollack MH, Meoni P, Otto MW, Simon N, Hackett D (2003) Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. *J Clin Psychopharmacol* 23(3):250–259
- Price RB, Mohlman J (2007) Inhibitory control and symptom severity in late life generalized anxiety disorder. *Behav Res Ther* 45(11):2628–2639
- Price RB, Eldreth DA, Mohlman J (2011) Deficient prefrontal attentional control in late-life generalized anxiety disorder: an fMRI investigation. *Transl Psychiatry* 1:e46
- Read KL, Comer JS, Kendall PC (2013) The intolerance of uncertainty scale for children (IUSC): discriminating principal anxiety diagnoses and severity. *Psychol Assess* 25(3):722–729
- Rettew DC, Doyle AC, Kwan M, Stanger C, Hudziak JJ (2006) Exploring the boundary between temperament and generalized anxiety disorder: a receiver operating characteristic analysis. *J Anxiety Disord* 20(7):931–945
- Rickels K, Rynn M (2001) Overview and clinical presentation of generalized anxiety disorder. *Psychiatr Clin North Am* 24(1):1–17
- Robichaud M, Dugas MJ, Conway M (2003) Gender differences in worry and associated cognitive-behavioral variables. *J Anxiety Disord* 17(5):501–516

- Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J et al (1988) The composite international diagnostic interview – an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. *Arch Gen Psychiatry* 45(12): 1069–1077
- Rodriguez BF, Weisberg RB, Pagano ME, Bruce SE, Spencer MA, Culpepper L et al (2006) Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. *J Nerv Ment Dis* 194(2):91–97
- Roemer L, Molina S, Litz BT, Borkovec TD (1996) Preliminary investigation of the role of previous exposure to potentially traumatizing events in generalized anxiety disorder. *Depress Anxiety* 4(3):134–138
- Roemer L, Orsillo SM, Salters-Pedneault K (2008) Efficacy of an acceptance-based behavior therapy for generalized anxiety disorder: evaluation in a randomized controlled trial. *J Consult Clin Psychol* 76(6):1083–1089
- Roemer L, Lee JK, Salters-Pedneault K, Erisman SM, Orsillo SM, Mennin DS (2009) Mindfulness and emotion regulation difficulties in generalized anxiety disorder: preliminary evidence for independent and overlapping contributions. *Behav Ther* 40(2):142–154
- Rubio G, Lopez-Ibor JJ (2007) Generalized anxiety disorder: a 40-year follow-up study. *Acta Psychiatr Scand* 115(5):372–379
- Saffren SA, Gershuny BS, Marzol P, Otto MW, Pollack MH (2002) History of childhood abuse in panic disorder, social phobia, and generalized anxiety disorder. *J Nerv Ment Dis* 190(7):453–456
- Salters-Pedneault K, Roemer L, Tull MT, Rucker L, Mennin DS (2006) Evidence of broad deficits in emotion regulation associated with chronic worry and generalized anxiety disorder. *Cogn Ther Res* 30(4):469–480
- Samochowiec J, Hajduk A, Samochowiec A, Horodnicki J, Stepien G, Grzywacz A et al (2004) Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. *Psychiatry Res* 128(1):21–26
- Sareen J, Cox BJ, Clara I, Asmundson GJG (2005) The relationship between anxiety disorders and physical disorders in the U.S. national comorbidity survey. *Depress Anxiety* 21: 193–202
- Schonfeld WH, Verboncoeur CJ, Fifer SK, Lipschutz RC, Lubeck DP, Buesching DP (1997) The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder. *J Affect Disord* 43(2):105–119
- Shear M, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto M et al (2001) Reliability and validity of a Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A). *Depress Anxiety* 13(4):166–178
- Shear K, Belnap BH, Mazumdar S, Houck P, Rollman BL (2006) Generalized anxiety disorder severity scale (GADSS): a preliminary validation study. *Depress Anxiety* 23:77–82
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 59(Suppl 20):22–33, quiz 34–57
- Shin LM, Liberzon I (2010) The neurocircuitry of fear, stress, and anxiety disorders. *Neuropsychopharmacology* 35(1):169–191
- Simon NM, Zalta AK, Worthington JJ, Hoge EA, Christian KM, Stevens JC et al (2006) Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. *Depress Anxiety* 23(6):373–376
- Sipila T, Kananen L, Greco D, Donner J, Silander K, Terwilliger JD et al (2010) An association analysis of circadian genes in anxiety disorders. *Biol Psychiatry* 67(12):1163–1170
- Spitzer RL, Kroenke K, Williams JBW, Lowe B (2006) A brief measure for assessing generalized anxiety disorder – the GAD-7. *Arch Intern Med* 166(10):1092–1097
- Stapinski LA, Abbott MJ, Rapee RM (2010) Evaluating the cognitive avoidance model of generalised anxiety disorder: impact of worry on threat appraisal, perceived control and anxious arousal. *Behav Res Ther* 48(10):1032–1040

- Starcevic V, Portman ME, Beck AT (2012) Generalized anxiety disorder between neglect and an epidemic. *J Nerv Ment Dis* 200(8):664–667
- Stein DJ (2013) Generalised anxiety disorder. *S Afr J Psychiatry* 19(3):175–179
- Stein MB, Heimberg RG (2004) Well-being and life satisfaction in generalized anxiety disorder: comparison to major depressive disorder in a community sample. *J Affect Disord* 79(1–3):161–166
- Stein DJ, Baldwin DS, Baldinetti F, Mandel F (2008) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. *Eur Neuropsychopharmacol* 18(6):422–430
- Steiner M, Allgulander C, Ravindran A, Kosar H, Burt T, Austin C (2005) Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder. *Hum Psychopharmacol Clin Exp* 20(1):3–13
- Stuedte S, Stalder T, Dettenborn L, Klumbies E, Foley P, Beesdo-Baum K et al (2011) Decreased hair cortisol concentrations in generalised anxiety disorder. *Psychiatry Res* 186(2–3):310–314
- Strawn JR, Bitter SM, Weber WA, Chu WJ, Whitsel RM, Adler C et al (2012) Neurocircuitry of generalized anxiety disorder in adolescents: a pilot functional neuroimaging and functional connectivity study. *Depress Anxiety* 29(11):939–947
- Tadic A, Rujescu D, Szegedi A, Giegling I, Singer P, Moller HJ et al (2003) Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. *Am J Med Genet B Neuropsychiatr Genet* 117B(1):1–6
- Tafet GE, Idoyaga-Vargas VP, Abulafia DP, Calandria JM, Roffman SS, Chiovetta A et al (2001) Correlation between cortisol level and serotonin uptake in patients with chronic stress and depression. *Cogn Affect Behav Neurosci* 1(4):388–393
- Thayer JF, Lane RD (2000) A model of neurovisceral integration in emotion regulation and dysregulation. *J Affect Disord* 61(3):201–216
- Tromp DP, Grupe DW, Oathes DJ, McFarlin DR, Hernandez PJ, Kral TR et al (2012) Reduced structural connectivity of a major frontolimbic pathway in generalized anxiety disorder. *Arch Gen Psychiatry* 69(9):925–934
- Tull MT, Stipelman BA, Salters-Pedneault K, Gratz KL (2009) An examination of recent non-clinical panic attacks, panic disorder, anxiety sensitivity, and emotion regulation difficulties in the prediction of generalized anxiety disorder in an analogue sample. *J Anxiety Disord* 23(2):275–282
- van Eijck FEAM, Branje SJT, Hale WW, Meeus WHJ (2012) Longitudinal associations between perceived parent-adolescent attachment relationship quality and generalized anxiety disorder symptoms in adolescence. *J Abnorm Child Psychol* 40(6):871–883
- Vesga-Lopez O, Schneier FR, Wang S, Heimberg RG, Liu SM, Hasin DS et al (2008) Gender differences in generalized anxiety disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry* 69(10):1606–1616
- Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT et al (2008) Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. *N Engl J Med* 359(26):2753–2766
- Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC (2005) Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 62:629–640
- Wetherell JL, Birchler GD, Ramsdell J, Unutzer J (2007) Screening for generalized anxiety disorder in geriatric primary care patients. *Int J Geriatr Psychiatry* 22(2):115–123
- WHO (1990) Composite International Diagnostic Interview (CIDI). World Health Organization, Geneva
- WHO (1993) The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. World Health Organization, Geneva
- Wittchen HU (2002) Generalized anxiety disorder: prevalence, burden, and cost to society. *Depress Anxiety* 16(4):162–171
- Wittchen H-U, Lieb R, Pfister H, Schuster P (2000) The waxing and waning of mental disorders: evaluating the stability of syndromes of mental disorders in the population. *Compr Psychiatry* 41(2 suppl 1):122–132

- Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J (2002) Generalized anxiety and depression in primary care: prevalence, recognition, and management. *J Clin Psychiatry* 63(Suppl 8):24–34
- Wittchen HU, Jacobi F, Rehm J, Gustavsson C, Svensson M, Jönsson B et al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* 21:655–679
- Wittchen H-U, Härtling S, Dukes E, Morlock R, Edelsberg J, Oster G et al (2012) Generalisierte Angststörung in der primärärztlichen Versorgung: Eine Analyse administrativ-epidemiologischer Daten zu Inanspruchnahme und Versorgungsmerkmalen [Generalised anxiety disorder in primary care: an analysis of administrative and epidemiological data on health-care utilisation and characteristics of patient-centered care]. *MMW Fortschr Med* 154(3):77–84
- Yonkers KA, Bruce SE, Dyck IR, Keller MB (2003) Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. *Depress Anxiety* 17(3):173–179
- You JS, Hu SY, Chen B, Zhang HG (2005) Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. *Psychiatr Genet* 15(1):7–11
- Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. *Acta Psychiatr Scand* 67(6):361–370

Panic Disorder

Borwin Bandelow and Katharina Domschke

Epidemiology

Like other anxiety disorders, panic disorder (PD) is more frequent in women than in men. In European prevalence studies, the female-to-male ratio was 2.5 for panic disorder and 3.1 for agoraphobia (Wittchen et al. 2011). In the US National Comorbidity Survey, the gender ratio was 1.8 for both panic disorder and agoraphobia. Men and women showed a similar age of onset of PD in one study (Barzega et al. 2001). In another study, men reported an earlier age of onset and a shorter duration of illness, while the clinical presentation was similar for both genders (Clayton et al. 2006). In a comparison of PD in women and men, it was found that the rate of agoraphobia was higher in women than in men and the course was more chronic, as evidenced by an increase in the recurrence of panic symptoms following remission (Yonkers et al. 1998).

Panic disorder is highly comorbid with other mental disorders, potentially in a gender-specific fashion. Women were reported to have higher rates of comorbid depression, dependent or histrionic personality disorders, and bulimia nervosa than men, while lower rates of cyclothymia, body dysmorphic disorder, depersonalization disorder, alcohol or substance abuse, and borderline and schizoid personality disorders were observed (Clayton et al. 2006; Barzega et al. 2001; Andrade et al. 1996).

B. Bandelow (✉)

Department of Psychiatry and Psychotherapy, University of Göttingen,
von-Siebold-Str. 5, Göttingen D-37075, Germany
e-mail: bbandel@gwdg.de

K. Domschke

Department of Psychiatry, Psychosomatics and Psychotherapy, University
of Würzburg, Germany, Würzburg, Germany

Diagnosis and Evaluation

Patients with panic disorder experience recurrent unexpected panic attacks, are persistently worried about having more panic attacks, or change their behavior in maladaptive ways because of the panic attacks. According to the DSM-5 criteria (APA 2013), panic attacks are abrupt surges of intense fear or discomfort that reach a peak within minutes, accompanied by at least 4 of 13 defined physical and cognitive symptoms. Panic attacks may occur for no apparent reason or in expected situations. In around two thirds of the cases, the individuals with panic disorder develop agoraphobia, which is the fear of two or more of the following situations: using public transportation; being in open spaces or enclosed places; standing in line or being in a crowd; or being outside of the home alone. The individuals fear these situations because of thoughts that escaping might be difficult or embarrassing when panic symptoms occur.

Specific panic scales have been developed for assessing severity of panic disorder and agoraphobia and for measuring treatment success. The Panic and Agoraphobia Scale (PAS; Bandelow 1999) and the Panic Disorder Severity Scale (Shear et al. 1997) do not only measure panic attack severity but also agoraphobic avoidance behavior, anticipatory anxiety, worries about health, and restrictions in quality of life.

Psychobiology

Psychosocial and neurobiological causes may contribute to the higher prevalence of panic disorder in women.

Psychosocial Factors

One possible explanation for a female-dominant susceptibility to anxiety disorders is that women have more reason to be anxious due to their lower physical strength. However, anxiety disorders are often characterized by unrealistic fears of harmless objects or situations, such as the fear of elevators, mice, or shopping malls, and not by fears that represent a real threat (e.g., being assaulted). Specific phobias have an evolutionary background (e.g., only individuals with an inborn fear of spiders, snakes, and other dangerous animals survived) instead of being a consequence of negative conditioning experiences (like having been bitten by a spider). Likewise, agoraphobia usually does not occur after experiences like being trapped in an elevator or being hurt in a mass panic. Therefore, it is difficult to explain the higher frequency of panic disorder and agoraphobia by a higher occurrence of dangerous situations in women.

Women are significantly affected by chronic stressors, such as domestic conflicts, a double role as homemaker and worker, lower wages, or lower promotion prospects (Belle and Doucet 2003). However, traumatic life events occur more frequently in men: The US National Comorbidity Survey found that 51.2 % of women and 60.7 % of men reported exposure to at least one traumatic event (Kessler et al. 1995).

Although there is no evidence from twin studies for gender differences in the underlying structure of environmental risk factors for anxiety disorders (Hettema et al. 2005), one single study observed that life events played a significant role in precipitating PD onset, specifically in women, with a particular impact of life events related to interpersonal conflict or health-related issues (Barzega et al. 2001). As women are more often subject to sexual abuse (Kessler et al. 1995), this could explain the higher prevalence rate in females. In a retrospective study, it was found that childhood sexual abuse was reported more often in adult patients with PD than in healthy controls (Bandelow et al. 2002). However, over 90 % of panic patients in this study did not report forced sexual acts during their childhood. Moreover, there should be some caution to interpret the association of sexual abuse and panic disorder in a retrospective study as a direct causal relationship without considering possible mediator variables. Future studies are warranted to further elucidate possible gender-specific effects of life events on the development of PD (see Klauke et al. 2010 for a review).

Differences in the Expression of Fears

Could gender differences in anxiety disorders simply represent an underreporting of symptoms by males? Corresponding to their social role of being brave and fearless, men may feel more uncomfortable than women fully disclosing their distress for fear of being viewed as vulnerable or weak. Some data did not support gender differences in “courage,” but found differences in cognitive domains, e.g., in “anxiety sensitivity” (Schmidt and Koselka 2000). Anxiety sensitivity, a cognitive risk factor for panic psychopathology and an intermediate phenotype of pathological anxiety, refers to fears of anxiety-related sensations particularly pertaining to physical concerns (McNally 2002). Apart from genetic factors (see below), differences in anxiety sensitivity have been explained by socialization processes that encourage fearfulness in girls (Stewart et al. 1997).

If gender specificity was mainly a cultural phenomenon, it could be expected that the female-to-male ratio would be different in different cultures. However, PD was found to be relatively consistent, with a few exceptions, in rates and patterns across different countries and there are no major differences between different cultures regarding the female-to-male ratio (Weissman et al. 1997).

Evolutionary Perspectives

From an evolutionary perspective, fearless men may have had a survival benefit, as they were more successful in killing wild animals for nourishing themselves and their families and defending their territory and food resources against intruders (McDonald et al. 2012). Most aggressive acts are committed by males, as reflected by the fact that only 13 % of jail inmates are women (Minton 2013). On the other hand, women who were more anxious about their children may have been more successful in guaranteeing the survival of their offspring during the evolution of humankind. On the other hand, data testing evolutionary hypotheses have indicated that gender roles are surprisingly variable across time and space.

Neurobiological Factors

Several neurobiological mechanisms that may possibly be involved in the etiology of PD have been investigated with regard to their gender specificity. Elucidating the biological substrate of gender-specific susceptibility to panic disorder may help to better understand the etiology of anxiety disorders in general.

Serotonin

As most drugs used for the treatment of PD influence serotonergic neurotransmission, and alterations of the serotonin system have been found in panic patients relative to healthy controls, serotonin (5-HT) seems to be one of the most important neurotransmitters in the pathophysiology of PD (Bandelow et al. 2014). In general, women and men show differences in serotonin brain concentration, baseline serotonin production, and metabolism and availability of serotonin transporter (SERT) (Sramek and Cutler 2011). For example, in a positron emission tomography (PET) study, lower brain regional 5-HT synthesis was found in women (Sakai et al. 2006).

Some studies have investigated gender differences in serotonin systems in patients with PD. In a SPECT study, reduced SERT binding was found in different brain regions, including the raphe nuclei in mainly female patients with current but not remitted PD (Maron et al. 2004a). In a study measuring 5-HT_{1A} receptor binding using PET and the radioligand [carbonyl-¹¹C]WAY-100635, women did not differ from men (Stein et al. 2008). A study employing an improved design using positron emission tomography (PET) and ¹¹C-MADAM did not provide evidence for differential serotonin transporter binding in female patients vs. controls, but identified higher SERT nondisplaceable binding potential in several brain regions, including cortical and raphe areas, and lower SERT binding potential in the hippocampus in males with PD as compared with healthy males (Maron et al. 2011). This result was replicated in a study using PET and the SERT-selective radioligand ¹¹C-DASB, showing increased SERT binding potential in males with PD relative to male controls in the anterior cingulate cortex and midbrain, while no difference was discerned in the female sample (Cannon et al. 2013).

Beta-Adrenergic Sensitivity

An early study observed significant gender differences between patients with PD and controls in electrodermal activity and epinephrine levels before stress exposure (Braune et al. 1994). In a study on potential gender differences in beta-adrenergic receptor sensitivity potentially contributing to the pathophysiology of PD, beta-adrenergic receptor sensitivity was found in female but not in male patients (Kim et al. 2004).

Dopamine

In a female-only sample of patients with PD, striatal DAT binding was evaluated using single-photon emission computed tomography and the ¹²³I-nor-beta-CIT tracer. Significantly higher DAT binding in the striatum was detected in remitted PD females as compared with both currently ill PD and control females (Maron et al. 2010).

Altogether, findings on gender differences in serotonin, adrenergic, and dopamine neurotransmitter systems are sparse, and it is therefore difficult to deduce any conclusions on the etiology and treatment of panic disorder in women from these results.

Hypothalamic-Pituitary-Adrenal (HPA) Axis

Alterations of the hypothalamic-pituitary-adrenal (HPA) axis have been reported in panic patients, with, however, controversial findings. A few studies looked for gender differences in HPA axis activity. In a trial investigating urinary cortisol excretion before and after a randomized, controlled trial (paroxetine vs. placebo/exercise/relaxation) in patients with PD, females showed a significantly higher variability of cortisol excretion compared to males at pre- and post-assessments (Wedekind et al. 2008). When assessing salivary cortisol levels following a 35 % CO₂ challenge (see below) in PD patients compared to healthy volunteers as a measurement of HPA axis activity, higher cortisol values were found in male PD patients (van Duinen et al. 2004). A pilot study exploring gender differences in the relationships between HPA axis alterations and the panic-agoraphobic spectrum (Panic Agoraphobic Spectrum-Self Report lifetime version; PAS-SR) in healthy subjects reported positive correlations of the total PAS-SR score and the panic-like symptoms domain scores with the dehydroepiandrosterone-sulfate (DHEA-S)/cortisol ratio in women only (Dell'Osso et al. 2012).

Carbon Dioxide (CO₂) Hypersensitivity

Patients with PD are hypersensitive to carbon dioxide inhalation (Battaglia et al. 2008). According to Klein's false suffocation alarm theory (Klein 1993), PD may be due to a dysfunctional suffocation alarm monitor misfiring an evolved suffocation alarm system because panic patients are abnormally sensitive to CO₂. A study differentially investigating sensitivity to CO₂ challenge in female patients with PD depending on the menstrual phase reported significantly stronger panic reactions in the early follicular phase than in the midluteal phase (Perna et al. 1995). Also, inhalation of CO₂-enriched air elicited more panic symptoms in healthy women than in male probands (Kelly et al. 2006; Nillni et al. 2010).

Cholecystokinin (CCK) Sensitivity

Another well-established panicogenic test is a challenge with an agonist at the central subtype of the cholecystokinin receptor CCK-4 that produces panic attacks in up to 100 % of patients with PD and, depending on the dose, in up to 50 % of healthy subjects (see Bradwejn and Koszycki 2001; Zwanzger et al. 2012). A study investigating the modulatory role of the serotonin precursor 5-hydroxytryptophan (5-HTP) on response to a CCK-4 challenge in healthy probands revealed that in females 5-HTP lowered panic attack rates and related cognitive symptoms, while in males only somatic symptoms of panic were alleviated, suggesting a gender-dependent protective effect of 5-HTP in CCK-4 induced panic (Maron et al. 2004b). Also, a 3-day pretreatment with medroxyprogesterone acetate (MP) prior to injection with the CCK-4 analog pentagastrin decreased panic response in women with

PD (Le Melleo et al. 2001), while in a sample of healthy male probands pretreatment with the progestational hormone megestrol showed no significant effect on panic responses to CCK-4 challenge, but did reduce baseline ACTH and cortisol levels, as well as ACTH and cortisol levels after administration of CCK-4 (Raedler et al. 2006). Pre-challenge treatment of male patients with PD and male controls with ethinyl estradiol did not reduce panic response to pentagastrin challenge, but attenuated the challenge-associated increase in heart rate (McManus et al. 2001).

Altogether, the findings regarding CO₂ and CCK hypersensitivity suggest a contribution of female reproductive hormones (below).

Structural/Functional Neuroimaging

To date, only a few neuroimaging studies in PD have paid particular attention to potential gender-specific effects (for comprehensive review, see Dresler et al. 2013). In one structural imaging study using optimized voxel-based morphometry (VBM), a significant volume reduction in the dorsolateral and ventrolateral prefrontal cortices, thalamus, and parietal cortex was identified in females only. Furthermore, volume reduction in the right superior temporal gyrus was found to be greater in females, while reduction in the right amygdala and the bilateral insular cortex was significantly greater in male patients (Asami et al. 2009).

Functional neuroimaging studies have found significantly stronger activation in the amygdala, and increased connectivity of the amygdala, prefrontal, temporal, occipital cortical areas, the basal ganglia and the thalamus in women compared to men during the processing of facial expressions of negative (angry, fearful) emotions (Ohrmann et al. 2010).

Hormonal Factors

Female reproductive hormone-related events (i.e., menstrual cycle and postpartum period) can influence the course of PD (Pigott 1999; Le Melleo and Baker 2004). In animal models, female rats consistently showed greater increases in corticosterone and ACTH in response to acute and chronic stressors. These differences have generally been attributed to the activational effects of gonadal steroids on elements of the HPA axis in females (Young et al. 2001). In humans, estrogen and progesterone may influence mood by interacting with serotonin and norepinephrine neurotransmitter systems implicated in the treatment and pathophysiology of mood and anxiety disorders. Estrogen influences serotonin transporter sites, synthesis, receptor sensitivity, and metabolism of serotonin and decreases monoamine oxidase (MAO) activity (Chakravorty and Halbreich 1997; Seeman 1997; Halbreich 1997). It also enhances noradrenergic neurotransmission by influencing norepinephrine synthesis, responsiveness of the α_2 -adrenergic receptor, and metabolism of norepinephrine (Etgen and Karknias 1994; Schmidt et al. 1997; Halbreich 1997). Estrogen treatment may effectively treat (Gregoire et al. 1996), or prevent the recurrence (Sichel et al. 1995) of postpartum depression. Progesterone may have anxiolytic and sedative properties, mediated by benzodiazepine-like action at the GABA

receptor binding site (Paul and Purdy 1992), but may also lead to dysphoric and mood-destabilizing effects (Pigott 1999; Buckwalter et al. 1999).

Pregnancy

A number of retrospective studies and case series have shown improvement of PD during pregnancy in the majority of women (Cowley and Roy-Byrne 1989; Villeponteaux et al. 1992; Klein et al. 1994; Northcott and Stein 1994; Meshberg-Cohen and Svikis 2007; Guler et al. 2008), although in some studies women continued to experience panic attacks or even had worsening of panic disorder during pregnancy (Cohen et al. 1994a, 1996; Wisner et al. 1996; Verburg et al. 1994; Griez et al. 1995; Dannon et al. 2006). In a larger study, we also found fewer panic manifestations during pregnancy (Bandelow et al. 2006). Moreover, in another large study, pregnant women were less likely to have PD than nonpregnant women (Meshberg-Cohen and Svikis 2007). During the postpartum period, a deterioration of panic symptomatology has consistently been found (Cowley and Roy-Byrne 1989; Sholomskas et al. 1993; Northcott and Stein 1994; Cohen et al. 1994b, 1996; Bandelow et al. 2006).

The changes of panic manifestations during pregnancy and after childbirth may be explained by hormonal changes. During pregnancy, progesterone and estradiol concentrations rise to a maximum at term, when they are several hundred times higher than during the nonpregnancy period (Martin and Hoffman 1986). Around 4–5 days after delivery, there is a precipitate drop in hormone concentrations (Harris et al. 1994). This coincides with the peak symptoms of “maternity blues,” potentially induced by a consecutive increase in monoamine oxidase (MAO) activity (cf. Sacher et al. 2010). Accordingly, we found an accumulation of new panic manifestations in the first 5 days after childbirth. In addition, women who had never been pregnant were found to have more panic manifestations than those who had had previous pregnancies (Bandelow et al. 2006; Meshberg-Cohen and Svikis 2007). In female rats, estrogen has been shown to attenuate postpartum-induced anxiety-like behaviors (Furuta et al. 2013), further underlining the notion that the observed increase of anxiety after childbirth may be a consequence of hormonal changes.

Premenstrual Syndrome

Premenstrual dysphoric disorder (PMDD) is an extreme variant of premenstrual syndrome (PMS) and is characterized by a number of psychological symptoms, including depressed mood, anxiety, fatigue, irritability, affective lability, food cravings, sleep disturbances, and physical symptoms (e.g., headache). An exacerbation of preexisting depressive and anxiety disorders has been observed during the premenstrual phase.

PMS is responsive to anxiolytic drugs (e.g., SSRIs; Steiner et al. 2008). Patients with PMDD or PMS, like patients with PD, showed higher sensitivity to laboratory panic provocation challenges (CO₂ or lactate) and higher skin conductance responses to anxiety-provoking stimuli, suggesting that both conditions may share a pathophysiological link (Vickers and McNally 2004; Perna et al. 1995; Facchinetti et al. 1992).

The premenstrual phase is characterized by a high level of progesterone, a moderate level of estrogen, and a gradual rise in follicle stimulating hormone (FSH). At

the end of the premenstrual phase, progesterone and estrogen levels decline rapidly. Although no relationship between progesterone level and premenstrual symptoms has been found (Nillni et al. 2011), it is possible that the rapid decrease in progesterone at the end of the premenstrual phase may be associated with an increase in anxiety vulnerability.

The influence of progesterone on mood and anxiety in the premenstrual phase has also been explained by a periodic opioidergic deficit (Facchinetti et al. 1998) or modulation of γ -aminobutyric acid (GABA_A) receptors, which are involved in the control of anxiety, by allopregnanolone, a neuroactive metabolite of progesterone (Nillni et al. 2011).

Among postmenopausal women, panic attacks are relatively common and appear to be an independent risk factor for cardiovascular morbidity and mortality (Smoller et al. 2007). A placebo-controlled study investigating estrogen replacement therapy found no improvements in mood or anxiety symptoms in nondepressive, hysterectomized, postmenopausal women (Demetrio et al. 2011). It has been suggested that progesterone derivatives such as allopregnanolone and other female hormones may play a future role in developing agents for the treatment of anxiety disorders (Le Melleo and Baker 2004).

Altogether, there is a clear association between changes in female reproductive hormones and anxiety manifestations in patients with panic disorder.

Genetic Factors

In first-degree relatives of patients with PD, an up to threefold increased prevalence of the disorder was observed, which indicates significant familiarity (Maier et al. 1993; Nocon et al. 2008). Twin studies have proposed a considerable contribution of genetic factors to the pathogenesis of PD, with heritability estimates ranging from 30 to 48 % for PD and over 50 % for agoraphobia (Hettema et al. 2001; Kessler et al. 2005). For “anxiety sensitivity,” a risk factor for PD, considerable heritability (37–48 %) has been reported in females only (Jang et al. 1999), although not all studies are consistent (van Beek and Griez 2003).

Segregation analyses have failed to identify a Mendelian mode of inheritance, and this points to a complex genetic inheritance with an interaction of multiple “risk genes,” each having only a minor individual influence, together with environmental influences (Vieland et al. 1996).

The most robustly identified risk genes of PD to date are the genes coding for the catechol-O-methyltransferase (COMT), the monoamine oxidase A (MAO_A), the serotonin receptor 1A (5-HT_{1A}), the cholecystokinin B (CCK_B) receptor, the adenosine A_{2A} receptor (ADORA_{2A}), and the neuropeptide S receptor (NPSR₁) (Deckert et al. 1998, 1999; Domschke et al. 2004, 2007, 2011; Hamilton et al. 2002, 2004; Hosing et al. 2004; Kennedy et al. 1999; Reif et al. 2012; Rothe et al. 2006; Samochowiec et al. 2004; Domschke and Deckert 2012). Interestingly, several female-specific genetic associations have been reported, with the most compelling evidence for the functional val158met polymorphism in the catechol-O-methyltransferase (COMT)

gene, which codes for one of the major methylation enzymes metabolizing monoaminergic neurotransmitters including norepinephrine and dopamine (Domschke et al. 2004, 2007; Hamilton et al. 2002; Samochowiec et al. 2004). This gender-specific finding – potentially mediated by a gene–estrogen interaction (Harrison and Tunbridge 2008; Tunbridge et al. 2008) – is mentioned in the section “Gender-related diagnostic issues” in the chapter on PD in the DSM-5 (APA 2013, p. 212): “There is some evidence for sexual dimorphism, with an association between PD and the catechol-O-methyltransferase (COMT) gene in females only.” Furthermore, the longer, more active alleles of a functional variable number tandem repeat polymorphism (VNTR) in the monoamine oxidase A (MAO_A) gene have repeatedly been found to be associated with panic disorder specifically in females, which may be due to the fact that the MAO_A gene is located on the X chromosome (Deckert et al. 1999; Maron et al. 2004b, 2005, 2007; Reif et al. 2012; Samochowiec et al. 2004). Furthermore, the risk-increasing effects of variation in the tryptophan hydroxylase 2 (TPH₂) (Maron et al. 2007), the neuropeptide S receptor (NPSR₁) (Domschke et al. 2011), the neuropeptide Y₅ receptor (NPY_{Y5}) (Domschke et al. 2008), the glutamate decarboxylase 1 (GAD₁) (Weber et al. 2012), and the hypocretin receptor 2 (HCRTR₂) (Annerbrink et al. 2011) genes on PD or CCK-4 induced panic attacks seem to be female-specific. Finally, genes involved in or interacting with sex hormones have been reported to influence the risk for PD in a potentially female-specific fashion, e.g., the gene for the aldo-keto reductase family 1 C₁ (AKR1C₁), most likely through changes in progesterone and allopregnanolone levels within and outside the brain (Quast et al. 2014), the gene coding for galanin (GAL) involved in hypothalamic-hypophysiotropic signaling, cosecreted with luteinizing hormone-releasing hormone and possibly acting as a mediator of estrogen action (Unschuld et al. 2008, 2010) or the progesterone receptor gene (PROG) (Ho et al. 2004). The role of female reproductive hormones is further supported by the association between anxiety disorders and estrogen ESR1 and ESR2 polymorphisms in older women (Ryan et al. 2011).

A potential male-specific genetic risk factor in the pathogenesis of PD has repeatedly been suggested for the functional insertion-deletion polymorphisms (I/D) in the angiotensin I-converting enzyme (ACE) gene (Bandelow et al. 2010; Bayoglu et al. 2012; Olsson et al. 2004).

Recently, epigenetic mechanisms such as DNA methylation have been proposed to potentially mediate the interaction between genetic and environmental factors. The first epigenetic study in PD suggests a female-specific association of monoamine oxidase A (MAO_A) gene DNA hypomethylation with PD, potentially mediating a detrimental influence of negative life events, while MAO_A hypermethylation – possibly conferred by positive life events – has been hypothesized to increase resilience towards the disorder (Domschke et al. 2012).

Treatment-genetic studies investigating the genetically controlled variation in therapy response reported the 5-HTT, 5-HT_{1A}, COMT, and MAO_A genes to influence the response to treatment with selective serotonin reuptake inhibitors (SSRIs) (Perna et al. 2005; Saeki et al. 2009; Yevtushenko et al. 2010) or cognitive-behavioral therapy (Lonsdorf et al. 2010; Reif et al. 2013) in PD. Also, in such studies, some

of these effects were female-specific/-dominant, e.g., for the 5-HTT gene in mediating response to treatment with paroxetine (Perna et al. 2005) or the MAO_A gene in driving response to cognitive-behavioral therapy (Reif et al. 2013).

Pharmacotherapy and Psychotherapy

Current first-line treatments for panic disorder are the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (Bandelow et al. 2008).

Psychotropic medications are more likely to be prescribed to women (Pigott 1999). This may simply be an expression of the higher frequency and severity of the treated disorders (depression, anxiety).

There are some issues that have to be taken into account when treating women with panic disorder. Randomized dose finding studies with psychopharmacological drugs usually do not differentiate between men and women, due to the statistical problems arising from multiple testing. Thus, dose recommendations for these drugs do not take gender differences in body weight, volume distribution, or pharmacokinetics into account. In a number of studies examining pharmacokinetic differences in patients taking antidepressants, higher plasma concentrations, greater volume distribution, greater elimination half-time, and other pharmacokinetic changes were found in women (Frackiewicz et al. 2000; Sramek and Cutler 2011).

However, it is not clear whether these differences affect treatment outcome. In one study, there was a modest trend for women with PD to show superior efficacy at the end of acute sertraline treatment (Clayton et al. 2006). In depression trials, most studies did not find significant differences in treatment response between men and women (Young et al. 2009; Kornstein et al. 2000, 2010).

Among psychological therapies, cognitive-behavioral therapy (CBT) is the most comprehensively studied method for treatment of panic disorder, according to multiple randomized controlled studies (Bandelow et al. 2008). There are no controlled studies showing that gender can moderate outcome of psychotherapy or suggesting specific therapeutic strategies for women with panic disorder.

Conclusion

It is most likely that higher anxiety susceptibility in women is due to a delicate interplay between psychosocial and neurobiological factors. Hypotheses about the role of gender-specific stressors, and gender differences in the expression of fears warrant further investigation. Sex-specific variance has been identified in numerous neurotransmitter systems. The serotonin system may be of particular importance, as most drugs used in the treatment of panic disorder enhance serotonin neurotransmission and alterations in the serotonergic system have been found in panic patients relative to healthy controls. It seems likely that female sex hormones are involved, as periods of fluctuating levels of estrogen and progesterone have been linked to increase or decrease of panic symptomatology.

There is converging support for a considerable genetic influence on the pathogenesis of PD with several genes, particularly the COMT and MAO_A genes, driving the disease risk in a female-specific manner. However, it is still not comprehensively understood how these genes act to confer disease risk on a functional level, in interaction with one other as well as with environmental factors. Therefore, the currently identified genetic risk factors are of limited diagnostic or predictive value. However, genetic research may encourage further biochemical, physiological, or pharmacological efforts to develop innovative drugs for the treatment of PD, preferably in an individually tailored and gender-specific manner.

Identification of the psychosocial contributors and the biological substrates of gender-specific susceptibility for PD may be useful for better understanding the etiology of anxiety disorders in general.

Although gender differences have been found in the metabolism of anxiolytic drugs, it remains unclear whether this significantly affects treatment outcome. When treating panic disorder during pregnancy and lactation, a number of safety considerations have to be taken into account.

References

- Andrade L, Eaton WW, Chilcoat HD (1996) Lifetime co-morbidity of panic attacks and major depression in a population-based study: age of onset. *Psychol Med* 26(5):991–996
- Annerbrink K, Westberg L, Olsson M, Andersch S, Sjodin I, Holm G, Allgulander C, Eriksson E (2011) Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene. *Psychiatr Genet* 21(2):85–89. doi:10.1097/YPG.0b013e328341a3db
- APA (2013) Diagnostic and statistical manual of mental disorders (DSM-5™), 5th edn. American Psychiatric Association, Washington, DC
- Asami T, Yamasue H, Hayano F, Nakamura M, Uehara K, Otsuka T, Roppongi T, Nihashi N, Inoue T, Hirayasu Y (2009) Sexually dimorphic gray matter volume reduction in patients with panic disorder. *Psychiatry Res* 173(2):128–134. doi:10.1016/j.psychres.2008.10.004
- Bandelow B (1999) Panic and agoraphobia scale (PAS): manual. Hogrefe & Huber Pub, Seattle
- Bandelow B, Spath C, Tichauer GA, Broocks A, Hajak G, Ruther E (2002) Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder. *Compr Psychiatry* 43(4):269–278. doi:10.1053/comp.2002.33492
- Bandelow B, Sojka F, Broocks A, Hajak G, Bleich S, Ruther E (2006) Panic disorder during pregnancy and postpartum period. *Eur Psychiatry* 21(7):495–500
- Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicium R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lepine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. *World J Biol Psychiatry* 9(4):248–312. doi:10.1080/15622970802465807, 904748294 [pii]
- Bandelow B, Saleh K, Pauls J, Domschke K, Wedekind D, Falkai P (2010) Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: a gender-specific effect? *World J Biol Psychiatry* 11(1):66–70. doi:10.3109/15622970701459810
- Bandelow B, Domschke K, Baldwin D (2014) Panic disorder and agoraphobia (Oxford Psychiatry Library). Oxford University Press, Oxford

- Barzega G, Maina G, Venturello S, Bogetto F (2001) Gender-related differences in the onset of panic disorder. *Acta Psychiatr Scand* 103(3):189–195
- Battaglia M, Pesenti-Gritti P, Spatola CA, Ogliari A, Tamba K (2008) A twin study of the common vulnerability between heightened sensitivity to hypercapnia and panic disorder. *Am J Med Genet B Neuropsychiatr Genet* 147B(5):586–593. doi:[10.1002/ajmg.b.30647](https://doi.org/10.1002/ajmg.b.30647)
- Bayoglu B, Cengiz M, Karacetin G, Uysal O, Kocabasoglu N, Bayar R, Balcioglu I (2012) Genetic polymorphism of angiotensin I-converting enzyme (ACE), but not angiotensin II type I receptor (ATr1), has a gender-specific role in panic disorder. *Psychiatry Clin Neurosci* 66(2):130–137. doi:[10.1111/j.1440-1819.2011.02318.x](https://doi.org/10.1111/j.1440-1819.2011.02318.x)
- Belle D, Doucet J (2003) Poverty, inequality, and discrimination as sources of depression among US women. *Psychol Women Q* 27(2):101–113. doi:[10.1111/1471-6402.00090](https://doi.org/10.1111/1471-6402.00090)
- Bradwejn J, Koszycki D (2001) Cholecystokinin and panic disorder: past and future clinical research strategies. *Scand J Clin Lab Invest Suppl* 234:19–27
- Braune S, Albus M, Frohler M, Hohn T, Scheibe G (1994) Psychophysiological and biochemical changes in patients with panic attacks in a defined situational arousal. *Eur Arch Psychiatry Clin Neurosci* 244(2):86–92
- Buckwalter JG, Stanczyk FZ, McCleary CA, Bluestein BW, Buckwalter DK, Rankin KP, Chang L, Goodwin TM (1999) Pregnancy, the postpartum, and steroid hormones: effects on cognition and mood. *Psychoneuroendocrinology* 24(1):69–84
- Cannon DM, Klaver JM, Klug SA, Carlson PJ, Luckenbaugh DA, Ichise M, Drevets WC (2013) Gender-specific abnormalities in the serotonin transporter system in panic disorder. *Int J Neuropsychopharmacol* 16(4):733–743. doi:[10.1017/S1461145712000776](https://doi.org/10.1017/S1461145712000776)
- Chakravorty SG, Halbreich U (1997) The influence of estrogen on monoamine oxidase activity. *Psychopharmacol Bull* 33(2):229–233
- Clayton AH, Stewart RS, Fayyad R, Clary CM (2006) Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies. *Arch Womens Ment Health* 9(3):151–157. doi:[10.1007/s00737-005-0111-y](https://doi.org/10.1007/s00737-005-0111-y)
- Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF (1994a) Impact of pregnancy on panic disorder: a case series. *J Clin Psychiatry* 55(7):284–288
- Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF (1994b) Postpartum course in women with preexisting panic disorder. *J Clin Psychiatry* 55(7):289–292
- Cohen LS, Sichel DA, Faraone SV, Robertson LM, Dimmock JA, Rosenbaum JF (1996) Course of panic disorder during pregnancy and the puerperium: a preliminary study. *Biol Psychiatry* 39(11):950–954
- Cowley DS, Roy-Byrne PP (1989) Panic disorder during pregnancy. *J Psychosom Obstet Gynaecol* 10:193–210
- Dannon PN, Iancu I, Lowengrub K, Grunhaus L, Kotler M (2006) Recurrence of panic disorder during pregnancy: a 7-year naturalistic follow-up study. *Clin Neuropharmacol* 29(3):132–137. doi:[10.1097/01.WNF.0000220821.73017.14](https://doi.org/10.1097/01.WNF.0000220821.73017.14)
- Deckert J, Nothen MM, Franke P, Delmo C, Fritze J, Knapp M, Maier W, Beckmann H, Propping P (1998) Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. *Mol Psychiatry* 3(1):81–85
- Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D, Nothen MM, Maffei P, Franke P, Fritze J, Maier W, Propping P, Beckmann H, Bellodi L, Lesch KP (1999) Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. *Hum Mol Genet* 8(4):621–624
- Dell’Osso L, Marazziti D, Da Pozzo E, Conversano C, Baroni S, Massimetti G, Martini C, Carmassi C (2012) Gender effect on the relationship between stress hormones and panic-agoraphobic spectrum dimensions in healthy subjects. *CNS Spectr* 17(4):214–220. doi:[10.1017/S1092852912000685](https://doi.org/10.1017/S1092852912000685)
- Demetrio FN, Renno J Jr, Gianfaldoni A, Goncalves M, Halbe HW, Filho AH, Gorenstein C (2011) Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women: a randomized double-blind, controlled study. *Arch Womens Ment Health* 14(6):479–486. doi:[10.1007/s00737-011-0241-3](https://doi.org/10.1007/s00737-011-0241-3)

- Domschke K, Deckert J (2012) Genetics of anxiety disorders – status quo and quo vadis. *Curr Pharm Des* 18(35):5691–5698
- Domschke K, Freitag CM, Kühlenbaumer G, Schirmacher A, Sand P, Nyhuis P, Jacob C, Fritze J, Franke P, Rietschel M, Garritsen HS, Fimmers R, Nothen MM, Lesch KP, Stogbauer F, Deckert J (2004) Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. *Int J Neuropsychopharmacol* 7(2):183–188
- Domschke K, Deckert J, O'Donovan MC, Glatt SJ (2007) Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. *Am J Med Genet B Neuropsychiatr Genet* 144(5):667–673
- Domschke K, Hohoff C, Jacob C, Maier W, Fritze J, Bandelow B, Krakowitzky P, Kastner F, Rothermundt M, Arolt V, Deckert J (2008) Chromosome 4q31-34 panic disorder risk locus: association of neuropeptide Y Y5 receptor variants. *Am J Med Genet B Neuropsychiatr Genet* 147B(4):510–516. doi:[10.1002/ajmg.b.30629](https://doi.org/10.1002/ajmg.b.30629)
- Domschke K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P, Pedersen A, Bauer J, Suslow T, Kugel H, Heindel W, Baumann C, Klauke B, Jacob C, Maier W, Fritze J, Bandelow B, Krakowitzky P, Rothermundt M, Erhardt A, Binder EB, Holsboer F, Gerlach AL, Kircher T, Lang T, Alpers GW, Strohle A, Fehm L, Gloster AT, Wittchen HU, Arolt V, Pauli P, Hamm A, Deckert J (2011) Neuropeptide S receptor gene – converging evidence for a role in panic disorder. *Mol Psychiatry* 16(9):938–948. doi:[10.1038/mp.2010.81](https://doi.org/10.1038/mp.2010.81)
- Domschke K, Tidow N, Kuithan H, Schwarte K, Klauke B, Ambree O, Reif A, Schmidt H, Arolt V, Kersting A, Zwanzger P, Deckert J (2012) Monoamine oxidase A gene DNA hypomethylation – a risk factor for panic disorder? *Int J Neuropsychopharmacol* 15(9):1217–1228. doi:[10.1017/S146114571200020X](https://doi.org/10.1017/S146114571200020X)
- Dresler T, Guhn A, Tupak SV, Ehliis AC, Herrmann MJ, Fallgatter AJ, Deckert J, Domschke K (2013) Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder. *J Neural Transm* 120(1):3–29. doi:[10.1007/s00702-012-0811-1](https://doi.org/10.1007/s00702-012-0811-1)
- Etgen AM, Karknias GB (1994) Estrogen regulation of noradrenergic signaling in the hypothalamus. *Psychoneuroendocrinology* 19(5–7):603–610
- Facchinetti F, Romano G, Fava M, Genazzani AR (1992) Lactate infusion induces panic attacks in patients with premenstrual syndrome. *Psychosom Med* 54(3):288–296
- Facchinetti F, Tarabusi M, Nappi G (1998) Premenstrual syndrome and anxiety disorders: a psychobiological link. *Psychother Psychosom* 67(2):57–60
- Frackiewicz EJ, Sramek JJ, Cutler NR (2000) Gender differences in depression and antidepressant pharmacokinetics and adverse events. *Ann Pharmacother* 34(1):80–88
- Furuta M, Numakawa T, Chiba S, Ninomiya M, Kajiyama Y, Adachi N, Akema T, Kunugi H (2013) Estrogen, predominantly via estrogen receptor alpha, attenuates postpartum-induced anxiety- and depression-like behaviors in female rats. *Endocrinology* 154(10):3807–3816. doi:[10.1210/en.2012-2136](https://doi.org/10.1210/en.2012-2136)
- Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW (1996) Transdermal oestrogen for treatment of severe postnatal depression. *Lancet* 347(9006):930–933
- Griez EJ, Hauer R, Meijer J (1995) Pregnancy and estrogen-induced panic. *Am J Psychiatry* 152(11):1688
- Guler O, Koken GN, Emul M, Ozbulut O, Gecici O, Uguz F, Gezginc K, Zeytinci IE, Karatayli S, Askin R (2008) Course of panic disorder during the early postpartum period: a prospective analysis. *Compr Psychiatry* 49(1):30–34. doi:[10.1016/j.comppsy.2007.06.007](https://doi.org/10.1016/j.comppsy.2007.06.007)
- Halbreich U (1997) Hormonal interventions with psychopharmacological potential: an overview. *Psychopharmacol Bull* 33(2):281–286
- Hamilton SP, Slager SL, Heiman GA, Deng Z, Haghighi F, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA (2002) Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. *Biol Psychiatry* 51(7):591–601
- Hamilton SP, Slager SL, De Leon AB, Heiman GA, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA (2004) Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. *Neuropsychopharmacology* 29(3):558–565. doi:[10.1038/sj.npp.1300311](https://doi.org/10.1038/sj.npp.1300311)

- Harris B, Lovett L, Newcombe RG, Read GF, Walker R, Riad-Fahmy D (1994) Maternity blues and major endocrine changes: Cardiff puerperal mood and hormone study II. *BMJ* 308(6934):949–953
- Harrison PJ, Tunbridge EM (2008) Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. *Neuropsychopharmacology* 33(13):3037–3045. doi:[10.1038/sj.npp.1301543](https://doi.org/10.1038/sj.npp.1301543)
- Hettema JM, Neale MC, Kendler KS (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. *Am J Psychiatry* 158(10):1568–1578
- Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS (2005) The structure of genetic and environmental risk factors for anxiety disorders in men and women. *Arch Gen Psychiatry* 62(2):182–189. doi:[10.1001/archpsyc.62.2.182](https://doi.org/10.1001/archpsyc.62.2.182)
- Ho HP, Westberg L, Annerbrink K, Olsson M, Melke J, Nilsson S, Baghaei F, Rosmond R, Holm G, Bjornorp P, Andersch S, Allgulander C, Eriksson E (2004) Association between a functional polymorphism in the progesterone receptor gene and panic disorder in women. *Psychoneuroendocrinology* 29(9):1138–1141. doi:[10.1016/j.psypneuen.2004.01.005](https://doi.org/10.1016/j.psypneuen.2004.01.005)
- Hosing VG, Schirmacher A, Kuhlenthal G, Freitag C, Sand P, Schlesiger C, Jacob C, Fritze J, Franke P, Rietschel M, Garritsen H, Nothen MM, Fimmers R, Stogbauer F, Deckert J (2004) Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. *J Neural Transm Suppl* 68:147–156
- Jang KL, Stein MB, Taylor S, Livesley WJ (1999) Gender differences in the etiology of anxiety sensitivity: a twin study. *J Genet Specif Med* 2(2):39–44
- Kelly MM, Forsyth JP, Karekla M (2006) Sex differences in response to a panicogenic challenge procedure: an experimental evaluation of panic vulnerability in a non-clinical sample. *Behav Res Ther* 44(10):1421–1430. doi:[10.1016/j.brat.2005.10.012](https://doi.org/10.1016/j.brat.2005.10.012)
- Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J, Fourie O (1999) Investigation of cholecystokinin system genes in panic disorder. *Mol Psychiatry* 4(3):284–285
- Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995) Posttraumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry* 52(12):1048–1060
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 62(6):593–602
- Kim YR, Min SK, Yu BH (2004) Differences in beta-adrenergic receptor sensitivity between women and men with panic disorder. *Eur Neuropsychopharmacol* 14(6):515–520. doi:[10.1016/j.euroneuro.2004.03.004](https://doi.org/10.1016/j.euroneuro.2004.03.004)
- Klauke B, Deckert J, Reif A, Pauli P, Domschke K (2010) Life events in panic disorder—an update on “candidate stressors”. *Depress Anxiety* 27(8):716–730. doi:[10.1002/da.20667](https://doi.org/10.1002/da.20667)
- Klein DF (1993) False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. *Arch Gen Psychiatry* 50(4):306–317
- Klein DF, Skrobala AM, Garfinkel RS (1994) Preliminary look at the effects of pregnancy on the course of panic disorder. *Anxiety* 1(5):227–232
- Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB (2000) Gender differences in treatment response to sertraline versus imipramine in chronic depression. *Am J Psychiatry* 157(9):1445–1452
- Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ (2010) Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. *J Clin Psychopharmacol* 30(3):294–299. doi:[10.1097/JCP.0b013e3181dcb594](https://doi.org/10.1097/JCP.0b013e3181dcb594)
- Le Melleo JM, Baker G (2004) Role of progesterone and other neuroactive steroids in anxiety disorders. *Expert Rev Neurother* 4(5):851–860. doi:[10.1586/14737175.4.5.851](https://doi.org/10.1586/14737175.4.5.851)
- Le Melleo J, Jhangri GS, Lott P, Tait GR, McManus K, Geddes M, Chrapko W, Lara N (2001) Effect of medroxyprogesterone pretreatment on pentagastrin-induced panic symptoms in females with panic disorder. *Psychiatry Res* 101(3):237–242
- Lonsdorf TB, Ruck C, Bergstrom J, Andersson G, Ohman A, Lindfors N, Schalling M (2010) The COMT Val158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. *BMC Psychiatry* 10:99. doi:[10.1186/1471-244X-10-99](https://doi.org/10.1186/1471-244X-10-99)

- Maier W, Lichtermann D, Minges J, Oehrlein A, Franke P (1993) A controlled family study in panic disorder. *J Psychiatr Res* 27(Suppl 1):79–87
- Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J (2004a) Reduced brain serotonin transporter binding in patients with panic disorder. *Psychiatry Res* 132(2):173–181. doi:[10.1016/j.psychres.2003.10.004](https://doi.org/10.1016/j.psychres.2003.10.004)
- Maron E, Tasa G, Toru I, Lang A, Vasar V, Shlik J (2004b) Association between serotonin-related genetic polymorphisms and CCK-4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers. *World J Biol Psychiatry* 5(3):149–154
- Maron E, Lang A, Tasa G, Liivlaid L, Toru I, Must A, Vasar V, Shlik J (2005) Associations between serotonin-related gene polymorphisms and panic disorder. *Int J Neuropsychopharmacol* 8(2):261–266. doi:[10.1017/S1461145704004985](https://doi.org/10.1017/S1461145704004985)
- Maron E, Toru I, Must A, Tasa G, Toover E, Vasar V, Lang A, Shlik J (2007) Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. *Neurosci Lett* 411(3):180–184. doi:[10.1016/j.neulet.2006.09.060](https://doi.org/10.1016/j.neulet.2006.09.060)
- Maron E, Nutt DJ, Kuikka J, Tiihonen J (2010) Dopamine transporter binding in females with panic disorder may vary with clinical status. *J Psychiatr Res* 44(1):56–59. doi:[10.1016/j.jpsychires.2009.04.014](https://doi.org/10.1016/j.jpsychires.2009.04.014)
- Maron E, Toru I, Hirvonen J, Tuominen L, Lumme V, Vasar V, Shlik J, Nutt DJ, Helin S, Nagren K, Tiihonen J, Hietala J (2011) Gender differences in brain serotonin transporter availability in panic disorder. *J Psychopharmacol (Oxford, England)* 25(7):952–959. doi:[10.1177/0269881110389207](https://doi.org/10.1177/0269881110389207)
- Martin MC, Hoffman PG (1986) The endocrinology of pregnancy. In: Greenspan FS, Forsham PH (eds) *Basic and clinical endocrinology*, 2nd edn. Lange, Los Altos, pp 476–500
- McDonald MM, Navarrete CD, Van Vugt M (2012) Evolution and the psychology of intergroup conflict: the male warrior hypothesis. *Philos Trans R Soc Lond B Biol Sci* 367(1589):670–679. doi:[10.1098/rstb.2011.0301](https://doi.org/10.1098/rstb.2011.0301)
- McManus K, Tait GR, Bellavance F, Le Melleo JM (2001) Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin. *J Affect Disord* 66(2–3):273–279
- McNally RJ (2002) Anxiety sensitivity and panic disorder. *Biol Psychiatry* 52(10):938–946
- Meshberg-Cohen S, Svikis D (2007) Panic disorder, trait anxiety, and alcohol use in pregnant and nonpregnant women. *Compr Psychiatry* 48(6):504–510. doi:[10.1016/j.comppsy.2007.06.004](https://doi.org/10.1016/j.comppsy.2007.06.004)
- Minton TD (2013) Jail inmates at midyear 2012 – statistical tables. U.S. Department of Justice, Bureau of Justice Statistics, Washington, DC
- Nilni YI, Rohan KJ, Bernstein A, Zvolensky MJ (2010) Premenstrual distress predicts panic-relevant responding to a CO₂ challenge among young adult females. *J Anxiety Disord* 24(4):416–422. doi:[10.1016/j.janxdis.2010.02.006](https://doi.org/10.1016/j.janxdis.2010.02.006)
- Nilni YI, Toufexis DJ, Rohan KJ (2011) Anxiety sensitivity, the menstrual cycle, and panic disorder: a putative neuroendocrine and psychological interaction. *Clin Psychol Rev* 31(7):1183–1191. doi:[10.1016/j.cpr.2011.07.006](https://doi.org/10.1016/j.cpr.2011.07.006)
- Nocon A, Wittchen HU, Beesdo K, Bruckl T, Hofler M, Pfister H, Zimmermann P, Lieb R (2008) Differential familial liability of panic disorder and agoraphobia. *Depress Anxiety* 25(5):422–434. doi:[10.1002/da.20425](https://doi.org/10.1002/da.20425)
- Northcott CJ, Stein MB (1994) Panic disorder in pregnancy. *J Clin Psychiatry* 55(12):539–542
- Ohrmann P, Pedersen A, Braun M, Bauer J, Kugel H, Kersting A, Domschke K, Deckert J, Suslow T (2010) Effect of gender on processing threat-related stimuli in patients with panic disorder: sex does matter. *Depress Anxiety* 27(11):1034–1043. doi:[10.1002/da.20721](https://doi.org/10.1002/da.20721)
- Olsson M, Annerbrink K, Westberg L, Melke J, Baghaei F, Rosmond R, Holm G, Andersch S, Allgulander C, Eriksson E (2004) Angiotensin-related genes in patients with panic disorder. *Am J Med Genet B Neuropsychiatr Genet* 127(1):81–84
- Paul SM, Purdy RH (1992) Neuroactive steroids. *FASEB J* 6(6):2311–2322
- Perna G, Brambilla F, Arancio C, Bellodi L (1995) Menstrual cycle-related sensitivity to 35 % CO₂ in panic patients. *Biol Psychiatry* 37(8):528–532. doi:[10.1016/0006-3223\(94\)00154-U](https://doi.org/10.1016/0006-3223(94)00154-U)
- Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L (2005) Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. *Neuropsychopharmacology* 30(12):2230–2235. doi:[10.1038/sj.npp.1300822](https://doi.org/10.1038/sj.npp.1300822)

- Pigott TA (1999) Gender differences in the epidemiology and treatment of anxiety disorders. *J Clin Psychiatry* 60(Suppl 18):4–15
- Quast C, Reif A, Bruckl T, Pfister H, Weber H, Mattheisen M, Cichon S, Lang T, Hamm A, Fehm L, Strohle A, Arolt V, Domschke K, Kircher T, Wittchen HU, Pauli P, Gerlach AL, Alpers GW, Deckert J, Rupprecht R, Binder EB, Erhardt A (2014) Gender-specific association of variants in the *Akr1c1* gene with dimensional anxiety in patients with panic disorder: additional evidence for the importance of neurosteroids in anxiety? *Depress Anxiety*. doi:10.1002/da.22229
- Raedler TJ, Jahn H, Goedecken B, Gescher DM, Kellner M, Wiedemann K (2006) Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. *Depress Anxiety* 23(3):139–144. doi:10.1002/da.20147
- Reif A, Weber H, Domschke K, Klauke B, Baumann C, Jacob CP, Strohle A, Gerlach AL, Alpers GW, Pauli P, Hamm A, Kircher T, Arolt V, Wittchen HU, Binder EB, Erhardt A, Deckert J (2012) Meta-analysis argues for a female-specific role of MAOA-uVNTR in panic disorder in four European populations. *Am J Med Genet B Neuropsychiatr Genet* 159B(7):786–793. doi:10.1002/ajmg.b.32085
- Reif A, Richter J, Straube B, Hofler M, Lueken U, Gloster AT, Weber H, Domschke K, Fehm L, Strohle A, Jansen A, Gerlach A, Pyka M, Reinhardt I, Konrad C, Wittmann A, Pfeleiderer B, Alpers GW, Pauli P, Lang T, Arolt V, Wittchen HU, Hamm A, Kircher T, Deckert J (2013) MAOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. *Mol Psychiatry*. doi:10.1038/mp.2012.172
- Rothe C, Koszycki D, Bradwejn J, King N, Deluca V, Tharmalingam S, Macciardi F, Deckert J, Kennedy JL (2006) Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. *Neuropsychopharmacology* 31(10):2237–2242
- Ryan J, Scali J, Carriere I, Scarabin PY, Ritchie K, Ancelin ML (2011) Estrogen receptor gene variants are associated with anxiety disorders in older women. *Psychoneuroendocrinology* 36(10):1582–1586. doi:10.1016/j.psyneuen.2011.04.011
- Sacher J, Wilson AA, Houle S, Rusjan P, Hassan S, Bloomfield PM, Stewart DE, Meyer JH (2010) Elevated brain monoamine oxidase A binding in the early postpartum period. *Arch Gen Psychiatry* 67(5):468–474. doi:10.1001/archgenpsychiatry.2010.32
- Saeki Y, Watanabe T, Ueda M, Saito A, Akiyama K, Inoue Y, Hirokane G, Morita S, Yamada N, Shimoda K (2009) Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. *Eur J Clin Pharmacol* 65(7):685–691. doi:10.1007/s00228-009-0633-8
- Sakai Y, Nishikawa M, Leyton M, Benkelfat C, Young SN, Diksic M (2006) Cortical trapping of alpha-[(11)C]methyl-l-tryptophan, an index of serotonin synthesis, is lower in females than males. *Neuroimage* 33(3):815–824. doi:10.1016/j.neuroimage.2006.08.004
- Samochowiec J, Hajduk A, Samochowiec A, Horodnicki J, Stepień G, Grzywacz A, Kucharska-Mazur J (2004) Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. *Psychiatry Res* 128(1):21–26. doi:10.1016/j.psychres.2004.05.012
- Schmidt NB, Koselka M (2000) Gender differences in patients with panic disorder: evaluating cognitive mediation of phobic avoidance. *Cogn Ther Res* 24(5):533–550. doi:10.1023/A:1005562011960
- Schmidt ME, Matochik JA, Goldstein DS, Schouten JL, Zametkin AJ, Potter WZ (1997) Gender differences in brain metabolic and plasma catecholamine responses to alpha 2-adrenoceptor blockade. *Neuropsychopharmacology* 16(4):298–310
- Seeman MV (1997) Psychopathology in women and men: focus on female hormones. *Am J Psychiatry* 154(12):1641–1647
- Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA (1997) Multicenter collaborative panic disorder severity scale. *Am J Psychiatry* 154(11):1571–1575
- Sholomskas DE, Wickamaratne PJ, Dogolo L, O'Brien DW, Leaf PJ, Woods SW (1993) Postpartum onset of panic disorder: a coincidental event? *J Clin Psychiatry* 54(12):476–480
- Sichel DA, Cohen LS, Robertson LM, Rutenberg A, Rosenbaum JF (1995) Prophylactic estrogen in recurrent postpartum affective disorder. *Biol Psychiatry* 38(12):814–818

- Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, Oberman A, Wong ND, Sheps D (2007) Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. *Arch Gen Psychiatry* 64(10):1153–1160. doi:[10.1001/archpsyc.64.10.1153](https://doi.org/10.1001/archpsyc.64.10.1153)
- Sramek JJ, Cutler NR (2011) The impact of gender on antidepressants. *Curr Top Behav Neurosci* 8:231–249. doi:[10.1007/7854_2010_118](https://doi.org/10.1007/7854_2010_118)
- Stein P, Savli M, Wadsak W, Mitterhauser M, Fink M, Spindelegger C, Mien LK, Moser U, Dudczak R, Kletter K, Kasper S, Lanzenberger R (2008) The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. *Eur J Nucl Med Mol Imaging* 35(12):2159–2168. doi:[10.1007/s00259-008-0850-x](https://doi.org/10.1007/s00259-008-0850-x)
- Steiner M, Ravindran AV, LeMelleo JM, Carter D, Huang JO, Anonychuk AM, Simpson SD (2008) Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. *J Clin Psychiatry* 69(6):991–998
- Stewart SH, Taylor S, Baker JM (1997) Gender differences in dimensions of anxiety sensitivity. *J Anxiety Disord* 11(2):179–200
- Tunbridge EM, Harrison PJ, Warden DR, Johnston C, Refsum H, Smith AD (2008) Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels. *Am J Med Genet B Neuropsychiatr Genet* 147B(6):996–999. doi:[10.1002/ajmg.b.30700](https://doi.org/10.1002/ajmg.b.30700)
- Unschuld PG, Ising M, Erhardt A, Lucae S, Kohli M, Kloiber S, Salyakina D, Thoeninger CK, Kern N, Lieb R, Uhr M, Binder EB, Muller-Myhsok B, Holsboer F, Keck ME (2008) Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. *J Affect Disord* 105(1–3):177–184
- Unschuld PG, Ising M, Roeske D, Erhardt A, Specht M, Kloiber S, Uhr M, Muller-Myhsok B, Holsboer F, Binder EB (2010) Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. *Neuropsychopharmacology* 35(7):1583–1592. doi:[10.1038/npp.2010.30](https://doi.org/10.1038/npp.2010.30)
- van Beek N, Griez E (2003) Anxiety sensitivity in first-degree relatives of patients with panic disorder. *Behav Res Ther* 41(8):949–957
- van Duinen MA, Schruers KR, Jaegers E, Maes M, Griez EJ (2004) Salivary cortisol in panic: are males more vulnerable? *Neuro Endocrinol Lett* 25(5):386–390
- Verburg C, Griez E, Meijer J (1994) Increase of panic during the second half of pregnancy. *Eur Psychiatry* 9:260–261
- Vickers K, McNally RJ (2004) Is premenstrual dysphoria a variant of panic disorder? A review. *Clin Psychol Rev* 24(8):933–956. doi:[10.1016/j.cpr.2004.08.001](https://doi.org/10.1016/j.cpr.2004.08.001)
- Vieland VJ, Goodman DW, Chapman T, Fyer AJ (1996) New segregation analysis of panic disorder. *Am J Med Genet* 67(2):147–153
- Villeponteaux VA, Lydiard RB, Lاراia MT, Stuart GW, Ballenger JC (1992) The effects of pregnancy on preexisting panic disorder. *J Clin Psychiatry* 53(6):201–203
- Weber H, Scholz CJ, Domschke K, Baumann C, Klauke B, Jacob CP, Maier W, Fritze J, Bandelow B, Zwanzger PM, Lang T, Fehm L, Strohle A, Hamm A, Gerlach AL, Alpers GW, Kircher T, Wittchen HU, Arolt V, Pauli P, Deckert J, Reif A (2012) Gender differences in associations of glutamate decarboxylase 1 gene (GAD1) variants with panic disorder. *PLoS One* 7(5):e37651. doi:[10.1371/journal.pone.0037651](https://doi.org/10.1371/journal.pone.0037651)
- Wedekind D, Sprute A, Broocks A, Huth G, Engel K, Falkai P, Bandelow B (2008) Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder. *Curr Pharm Des* 14(33):3518–3524
- Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine JP, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen HU, Yeh EK (1997) The cross-national epidemiology of panic disorder. *Arch Gen Psychiatry* 54(4):305–309
- Wisner KL, Peindl KS, Hanusa BH (1996) Effects of childbearing on the natural history of panic disorder with comorbid mood disorder. *J Affect Disord* 41(3):173–180

- Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* 21(9):655–679. doi:[10.1016/j.euroneuro.2011.07.018](https://doi.org/10.1016/j.euroneuro.2011.07.018)
- Yevtushenko OO, Oros MM, Reynolds GP (2010) Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. *J Affect Disord* 123(1–3):308–311. doi:[10.1016/j.jad.2009.09.007](https://doi.org/10.1016/j.jad.2009.09.007)
- Yonkers KA, Zlotnick C, Allsworth J, Warshaw M, Shea T, Keller MB (1998) Is the course of panic disorder the same in women and men? *Am J Psychiatry* 155(5):596–602
- Young EA, Altemus M, Parkison V, Shastry S (2001) Effects of estrogen antagonists and agonists on the ACTH response to restraint stress in female rats. *Neuropsychopharmacology* 25(6):881–891
- Young EA, Kornstein SG, Marcus SM, Harvey AT, Warden D, Wisniewski SR, Balasubramani GK, Fava M, Trivedi MH, John Rush A (2009) Sex differences in response to citalopram: a STAR*D report. *J Psychiatr Res* 43(5):503–511. doi:[10.1016/j.jpsychires.2008.07.002](https://doi.org/10.1016/j.jpsychires.2008.07.002)
- Zwanzger P, Domschke K, Bradwejn J (2012) Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. *Depress Anxiety* 29(9):762–774. doi:[10.1002/da.21919](https://doi.org/10.1002/da.21919)

Social Anxiety Disorder

Franklin Schneier and Julia Goldmark

Introduction

Social anxiety disorder (SAD), also referred to as social phobia, is characterized by persistent fear and avoidance of social situations due to fears of evaluation by others. SAD can be highly distressing, and it can interfere with school, work, and social life as sufferers avoid social or performance situations. Although many individuals with SAD report that their level of anxiety varies with the gender of those with whom they interact, and it has long been observed that men are overrepresented among patients seeking treatment for SAD relative to other anxiety disorders, there has been little study of gender differences in SAD. The gender literature that does exist for SAD, however, offers interesting implications for researchers and clinicians. This chapter will provide an overview of SAD with a specific focus on evidence for gender differences within this disorder.

Epidemiology

Prevalence, Demographics, and Clinical Features

Large epidemiological studies have established that SAD is one of the most common psychiatric disorders. The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), for example, recently found a lifetime prevalence of 5.0 % and 12-month prevalence of 2.8 % for SAD among 43,093 adults in the

F. Schneier (✉)

Anxiety Disorders Clinic, New York State Psychiatric Institute
and Columbia University, New York, NY, USA
e-mail: Fschneier@nyspi.columbia.edu

J. Goldmark

Clinical Psychology, Pace University, New York, NY, USA

United States (Grant et al. 2005). A recent review (Fehm et al. 2005) of 21 community studies in European countries found median lifetime and 12-month prevalence rates of SAD of 6.7 % and 2.0 %, respectively. The WHO World Mental Health (WMH) Survey Initiative (Stein et al. 2010) found that lifetime social fears are common in both developed (15.9 %) and developing (14.3 %) countries; however, lifetime SAD has a higher prevalence in developed countries (6.1 %) compared to developing countries (2.1 %).

Mean age of onset is in the mid-teens, and onset after age 30 is uncommon (Schneier et al. 1992). Although prevalence of SAD is greatest among young adults, for many sufferers the disorder is chronic. Prevalence is also greater among persons who are less educated and those who are single (Schneier et al. 1992; Blanco et al. 2011). Additionally, SAD is usually accompanied by comorbid disorders, such as depression, substance abuse, or other anxiety disorders, which can further impair functioning (Fehm et al. 2005).

SAD has been shown in many studies to be associated with impairment and disability. SAD increases the risk of dropout from school, work absence, unemployment, and utilization of social welfare, causing significant financial costs for society (Lecrubier et al. 2000). When compared with persons with no psychiatric disorder, having SAD is associated with financial dependency and increased rates of suicidal ideation (Schneier et al. 1992; Cogle et al. 2009; Olfson et al. 2000). Katzelnick et al. (2001) examined costs and impairment associated with SAD in a community sample of 1,017 subjects. Subjects with generalized SAD and no comorbidity reported significant impairment in terms of family relations, romantic relationships, social network, and ability to moderate alcohol use, compared to those with no diagnosis. Generalized SAD was associated with significantly lower health-related quality of life, work productivity and earnings, and greater utilization of health services. During the month before participating in the survey, 12.2 % of subjects with SAD reported having had thoughts of suicide.

Several subtypes of SAD have been described. Generalized SAD has been the most studied subtype, and it was defined in DSM-III-R and DSM-IV by fear of most social situations (American Psychiatric Association 2000). Persons with generalized SAD tend to have more severe symptoms and impairment, and are more likely to seek treatment. The National Comorbidity Survey (1998) reported significantly greater comorbidity among persons with SAD and at least one feared situation other than public speaking. Persons with SAD involving three or more social fears also evidenced greater chronicity and impairment. Most persons with the nongeneralized type of SAD, or with the performance type newly described in DSM-5 (American Psychiatric Association 2013), have predominantly fears of performance such as public speaking, with relative sparing of social interaction situations.

Gender Differences in Community Samples

Prevalence of SAD among women has been found to be elevated relative to the rate in men in most community studies. In the NESARC study (Grant et al. 2005), 12-month prevalences were 2.1 % for men and 3.3 % for women; lifetime

prevalences were 4.2 % for men and 5.7 % for women. Similarly, elevated rates of SAD in women have been reported in European samples (Fehm et al. 2005). The female-to-male ratio of 1.35 for lifetime prevalence of SAD in the NESARC study (Xu et al. 2012) is within the range of previous epidemiological studies (Kessler et al. 1994; Ohayon and Schatzberg 2010). The ratio is lower, however, than gender ratios reported for other anxiety disorders in major epidemiologic studies, which have ranged from 1.8 for generalized anxiety disorder in the National Comorbidity Survey (Kessler et al. 1994) to 2.7 for agoraphobia in the Epidemiological Catchment Area (Bourdon et al. 1988). Xu et al. (2012) also found that men with SAD were more likely than women with SAD to have never been being married, or to be separated or divorced.

Crome et al. (2012) sought to investigate whether the preponderance of women among those diagnosed with SAD by community surveys was due to a response bias of women being more likely to respond positively to questions about SAD. The study involved a subsample of 1,755 participants in the Australian National Survey of Mental Health and Wellbeing who had reported at least one social fear. A series of factor analyses suggested that men and women tended to respond comparably to SAD diagnosis items. Men, however, tended to report lower levels of physical symptoms at low levels of social fear, compared to women. Overall, findings supported the legitimacy of higher rates of SAD among women.

Gender differences among persons with SAD were examined in a recent cross-sectional study by MacKenzie and Fowler (2013) of 36,984 Canadians aged 15–80 years. Men with SAD were more likely to be single, unattached, and living alone than women with SAD. Women with SAD were more likely to be widowed, separated, or divorced, and they were more likely to be a single parent. Women also reported poorer mental health and greater stress levels than men with SAD.

Several studies have examined the course of SAD in women and men. Gender differences in prevalence of SAD were small in the pre-school and elementary school years but increased after the age of 12, according to a retrospective study of 8,116 Canadian adults (DeWit et al. 2005). For persons with the generalized subtype of SAD, at every age from pre-school to early adulthood, the proportion of females who had developed SAD exceeded the proportion of males. In contrast, a female preponderance for the development of *nongeneralized* SAD began to emerge only after the age of 12. In a study of 2,128 Swedish students aged 12–14, the prevalence of SAD was 6.6 % among girls versus 1.8 % among boys (Gren-Landell et al. 2009), and 91.4 % of the children with SAD reported impairment in school functioning.

Gender differences in the prevalence of specific types of social fears have also been reported. A survey of 526 community respondents (Stein et al. 1994) showed that women reported significantly greater anxiety about public speaking, speaking to strangers, meeting new people, and dealing with people in authority, but that men and women did not differ significantly in severity of anxiety while writing in front of others, eating in front of others, or attending social gatherings. Women with SAD in the community also experienced higher rates of some social fears (Xu et al. 2012). Men and women with lifetime SAD differed significantly in rates of fear of dating (men 29.5 % vs. women 22.3 %), being interviewed (men 39.7 % vs. women 52.0 %), and speaking at a meeting (men 69.4 % vs. women 74.9 %).

Several community studies have examined gender differences in comorbidity among individuals with SAD. Xu et al. (2012) found that men with a lifetime diagnosis of SAD were more likely to have lifetime alcohol abuse and dependence, drug abuse and dependence, pathological gambling, conduct disorder, and antisocial personality disorder. Women were more likely to suffer from mood and anxiety disorders, except bipolar I and II disorders, which had the same probability to be diagnosed in both genders. Women with SAD were thus more likely to have comorbid internalizing disorders and less likely to have comorbid externalizing disorders.

Rodebaugh et al. (2012) examined the impact of psychiatric disorders on friendship quality by gender, among participants in the National Comorbidity Survey (Kessler et al. 2004). SAD had a negative effect on friendship quality in both men and women, although in men this was exacerbated when comorbid generalized anxiety disorder was present, whereas in women comorbid major depression was associated with an additional negative impact on friendship quality.

In adolescents, a Finnish study (Väänänen et al. 2011) found gender differences in the longitudinal relationship between SAD and depression. In this population-based prospective study of 15-year-olds ($N=2,038$), SAD at baseline increased the risk for depression over the next 2 years in boys only. Among adolescent girls, baseline depression was a risk factor for subsequent SAD. Wu and colleagues (2010) looked at gender differences in the relationship between SAD and substance use among 781 adolescents in the community. In girls, there was a trend for SAD to be associated with lower rates of substance use. In boys, however, cigarette smoking was significantly associated with SAD.

Buckner and colleagues have further investigated the interactions between SAD, substance use disorders, and gender. In one study, Buckner et al. (2006) examined the relationship between cannabis use disorder, SAD, and peer influence in 123 male and female undergraduates. Symptoms of SAD were significantly related to symptoms of cannabis use disorder only among women. This relationship was further moderated in women by the influence of peers and their use of alcohol and cannabis. Specifically, women with more SAD symptoms were particularly prone to problematic cannabis use and more vulnerable to influences from peers. In another study (Buckner and Turner 2009), SAD was a risk factor for development of alcohol use disorders among women only, in a 3-year prospective study of 1,803 young adults from the National Comorbidity Survey. The risk of women developing an alcohol use disorder was further moderated by lower family cohesion and more adverse family relations.

In respect to treatment seeking, individuals with SAD typically do not seek treatment until their late 20s to 30s, despite a mean age of onset of SAD in early adolescence (Mannuzza et al. 1995). Xu et al. (2012) reported that among persons with lifetime SAD in the community, men and women did not differ in their overall probability of treatment seeking for SAD. Lifetime rates of treatment seeking for SAD were 17.9 % for men and 19.2 % for women; lifetime rates of use of medication for SAD were 8.8 % for men and 12.4 % for women. Thus, over 80 % of individuals with SAD in the NESARC study had received no treatment for it, and the mean age at first treatment was 27.2 years (Grant et al. 2005).

Gender Differences in Clinical Samples

There have been relatively few studies of gender differences in clinical samples of SAD patients. One study assessed gender differences in SAD features and treatment outcome in an anxiety clinic sample with 108 men and 104 women, of whom a similar proportion of men and women had received a diagnosis of SAD (63.9 % vs. 71.2 %) (Turk et al. 1998). Among patients with SAD, men and women reported suffering from SAD for similar lengths of time (19.3 vs. 20.3 years). There were no significant differences in the proportions of men and women who reported previous psychotherapy (61.6 % vs. 63.6 %) or treatment with pharmacotherapy (38.4 % vs. 31.8 %). Men and women did not differ significantly in rates of comorbid mood disorders (21.9 % vs. 27.3 %) or anxiety disorders (38.4 % vs. 48 %). Women reported more severe social fears and differences in pattern of feared situations, however. Women reported significantly greater fear in situations of talking to authority figures, performing/giving a speech in front of an audience, working while being observed, entering a room while others are already seated, being the center of attention, speaking up at a meeting, expressing disagreement or disapproval to people they do not know very well, giving a report to a group, and giving a party. Men reported significantly more fear than women when urinating in public bathrooms and returning goods to a store.

Yonkers and colleagues (2003) studied a sample of 66 men and 96 women patients with SAD who were participating in an 8-year naturalistic study. There was a nonsignificant trend for onset of SAD to have occurred at an earlier age in women, 14 years, compared to 16 years for men. The probability of remission of SAD over the follow-up period of up to 8 years was only 31 % and did not differ by gender. Among 105 adolescent patients with a gender identity disorder, there was a higher rate of SAD in those who had been assigned male gender at birth (15.1 %) than those who had been assigned female gender (3.8 %) (DeVries et al. 2011). Ham et al. (2005) examined perceived social support quantity and satisfaction in 23 women and 28 men seeking treatment for SAD. Men and women did not differ on measures of social support. Among the women with SAD, however, younger, unmarried women reported having smaller social support networks and less satisfaction with their social support networks than older, married women. This pattern was not present among the socially anxious men. Randall and colleagues (2000) compared 110 male and female patients with SAD and alcohol use disorders. Women had higher fear ratings on SAD measures compared to men. They also experienced more distress in social and family functioning and had a higher rate of psychiatric comorbidity.

Psychobiology

Neural Circuitry

A growing number of neuroimaging studies of SAD during the last decade have attempted to elucidate the neural mechanisms of the disorder. The most consistent findings have demonstrated increased activation of the amygdala and surrounding

cortices, including the hippocampus (Schmidt et al. 2010) in persons with SAD during exposure to emotional threat stimuli, such as angry faces. Functional neuroimaging studies have reported that exaggerated amygdala activation is positively correlated with symptom severity and decreases after successful treatment (Furmark et al. 2002). Furthermore, treatment studies indicate that both pharmacotherapy and psychotherapy of SAD normalize activation in the amygdala and related structures (Goldin and Gross 2010).

Pathophysiology

A variety of neurotransmitter systems, including serotonin, norepinephrine, dopamine, GABA, and glutamate have evidenced abnormalities in SAD. Dysfunction of the hypothalamic-pituitary-adrenal axis has also been reported. Few of these studies, however, have assessed outcome by gender. In a study of 53 patients seeking treatment for SAD, however, heart rate variability, an index of autonomic control, was reduced in SAD overall, but also more specifically among women with SAD (Alvares et al. 2013). This may indicate a greater sensitivity to the effects of social anxiety on parasympathetic nervous system reactivity in women.

The prototypical onset of SAD in early adolescence has raised questions about the impact of physiological and psychosocial changes of puberty. Deardorff et al. (2007) assessed 106 children aged 9–11 for pubertal status and social anxiety. Advanced pubertal development was associated with higher levels of social anxiety among girls only, consistent with findings of gender differences in depression.

Genetics and Family Studies

Family studies have shown that SAD is familial (e.g., Lieb et al. 2000), with first-degree relatives of adults with SAD being three times as likely as relatives of control subjects to suffer from SAD (Fyer et al. 1995). Some studies have further suggested that the generalized subtype may be more familial than the specific subtype (Stein et al. 1998). Part of this familial risk is attributable to genetic heritability, and twin studies suggest that the underlying structure of the genetic and environmental risk factors is similar between men and women (Hettema et al. 2005).

Genetic influences on the development of SAD may be specific to the disorder, or may be related to relatively nonspecific factors, such as negative affect. A highly heritable temperamental trait that is thought to predispose individuals to SAD is behavioral inhibition, characterized by a consistent pattern of behavioral, physiological, and emotional responses to unfamiliar people and novel situations. Inhibited children usually respond with restraint and withdrawal to novel objects and situations, and they are usually shy with unfamiliar people (Kagan 1994). In a longitudinal study of 238 children, girls evidenced greater inhibition and afternoon cortisol levels as preschoolers, and they were at greater risk for developing chronic high inhibition and SAD (Essex et al. 2010).

Psychological Aspects of Pathogenesis

Psychosocial factors, such as parenting, peer interactions, and culture can play an important role in the development of SAD. Socially anxious adults often report having experienced negative parenting qualities such as overprotection, lack of warmth, excessive concern with the opinion of others, and rejection during their childhood (Caster et al. 1999). Adults with SAD are more likely to recall their parents as excessively protective and controlling (Rapee and Melville 1997).

Childhood maltreatment has been associated with symptom severity, reduced quality of life, and impaired functioning in adults with SAD (Bruce et al. 2012). Data were obtained from 156 treatment-seeking patients with a primary diagnosis of generalized SAD who had a history of childhood trauma. Childhood emotional abuse, emotional neglect, and physical neglect, but not sexual or physical abuse, predicted more severe symptoms in patients with SAD. Of the maltreatment subtypes, emotional abuse was the strongest predictor of severity of social anxiety, disability, and decreased quality of life. Other studies have linked SAD with early sexual abuse. Feerick and Snow (2005) examined the relationship between childhood sexual abuse and SAD in a sample of 313 undergraduate women. In this study, 31 % of the women reported that they had experienced some form of sexual abuse in childhood. Women with a history of sexual abuse reported more symptoms of anxiety and distress in social situations than women who had not experienced sexual abuse. Those women whose abuse included actual or attempted intercourse had higher scores for social avoidance than women who had not been abused, or who had experienced other forms of abuse such as exposure or fondling. In addition to the type of abuse experienced, earlier age of onset of abuse also significantly predicted greater avoidance and distress in adulthood.

McGabe et al. (2003) found a relationship between bullying in childhood and adolescence and SAD later in life. This study assessed the relationship between childhood memories for teasing and SAD in adulthood. Five hundred and fourteen undergraduates completed a questionnaire that measured the degree to which people recall having been teased during childhood and also completed established measures of SAD. Men and women recalled having been teased with similar frequency; however item-by-item analysis suggested that boys had a more negative experience with teasing than girls (e.g., men remembered having been teased about not doing well at school and being a troublemaker more often than women).

Parents impact their children's social interactions directly by arranging play dates, overseeing play situations, and supervising peer interactions (Masia and Morris 1998). Thus, parents' relationships and skills related to their child's development could influence their social and emotional development. Maternal SAD has been shown to significantly predict SAD in offspring (Bögels et al. 2001). Although most of the research on parenting has focused on mothers, paternal influences may also be important (Greco and Morris 2002). The influence of fathers is smaller, however, and more significant later in the child's life (Connel and Goodman 2002).

Contemporary theories of SAD emphasize the role of cognitive processes in the maintenance of the disorder, and a theoretical model has been proposed

(Clark and Wells 1995). According to this model, individuals with SAD are apprehensive in social situations because they perceive the social standard as being high and they doubt that they are able to make a favorable impression, which will result in disastrous consequences (Leary 2001). This leads to a further increase in apprehension and increased self-focused attention, which triggers a number of additional cognitive processes (Hirsch and Clark 2004). As a result, the individual with SAD anticipates social mishaps and engages in avoidance and/or safety behaviors (Wells et al. 1995).

Avoidance and safety behaviors play an important role in the maintenance of SAD, because they reinforce social fears and diminish opportunities for positive social experiences. Individuals with SAD engage in safety behaviors in social situations in order to minimize negative evaluations from others; typical examples of safety behaviors include avoiding eye contact, monitoring one's speech, and avoiding pauses while talking (Kim 2005). When safety behaviors are used, the individual attributes the nonoccurrence of feared catastrophes to the implementation of the safety behavior. Therefore, safety behaviors are maladaptive, because they prevent exposure to the feared social situations and processing of the emotional information, for example, individuals who speak little in social encounters because they fear negative evaluation are less likely to receive positive feedback from others (Clark 2001).

In addition to the previously mentioned cognitive and behavioral factors that contribute to the development and/or maintenance of SAD, recent evidence also suggests a contributing role of exaggerated negative emotional reactions, attenuated positive emotional reactions, and emotion regulation difficulties in producing functional impairment (Goldin et al. 2009). While there are numerous ways of affecting one's emotional experiences, two specific strategies have received substantial scientific attention: cognitive reappraisal and emotion suppression. Cognitive reappraisal involves changing one's perspective to downplay or enhance a situation's emotional impact and altering the interpretation of emotional information (Gross 2002). Emotion suppression involves inhibiting emotional responses to a situation by downregulating the expression of the emotion. People with SAD report frequently suppressing both positive (Werner and Gross 2010) and negative emotions (Erwin et al. 2003). Excessive use of suppression can have negative impact on the positive experiences of people with SAD. A meta-analysis of 19 studies found a stable, moderate relationship between SAD and less frequent and intense positive emotions (Kashdan 2007). Maladaptive emotion regulation contributes to the adverse impact of social anxiety on positive events in daily life, and people high in SAD report using more positive emotion suppression (Turk et al. 2005). One reason for this may be that individuals with SAD find expressing positive emotions in social-evaluative situations to be uncomfortable (Kashdan et al. 2011). While suppressing positive emotions may help individuals with SAD to minimize social attention towards them, it may also contribute to sustained anxiety and avoidance of interactions.

Diagnosis

DSM-5

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (American Psychiatric Association 2013), offers operationalized criteria for the diagnosis of psychiatric disorders by clinicians and researchers. In 2013, the publication of the Fifth Edition of the DSM incorporated several changes to the criteria for SAD (Heimberg et al. 2014). First, while “social anxiety disorder” had been previously considered a secondary name for “social phobia,” it is now recognized in DSM-5 as the principal name for this diagnosis, because it was felt to better convey the sense of pervasiveness and impairment associated with the disorder. The description of primary fear in SAD was broadened beyond showing embarrassing or humiliating anxiety symptoms, to include fear of showing symptoms that will be negatively evaluated. Whereas DSM-IV required that the person must recognize that the fear is excessive or unreasonable, DSM-5 instead requires that the fear be out of proportion to the actual threat, and encourages consideration of cultural context. Another change was to allow the diagnosis of SAD to be made in the presence of another embarrassing medical condition, as long as the social anxiety symptoms are either unrelated to the medical condition or excessive, in the clinician’s judgment.

DSM-5 criteria for SAD require two key features:

- A marked fear or anxiety about social situations or performance situation in which scrutiny by others could occur. For a child to be diagnosed, the anxiety must occur with peers, and not only with adults.
- The individual fears showing behaviors or anxiety symptoms that will result in negative evaluation by others, and experiences such as embarrassment or rejection by others.

In addition, DSM-5 criteria require that the social situations must almost always provoke fear or anxiety, and the situations are avoided or endured with fear and anxiety. The fear or anxiety must be out of proportion to the actual threat posed by the social situation. Symptoms must have persisted for at least 6 months or more, and they must cause clinically significant distress or impairment in social or occupational functioning. Finally, social anxiety and avoidance cannot be due to the physiological effects of a drug of abuse, a medication, or another medical condition. It also must not be better explained by the symptoms of another mental disorder, such as when social avoidance occurs in depression due to lack of social interest. Social anxiety disorder can be diagnosed in the presence of another potentially embarrassing medical condition, such as essential tremor or disfigurement from burns, if the fear, anxiety, and avoidance are unrelated to the medical condition or is excessive.

ICD-10

The International Classification of Disease, 10th Edition (ICD-10) criteria for social phobia, developed by the World Health Organization (WHO) are as follows:

All of the following criteria should be fulfilled for a definite diagnosis:

- (a) The psychological, behavioral, or autonomic symptoms must be primarily manifestations of anxiety and not secondary to other symptoms such as delusions or obsessional thoughts.
- (b) The anxiety must be restricted to or predominate in particular social situations.
- (c) The phobic situation is avoided whenever possible.
Includes: anthropobia; social neurosis

Differential Diagnosis

Below we briefly review some of the clinical issues in distinguishing SAD from other common conditions. In addition to trying to distinguish SAD from related disorders, it must be recognized that any of these conditions can also occur comorbidly with SAD.

Shyness Shyness is a personality trait that is not inherently pathological. While many persons with SAD may consider themselves shy, SAD differs in having a significant adverse impact on social, occupational, and other important areas of functioning.

Agoraphobia Individuals suffering from agoraphobia may fear and avoid social situations; however, their primary fear is that escape from a social situation may be difficult in the event of incapacitation or panic-like symptoms, whereas individuals with SAD are primarily fearful of the potential for scrutiny by others that is inherent in an interpersonal situation.

Panic disorder Individuals with SAD may have panic attacks, but such panic attacks are manifestation of their primary concern about fear of negative evaluation, and the panic attacks are limited to being in or thinking about a social situation. In panic disorder, panic attacks usually occur in situations both with and without others present, and the primary concern is about the panic attacks themselves, rather than fear of scrutiny.

Generalized anxiety disorder Social worries are common in generalized anxiety disorder, but they constitute just one focus among broader concerns that may include worries about health, money, and safety.

Separation anxiety disorder Individuals with separation anxiety disorders may avoid social settings because of concerns about being separated from attachment figures. People with separation anxiety disorder are generally comfortable in social settings when the attachment figure is present or when they are at home.

Specific phobia Individuals with specific phobias may fear humiliation or embarrassment secondarily to their primary phobia (e.g., embarrassment about being seen fainting when blood is drawn), but they do not more generally fear negative evaluation in other public or social situations.

Major depressive disorder Individuals with major depressive disorder may be concerned about negative evaluation because they feel they are not worthy of being liked, and they may avoid social situations out of lack of motivation and interest.

Body dysmorphic disorder Individuals with body dysmorphic disorder are preoccupied with perceived flaws in their physical appearance that are not observable to others. They are primarily concerned with their own evaluation of these flaws, rather than by negative evaluation by others.

Psychotic disorders Individuals with psychotic disorders may avoid interpersonal situations due to paranoid belief of the threat of harm from others. Persons with SAD, however, generally have good insight that their beliefs are out of proportion to the actual threat posed by the social situation.

Autism spectrum disorder Social anxiety and social communication deficits are hallmarks of autism spectrum disorder. However, individuals with SAD usually have adequate age-appropriate social relationships and capacity for social communication.

Personality disorders Due to its frequent onset in childhood and persistence into adulthood, SAD shares features with personality disorders. Avoidant personality disorder criteria greatly overlap those of SAD, so they often co-occur, especially among persons with more severe and pervasive SAD.

Eating disorder Persons with anorexia or bulimia nervosa may have excessive concerns about negative evaluation related to their body image or secondary to others observing their problematic eating behavior. In persons with SAD, however, social fears are not limited to concerns about body image or eating behaviors.

Medical conditions that draw unwanted attention Medical conditions can produce symptoms that may be embarrassing for some sufferers (e.g., trembling in Parkinson's disease). These persons are not diagnosed with SAD unless the symptoms of SAD are out of proportion to that expected from the level of the symptoms of their other medical condition.

Evaluation

As patients with SAD often present with other symptoms, such as depression, and they sometimes initially minimize social anxiety symptoms that have often been highly chronic, an evaluation should proactively probe functioning across a variety of social situations to map the scope of the disorder. Rating scales may be helpful in assessing severity of SAD and monitoring improvement during treatment. One of the most commonly used measures to assess symptom severity in SAD is the Liebowitz Social Anxiety Scale, which assesses fear and avoidance of 24 social situations. It can be administered by a clinician or self-rated, has good internal consistency, and correlates with other measures of social anxiety (Heimberg et al. 1999). The Social Interaction Anxiety Scale (Mattick and Clarke 1998) is a self-report measure that consists of 20 items and evaluates anxiety experienced in dyadic and group interactions. The Social Phobia Scale (Mattick and Clarke 1998) is another self-report measure that assesses fear of performance and observation situations.

Evaluation of SAD should take into account developmental factors. Increases in fears of social evaluation are part of normal development; however, for some children and adolescents these fears become extreme and do not dissipate over time. The vast majority of children and adolescents with SAD go unrecognized by both parents and professionals, including school personnel. When recognized, the diagnosis and assessment of SAD among children and adolescents is complicated by several factors. First, children's and adolescents, level of cognitive development affects the degree to which they are able to articulate concerns and fears of humiliation, which is more difficult for younger children (Southam-Gerow and Kendall 2000). Second, the manifestation of SAD varies by age. Younger children have more crying and episodic illusions, such as being looked at and talked about by strangers (Abe and Suzuki 1986), whereas adolescents present more externalizing problems such as fighting, truancy, and covert antisocial behavior (Davidson et al. 1994). Third, boundaries between normal and pathological fears are often ambiguous, especially in adolescence in which concerns about peer acceptance and body image are common (Petersen and Leffert 1995).

Pharmacotherapy

Pharmacotherapy, along with CBT and other psychotherapies discussed below, constitutes one of the most common modalities of treatment for SAD. Below we review the main classes of medications that have evidence for efficacy in SAD. These include the serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, monoamine oxidase inhibitors, and others.

Serotonin reuptake inhibitors are the first-line medication option for treatment of SAD, based on evidence from over 20 randomized controlled trials (RCTs) of five medications within this class. Paroxetine, sertraline, and fluvoxamine are FDA-approved for the indication of SAD in United States. The serotonin-norepinephrine reuptake inhibitor venlafaxine has also been FDA-approved for SAD on the basis of

several RCTs. A meta-analysis of medication trials found that, relative to placebo, treatment response was superior for the SSRIs ($N=19$ studies; relative risk of response (RR)=1.69; 95 % CI: 1.49, 1.90; Total sample $N=4,615$) and for venlafaxine ($N=4$; RR=1.59; 95 % CI: 1.38, 1.83; $N=1,173$) (Ipser et al. 2008).

Treatment with SSRIs and SNRIs is dosed similarly to dosing used in depression (i.e., median effective paroxetine dose 20 mg/day). An adequate trial of SSRI or SNRI medication may require 8–12 weeks to assess efficacy (Stein et al. 2002). Advantages of SSRIs include a relatively mild adverse-effect profile, safety in overdose or with concurrent use of alcohol, and a broad spectrum of efficacy for comorbid anxiety and affective disorders. Common side effects include nausea and sexual dysfunction.

The benzodiazepines have been far less studied for SAD, but the best evidence for efficacy in this class exists for clonazepam. Davidson et al. (1993) reported that in a 10-week double-blind, placebo-controlled study of clonazepam in 75 patients, 78 % of those on clonazepam (mean standing dose of 2.4 mg/day) and 20 % of those on placebo were rated as at least moderately improved. Another randomized clinical trial found that clonazepam and cognitive-behavioral group therapy were equally effective after 12 weeks of treatment (Otto et al. 2000). In a placebo-controlled discontinuation trial among SAD patients effectively treated with clonazepam, 79 % were able to tolerate slow taper (0.25 mg reduction every 2 weeks) and discontinuation without relapse (Connor et al. 1998). Benzodiazepines are a second-line medication treatment due to their lack of efficacy for comorbid depression, risk of abuse, contraindication in the presence of comorbid substance abuse, potential adverse effects on cognition and coordination, and routine development of physiological dependence requiring slow taper when drug is to be discontinued.

The monoamine oxidase inhibitors (MAOIs) are another class of medications that have appeared efficacious in multiple RCTs, but they are reserved for refractory cases due to dietary restrictions and risk of serious side effects (see Schneier 2011 for more complete review of SAD pharmacotherapy). Reversible inhibitors of monoamine oxidase, such as moclobemide, appear safer but probably less efficacious. Other medications with evidence of efficacy in at least one RCT include the antidepressant mirtazapine and the alpha-2-delta calcium channel agents gabapentin and pregabalin.

Reviews of medication treatment of SAD generally have not found gender to be a significant moderator of treatment response (e.g., Stein et al. 2004). An exception to this was the two-site RCT of gabapentin (Pande et al. 1999), in which placebo-treated women had higher response rates than placebo-treated men (42 % vs. 0 %), but genders did not differ in response rates to active gabapentin.

Psychotherapy

Cognitive-behavioral therapy (CBT) is the most comprehensively studied psychotherapeutic method for treatment of SAD, and its effectiveness has been established in multiple RCTs (Heimberg 2002). CBT is commonly comprised of

two main components: exposure, which involves strategies to confront feared situations and to test for feared consequences by conducting behavioral experiments, and cognitive restructuring, with the goal of challenging maladaptive cognitions and developing more helpful coping thoughts. CBT is typically conducted weekly over a 3–6 month period, in group or individual format. After initial psychoeducation, the patient and therapist develop a hierarchy of anxiety-provoking situations. Exposures typically begin with one of the least feared situations and then gradually approach more difficult situations as a sense of mastery is achieved.

In the cognitive restructuring component of CBT, individuals are taught to:

1. Identify negative thoughts related to the anxiety-provoking situations
2. Evaluate the accuracy of their beliefs
3. Derive alternative thoughts based on the information

Several meta-analyses of a variety of CBT support the clinical efficacy of CBT for SAD (Federoff and Taylor 2001; Feske and Chambless 1995; Taylor 1996). Effectiveness of social skills training and cognitive restructuring without exposure were evaluated in three meta-analyses (Federoff and Taylor 2001; Taylor 1996). These treatments yielded more modest effect sizes.

Other forms of psychotherapy have received support for efficacy but have been less studied. Mindfulness and acceptance-based therapies emphasize present-moment focus and a nonjudgmental awareness of cognitive, emotional, and physiological processes (e.g., Kabat-Zinn 2003). Interpersonal Psychotherapy (IPT), which focuses on correcting dysfunctional patterns in interpersonal relationships, is a time-limited approach that employs specific techniques, such as reassurance, role-playing, and control of emotions. In psychodynamic therapy for SAD, the patient is encouraged to examine beliefs about negative judgment and abandonment (Leichsenring et al. 2013).

Gender has not been shown to moderate outcome of psychotherapy, but psychotherapists need to be sensitive to how a patient's culture may influence attitudes about approaching others of the opposite sex, or how an office subculture's attitudes about gender may impact a patient's efforts to increase assertiveness. Turk et al. (1998) also noted that evidence for gender differences in pattern of social fears supports the practice of attending to the gender composition of therapy groups when CBT for SAD is offered in group format. They observed that men and women with SAD more easily identify with the experiences of same-gender peers, and therefore treatment groups that have a very small number of male or female participants put the underrepresented gender at risk for dropping out. Additionally, offering feedback in the form of reviewing videos of CBT exposures has been reported in some studies to help patients become aware of the discrepancy between their beliefs about their behavior versus their actual social performance. One report, however, suggests that use of video feedback in CBT may be less effective in men (Chen et al. 2010).

Conclusions

A growing body of studies has explored gender differences in SAD, one of the most common anxiety disorders. SAD, like most anxiety and depressive disorders, is more common among women overall. Although women in the community do not report lesser severity of SAD or lesser rates of treatment seeking, clinical samples of SAD have often been found to include equal representations of men and women, or even a predominance of men. Men are more likely to report dating problems, whereas women have higher rates of difficulty speaking up in groups or work situations. Women are more likely to experience comorbid internalizing disorders, and men are more likely to have substance use disorders. It is likely that these patterns of difference reflect differences in both societal influences and physiology.

A smaller number of developmental studies suggest that a variety of gender-related influences play a role in the development of SAD. These range from the psychosocial, such as increased rates of abuse among girls, to complex influences, such as the combined hormonal and social mechanisms by which early puberty may lead to increased social anxiety in girls, to physiological differences in cortisol and heart rate variability. The findings highlight the need for further research to disentangle the complicated influences of gender on SAD, and the importance for clinicians to be sensitive to potential gender differences in etiology and the need to target treatments to the personal characteristics of the individual.

References

- Abe K, Suzuki T (1986) Prevalence of some symptoms in adolescence and maturity: social phobias, anxiety symptoms, episodic illusions, and idea of reference. *Psychopathology* 19: 200–205
- Alvares GA, Quintana DS, Kemp AH et al (2013) Reduced heart rate variability in social anxiety disorder: associations with gender and symptom severity. *PLoS One* 8:e70468. doi:[10.1371/journal.pone.0070468](https://doi.org/10.1371/journal.pone.0070468)
- American Psychiatric Association (2000) *Diagnostic and statistical manual of mental disorders* 4th edn. text revision. American Psychiatric Publishing, Arlington
- American Psychiatric Association (2013) *Diagnostic and statistical manual of mental disorders*, 5th edn. American Psychiatric Publishing, Arlington
- Blanco C, Xu Y, Schneier FR et al (2011) Predictors of persistence of social anxiety disorder: a national study. *J Psychiatr Res* 45:1557–1563
- Bögels SM, van Oosten A, Muris P et al (2001) Familial correlates of social anxiety in children and adolescents. *Behav Res Ther* 39:273–287
- Bourdon K, Boyd J, Rae D et al (1988) Gender differences in phobias: results of the ECA community survey 1. *J Anxiety Disord* 2:227–241
- Bruce LA, Heimberg RG, Blanco C et al (2012) Childhood maltreatment and social anxiety disorder: implications for symptom severity and response to pharmacotherapy. *Depress Anxiety* 29:131–138
- Buckner JD, Turner RJ (2009) Social anxiety disorder as a risk factor for alcohol use disorders: a prospective examination of parental and peer influences. *Drug Alcohol Depend* 100:128–137
- Buckner JD, Mallott MA, Schmidt NB et al (2006) Peer influence and gender differences in problematic cannabis use among individuals with social anxiety. *J Anxiety Disord* 20:1087–1102

- Caster JB, Inderbitzen HM, Hope D (1999) Relationship between youth and parent perceptions of family environment and social anxiety. *J Anxiety Disord* 13:237–251
- Chen J, Furukawa TA, Nakano Y et al (2010) Video feedback with peer ratings in naturalistic anxiety-provoking situations for social anxiety disorder: preliminary report. *J Behav Ther Exp Psychiatry* 41:6–10
- Clark DM (2001) A cognitive perspective on social phobia. In: Crozier WR, Alden LE (eds) *International handbook of social anxiety: concepts, research and interventions relating to the self and shyness*. Wiley, New York, pp 405–430
- Clark DM, Wells A (1995) A cognitive model of social phobia. In: Heimberg R, Liebowitz MR, Hope DA, Schneier FR (eds) *Social phobia: diagnosis, assessment and treatment*. Guilford Press, New York, pp 69–93
- Connel AM, Goodman SH (2002) The association between psychopathology in fathers versus mothers and children's internalizing and externalizing behavior problems: a meta-analysis. *Psychol Bull* 128:746–773
- Connor KM, Davidson JRT, Potts NLS et al (1998) Discontinuation of clonazepam in the treatment of social phobia. *J Clin Psychopharmacol* 18:373–378
- Cougle JR, Keough ME, Ricarrdi CJ et al (2009) Anxiety disorders and suicidality in the national comorbidity survey-replication. *J Psychiatr Res* 43(9):825–829
- Crome E, Baillie A, Taylor A et al (2012) Are male and female responses to social phobia diagnostic criteria comparable. *Int J Methods Psychiatr Res* 21(3):222–231
- Davidson JRT, Potts N, Richichi E et al (1993) Treatment of social phobia with clonazepam and placebo. *J Clin Psychopharmacol* 13:423–428
- Davidson JRT, Hughes DC, George LK et al (1994) The boundary of social phobia: exploring the threshold. *Arch Gen Psychiatry* 51:975–983
- Deardorff J, Hayward C, Wilson KA et al (2007) Puberty and gender interact to predict social anxiety symptoms in early adolescence. *J Adolesc Health* 41(1):102–104
- DeVries ALC, Doreleijers TAH, Steensma TD et al (2011) Psychiatric comorbidity in gender dysphoric adolescents. *J Child Psychol Psychiatry* 52(11):1195–1202
- DeWit DJ, Chandler-Coutts M, Offord DR et al (2005) Gender differences in the effects of family adversity on the risk of onset of DSM-III-R social phobia. *J Anxiety Disord* 19:479–502
- Erwin BA, Heimberg RG, Schneier FR et al (2003) Anger experience and anger expression in social anxiety disorder: pretreatment profile and predictors of attrition and response to cognitive-behavioral treatment. *Behav Ther* 34(3):331–350
- Essex MJ, Klein MH, Slattery MJ et al (2010) Early risk factors and developmental pathways to chronic high inhibition and social anxiety disorder in adolescence. *Am J Psychiatry* 167(1):40–46
- Federoff IC, Taylor S (2001) Psychological and pharmacological treatments for social phobia: a meta-analysis. *J Clin Psychopharmacol* 21:311–324
- Feerick MM, Snow KL (2005) The relationship between childhood sexual abuse, social anxiety and symptoms of posttraumatic stress disorder in women. *J Fam Violence* 20(6):409–419
- Fehm L, Pelissolo A, Furmark T et al (2005) Size and burden of social phobia in Europe. *Eur Neuropsychopharmacol* 15:453–462
- Feske U, Chambless DL (1995) Cognitive behavioral versus exposure only treatment for social phobia: a meta-analysis. *Behav Ther* 26:695–720
- Furmark T, Tillfors M, Marteinsdottir I et al (2002) Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. *Arch Gen Psychiatry* 59(5):425–433
- Fyer AJ, Mannuzza S, Chapman TF et al (1995) Specificity in familial aggregation of phobic disorders. *Arch Gen Psychiatry* 52:564–573
- Goldin PR, Gross JJ (2010) Effects of mindfulness-based stress reduction (MBSR) on emotion regulation in social anxiety disorder. *Emotion* 10(1):83–91
- Goldin PR, Manber T, Hakimi S et al (2009) Neural bases of social anxiety disorder emotional reactivity and cognitive regulation during social and physical threat. *Arch Gen Psychiatry* 66(2):170–180

- Grant BF, Hasin DS, Blanco C et al (2005) The epidemiology of social anxiety disorder in the United States: results from the national epidemiologic survey on alcohol and related conditions. *J Clin Psychiatry* 66:1351–1361
- Greco LA, Morris TL (2002) Paternal child-rearing style and child social anxiety: investigations of child perceptions and actual father behavior. *J Psychopathol Behav Assess* 24:259–267
- Gren-Landell M, Tillfors M, Furmark T et al (2009) Social phobia in Swedish adolescents: prevalence and gender differences. *Soc Psychiatry Psychiatr Epidemiol* 44:1–7
- Gross JJ (2002) Emotion regulation: affective, cognitive, and social consequences. *Psychophysiology* 39(3):281–291
- Ham L, Hayes SA, Hope DA (2005) Gender differences in social support for socially anxious individuals. *Cogn Behav Ther* 34:201–206
- Heimberg RG (2002) Cognitive-behavioral therapy for social anxiety disorder: current status and future directions. *Biol Psychiatry* 51:101–108
- Heimberg RG, Horner KJ, Juster HR (1999) Psychometric properties of the Liebowitz Social Anxiety Scale. *Psychol Med* 29:199–212
- Heimberg RG, Hofmann SG, Liebowitz MR et al (2014) Social anxiety disorder in DSM-5. *Depress Anxiety*. doi:10.1002/da.2223
- Hettema JM, Prescott CA, Myers JM et al (2005) The structure of genetic and environmental risk factors for anxiety disorders in men and women. *Arch Gen Psychiatry* 62:182–189
- Hirsch CR, Clark DM (2004) Information-processing bias in social phobia. *Clin Psychol Rev* 24(7):799–825
- Ipser JC, Karjuki CM, Stein DJ (2008) Pharmacotherapy for social anxiety disorder: a systematic review. *Expert Rev Neurother* 8:235–257
- Kabat-Zinn J (2003) Mindfulness-based stress reduction (MBSR). *Constr Hum Sci* 8:73–107
- Kagan J (1994) Galen's prophecy: temperament in human nature. Basic Books, New York
- Kashdan TB (2007) Social anxiety spectrum and diminished positive experiences: theoretical synthesis and meta-analysis. *Clin Psychol Rev* 27:348–365
- Kashdan TB, Weeks JW, Savostyanova AA (2011) Whether, how, and when social anxiety shapes positive experiences and events: a self-regulatory framework and treatment implications. *Clin Psychol Rev* 31(5):786–799
- Katzelnick DJ, Kobak KA, DeLeire T et al (2001) Impact of generalized social anxiety disorder in managed care. *Am J Psychiatry* 158:1999–2007
- Kessler RC, McGonagle KA, Zhao S et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National comorbidity survey. *Arch Gen Psychiatry* 51:8–19
- Kessler RC, Stein MB, Berglund P (1998) Social phobia subtypes in the national comorbidity survey. *Am J Psychiatry* 155(5):613–619
- Kessler RC, Berglund P, Chiu WT et al (2004) The US national comorbidity survey replication (NCS-R): design and field procedures. *Int J Methods Psychiatr Res* 13:69–92
- Kim EJ (2005) The effect of the decreased safety behaviors on anxiety and negative thoughts in social phobics. *J Anxiety Disord* 19(1):69–86
- Leary MR (2001) Social anxiety as an early warning system: a refinement and extension of the self-presentation theory. In: Hofmann SG, DiBartolo PM (eds) From social anxiety to social phobia: multiple perspectives. Allyn & Bacon, Boston, pp 321–334
- Lecrubier Y, Wittchen HU, Faravelli C et al (2000) A european perspective on social anxiety disorder. *Eur Psychiatry* 15:5–16
- Leichsenring F, Salzer S, Beutel M et al (2013) Psychodynamic therapy and cognitive therapy in social anxiety disorder: a multi-center randomized controlled trial. *Am J Psychiatry* 170(7):759–767
- Lieb R, Wittchen HU, Hofler M et al (2000) Parental psychopathology, parenting styles and the risk of social phobia in offspring: a prospective-longitudinal community study. *Arch Gen Psychiatry* 57:859–866
- MacKenzie MB, Fowler KF (2013) Social anxiety disorder in the Canadian population: exploring gender differences in sociodemographic profile. *J Anxiety Disord* 27:427–434

- Mannuzza S, Schneier FR, Chapman TF et al (1995) Generalized social phobia: reliability and validity. *Arch Gen Psychiatry* 52:230–237
- Masia CL, Morris TL (1998) Parental factors associated with social anxiety: methodological limitations and suggestions for integrated behavioral research. *Clin Psychol Sci Pract* 5(2):211–228
- Mattick R, Clarke J (1998) Development and validation of measures of social phobia fear and social interaction anxiety. *Behav Res Ther* 36:455–470
- McGabe RE, Antony MM, Summerfeldt LJ et al (2003) Preliminary examination of the relationship between anxiety disorders in adults and self-reported history of teasing or bullying experiences. *Cogn Behav Ther* 32(4):187–193
- Ohayon MM, Schatzberg AF (2010) Social phobia and depression: prevalence and comorbidity. *J Psychosom Res* 68:235–243
- Olfson M, Guardino M, Struening E et al (2000) Barriers to the treatment of social anxiety. *Am J Psychiatry* 157:521–527
- Otto MW, Pollack MH, Gould RA et al (2000) A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. *J Anxiety Disord* 14:345–358
- Pande AC, Davidson JRT, Jefferson JW et al (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. *J Clin Psychopharmacol* 19:341–348
- Petersen AC, Leffert N (1995) What is special about adolescence? In: Rutter M (ed) *Psychosocial disturbances in young people: challenges for prevention*. Cambridge University Press, London, pp 3–37
- Randell CL, Thomas SE, Thevos AK (2000) Gender comparison in alcoholics with concurrent social phobia: implications for alcoholism treatment. *Am J Addict* 9(3):202–215
- Rapee RM, Melville LF (1997) Recall of family factors in social phobia and panic disorder: comparison of mother and offspring reports. *Depress Anxiety* 5(1):7–11
- Rodebaugh TL, Fernandez KC, Levinson CA (2012) Testing the effects of social anxiety disorder on friendship quality across gender and ethnicity. *Cogn Behav Ther* 41(2):130–139
- Schmidt S, Mohr A, Miltner WHR et al (2010) Task-dependent neural correlates of the processing of verbal threat-related stimuli in social phobia. *Biol Psychol* 84:304–312
- Schneier FR (2011) Pharmacotherapy of social anxiety disorder. *Expert Opin Pharmacother* 12(4):615–625. doi:[10.1517/14656566.2011.534983](https://doi.org/10.1517/14656566.2011.534983)
- Schneier FR, Johnson J, Hornig CD et al (1992) Social phobia: comorbidity and morbidity in an epidemiologic sample. *Arch Gen Psychiatry* 49(4):282–288
- Southam-Gerow MA, Kendall PC (2000) A preliminary study of the emotion understanding of youth referred for treatment of anxiety disorders. *J Clin Child Psychol* 29:319–327
- Stein MB, Walker JR, Ford DR (1994) Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. *Am J Psychiatry* 151:408–412
- Stein MB, Chartier M, Hazen A et al (1998) A direct-interview family study of generalized social phobia. *Am J Psychiatry* 155:90–97
- Stein DJ, Stein MB, Pitts CD et al (2002) Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. *J Clin Psychiatry* 63:152–155
- Stein DJ, Kasper S, Andersen EW (2004) Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. *Depress Anxiety* 20(4):175–181
- Stein DJ, Ruscio AM, Lee S et al (2010) Subtyping social anxiety disorder in developed and developing countries. *Depress Anxiety* 27:390–403
- Taylor S (1996) Meta-analysis of cognitive-behavioral treatment for social phobia. *J Behav Ther Exp Psychiatry* 27:1–9
- Turk C, Heimberg R, Orsillo S et al (1998) An investigation in gender differences in social phobia. *J Anxiety Disord* 12:209–223
- Turk CL, Heimberg RG, Luterek JA et al (2005) Emotion dysregulation in generalized anxiety disorder: a comparison with social anxiety disorder. *Cogn Ther Res* 29(1):89–106
- Väänänen JM, Fröjd S, Ranta K et al (2011) Relationship between social phobia and depression differs between boys and girls in mid-adolescence. *J Affect Disord* 133:97–104

- Wells A, Clark DM, Salkovskis P et al (1995) Social phobia: the role of in-situation safety behaviors in maintaining anxiety and negative beliefs. *Behav Ther* 26:153–161
- Werner K, Gross J (2010) Emotion regulation and psychopathology: a conceptual framework. In: Kring AM, Sloan DE (eds) *A transdiagnostic approach to etiology and treatment*. Guilford Press, New York, pp 13–37
- Wu P, Goodwin RD, Fuller C et al (2010) The relationship between anxiety disorders and substance use among adolescents in the community: specificity and gender differences. *J Youth Adolesc* 39:177–188
- Xu Y, Schneier FR, Heimberg RG et al (2012) Gender differences in social anxiety disorder: results from the national epidemiologic sample on alcohol and related conditions. *J Anxiety Disord* 26:12–19
- Yonkers KA, Bruce SE, Dyck RI et al (2003) Chronicity, relapse and illness – course of panic disorder, social phobia and generalized anxiety disorder findings in men and women from 8 years of follow-up. *Depress Anxiety* 17:173–179

Obsessive-Compulsive Disorder

Lauren S. Hallion, Laura E. Sockol, and Sabine Wilhelm

Introduction

Previously classified as an anxiety-related disorder, obsessive-compulsive disorder (OCD) was moved to a new “Obsessive-Compulsive and Related Disorders” section in the *Diagnostic and Statistical Manual of Mental Disorders* (5th ed.; *DSM-5*; American Psychiatric Association [APA], 2013). This section also includes body dysmorphic disorder (BDD), hoarding disorder (previously considered a subtype of OCD), trichotillomania (hair-pulling disorder), and excoriation (skin-picking disorder; APA 2013). In *DSM-5*, OCD is characterized by the presence of obsessions and compulsions (Criterion A), which must be time-consuming or cause clinically significant distress or impairment (Criterion B; APA 2013, p. 238). *Obsessions* are egodystonic “repetitive and persistent thoughts, images, or urges” (APA 2013, p. 238), while *compulsions* are “repetitive behaviors ... that the individual feels driven to perform in response to an obsession or according to rules that must be applied rigidly” (APA 2013, p. 237). Whereas obsessions are strictly mental activities, compulsions can be observable (e.g., checking locks or washing hands) or covert (e.g., counting or mentally repeating certain words or phrases).

L.S. Hallion (✉)

Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA

Anxiety Disorders Center/Center for CBT, Hartford Hospital, Hartford, CT, USA

e-mail: lauren.hallion@hhchealth.org

L.E. Sockol

Department of Psychology, Williams College, Williamstown, MA, USA

S. Wilhelm

Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA

Epidemiology

OCD is a relatively common disorder, affecting 1–3 % of the general population in a given year (Apter et al. 1996; Ruscio et al. 2010). Approximately half of all treatment-seeking adults with OCD are women (Rasmussen and Eisen 1992). In community samples, women represent slightly more than half of all adults with OCD (Bebbington 1998). In pediatric samples, the gender difference is skewed toward males, with an approximately 2:1 male-to-female ratio (e.g., Hanna 1995). This difference may reflect the earlier modal age of onset for OCD in males (modal age 13–15) compared to females (20–24; Rasmussen and Eisen 1990).

Several gender differences in OCD phenomenology have been identified. For example, women are more likely than men to report obsessions focusing on contamination (e.g., fears of spreading or contracting illness) and corresponding cleaning compulsions (e.g., excessive hand-washing and cleaning; de Mathis et al. 2011). This gender difference appears to be stable across cultures, indicating that biological factors or cross-cultural gender role norms may play a role in OCD presentation (de Mathis et al. 2011). Conversely, sexual obsessions (e.g., fears of pedophilia and homosexuality) are more frequently observed in men than women, as are ordering and symmetry obsessions (Lensi et al. 1996).

Gender differences in OCD-related impairment have also been identified. In a large Brazilian sample (Torresan et al. 2013), men with OCD were more likely than women to be single (61 % of men vs. 47 % of women), to be unemployed (20 % vs. 14 %), and to live with their family of origin or in assisted living facilities (50–66 % vs. 20–40 %). Although some studies have reported that OCD symptoms are more severe in women on average (Torresan et al. 2013), other studies have found no gender differences in OCD severity (Labad et al. 2008).

Subtypes

Perinatal OCD

Intrusive thoughts and compulsive behaviors similar to those that characterize OCD are common among new and expectant parents (Abramowitz et al. 2003a, b; Fairbrother and Abramowitz 2007; Zambaldi et al. 2009). Prevalence estimates of OCD during pregnancy range from 0.2 % (Zar et al. 2002) to 29 % (Chaudron and Nirodi 2010), with many studies reporting prevalence estimates in the range of 1–2 % (Russell et al. 2013). Onset of OCD after the birth of a child (often called postpartum OCD) is more likely to occur in women than men (13 % vs. 6.5 % of individuals with OCD; Torresan et al. 2013). During the postpartum period, prevalence estimates range from 0.7 % (Navarro et al. 2008) to 9 % (Zambaldi et al. 2009), with many estimates in the 2–4 % range (Russell et al. 2013). A recent meta-analysis estimated the prevalence of OCD to be 2.1 % during pregnancy and 2.4 % during the first year postpartum; this review found that the perinatal period is associated with a 79 % increase in risk for OCD compared to the general female population (Russell et al. 2013).

Among individuals with OCD, pregnancy and childbirth are commonly nominated as events precipitating the onset of symptoms (Maina et al. 1999). Among women with preexisting OCD, there does not seem to be a consistent relationship between pregnancy and OCD symptoms (Forray et al. 2010; Williams and Koran 1997). However, many women with OCD report that their symptoms worsen during the postpartum period (Labad et al. 2005; Williams and Koran 1997).

Interestingly, the content of obsessions and compulsions in this population appears to be influenced by the perinatal context. OCD with onset during pregnancy is commonly characterized by contamination obsessions and corresponding washing and cleaning compulsions, while OCD with onset during the postpartum period is commonly associated with harm obsessions and corresponding checking or avoidance compulsions (Buttolph and Holland 1990; Sichel et al. 1993). Obsessions related to harming the infant can be distinguished from infanticidal ideation that may occur in severe postpartum depression or psychosis by the egodystonic nature of the obsessions; women with postpartum OCD often engage in extensive avoidance and rituals to address their fears of harming their infants (Abramowitz et al. 2003b). To date, no cases of a woman with “pure” OCD causing harm to her infant have been documented (Ross and McLean 2006).

H-OCD

One specific manifestation of OCD includes concerns related to sexual orientation, including doubts regarding one’s sexual orientation and fears that one may be homosexual (H-OCD; Williams 2008). These symptoms are often misdiagnosed; obsessions related to sexual orientation are commonly misattributed to “latent homosexuality” or interpreted as indicative that the patient is actually uncertain of his or her sexual orientation (Williams 2008). In a sample of 409 patients in OCD specialty clinics, 8 % of the sample reported current obsessions related to sexual orientation and 3.9 % endorsed a lifetime history of these obsessions; men were twice as likely to endorse these obsessions (Williams and Farris 2011).

Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS)

PANDAS is a pediatric variant of OCD, the defining feature of which is a sudden onset of OCD following a Group A *streptococcus* infection (Giedd et al. 2000). OCD-related PANDAS symptoms are similar to those found in classic pediatric OCD. Mood lability, personality changes, hyperactivity, tics, decreased handwriting quality, and other symptoms are also frequently observed (Murphy et al. 2012). To date, no large-scale epidemiological studies of PANDAS have been conducted. However, a recent study of 109 children ages 4–17 with OCD found that 41 of these children (68 % male) met criteria for PANDAS, suggesting a higher prevalence in boys than girls (Murphy et al. 2012). In that study, children with PANDAS were more likely than those with non-PANDAS OCD to report an episodic course characterized by full remission and subsequent “flare-ups,” to show symptom remission during antibiotic therapy, and to have elevated streptococcal titers.

Comorbidity

The majority of individuals who meet criteria for OCD also meet criteria for at least one additional psychiatric disorder (Rasmussen and Eisen 1990; Steketee et al. 2001). In the National Comorbidity Survey-Replication study (NCS-R), 90 % of adult respondents who met lifetime DSM-IV criteria for OCD also met criteria for another lifetime disorder (Ruscio et al. 2010). The most common comorbid conditions were anxiety disorders, followed by mood disorders, impulse control disorders, and substance use disorders (Ruscio et al. 2010). Comorbid obsessive-compulsive and related disorders are also common (Richter et al. 2003).

Gender differences in patterns of comorbidity appear to reflect overall gender differences in the prevalence of psychiatric disorders. Women with OCD are more likely to present with comorbid eating disorders (Bogetto et al. 1999; Lochner et al. 2004; Torresan et al. 2009, 2013), major depression (Castle et al. 1995; Labad et al. 2008), and impulse control disorders (Bogetto et al. 1999; Torresan et al. 2009, 2013). Conversely, men are more likely to present with comorbid social phobia (Bogetto et al. 1999; Jaisoorya et al. 2009; Torresan et al. 2013; Tükel et al. 2004), tic disorders (Jaisoorya et al. 2009; Torresan et al. 2009, 2013), substance use disorders (Bogetto et al. 1999; Lochner et al. 2004; Torresan et al. 2013), and bipolar disorder (Bogetto et al. 1999; Lensi et al. 1996).

Many patients with OCD also meet criteria for at least one personality disorder (Baer and Jenike 1992; Steketee et al. 2001). The most common comorbid *DSM-IV* Axis II disorders are those on Cluster C, the “anxious cluster” (Steketee et al. 2001). There is some evidence that men with OCD report higher levels of traits associated with the Cluster C personality disorders than do women (Castle et al. 1995; Lensi et al. 1996).

Psychobiology

Neuropsychology

Although a growing body of research has investigated neuropsychological performance in OCD, few studies have explicitly examined sex and gender differences in these domains. The existing studies suggest few, if any, consistent sex differences in executive functioning and neuropsychological performance. One of the largest such studies (Mataix-Cols et al. 2006) examined performance on a wide range of neuropsychological tests in a sample of 33 men and 23 women with OCD and 40 healthy controls (50 % women, matched to the OCD sample on age, education level, and handedness). The study revealed a significant sex by group interaction for verbal fluency: Women with OCD performed more poorly than healthy control women; no difference was found for men. No significant interactions were observed for any other domain, including general nonverbal intelligence, attention, working memory, set-shifting, or inhibition.

A subsequent study using a similar sample (31 men and 19 women with OCD and a healthy control group matched for sex, age, education, and handedness;

Segalàs et al. 2010) did not replicate the previous finding of poorer verbal fluency among women with OCD. Instead, the study found poorer nonverbal memory performance in men with OCD compared to healthy control men. This difference was not observed for women. No interactions were found for verbal memory, general intelligence, attention, or working memory.

In several studies that did not explicitly examine gender, adults and children with OCD demonstrated deficits in response inhibition, defined as the ability to override a dominant or prepotent response (e.g., turning right to drive home) to make a less dominant, task-appropriate response (e.g., turning left to stop by the supermarket; Miyake et al. 2000). This finding does not appear to vary by sex (Kang et al. 2013). Impairments have also been observed in some studies of planning and decision-making, although other studies have failed to replicate these findings (Menzies et al. 2008). Other studies have found few or no impairments on a range of executive functioning tasks in individuals with OCD (Abramovitch et al. 2012).

Neurobiology

Neuroimaging research has revealed several brain regions and circuits that may play a role in the pathophysiology of OCD. Again, however, small sample sizes and a relative lack of research preclude strong conclusions about sex differences in these circuits. Leading neurobiological models of OCD focus on abnormalities in several interconnected brain regions, including the orbitofrontal cortex (OFC; particularly lateral and medial regions), anterior cingulate cortex (ACC, particularly dorsal regions), thalamus, and basal ganglia, which contains the striatum, nucleus accumbens, and other subregions (Graybiel and Rauch 2000; Milad and Rauch 2012).

The OFC is most commonly recognized for its role in emotional and motivational facets of behavior, including evaluating and monitoring changes in the reward value of a stimulus (Rolls 2004). Findings from structural and functional neuroimaging studies suggest several OCD-related abnormalities in the OFC and its subregions. Compared to healthy controls, adults with OCD tend to show reduced OFC volume (Menzies et al. 2008; Rotge et al. 2009) but increased glucose metabolism at rest (Harrison et al. 2009) and in response to symptom-provocation paradigms, wherein OCD symptoms are elicited in the scanner (Rotge et al. 2009). Notably, this hypermetabolism in the OFC and in several other regions is normalized following effective cognitive-behavioral therapy or pharmacotherapy for OCD (see Abramovitch et al. 2012 for a review).

The OFC is strongly interconnected with the basal ganglia and its subregions, which play a strong role in selecting and initiating motor behaviors (Alexander and Crutcher 1990). Basal ganglia abnormalities are often observed in patients with OCD and phenomenologically similar disorders, including PANDAS (Giedd et al. 2000) and Tourette's disorder (Mink 2001). In adults with OCD, reduced striatal volumes have been observed in some studies but not others (Aylward et al. 1996; Rotge et al. 2009).

OCD-related hypermetabolism has also been found in the ACC, which plays a major role in error detection as well as the assessment and regulation of emotional information (Diler et al. 2004). This elevated activity may relate to the “not just right” feeling endorsed by many individuals with OCD (Aouizerate et al. 2004). OCD is also associated with increases in the volume of the thalamus, a midline structure that serves as a “switchboard” for several brain regions, among other functions (Gilbert et al. 2000; Rotge et al. 2009). In one pediatric OCD study, elevated thalamic volume was normalized following 12 weeks of effective treatment with paroxetine, a selective serotonin reuptake inhibitor (SSRI; Gilbert et al. 2000). These volumetric changes were associated with changes in OCD symptom severity.

Inconsistencies in neuropsychological and neurobiological OCD research may be due to a number of factors, including small sample sizes, insufficiently sensitive tests, or heterogeneity of OCD symptoms (Abramovitch et al. 2012; Milad and Rauch 2012). For example, compulsive hoarding was previously considered a subtype of OCD (APA 1994) but has been reclassified as a distinct OC-spectrum disorder in *DSM-5* (APA 2013). Individuals with hoarding disorder differ from those with OCD in terms of neural activity during some neuropsychological tasks (Tolin et al. 2014) and in several other domains (Frost et al. 2012). Thus, the inclusion of hoarding in previous OCD samples may have masked (or spuriously enhanced) true differences between individuals with OCD and healthy controls.

Genetics

OCD is a strongly heritable disorder, with strong concordance reported in monozygotic twins (Pauls 2010). Stronger familial concordance has been observed for early-onset OCD (before 18 years; more commonly observed in males) than for later-onset OCD (Pauls et al. 1995). Genetic linkage analyses suggest that a locus on chromosome 9 may contribute to OCD genetic vulnerability (Hanna et al. 2002), as may certain polymorphisms in the 5-HT_{2A} promoter gene, which plays a role in regulation of serotonin (Hu et al. 2006). However, other studies have failed to replicate these findings (Pauls 2008). More recently, a genome-wide association study found evidence for enriched methylation of quantitative trait loci (QTLs) in the single-nucleotide polymorphisms (SNPs) that were most associated with OCD (Stewart et al. 2013). Taken together, these findings suggest that OCD is almost certainly the result of multiple genetic and environmental factors and that additional research is needed to elucidate the genetic underpinnings of OCD.

Some sex differences in the genetic diatheses for OCD have been identified. Women with OCD are more likely than men to possess a low activity-related allele of the monoamine oxidase A gene, whereas men are more likely to possess a low activity-related allele of the catechol-O-methyltransferase (COMT) gene (Lochner et al. 2004). Both genes are responsible for degrading a number of neurotransmitters, including serotonin, dopamine, and norepinephrine (Lochner et al. 2004). Additionally, some genetic polymorphisms (e.g., in the 5-HT_{2A} promoter

gene) have been associated with OCD symptoms only in women (Enoch et al. 2001), whereas other polymorphisms (e.g., SLC1A1, a polymorphism of the glutamate transporter gene) have been linked to OCD only in men (Dickel et al. 2006; Arnold et al. 2006).

Diagnosis

Many individuals without OCD report some obsessions or compulsions (Rachman and De Silva 1978; Salkovskis and Harrison 1984); therefore, OCD is diagnosed only when symptoms reach clinically significant levels of interference or distress (APA 2013). A wide variety of screening and diagnostic measures for OCD are available, including self-report measures and semistructured diagnostic interviews. For an in-depth review of assessment measures for OCD, see Feske and Chambless (2000).

In primary care settings, the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PHQ; Spitzer et al. 1999) is often used. The PHQ is a brief self-report measure that screens for OCD as well as several mood, anxiety, and substance use disorders. It shows fair-to-good reliability with diagnoses assigned by mental health professionals (Spitzer et al. 1999). There are also several OCD-specific self-report measures that can be used with adults and older adolescents. The revised versions of the Obsessive-Compulsive Inventory (OCI-R; Foa et al. 2002) and Padua Inventory (PI-R; Burns et al. 1996) contain symptom-specific subscales and have generally strong psychometric properties. Feske and Chambless (2000) note that the PI-R can be particularly useful for assessing treatment outcome.

Some of the most common clinical interviews for diagnosing OCD in adults are the Anxiety Disorders Interview Schedule-IV (ADIS-IV; Brown et al. 1994) and the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID; First et al. 1996). These measures assess DSM-IV criteria for OCD; the ADIS-IV in particular provides information regarding the type and severity of obsessions and compulsions, including their frequency and persistence (Di Nardo et al. 1994).

A more precise OCD severity rating can be obtained using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS; Goodman et al. 1989). The Y-BOCS is a gold standard semistructured interview that assesses current and lifetime presence of 36 types of obsessions and 23 types of compulsions. The Y-BOCS provides ratings for severity, time spent, interference, distress, resistance, and perceived control for the individual's primary obsessions and compulsions (Goodman et al. 1989). Administration of the Y-BOCS is generally preceded by assessment with the Y-BOCS Checklist (Steketee et al. 1996), which can be self- or clinician-administered. On the checklist, participants note the absence or presence of 58 obsessions and compulsions, identify the three main obsessions and compulsions, and rate the time spent, interference, distress, resistance, and control for each on a Likert scale (Steketee et al. 1996).

When screening for OCD in younger children, an interviewer may phrase typical assessment questions more simply; for example, "do you do things over and over or

have habits you can't stop?" (Geller et al. 2012, p. 102). The parent-report Child Behavior Checklist (Achenbach 1991) shows good sensitivity and specificity in screening for pediatric OCD (Nelson et al. 2001).

Some of the most widely used clinician-administered measures for diagnosing and evaluating OCD in pediatric samples include the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS; Kaufman et al. 1997) and the Children's Y-BOCS (CY-BOCS, Scahill et al. 1997). The K-SADS covers a broad range of psychiatric disorders, including psychotic and externalizing disorders (see Lewin and Piacentini 2010 for a review). The CY-BOCS is generally considered to be the gold standard interview for assessing OCD in pediatric samples (Lewin and Piacentini 2010). The CY-BOCS is structured similar to the adult Y-BOCS and assesses the presence, frequency, interference, distress, resistance, and perceived control of obsessions and compulsions (Scahill et al. 1997). The symptom checklist of the Children's Y-BOCS (CY-BOCS; Scahill et al. 1997) can also be particularly informative when administered to both parents and children (Geller et al. 2012).

Evaluation

When evaluating OCD, several considerations are warranted. Independent of gender, individuals with OCD may be reluctant to describe their symptoms in detail. This hesitation may occur because the obsessions are embarrassing, alarming, or upsetting to the patient (e.g., in the case of sexual obsessions); because of the belief that describing the symptoms may cause the negative consequences that the person is trying to avoid via compulsions (a phenomenon called thought-action fusion, wherein the individual believes that having a thought is equivalent to acting on the thought; Shafran et al. 1996); or for fear that the patient will be misperceived as dangerous (e.g., in the case of harm obsessions) or psychotic.

In our clinical experience, underreporting is a particular risk for sexual and harm obsessions, often because of shame and fears of being misinterpreted or viewed as potentially dangerous. In the case of sexual obsessions, this apprehension may be increased when the interviewer is of a different gender than the patient (e.g., a male patient and a female interviewer). Therefore, it is important for the interviewer to normalize these symptoms. For example, an interviewer might state that individuals with OCD often experience unwanted, socially undesirable obsessions, such as obsessions related to harming oneself or someone else, of being a pedophile, of being gay, or of harming one's child. Such normalizing statements often make patients more comfortable describing their symptoms and can increase "buy-in" for the treatment.

Independent of gender, it is critical to evaluate insight in patients with OCD. Most individuals with OCD recognize that their symptoms are unreasonable, unnecessary, or take up more time than is warranted (APA 2013). However, a subset of individuals truly believe that their compulsions are necessary and appropriate. These individuals, who can be assigned the diagnostic specifier "with poor insight," show poorer treatment response (Ravi Kishore et al. 2004) and may require different or additional interventions (e.g., adjunctive antipsychotic pharmacotherapy; Ravi Kishore et al. 2004).

The Brown Assessment of Beliefs Scale (BABS; Eisen et al. 1998) is a relatively brief, well-validated, clinician-administered measure that assesses patients' insight into their symptoms (Eisen et al. 1998). When possible, formal assessment with the BABS or a similar standardized assessment method (e.g., item 11 from the Yale-Brown Obsessive-Compulsive Scale; Y-BOCS; Goodman et al. 1989) is advisable.

Differential Diagnosis

OCD shares many clinical features with other emotional disorders. Individuals with body dysmorphic disorder (BDD) also report intrusive thoughts and engage in compulsive behaviors in an attempt to reduce the resulting anxiety. However, in BDD, individuals' obsessions and compulsions are limited to concerns related to physical appearance (APA 2013). If obsessions and compulsions are limited to concerns about weight or body shape, an eating disorder diagnosis should also be considered (APA 2013). While impulse control disorders (e.g., kleptomania) are characterized by behaviors that may be described as "compulsive," these disorders can be distinguished from OCD by the absence of egodystonic obsessions (APA 2013). Furthermore, the compulsive behaviors associated with these disorders are frequently egosyntonic, and the distress experienced by the individual results from the consequences of their compulsive behavior, rather than the behaviors themselves (Dell'Osso et al. 2006).

Hoarding disorder is characterized by persistent difficulty discarding possessions due to a perceived need to save items, distress associated with discarding items, and problematic accumulation of possessions. In contrast to OCD, hoarding disorder is more likely to be egosyntonic and characterized by an absence of attempts to resist hoarding (Frost et al. 2012; Mataix-Cols et al. 2010).

Both mood and anxiety disorders may also be characterized by the experience of repetitive or intrusive thoughts. Of the anxiety disorders, generalized anxiety disorder (GAD) is most phenomenologically similar to OCD (Steketee and Barlow 2002). GAD can be distinguished from OCD by the nature of the repetitive thoughts. In GAD, intrusive thoughts are characterized by excessive anxiety and worry about real-life concerns. In OCD, intrusive thoughts often have odd, irrational, or "magical" content (APA 2013). GAD can also be distinguished from OCD by the absence of compulsions. Additionally, while individuals with major depressive disorder (MDD) may experience intrusive rumination, these thoughts are usually mood-congruent and somewhat egosyntonic. MDD can also be distinguished from OCD by the absence of compulsions (APA 2013).

OCD can be distinguished from psychotic disorders by the absence of other characteristic features of these disorders, such as hallucinations and a formal thought disorder (APA 2013). However, OCD can be characterized by delusional beliefs (O'Dwyer and Marks 2000); these can be diagnosed using the "no insight" specifier in DSM-5.

Finally, despite the similarity in name, most individuals with OCD do not meet criteria for comorbid obsessive-compulsive personality disorder (OCPD; Steketee

et al. 2001). Unlike OCD, which is characterized by intrusive thoughts and repetitive behaviors, OCPD is often characterized by rigidity and egosyntonic preoccupation with orderliness, perfectionism, and control (APA 2013). Individuals exhibiting both obsessions/compulsions and pervasive, maladaptive perfectionism, and rigidity may be diagnosed with both OCD and comorbid OCPD (Coles et al. 2008).

Pharmacotherapy

Meta-analyses suggest a significant benefit from several forms of pharmacotherapy for OCD, with relatively few studies noting sex or gender differences in treatment response. The most widely investigated pharmacological treatments for OCD include clomipramine, a tricyclic antidepressant, and selective serotonin reuptake inhibitors (SSRIs; Soomro, Altman, Rajagopal, & Oakley Browne, 2008). Other biological interventions, which are typically used as an adjunct to conventional treatment or in the case of treatment-resistant OCD, include atypical antipsychotics, deep brain stimulation, transcranial magnetic stimulation (TMS), and D-cycloserine, among others.

Clomipramine, which inhibits the reuptake of serotonin and norepinephrine, was the first drug approved by the Food and Drug Administration (FDA) for the treatment of OCD. Several meta-analyses demonstrate that clomipramine is more effective than placebo in both adults (Ackerman & Greenland, 2002; Greist et al. 1995) and children (Watson and Rees 2008). Importantly, clomipramine can produce undesirable side effects, including dizziness, blurred vision, sedation, constipation, and weight gain. This problematic side effect profile has favored the increased use of SSRIs as a treatment for OCD.

SSRIs produce a clinically significant response in about 40–60 % of OCD patients (Jenike 2004). SSRIs are more effective than placebo even at low doses, but higher doses (e.g., 60–80 mg of fluoxetine and its equivalents) produce greater reductions in symptoms (Bloch et al. 2010). A Cochrane review comparing different types of SSRIs (fluoxetine, fluvoxamine, sertraline, paroxetine, and citalopram) found no significant differences in the effectiveness of each medication (Soomro et al. 2008). Side effects of SSRIs can include dizziness, weight gain, decreased libido and anorgasmia, drowsiness, and insomnia; these and other side effects can be particularly pronounced at the higher doses required to treat OCD.

Randomized controlled trials and meta-analyses that have compared clomipramine and SSRIs have produced mixed results. Some meta-analyses suggest that clomipramine produces larger reductions in symptoms compared to SSRIs in both adults and children (Greist et al. 1995; Sánchez-Meca et al. 2014). However, other meta-analyses have found no differences in efficacy between the treatments (Ackerman et al. 2002). Given the lower risk profile and potentially greater tolerability of SSRIs as compared to clomipramine, SSRIs are generally recommended as a first-line psychopharmacological treatment for both adults (Decloedt and Stein 2010) and, in severe cases, children (Geller et al. 2012) with OCD.

In one study of gender differences in medication response (Mundo et al. 1999), men were more likely than women to experience a worsening of symptoms following administration of intravenous clomipramine (no patients improved following IV clomipramine administration). Following the IV administration, participants were randomly assigned to receive 10 weeks of standard oral treatment with clomipramine or fluvoxamine. Women were more likely than men to experience a reduction in symptoms with clomipramine (94.1 % of women improved relative to post-IV clomipramine treatment vs. 57.1 % of men); no significant gender differences were found for fluvoxamine.

Atypical antipsychotics are sometimes used to augment clomipramine or SSRIs in individuals with treatment-resistant OCD. Risperidone and quetiapine show some promise as adjunctive treatments for treatment-resistant OCD (Fineberg et al. 2006). However, as atypical antipsychotics can cause unpleasant and potentially dangerous side effects, careful consideration is warranted when considering their use (Fineberg et al. 2006).

Several studies have investigated the use of psychotropic medications in postpartum OCD. An open-label trial of fluoxetine for postpartum OCD found that the majority of patients experienced a positive response (Arnold 1999). Another open trial found that augmentation with quetiapine was effective for postpartum women with OCD that had not responded to SSRI or SNRI monotherapy (Misri and Milis 2004). Several case reports suggest that perinatal OCD can be effectively treated with clomipramine (Chelmow and Halfin 1997), fluoxetine (Buttolph and Holland 1990), and various other SSRIs (Sichel et al. 1993).

Importantly, although psychotropic medications are often effective for reducing OCD symptoms, the benefit is often lost when medication is discontinued (Fineberg et al. 2013). Given the short-lived treatment gains and the side effects associated with psychopharmacological treatment, cognitive-behavioral psychotherapy is recommended as a frontline treatment for OCD (NICE 2005; see Psychotherapy below).

In the past decade, advances in neurotherapeutics have highlighted several promising adjunctive and alternative treatments for treatment-resistant OCD. In deep brain stimulation, an electrode is implanted in the brain (typically in the striatum) and electrical impulses are transmitted to interfere with neuronal activity. This approach, although invasive, has been associated with positive short- and long-term results in individuals with chronic, intractable OCD (Greenberg et al. 2006). A newer approach is repetitive TMS (rTMS), wherein a noninvasive handheld device is used to alter magnetic activity in the brain. A recent meta-analysis suggests that rTMS produces a moderate improvement in OCD symptoms compared to placebo or “sham” stimulation (Berlim et al. 2013).

Psychotherapy

Behavioral, cognitive, and combined cognitive-behavioral therapies have demonstrated efficacy in the treatment of OCD. Exposure and response (ritual) prevention (ERP) is a behavioral treatment in which patients are exposed to situations which

normally elicit distress, while compulsions (rituals) are resisted or prevented (Abramowitz 2006; Steketee and Barlow 2002). In contemporary practice, ERP involves “therapist-guided, systematic, repeated, and prolonged exposure to situations that provoke obsessional fear, along with abstinence from compulsive behaviors” (Abramowitz 2006, p. 409). Several meta-analyses have found that ERP produces large and significant reductions in OCD symptoms (Abramowitz 1997; Abramowitz et al. 2002).

Cognitive therapies for OCD focus on identifying and challenging the beliefs that support patients’ OCD behaviors and correcting problematic beliefs (Steketee and Barlow 2002; Wilhelm and Steketee 2006). An early meta-analysis of cognitive-behavioral interventions for OCD found that the effect of cognitive interventions was not reliably different from zero, but this null finding was attributed this to the small number of studies directly assessing cognitive interventions (Abramowitz et al. 2002). More recently, a meta-analysis of 16 randomized controlled trials of cognitive-behavioral interventions for OCD found no difference in efficacy between interventions using ERP and those using primarily cognitive interventions; both interventions produced clinically significant reductions in OCD symptoms (Olatunji et al. 2012). Thus, ERP has been classified as a “well-established treatment” for OCD, while cognitive therapy has been classified as a “probably efficacious treatment” (Chambless et al. 1998; DeRubeis and Crits-Cristoph 1998). ERP is generally considered the first-line treatment for adults (NICE 2005) and children (Geller et al. 2012) with OCD. In the case of severe, treatment-refractory pediatric OCD, concurrent psychopharmacological treatment with SSRIs is also recommended (Geller et al. 2012).

D-cycloserine (DCS), an antibiotic that operates on a specific glutamate receptor, has been used to augment CBT for OCD and several anxiety disorders. Preliminary evidence suggests that, although DCS does not appear to alter long-term outcomes, it may reduce the number of sessions required for successful extinction learning and, correspondingly, symptom reduction (Abramowitz et al. 2009; Wilhelm et al. 2008).

Surprisingly, we found only a single study that directly investigated gender differences in treatment response for OCD, although a number of studies have examined gender as a moderator of treatment response. In a study of predictors of response to intense residential treatment for individuals with severe OCD, Stewart and colleagues (2006) found that men were significantly less likely to be classified as treatment responders than women. A meta-analysis of 16 studies of CBT for OCD found that the percentage of females in each study was not significantly associated with effect size (Olatunji et al. 2012). As psychotherapy outcome studies are often underpowered to detect gender differences in treatment response, it is currently unclear whether there are gender differences in the efficacy of ERP for OCD.

Although few studies have investigated treatments specific to perinatal populations with OCD, there is no theoretical basis to believe that OCD in perinatal samples should respond differently to established treatments for OCD (Abramowitz et al. 2003a). In the only existing randomized controlled trial in this population, Timpano and colleagues (2011) found that a cognitive-behavioral prevention

program for pregnant women at risk for OCD resulted in significant reductions in obsessions and compulsions during the first 6 months postpartum. Case studies have also demonstrated successful treatment of perinatal OCD with CBT, either as a stand-alone treatment (Christian and Storch 2009) or with adjunctive pharmacotherapy (Flosnik and Khin 2012).

Several studies and meta-analyses have evaluated the utility of combined treatment (i.e., ERP plus pharmacotherapy) for OCD. A recent meta-analysis suggests that ERP alone is as effective as ERP plus pharmacotherapy for the treatment of pediatric OCD; both approaches were superior to pharmacotherapy alone (Sánchez-Meca et al. 2014). In adults, a meta-analysis of four studies comparing combined ERP and serotonergic pharmacotherapy to pharmacotherapy alone suggested a small but significant benefit of combined treatment over ERP alone, while ERP alone and combined treatment were both superior to pharmacotherapy alone (Tolin 2012). These results suggest that, when available, ERP should be the frontline treatment for OCD, but that the addition of SSRIs or other serotonergic medications may also be of some benefit.

Conclusions

A small but growing body of research suggests several differences in the prevalence, clinical features, and genetic underpinnings of OCD. In pediatric samples, OCD is twice as common in males than females, corresponding to an earlier age of onset in males than females. In adult community samples, the gender distribution is roughly equal, whereas treatment-seeking samples are characterized by a slightly higher percentage of women. Phenomenologically, women are more likely than men to report cleaning and contamination obsessions, particularly in the context of perinatal OCD, whereas men are more likely to report sexual and symmetry-related obsessions. Patterns of comorbidity correspond to commonly observed gender differences in other disorders; for example, men with OCD are more likely to experience comorbid substance-related disorders, whereas women more commonly experience comorbid mood and anxiety disorders. Corresponding to these epidemiological and phenomenological differences, genetic research hints at sex differences in the genetic underpinnings of OCD. Few gender-related differences in OCD treatment responsivity have been identified. As such, cognitive-behavioral therapy and pharmacotherapy with SSRIs are considered frontline treatments for OCD irrespective of gender.

References

- Abramovitch A, Mittleman A, Henin A, Geller D (2012) Neuroimaging and neuropsychological findings in pediatric obsessive-compulsive disorder: a review and developmental considerations. *Neuropsychiatry* 2(4):313–329
- Abramowitz JS (1997) Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. *J Consult Clin Psychol* 65(1):44–52
- Abramowitz JS (2006) The psychological treatment of obsessive-compulsive disorder. *Can J Psychiatry* 51(7):407–416

- Abramowitz JS, Franklin ME, Foa EB (2002) Empirical status of cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analytic review. *Rom J Cogn Behav Psychotherapies* 2:89–104
- Abramowitz JS, Schwartz SA, Moore KM (2003a) Obsessional thoughts in postpartum females and their partners: content, severity, and relationship with depression. *J Clin Psychol Med Settings* 10(3):157–164
- Abramowitz JS, Schwartz SA, Moore KM, Luenzmann KR (2003b) Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature. *J Anxiety Disord* 17(4):461–478
- Abramowitz JS, Taylor S, McKay D (2009) Obsessive-compulsive disorder. *Lancet* 374:491–499
- Achenbach TM (1991) Integrative guide for the 1991 CBCL/4-18, YSR, and TRF profiles. University of Vermont, Department of Psychiatry, Burlington
- Ackerman DL, Greenland S (2002). Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. *Journal of clinical psychopharmacology*, 22(3), 309–317
- Alexander GE, Crutcher MD (1990) Functional architecture of the basal ganglia circuits: Neural substrates of parallel processing. *Trends Neurosci* 13(7):266–271
- American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. Author, Washington, DC
- American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington
- Aouizerate B, Guehl D, Cuny E, Rougier A, Bioulac B, Tignol J, Burband P (2004) Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery, and physiology. *Prog Neurobiol* 73(3):195–221
- Apter A, Fallon TJ, King RA, Ratzoni G, Zohar AH, Binder M, Weizman A, Leckman JF, Pauls DL, Kron S, Cohen DJ (1996) Obsessive-compulsive characteristics: from symptoms to syndrome. *J Am Acad Child Adolesc Psychiatr* 35(7):907–912
- Arnold LM (1999) A case series of women with postpartum-onset obsessive-compulsive disorder. *Prim Care Companion J Clin Psychiatr* 1(4):103–108
- Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006) Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. *Arch Gen Psychiatry* 63(7):769–776
- Aylward EH, Harris GJ, Hoehn-Saric R, Barta PE, Machlin SR, Pearlson GD (1996) Normal caudate nucleus in obsessive-compulsive disorder assessed by quantitative neuroimaging. *Arch Gen Psychiatry* 53:577–584
- Baer L, Jenike MA (1992) Personality disorders in obsessive compulsive disorder. *Psychiatr Clin North Am* 15(4):803–812
- Bebbington PE (1998) Epidemiology of obsessive-compulsive disorder. *Br J Psychiatr Suppl* 35:2–6
- Berlim MT, Neufeld NH, Van den Eyne F (2013) Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory meta-analysis of randomized and sham-controlled trials. *J Psychiatr Res* 47(8):999–1006
- Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C (2010). Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. *Molecular psychiatry*, 15(8), 850–855
- Bogetto F, Venturolo S, Albert U, Maina G, Ravizza L (1999) Gender-related clinical differences in obsessive-compulsive disorder. *Eur Psychiatry* 14(8):434–441
- Brown TA, Di Nardo PA, Barlow DH (1994) Anxiety Disorders Interview Schedule for DSM-IV: adult and lifetime version, clinician manual. Graywind Publications, Albany
- Burns LG, Keortage SG, Formea GM, Sternberger LG (1996) Revision of the Padua inventory of obsessive compulsive disorder symptoms: distinctions between worry, obsessions, and compulsions. *Behav Res Ther* 34:163–173
- Buttolph ML, Holland AD (1990) Obsessive-compulsive disorders in pregnancy and childbirth. In: Jenike MA, Baer L, Minichiello WE (eds) *Obsessive-compulsive disorder: theory and management*, 2nd edn. Yearbook Medical Publishers, Chicago, pp 89–95

- Castle DJ, Deale A, Marks IM (1995) Gender differences in obsessive compulsive disorder. *Aust N Z J Psychiatr* 29(1):114–117
- Chambless DL, Baker MJ, Baucom DH, Beutler LE, Calhoun KS, Crits-Christoph P, Daiuto A, DeRubeis R, Detweiler J, Haaga DAF, Bennett Johnson S, McCurry S, Mueser KT, Pope KS, Sanderson WC, Shoham V, Stickle T, Williams DA, Woody SR (1998) Update on empirically validated therapies. II. *Clin Psychol* 51(1):3–16
- Chaudron LH, Nirodi N (2010) The obsessive–compulsive spectrum in the perinatal period: a prospective pilot study. *Arch Womens Ment Health* 13(5):403–410
- Chelmos D, Halfin VP (1997) Pregnancy complicated by obsessive-compulsive disorder. *J Matern Fetal Med* 6(1):31–34
- Christian LM, Storch EA (2009) Cognitive behavioral treatment of postpartum onset obsessive compulsive disorder with aggressive obsessions. *Clin Case Stud* 8(1):72–83
- Coles ME, Pinto A, Mancebo MC, Rasmussen SA, Eisen JL (2008) OCD with comorbid OCPD: a subtype of OCD? *J Psychiatr Res* 42(4):289–296
- de Mathis MA, Alvarenga PD, Funaro G, Torresan RC, Moraes I, Torres AR, Zilberman ML, Hounie AG (2011) Gender differences in obsessive-compulsive disorder: a literature review. *Rev Bras Psiquiatr* 33(4):390–399
- Decloedt EH, Stein DJ (2010). Current trends in drug treatment of obsessive–compulsive disorder. *Neuropsychiatric disease and treatment*, 6, 233
- Dell’Osso B, Altamura AC, Allen A, Marazziti D, Hollander E (2006) Epidemiologic and clinical updates on impulse control disorders: a critical review. *Eur Arch Psychiatry Clin Neurosci* 256(8):464–475
- DeRubeis RJ, Crits-Christoph P (1998) Empirically supported individual and group psychological treatments for adult mental disorders. *J Consult Clin Psychol* 66(1):37–52
- Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M, Himle JA, Leventhal BL, Cook EH Jr, Hanna GL (2006) Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. *Arch Gen Psychiatry* 63(7):778–785
- Diler RS, Kibar M, Avci A (2004) Psychotherapy and regional cerebral blood flow in children with obsessive compulsive disorder. *Yonsei Med J* 45(1):90–99
- Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA (1998) The brown assessment of beliefs scale: reliability and validity. *Am J Psychiatr* 155(1):102–108
- Enoch M, Greenberg BD, Murphy DL, Goldman D (2001) Sexually dimorphic relationship of a 5-HT_{2A} promoter polymorphism with obsessive compulsive disorder. *Biol Psychiatry* 49(4):385–388
- Fairbrother N, Abramowitz JS (2007) New parenthood as a risk factor for the development of obsessional problems. *Behav Res Ther* 45(9):2155–2163
- Feske U, Chambless DL (2000) A review of assessment measures for obsessive-compulsive disorder. In: Goodman WK, Rudorfer MV, Maser JD (eds) *Obsessive-compulsive disorder: contemporary issues in treatment*. Lawrence Erlbaum Associates Publishers, Mahwah, pp 157–182
- Fineberg NA, Gale TM, Sivakumaran T (2006) A review of antipsychotics in the treatment of obsessive compulsive disorder. *J Psychopharmacol* 20(1):97–103
- Fineberg NA, Reghunandan S, Brown A, Pampaloni I (2013) Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. *Aust N Z J Psychiatr* 47(2):121–141
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV). American Psychiatric Press, Inc., Washington, DC
- Flosnik DL, Khin EK (2012) Cognitive-behavioral therapy for obsessive-compulsive disorder in pregnancy. *Psychiatr Ann* 42(7):269–271
- Foa EB, Huppert JD, Leiberg S, Langner R, Kichic R, Hajcak G, Salkovskis PM (2002) The obsessive–compulsive inventory: development and validation of a short version. *Psychol Assess* 14(4):485–496

- Foa EB, Yadin E, Lichner TK (2012) Exposure and response (ritual) prevention for obsessive-compulsive disorder: therapist guide. Oxford University Press, New York
- Furray A, Focseneanu M, Pittman B, McDougle CJ, Epperson CN (2010) Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period. *J Clin Psychiatry* 71(8):1061–1068
- Frost RO, Steketee G, Tolin DF (2012) Diagnosis and assessment of hoarding disorder. *Annu Rev Clin Psychol* 8:219–242
- Geller DA, March J, Walter HJ, Bukstein OG, Benson RS, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S (2012) Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. *J Am Acad Child Adolesc Psychiatry* 51:98–113
- Giedd JN, Rapoport JL, Garvey MA, Perlmutter S, Swedo SE (2000) MRI assessment of children with obsessive-compulsive disorders or tics associated with streptococcal infection. *Am J Psychiatry* 157(2):281–283
- Gilbert AR, Moore GJ, Keshavan MS, Paulson LD, Narula V, MacMaster FP, Stewart CM, Rosenberg DR (2000) Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. *Arch Gen Psychiatry* 57(5):449–456
- Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989) The Yale-brown obsessive compulsive scale: I. development, use, and reliability. *Arch Gen Psychiatry* 46(11):1006–1011
- Graybiel AM, Rauch SL (2000) Toward a neurobiology of obsessive-compulsive disorder. *Neuron* 28(2):343–347
- Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA (2006) Three year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. *Neuropsychopharmacology* 31:2384–2393
- Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Sikes, C (1995). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. *Archives of General Psychiatry*, 52(4), 289–295
- Hanna GL (1995) Demographic and clinical features of obsessive-compulsive disorder in children and adolescents. *J Am Acad Child Adolesc Psychiatry* 34(1):19–27
- Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis GC, Leventhal BL, Cook EH (2002) Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. *Am J Med Genet* 114:541–552
- Harrison BJ, Soriano-Mas C, Pujol J, Ortiz H, López-Solà M, Hernández-Ribas R, Deus J, Alonso P, Yücel M, Pantelis C, Menchon JM, Cardoner N (2009) Altered corticostriatal functional connectivity in obsessive-compulsive disorder. *Arch Gen Psychiatry* 66(11):1189–2000
- Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D (2006) Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. *Am J Hum Genet* 78(5):815–826
- Jaisoorya TS, Janardhan Reddy YC, Srinath S, Thennarasu K (2009) Sex differences in Indian patients with obsessive-compulsive disorder. *Compr Psychiatry* 50(1):70–75
- Jenike MA (2004). Obsessive-compulsive disorder. *New England Journal of Medicine*, 350(3), 259–265
- Kang DH, Jang JH, Han JY, Jung WH, Choi JS, Choi CH, Kwon JS (2013) Neural correlates of altered response inhibition and dysfunctional connectivity at rest in obsessive-compulsive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 40(10):340–346
- Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Morei P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-Age children – present and lifetime version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry* 36(7):980–988
- Labad J, Menchon JM, Alonso P, Segalàs C, Jimenez S, Vallejo J (2005) Female reproductive cycle and obsessive-compulsive disorder. *J Clin Psychiatry* 66(4):428–435

- Labad J, Menchon JM, Alonso P, Segalàs C, Jimenez S, Jaurieta N, Leckman JF, Vallejo J (2008) Gender differences in obsessive-compulsive symptom dimensions. *Depress Anxiety* 25(10):832–838
- Lensi P, Cassano GB, Correddu G, Ravagli S, Kunovac JL, Akiskal HS (1996) Obsessive-compulsive disorder: familial-developmental history, symptomatology, comorbidity and course with special reference to gender-related differences. *Br J Psychiatry* 169(1):101–107
- Lewin AB, Piacentini J (2010) Evidence-based assessment of child obsessive compulsive disorder: recommendations for clinical practice and treatment research. *Child Youth Care Forum* 39:73–90
- Lochner C, Hemmings SM, Kinnear CJ, Moolman-Smook JC, Corfield VA, Knowles JA, Niehaus DJ, Stein DJ (2004) Gender in obsessive-compulsive disorder: clinical and genetic findings. *Eur Neuropsychopharmacol* 14(2):105–113
- Maina G, Albert U, Bogetto F, Vaschetto P, Ravizza L (1999) Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. *Psychiatry Res* 89(1):49–58
- Mataix-Cols D, Rahman Q, Spiller M, Alonso M, Piffarré J, Menchón JM, Vallejo J (2006) Are there sex differences in neuropsychological functions among patients with obsessive-compulsive disorder? *Appl Neuropsychol* 13(1):42–50
- Mataix-Cols D, Frost RO, Pertusa A, Clark LA, Saxena S, Leckman JF, Wilhelm S (2010) Hoarding disorder: a new diagnosis for DSM-V? *Depress Anxiety* 27(6):556–572
- Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET (2008) Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. *Neurosci Biobehav Rev* 32(3):525–549
- Milad MR, Rauch S (2012) Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. *Trends Cogn Sci* 16(1):43–51
- Mink JW (2001). Basal ganglia dysfunction in Tourette's syndrome: a new hypothesis. *Pediatric neurology*, 25(3), 190–198
- Misri S, Milis L (2004) Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation. *J Clin Psychopharmacol* 24(6):624–627
- Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD (2000) The unity and diversity of executive functions and their contributions to complex “frontal lobe” tasks: a latent variable analysis. *Cogn Psychol* 41:49–100
- Mundo E, Bareggi SR, Pirola R, Bellodi L (1999) Effect of acute intravenous clomipromine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? *Biol Psychiatry* 45:290–294
- Murphy TK, Storch EA, Lewin AB, Edge PJ, Goodman WK (2012) Clinical factors associated with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. *J Pediatr* 160(2):314–319
- National Institute for Health and Clinical Excellence (2005) Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. Institute for Health and Clinical Excellence, National
- Navarro P, García-Esteve L, Ascaso C, Aguado J, Gelabert E, Martín-Santos R (2008) Non-psychotic psychiatric disorders after childbirth: prevalence and comorbidity in a community sample. *J Affect Disord* 109(1):171–176
- Nelson EC, Hanna GL, Hudziak JJ, Borterton KN, Heath AC, Todd RD (2001) Obsessive-compulsive scale of the child behavior checklist: specificity, sensitivity, and predictive power. *Pediatrics* 108(1):E14
- O'Dwyer AM, Marks I (2000) Obsessive-compulsive disorder and delusions revisited. *Br J Psychiatry* 176(3):281–284
- Olatunji BO, Davis ML, Powers MB, Smits JA (2012) Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators. *J Psychiatr Res* 47:33–41
- Pauls DL (2008) The genetics of obsessive compulsive disorder: a review of the evidence. *Am J Med Genet C Semin Med Genet* 148C(2):133–139

- Pauls DL (2010) The genetics of obsessive-compulsive disorder: a review. *Dialogues Clin Neurosci* 12(2):149–163
- Pauls DL, Alsobrook JP, Goodman W, Rasmussen S, Leckman JF (1995) A family study of obsessive-compulsive disorder. *Am J Psychiatry* 152(1):76–84
- Rachman S, de Silva P (1978) Abnormal and normal obsessions. *Behav Res Ther* 16(4):233–248
- Rasmussen SA, Eisen JL (1990) Epidemiology of obsessive compulsive disorder. *J Clin Psychiatry* 51(2):10–13
- Rasmussen SA, Eisen JL (1992) The epidemiology and clinical features of obsessive-compulsive disorder. *Psychiatr Clin North Am* 15(4):743–758
- Ravi Kishore V, Samar R, Janardhan Reddy YC, Chandrasekhar CR, Thennarasu K (2004) Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder. *Eur Psychiatry* 19(4):202–208
- Richter MA, Summerfeldt LJ, Antony MM, Swinson RP (2003) Obsessive-compulsive spectrum conditions in obsessive-compulsive disorder and other anxiety disorders. *Depress Anxiety* 18(3):118–127
- Rolls ET (2004) The functions of the orbitofrontal cortex. *Brain Cogn* 55:11–29
- Ross LE, McLean LM (2006) Anxiety disorders during pregnancy and the postpartum period: a systematic review. *J Clin Psychiatry* 67(8):1285–1298
- Rotge J, Guehl D, Dilharreguy B, Tignol J, Bioulac B, Allard M, Burbaud P, Auouizerate B (2009) Meta-analysis of brain volume changes in obsessive-compulsive disorder. *Biol Psychiatry* 65:75–83
- Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2010) The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. *Mol Psychiatry* 15(1):53–63
- Russell EJ, Fawcett JM, Mazmanian D (2013) Risk of obsessive-compulsive disorder in pregnant and postpartum women: a meta-analysis. *J Clin Psychiatry* 74(4):377–385
- Salkovskis PM, Harrison J (1984) Abnormal and normal obsessions: a replication. *Behav Res Ther* 22(5):549–552
- Sánchez-Meca J, Rosa-Alcázar AI, Iniesta-Sepúlveda M, Rosa-Alcázar Á (2014). Differential efficacy of cognitive-behavioral therapy and pharmacological treatments for pediatric obsessive-compulsive disorder: A meta-analysis. *Journal of anxiety disorders*, 28(1), 31–44
- Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF (1997) Children's Yale-Brown obsessive compulsive scale: reliability and validity. *J Am Acad Child Adolesc Psychiatry* 36(6):844–852
- Segalàs C, Alonso P, Labad J, Real E, Pertusa A, Jaurrieta N, Jiménez-Murcia S, Menchón JM, Vallejo J (2010) A case-control study of sex differences in strategic processing and episodic memory in obsessive-compulsive disorder. *Compr Psychiatry* 51:303–311
- Shafraan R, Thordarson DS, Rachman S (1996) Thought-action fusion in obsessive compulsive disorder. *J Anxiety Disord* 10(5):379–391
- Sichel DA, Cohen LS, Dimmock JA, Rosenbaum JF (1993) Postpartum obsessive compulsive disorder: a case series. *J Clin Psychiatry* 54(4):156–159
- Soomro GM, Altman DG, Rajagopal S, Oakley Browne M (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). *The Cochrane Library*.
- Spitzer R, Kroenke K, Williams J (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. *JAMA* 282:1737–1744
- Steketee G, Barlow DH (2002) Obsessive-compulsive disorder. In: Barlow DH (ed) *Anxiety and its disorders*. The Guilford Press, New York, pp 516–676
- Steketee G, Frost R, Bogart K (1996) The Yale-Brown Obsessive Compulsive Scale: interview versus self-report. *Behav Res Ther* 34(8):675–684
- Steketee G, Chambless DL, Tran GQ (2001) Effects of Axis I and II comorbidity on behavior therapy outcome for obsessive-compulsive disorder and agoraphobia. *Compr Psychiatry* 42(1):76–86
- Stewart SE, Yen CH, Stack DE, Jenike MA (2006) Outcome predictors for severe obsessive-compulsive patients in intensive residential treatment. *J Psychiatr Res* 40(6):511–519

- Stewart SE, Yu D, Sharf JM, Neale BM, Fagerness JA et al (2013) Genome-wide association study of obsessive-compulsive disorder. *Mol Psychiatry* 18:1–11
- Timpano KR, Abramowitz JS, Mahaffey BL, Mitchell MA, Schmidt NB (2011) Efficacy of a prevention program for postpartum obsessive-compulsive symptoms. *J Psychiatr Res* 45(11):1511–1517
- Tolin DF (2012) Combining pharmacotherapy and psychological treatments for OCD. In: Steketee G (ed) *Oxford handbook of obsessive compulsive and spectrum disorders*. Oxford University Press, New York, pp 365–375
- Tolin DF, Witt ST, Stevens MC (2014) Hoarding disorder and obsessive-compulsive disorder show different patterns of neural activity during response inhibition. *Psychiatry Res* 221:142–148
- Torresan RC, de Abreu Ramos-Cerqueira AT, de Mathis MA, Diniz JB, Ferrão YA, Miguel EC, Torres AR (2009) Sex differences in the phenotypic expression of obsessive-compulsive disorder: an exploratory study from Brazil. *Compr Psychiatry* 50(1):63–69
- Torresan RC, Ramos-Cerqueira ATA, Shavitt RG, do Rosário MC, de Mathis MA, Miguel EC, Torres AR (2013) Symptom dimensions, clinical course and comorbidity in men and women with obsessive-compulsive disorder. *Psychiatry Res* 209:186–195
- Tükel R, Polat A, Genç A, Bozkurt O, Atlı H (2004) Gender-related differences among Turkish patients with obsessive-compulsive disorder. *Compr Psychiatry* 45(5):362–366
- Watson HJ, Rees CS (2008). Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. *Journal of Child Psychology and Psychiatry*, 49(5), 489–498
- Wilhelm S, Steketee GS (2006) *Cognitive therapy for obsessive compulsive disorder: a guide for professionals*. New Harbinger Publications, Oakland
- Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL (2008) Augmentation of behavior therapy with d-cycloserine for obsessive compulsive disorder. *Am J Psychiatry* 165(3):335–341
- Williams MT (2008) Homosexuality anxiety: a misunderstood form of OCD. In: Sebeki LV (ed) *Leading-edge health education issues*. Nova Science, New York, pp 195–205
- Williams MT, Farris SG (2011) Sexual orientation obsessions in obsessive-compulsive disorder: prevalence and correlates. *Psychiatry Res* 187(1):156–159
- Williams K, Koran L (1997) Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstrual. *J Clin Psychiatry* 58:330–334
- Zambaldi CF, Cantilino A, Montenegro AC, Paes JA, de Albuquerque TLC, Sougey EB (2009) Postpartum obsessive-compulsive disorder: prevalence and clinical characteristics. *Compr Psychiatry* 50(6):503–509
- Zar M, Wijma K, Wijma B (2002) Relations between anxiety disorders and fear of childbirth during late pregnancy. *Clin Psychol Psychother* 9(2):122–130

Obsessive-Compulsive Related Disorders

Elsie Breet and Christine Lochner

Background

Significant advances have been made in characterizing the phenomenology and psychobiology of obsessive-compulsive disorder (OCD) and OCD related disorders (OCRDs) in recent years. It has become increasingly evident that these conditions are not homogeneous entities. Indeed, it has been argued that the heterogeneity typical of OCRDs and related disorders has possibly confounded clinical and biological investigation and may explain some of the inconsistencies across studies.

There is increasing recognition of the role that gender plays in the heterogeneity of these conditions. For example, in OCD, the literature supports a role for gender in obsessive-compulsive symptomatology, comorbidity patterns, genetics, and course of the illness (Lochner and Stein 2003) (covered in Chap. 4). Thus, we undertook a review of the literature on the other OCRDs as categorized in DSM-5 (i.e. body dysmorphic disorder [BDD], hoarding disorder, trichotillomania (hair-pulling disorder) [HPD], and excoriation (skin picking) disorder [SPD]) with a specific focus on gender. In this chapter, each of these conditions will be discussed focusing on phenomenology, psychobiology, pharmacotherapy, and psychotherapy, with special reference to the effects of gender in each section.

E. Breet • C. Lochner (✉)

MRC Unit on Anxiety and Stress Disorders, Department of Psychiatry,
University of Stellenbosch, Stellenbosch, South Africa
e-mail: cl2@sun.ac.za

Body Dysmorphic Disorder (BDD)

Diagnosis

BDD is characterized by a preoccupation with barely perceptible or imagined flaws or defaults about physical appearance that the person may believe is deformed or unattractive (American Psychiatric Association (APA) 2013). Although the word ‘preoccupation’ is not operationalized in the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5) (APA 2013), it is understood to mean that thoughts of the perceived defect should last for at least an hour or longer per day (Phillips 2009). These preoccupations can focus on any body part, such as skin (e.g. wrinkles), hair (e.g. excessive body hair), and nose (e.g. size) (Phillips and Kaye 2007). Among adolescent samples, preoccupations have been found to focus mainly on skin, hair, and stomach (Phillips et al. 2006a).

BDD differs from normal appearance concerns in that BDD is associated with excessive preoccupations and consequent behaviours related to the person’s appearance (e.g. mirror-checking, asking for reassurance) that are time-consuming, difficult to control/resist and that cause significant distress or impairment in functioning (APA 2013). Level of insight may vary; the specifiers used to describe insight regarding beliefs about appearance are good/fair, poor, and delusional/absent. The poor insight specifier is most commonly used in BDD (Vargel and Ulusahin 2001).

Males and females generally present with similar body dysmorphic symptomatology, however, muscle dysmorphia is a form of BDD that occurs almost exclusively in males and is described as a preoccupation that one’s body is too small, ‘puny’, and inadequately muscular (Pope et al. 2000).

Epidemiology

BDD is a relatively common disorder, affecting 0.7–2.4 % of the general population (Faravelli et al. 1997; Koran et al. 2008; Otto et al. 2001; Rief et al. 2006). Gender distribution appears to be equal across the globe; for example, 2.2 % of males and 2.5 % of females in the USA (Koran et al. 2008); and 1.4 % of males and 1.9 % of females in Germany (Buhlmann et al. 2010; Koran et al. 2008). The prevalence rate of BDD differs across settings; however, studies in clinical samples report a prevalence of 9–12 % among dermatology patients and 3–53 % among cosmetic surgery patients, 8–37 % among OCD patients, 11–13 % among social anxiety disorder patients, and 26 % among individuals with HPD (Aouizerate et al. 2003; Brawman-Mintzer et al. 1995; Castle et al. 2004; Hollander et al. 1993; Ishigooka et al. 1998; Perugi et al. 1997; Phillips et al. 1996, 2000; Sarwer et al. 1998; Uzun et al. 2003; Vargel and Ulusahin 2001; Vindigni et al. 2002). In adolescent samples, prevalence rates ranging between 6.7 and 14 % in psychiatric inpatient settings (Phillips and Rogers 2011) and 2.2 % in high school settings (Mayville et al. 1999) have been reported. Gender distribution within these contexts is not, however, always reported.

Developmental Course

BDD usually begins during adolescence and follows a chronic course if not treated (Phillips et al. 2005; Phillips and Diaz 1997). Regarding gender differences, some studies report that females demonstrate a slightly higher prevalence and earlier symptom onset of BDD compared to males, while other studies suggested that there are more similarities than differences between males and females with BDD (Phillips and Diaz 1997; Phillips et al. 2006b). In one study, males with BDD were significantly older, more likely than females to be obsessed with their genitals, body build, and thinning hair/balding, excessive weight lifting, and to have comorbid substance use disorders (Phillips et al. 2006b). On the other hand, females were more likely than males to obsess about their skin, stomach, weight, breasts/chest, buttocks, thighs, legs, hips, toes, and excessive body/facial hair, while also being excessively concerned with more body areas compared to males (Phillips et al. 2006b). Females also reported performing more repetitive and safety behaviours, and were more likely to use camouflaging techniques, check mirrors, change their clothes, pick their skin, and have comorbid eating disorders (Phillips et al. 2006b). BDD may occur in older individuals although not many studies have included an older age group and with some reporting a decrease in the prevalence of BDD after the age of 44 years (Koran et al. 2008). The clinical features of BDD in adolescents and adulthood share many similarities. Differences include higher reported rates of delusional BDD beliefs and lifetime rates of suicide attempts among adolescents when compared with adults (Phillips et al. 2006a).

Psychobiology

Genetics

In two different samples, Phillips and colleagues found that between 5.8 and 6.4 % of first-degree relatives of BDD probands had BDD (Phillips et al. 2005). There also is some evidence to suggest a familial link with OCD (Bienvenu et al. 2000). However, further genetic investigation is needed in order to identify candidate genes involved in BDD (Chosak et al. 2008).

Neuroimaging

There have been relatively few neuroimaging studies have of BDD. An early SPECT study suggested that changes in frontostriatal and temporoparietaloccipital circuits may play a role in BDD (Carey et al. 2004). A more recent fMRI study concluded that abnormalities in visual processing and frontostriatal systems may be associated with the BDD (Feusner et al. 2010). A study of brain morphology reports significantly smaller mean volumes of orbitofrontal cortex and anterior cingulate cortex in individuals with BDD when compared to healthy controls (Atmaca et al. 2010).

Further work is needed to determine whether genetic and neuroimaging findings differ by sex in BDD.

Evaluation

Assessment

There are a number of measures that may be used to assess BDD. These include the *Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS)* (Phillips et al. 1997), the *Body Dysmorphic Disorder Examination (BDDE)* (Rosen and Reiter 1996), and the *Psychiatric Status Rating Scale for Body Dysmorphic Disorder (BDD-PSR)* (Phillips et al. 2006b). Insight into the excessiveness or irrationality of symptoms can be assessed with the *Brown Assessment of Belief Scale (BABS)* (Eisen et al. 1998). Although these measures can be used to assess BDD in both males and females, there may be sex differences across the scales. For example, in a study of 200 participants in the USA, the BDDE reported more severe BDD among females, whereas in the same sample, the BDD-PSR reported more severe BDD among males compared to females (Phillips et al. 2006b).

Differential Diagnosis

BDD shares many clinical features with other psychiatric disorders. If concerns are focused on being fat, an eating disorder should be diagnosed instead of BDD (APA 2013). In BDD, the preoccupations and repetitive behaviours are concerned with appearance; this is not the focus of obsessions and compulsions found in other obsessive-compulsive and related disorders. For example, if any form of hair removal (e.g. plucking or pulling) is done in order to improve a perceived flaw or impairment in facial appearance, BDD should be diagnosed and not HPD (APA 2013). Illness anxiety disorder is distinguished from BDD in that BDD is not preoccupied with having or acquiring any serious illness (APA 2013). Depression is differentiated from BDD because in BDD preoccupations and repetitive behaviours are focused on appearance (APA 2013). Although anxiety disorders are common in BDD, the social anxiety or avoidance in BDD is due to perceived appearance-related defects or fear that others may reject or ridicule the patient because of perceived flaws or defects (APA 2013). BDD is distinguished from psychotic disorders in that the delusions are related to appearance and other psychotic symptoms (e.g. disorganized behaviour) are absent (APA 2013).

Psychotherapy

Cognitive-behavioural therapy (CBT) that specifically targets BDD symptoms is currently considered first-line psychotherapy for this condition (Phillips and Rogers 2011). Similar to OCD, CBT for BDD primarily consists of cognitive restructuring (to change the assumptions and beliefs of the perceived flaw) and exposure and response prevention (ERP) (Gupta et al. 2013). These cognitive-behavioural strategies are aimed at changing maladaptive beliefs and perceived defaults/flaws, and in doing so, placing less focus on the minor details of physical appearance (Gupta et al. 2013). The ERP part of therapy entails revealing a perceived defect in social

situations (e.g. in a shopping mall) without the usual ‘cover up’ rituals (e.g. wearing excessive make-up to cover it). CBT consisting of cognitive restructuring and ERP has been used effectively to decrease preoccupation and time spent on repetitive behaviours in BDD (McKay et al. 1997). Additional strategies – such as perceptual retraining with mirrors, or habit reversal for BDD-related skin picking – may also be used (Phillips and Rogers 2011). Notably, intensive engagement and ongoing motivational interventions are often needed when treating BDD patients as many of these patients have poor or absent insight (Phillips et al. 2010; Phillips and Rogers 2011). Although BDD-specific CBT has been used to effectively treat this disorder among adolescents, there is a paucity of work investigating whether and how these techniques have been adapted and tested in this age group (Phillips and Rogers 2011). No sex differences have been reported in response to psychotherapy BDD.

Pharmacotherapy

In BDD, SRIs such as clomipramine, fluvoxamine, fluoxetine and citalopram have all shown efficacy or partial efficacy (Allen and Hollander 2000). There are preliminary data (Allen et al. 2008; Phillips et al. 1996) that suggest that serotonin-norepinephrine reuptake inhibitors such as venlafaxine may also be efficacious for BDD. Currently, it is recommended that SSRIs should be used for at least 12 weeks and should be taken at higher doses for the optimal therapeutic effect (Phillips and Hollander 2008). Antipsychotics, benzodiazepines, lithium, antiepileptics, and monoamine oxidase inhibitors (MAOIs) have also been used to treat BDD with varied success (Gupta et al. 2013). Although the research is limited, SRIs are more effective when compared to non-SRI antidepressants or other types of psychotropic medication (Phillips and Hollander 2008). In children and adolescents, SRIs have also shown clinically significant improvement in BDD symptoms (Albertini et al. 1996; Phillips et al. 1995). However, caution is necessary when treating patients in this age group given concerns about suicidality and SRI use in adolescents (Phillips and Rogers 2011). If successful, SRI treatment may result in less frequent and intense appearance preoccupations, decreased BDD-related stress, and less intense urges and less time spent performing compulsive/safety behaviours (Phillips and Hollander 2008). Anecdotally, some patients with BDD may obtain added benefit from the combination of an SRI and CBT, but there are no systematic comparisons of pharmacotherapy, psychotherapy, and their combination. No studies report sex differences with regard to treatment outcomes in response to pharmacotherapy in BDD.

Hoarding Disorder

Diagnosis

The core feature of hoarding disorder is persistent difficulty discarding or parting with possessions regardless of their actual value (APA 2013). Here, the word

‘persistent’ refers to a long-standing difficulty rather than a temporary situation/event (e.g. inheriting property) that results in excessive clutter. The difficulty associated with discarding possessions may be related to sentimental significance, beliefs that the item may be needed in the future, that getting rid of the possession may be wasteful (Gilliam and Tolin 2010), or to aesthetic issues (Frost et al. 2011b). Use of the word ‘discarding’ in DSM suggests that the difficulty experienced by the individual with hoarding disorder is not only limited to the act of throwing away of possessions but also includes any attempt to sell, give away, or recycle possessions (Frost et al. 2011b). Since children are often not in control of their living environment and discarding behaviour it may be necessary to consider adapting some of the criteria (e.g. Criterion C) used to diagnose hoarding disorder (Plimpton et al. 2009). The items saved by people who hoard are not necessarily limited to worthless or worn-out things but may also include things that are new (Frost et al. 2011b). Commonly saved items are magazines or newspapers, books, notes, and clothes (Frost and Gross 1993; Frost and Hartl 1996).

Individuals with hoarding disorder *purposefully* save possessions or are reluctant to discard items, so the saving behaviour is not passive or merely due to messiness/laziness (Frost et al. 2011b). Disorganized clutter is the hallmark consequence of hoarding disorder and results in an area becoming so cluttered or filled up that it is nearly impossible to use the space for its intended use or to find important items among the clutter (Tollin et al. 2008b). For example, the individual who hoards may not be able to sleep in the bed, sit in a chair, or eat at the table due to the clutter. These spaces usually refer to living areas of the home (e.g. kitchen) rather than to areas of the home that are commonly used for storage (e.g. garage) (Saxena and Maidment 2004).

Pathological hoarding results in clinically significant distress or impairment in functioning. For example, utilities such as water or electricity may be cut off (Kim et al. 2001), health may be compromised due to unsanitary living conditions (Frost et al. 2000), or relationships may deteriorate due to the hoarding (Tolin et al. 2008b).

In addition to the diagnostic criteria, DSM-5 also includes a specifier for excessive acquisition. Individuals with hoarding disorder may exhibit excessive acquisition behaviour in the form of compulsive buying, excessive acquiring of free items (Frost et al. 2001; Frost et al. 2009), and stealing (Nordsletten et al. 2013). Insight into the hoarding behaviour and its implications may vary, and DSM-5 has included a specifier to indicate good/fair, poor, or absent insight/delusional beliefs. Generally, patients with hoarding disorder demonstrate poor insight (Frost and Hartl 1996; Matsunaga et al. 2010) necessitating that family and friends report the case to the relevant authorities or seek help (Tolin et al. 2010a).

The phenomenology of hoarding disorder does not differ significantly between males and females. Therefore, DSM-5 criteria are equally suitable for both sexes (Mataix-Cols et al. 2010). There is a paucity of studies on gender differences in comorbidity patterns among individuals with hoarding disorder. Nevertheless, in one study, it was found that in adults with hoarding disorder, males with hoarding disorder were more likely than females to meet the diagnostic criteria for OCD (Frost et al. 2011a). In children with OCD, more girls compared to boys report symptoms of hoarding (Mataix-Cols et al. 2008).

Epidemiology

The point prevalence of clinically significant hoarding among community samples in the USA and Europe ranges from 2 to 5 % (Iervolino et al. 2009; Mueller et al. 2009; Samuels et al. 2008). It is possible that the prevalence of hoarding increases with age because compulsive hoarding is a chronic and progressive disorder (Grisham and Norberg 2010). Certainly, older individuals are more likely than children/adults to report clinically significant symptoms of hoarding disorder (Samuels et al. 2008). Notably, one study reported that hoarding was almost three times more prevalent in individuals over the age of 54 years when compared to younger individuals aged 34–44 years (Samuels et al. 2008).

Research findings have yielded mixed results with regard to sex differences in the prevalence of hoarding disorder. Two epidemiological studies reported that adult males were twice as likely to report symptoms related to hoarding (Iervolino et al. 2009; Samuels et al. 2008) than females. In adolescence, prevalence rates of 2 % have been reported with higher rates among girls than boys (Ivanov et al. 2013).

Development Course

Hoarding disorder generally develops during childhood or adolescence (Grisham et al. 2006), usually between 11 and 15 years (Ayers et al. 2010), although age of onset can be as young as 4 years (Ayers et al. 2010; Plimpton et al. 2009). One study found that 60 % of participants reported having experienced hoarding symptoms before the age of 12 years, while 80 % reported age of onset by the age of 18 years (Grisham et al. 2006). Although the majority of individuals with pathological hoarding experience a gradual increase of these symptoms throughout their lifetime (Samuels et al. 2008), others may develop symptoms related to hoarding disorder after experiencing a stressful life event (Grisham et al. 2006). Hoarding disorder appears to follow a chronic course with few individuals reporting full remission (Pinto et al. 2007). Clinically significant problems of hoarding are more frequently reported among older (mean age 50 years) compared to younger individuals (Pertusa et al. 2008; Samuels et al. 2008).

Evaluation

Assessment

Earlier measures that assessed hoarding did so with the assumption that hoarding was a form of OCD (Frost et al. 2011b); i.e. hoarding obsessions and compulsions have been measured with the Yale–Brown Obsessive Compulsive Scale (Y-BOCS) (Goodman et al. 1989). More recently, self-report (e.g. Saving Inventory-Revised) (Frost et al. 2004), interview (Hoarding Rating Scale-Interview) (Tolin et al. 2010b), and observational measures (The Clutter Image Rating Scale) (Frost et al. 2008) have been developed to specifically assess hoarding behaviour. Although males and females do not seem to differ in terms of clutter or difficulties discarding items, some

studies have reported sex differences in acquisition (Frost et al. 2011a). For example, in one study, females scored higher than males on the excessive acquisition subscale of the Saving Inventory-Revised (Frost et al. 2004). However, not all data are consistent; one study found that females with hoarding disorder scored higher on the compulsive buying but not the excessive acquisition of free things when assessed with the Compulsive Acquisition Scale (CAS) (Frost et al. 2002).

Psychobiology

Genetic

Many individuals with hoarding disorder report at least one first-degree relative with hoarding symptoms (Pertusa et al. 2008; Samuels et al. 2007; Seedat and Stein 2002). Family studies report that both genetic and non-shared environmental factors account for the variance in symptoms of hoarding (Iervolino et al. 2009). Twin studies have reported a strong phenotypic correlation between excessive acquisition and difficulty discarding, suggesting that there may be a significant genetic overlap in their co-occurrence in hoarding disorder (Nordsletten et al. 2013). Twin studies among adolescents provided support for a genetic influence in the variation of hoarding symptoms among boys but not girls (Ivanov et al. 2013). Rather, shared and non-shared environmental effects explained a significant portion of the variance in hoarding symptoms among girls (Ivanov et al. 2013). Research to investigate candidate genes for hoarding disorder is still in its infancy, and there are no known studies reporting sex difference in this regard.

Neuroimaging

Compared to individuals with OCD with hoarding symptoms, individuals with hoarding disorder show abnormal activity in the frontal cortical regions and the anterior cingulate cortex (ACC) (e.g. areas which are involved in executive functioning such as decision-making) (Krain et al. 2006; van Veen and Carter 2002), prefrontal cortex (Tolin et al. 2009), and the temporal regions (involved in memory) (Read 1981). In a study to examine the neural mechanisms of impaired decision-making in hoarding disorder, the authors concluded that biphasic abnormality in ACC and insula function was associated with problems in identifying the emotional significance of a stimulus, generating appropriate emotional responses, or regulating affective state during decision-making (Tolin et al. 2012). Functional magnetic resonance imaging in a sample of OCD participants in which some met the criteria for hoarding disorder suggested that participants with comorbid hoarding disorder have increased activity in the left lateral OFC and parahippocampal gyrus when compared to participants with only OCD (Tolin et al. 2009). These neuroimaging studies did not report on sex differences.

Neuropsychological Testing

Neuropsychological testing has shown deficits in attention (Grisham et al. 2007), organization, decision-making/planning (Lawrence et al. 2006), and memory (Hartl

et al. 2004) among individuals with pathological hoarding. A study that investigated executive functioning in older individuals with hoarding disorder suggested significant dysfunction in certain areas (e.g. mental control, inhibition, working memory, and set shifting) compared to healthy controls, and this impairment was associated with increased symptom severity (Ayers et al. 2013). To our knowledge, there is currently no literature on differences between males and females in terms of neuropsychological functioning in HD.

Differential Diagnosis

Hoarding disorder is not diagnosed if the symptoms are related to a medical condition (e.g. brain lesions in the anterior ventromedial prefrontal and cingulate cortices following injury) (Anderson et al. 2005). A distinction should be made between symptoms related to hoarding disorder, neurodevelopmental disorders (Ivanov et al. 2013), or neurodegenerative disorders like Alzheimer's disease. A diagnosis of hoarding disorder should not be made if the accumulation of items is due to delusions or symptoms related to schizophrenia spectrum or psychotic disorders (APA 2013). The accumulation of items may also be due to psychomotor retardation, fatigue, or loss of energy during a major depressive episode in which case hoarding disorder should not be diagnosed (APA 2013). In OCD, the hoarding behaviour is usually unwanted and distressing (APA 2013). Moreover, excessive acquisition is generally not present in OCD, but if it does occur, the behaviour is usually related to a specific obsession (e.g. buying items that have been accidentally touched in order to avoid contamination of others) (Mataix-Cols et al. 2010). Individuals who exhibit hoarding behaviour that is related to OCD are more likely to accumulate bizarre items (e.g. such as rotten food or bodily products) (Mataix-Cols et al. 2010).

Psychotherapy

Since CBT used to treat OCD has not yielded effective treatment outcomes in individuals with hoarding disorder (Frost and Tolin 2008; Steketee and Frost 2003, 2007), a CBT model adjusted for compulsive hoarding was developed. This model targets motivational concerns, improving information-processing deficits, cognitive reconstruction of beliefs about and attachment to possessions, and behavioural avoidance that is maintaining hoarding symptoms (Gilliam and Tolin 2010). In addition to ERP, CBT for hoarding disorder also includes excavation of saved material and decision-making training (Saxena and Maidment 2004). Compulsive hoarding has been treated successfully with this particular CBT model of hoarding (Frost 2010) with no apparent sex differences in outcome. The combination of CBT and pharmacotherapy may anecdotally be useful in the treatment of hoarding disorder (Saxena 2011).

Pharmacotherapy

There is preliminary evidence that some of the SRIs, e.g. paroxetine, or other medications like the serotonin-norepinephrine reuptake inhibitor venlafaxine may be effective in the treatment of hoarding disorder (Saxena 2011). It is not known, however, whether males and females with hoarding disorder differ with regard to their response to these medications.

Trichotillomania (Hair-Pulling Disorder)

Diagnosis

In DSM-5, a key diagnostic criterion for trichotillomania (hair-pulling disorder or HPD) is the recurrent pulling of one's own hair, resulting in hair loss (APA 2013). Hair-pulling may occur anywhere on the body where hair grows, the most common areas being the scalp, eyebrows, and eyelashes (Papadopoulos et al. 2003; Reeve et al. 1992; Stanley et al. 1994). Although hair-pulling may be localized and visible, it may also be distributed across different areas in order to make the hair-pulling less noticeable (Stein et al. 2010). Males are more likely than females to pull hair from a variety of areas, and more frequently pull hair from the face, chest, and abdomen (Christenson et al. 1994). Hair-pulling behaviour may occur for brief periods, prolonged episodes, or occur dozens of times a day for seconds or minutes at a time (Walsh and McDougle 2001). Individuals who meet the diagnostic criteria for HPD make repeated attempts to decrease or stop the hair-pulling (Lochner et al. 2012b; APA 2013). Some barriers that may be used to decrease or stop hair-pulling include wearing hats/mittens, or alternative activities (e.g. sitting on hands) (Walsh and McDougle 2001). Pathological hair-pulling may cause clinically significant distress in several areas (e.g. social, occupational, or academic) of the individual's life (APA 2013). For example, HPD has been found to be associated with impaired social functioning, lowered career aspirations, missed work days, (Diefenbach et al. 2005; Seedat and Stein 1998; Woods et al. 2006), and family rupture (Moore et al. 2009).

Epidemiology

Earlier research considered HPD to be a rare disorder; however, today it is considered to be much more common. Slight discrepancies across prevalence studies may be due to methodological issues (e.g. different definitions used) and cultural norms (e.g. hair loss may be more acceptable among males than females) (Duke et al. 2010). Large-scale epidemiological studies are needed to establish prevalence rates of HPD among different age groups.

HPD is more frequently noted in females than males. A study of college students reported a life time prevalence of 0.6–3.4 % in females and 0.6–1.5 % in males (Christenson et al. 1991). One study in children with HPD reported a female-to-male ratio of 2.5:1 (Oranje et al. 1986). Similarly, an adult sample showed a

female-to-male ratio of 2:1 (King et al. 1995). During toddlerhood through to early childhood, there appears to be approximately equal reported rates of HPD between males and females, while in late childhood through to adulthood more females compared to males report HPD (Labouliere and Storch 2012).

Developmental Course

HPD demonstrates a bimodal symptom onset, occurring either in infancy or in adolescence (Swedo and Rapoport 1991). The mean age of onset for adult HPD is 13 years with a later age onset considered to be associated with more severe symptoms, greater treatment resistance, and a higher likelihood of comorbidity with other mental disorders (Swedo et al. 1992; Winchel 1992). The symptom severity of HPD tends to increase through adolescence, peaking from the age of 16 to 18 years, and decreasing in severity with age (Flessner et al. 2008b).

Psychobiology

The specific causes of HPD have not yet been established. Multiple independent or interdependent pathways that may be biological, psychological, or social may be relevant (Diefenbach et al. 2000). For example, an individual with a genetic vulnerability to emotional dysregulation through biological processes may develop hair-pulling behaviour triggered by a traumatizing or stressful life event (i.e. hair-pulling to reduce anxiety) (Duke et al. 2010).

Genetic

A twin study to investigate differences in HPD rates among monozygotic and dizygotic twin pairs provided some evidence for the heritability of HPD (Novak et al. 2009). Mutations on the SLITRK1 genes have been suggested to be implicated in HPD (Zuchner et al. 2006). More recent findings indicate that sapap3 gene variants may play a role in HPD as well as OCD (Hemmings et al. 2011; Zuchner et al. 2009). More research is needed to investigate whether or not sex differences are relevant to these findings.

Neuroimaging

HPD has been associated with reduced neural activity in the left putamen (Chamberlain et al. 2007) and heightened brain metabolism in the cerebellum as well as right superior parietal cortex (Swedo and Rapoport 1991). Positron emission tomography indicated that females with HPD had significantly increased global grey matter and normalized cerebellar as well as right superior parietal glucose metabolic rates when compared to healthy controls (Swedo et al. 1992). More recently, increased grey matter density was found in the left amygdalohippocampal complex, left striatum, and numerous cortical regions among individuals with HPD (Chamberlain et al. 2008). In terms of white matter, more work is needed; findings vary across studies (Chamberlain et al. 2010; Roos et al. 2013).

Hormonal System

Early research studies provided some evidence for premenstrual exacerbation of HPD symptoms (Christenson et al. 1992; Keuthen et al. 1997). One study to assess compulsive hair-pulling among a sample of pregnant females reported that in some females pregnancy may be associated with increased symptoms of hair-pulling (Keuthen et al. 1997).

Evaluation

Assessment

HPD assessment should consist of making a diagnosis, developing a functional analysis that informs treatment planning, and determining a baseline symptom severity in order to track treatment progress (Diefenbach et al. 2005). A number of diagnostic interviews and symptom severity measures are available (Duke et al. 2010). For example, self-report measures include the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) to measure hair-pulling severity and urges associated with pulling (Keuthen et al. 1995) and the Milwaukee Inventory for Style of Trichotillomania-Adult Version (MIST-A) to assess automatic and focused trichotillomania subtypes (Flessner et al. 2008c). The Psychiatric Institute Trichotillomania Scale (PITS) is a clinician rating scale used to assess pulling sites, duration, frequency, interference, distress, and severity of hair loss (Stanley et al. 1999). The NIMH Trichotillomania Severity Scale (NIMH-TSS) is a clinical interview used to assess time, resistance, distress, and interference (Goodman et al. 1989). In children, the Trichotillomania Scale for Children (TSC) (Tolin et al. 2008a) may be used to assess distress and severity, while the Milwaukee Inventory for Style of Trichotillomania-Child Version (MIST-C) (Flessner et al. 2007) is used to measure the degree to which children and adolescents engage in focused and automatic hair-pulling.

Differential Diagnosis

HPD is not diagnosed when hair loss/removal is due to normative hair removal/manipulation (e.g. to improve physical appearance), concerns related to other obsessive-compulsive and related disorders (e.g. body dysmorphic disorder) (APA 2013), neurodevelopmental disorders (e.g. tic disorders) (Duke et al. 2010), a psychotic disorder (e.g. delusions that by pulling the hair out is a way of riding oneself from demons) (Franklin and Tolin 2007), or another medical condition (e.g. alopecia areata) (Sah et al. 2008).

Psychotherapy

Various types of behavioural modification approaches are used to treat HPD. Habit-reversal techniques are considered effective in children/adolescents as well as adults (Labouliere and Storch 2012; Ninan et al. 2000). The main components of this treatment modality are self-monitoring pulling behaviours, developing coping strategies

(i.e. addressing situations where pulling occurs and using alternative behaviours to avoid pulling), obtaining social support networks, relaxation therapy, learning competing responses (e.g. clenching fists or sitting on hands) (Sah et al. 2008), and awareness training (e.g. to help the individual become alert to hair-pulling triggers) (Flessner et al. 2008a). During therapy, patients should also be encouraged to learn from relapses rather than considering them to be failures. Some evidence suggests that behavioural therapy is more effective than pharmacotherapy (Flessner et al. 2008a; Ninan et al. 2000). However, the effect of behavioural and cognitive strategies may vary across individuals (Mansueto et al. 1999). There is no evidence to suggest that males and females differ with regard to treatment outcomes with psychotherapy.

Pharmacotherapy

The effectiveness of SSRIs in the treatment of HPD has yielded mixed findings with a number of studies indicating that SSRIs are not efficacious in reducing hair-pulling symptoms among children/adolescents or adults (Franklin et al. 2011; Labouliere and Storch 2012). More recent pharmacotherapy developments suggest that treatment approaches that address non-serotonergic neurotransmitter systems may be effective in reducing pulling behaviour and pulling urges (Franklin et al. 2011). For example, a glutamate modulator (*N*-acetylcysteine [NAC]) (Grant et al. 2009), an opioid antagonist (naltrexone) (De Sousa 2008), and an atypical neuroleptic (olanzapine) (Van Ameringen et al. 2010) have been reported to be effective in treating HPD. There is some evidence that combined treatment of behavioural therapy with pharmacotherapy may be useful (Franklin et al. 2011). No sex differences have been reported with regard to pharmacotherapy in HPD.

Excoriation (Skin Picking) Disorder

Diagnosis

Excoriation (skin-picking) disorder (SPD) is characterized by recurrent picking of skin that leads to tissue damage (Grant et al. 2012a; APA 2013). Individuals may spend a significant portion of each day picking their skin with many reporting that they spend several hours each day engaged in skin picking behaviour (Tucker et al. 2011; Keuthen et al. 2000; Wilhelm et al. 1999). The triggers for skin picking vary and may be associated with the individual's emotional state (e.g. feelings of stress, anxiety, boredom, or anger) or by the feel (e.g. a scab) or appearance (e.g. insect bite) of the skin (Grant et al. 2012a). Generally, individuals will use their fingernails to pick their skin, but an instrument (e.g. tweezers, pins) may also be used (Hayes et al. 2009). Those who engage in skin picking often pick areas on the face, back, neck, or scalp (Arnold et al. 1998; Bohne et al. 2002; Keuthen et al. 2000; Wilhelm et al. 1999). Individuals may initially not be aware that they are picking but become aware of this over a certain period of time, for example, when someone else brings it to their attention (Grant et al. 2007; Keuthen et al. 2000). Individuals with SPD

make repeated attempts to decrease or stop picking their skin (Lochner et al. 2012a; APA 2013). The picking causes significant distress or impairment in social, academic, work, or other areas of functioning (Flessner and Woods 2006; Lochner et al. 2012a). The word *distress* emphasises the negative effects – such as shame and embarrassment – that may be experienced by the individual with SPD (Hayes et al. 2009). Pathological skin picking is more frequently diagnosed in females than males (Grant et al. 2012a; Hayes et al. 2009).

Epidemiology

Prevalence rates for skin picking disorder vary from 1.2 to 5.4 % in student, community, and dermatology samples (Odlaug and Grant 2012). In the general population, a lifetime prevalence of 1.4 % has been estimated (Keuthen et al. 2010). Although SPD is common in both sexes, there is a trend that females are more likely than males to report skin picking (Grant et al. 2012a).

Development Course

The age of onset for SPD varies. The condition may occur in childhood (<10 years old), adolescence (estimated mean age 13–15 years), or later in life (between ages 30 and 45) (Arnold et al. 1998; Calikusu et al. 2003; Keuthen et al. 2000; Odlaug and Grant 2007; Simeon et al. 1997). Clinical studies show that SPD is chronic (Bohne et al. 2005).

Early onset of SPD has been associated with a longer duration of skin picking before seeking treatment, and more frequent non-conscious picking when compared to individuals with late onset SPD (Odlaug and Grant 2007). The same study found no significant difference between early and late onset SPD with regard to symptom severity, comorbidity, and social functioning (Odlaug and Grant 2007a). One study suggested that males with SPD derived more pleasure from skin picking, and picked from areas that were less visible (Calikusu et al. 2012).

Psychobiology

Neuroimaging

There is a paucity of neuroimaging studies in SPD. A diffusion tensor imaging (DTI) study has, however, indicated that disorganization of the tracts involved in motor generation and suppression is implicated in the pathophysiology of SPD (Grant et al. 2012b).

Neuropsychological Testing

Impaired inhibitory control may be implicated in SPD (Grant and Odlaug 2009). Response inhibition is dependent on neural circuitry that includes the inferior

frontal gyrus and is affected by the noradrenaline system suggesting that dysregulation in noradrenaline and the inhibitory network may play a role in SPD (Grant and Odlaugh 2009). Sex differences in such inhibitory control have not, however, been reported in SPD.

Evaluation

Assessment

The initial interview should assess clinical characteristics of the skin picking behaviour. Clinical questions are aimed at establishing the time spent picking per day, the portion of the time spent on picking, the triggers for picking behaviour, the areas of the body picked, and whether picking caused medical complications. Individuals with SPD should also be screened for comorbid psychiatric disorders. The individual should also be screened for alcohol and drug use as skin picking may result from the use of cocaine or methamphetamine.

Differential Diagnosis

SPD should be differentiated from psychotic disorders when the picking of skin is due to a delusion or tactile hallucination (i.e. formication) (APA 2013). Discrimination between disorders with compulsive and impulsive features is necessary to distinguish SPD from other OCDs. For example, when the skin is picked in order to improve appearance, BDD should be diagnosed and not SPD (Grant et al. 2006). Stereotypical movement disorders may be characterized by repetitive self-injurious behaviour, but onset occurs in the early developmental period, e.g. patients with Prader-Willi syndrome exhibit early onset skin picking (Banga and Connor 2012). SPD is not diagnosed when skin lesions are attributable to factitious disorder in which patients act intentionally similar to individuals with skin picking disorder (Hlal et al. 2013). If the skin picking occurs with the intention to harm oneself, non-suicidal self-injury is diagnosed and not SPD (Snorrason et al. 2012).

Psychotherapy

More females than males seek treatment for SPD (Bohne et al. 2005). A variety of psychotherapeutic approaches have been used to treat SPD. Similar to HPD, HRT (Teng et al. 2006) and acceptance-enhanced behavioural therapy (i.e. combination of habit reversal therapy and commitment therapy) (Flessner et al. 2008a) have demonstrated significant reductions in skin picking. Internet-based treatment may also be useful and requires no patient-therapist interaction (Grant and Odlaugh 2009). Picking behaviour in individuals with a neurodevelopmental disorder or disability may require specialized treatment interventions such as use of protective

clothing (e.g. hat, gloves), response interruption and redirection, punishment, and extinction (Lang et al. 2010). There is currently no literature to suggest that males and female respond differently to the different psychotherapeutic modalities.

Pharmacotherapy

SSRIs such as fluoxetine, escitalopram, or citalopram, and opioid receptor antagonists such as naltrexone and NAC may demonstrate benefit for the treatment of SPD (Banga and Connor 2012; Odlaug and Grant 2007b). No sex differences have been reported in terms of therapeutic outcomes to pharmacotherapy.

Conclusion

This chapter covered a review of the literature on the phenomenology, psychobiology, pharmacotherapy, and psychotherapy of OCDs in DSM-5 with a specific focus on sex. Data have been accumulating on sex differences in prevalence and comorbidity, but there are few data on sex differences in psychobiology or treatment response. Further research is therefore needed to address whether these exist, and if so what the clinical implications are.

References

- Albertini RS, Phillips KA, Guevremont D (1996) Body dysmorphic disorder. *J Am Acad Child Adolesc Psychiatry* 35:1425–1426
- Allen A, Hollander E. 2000. Body dysmorphic disorder. *Psychiatr Clin North Am.* 23(3):617–628
- Allen A, Hadley SJ, Kaplan A, Simeon D, Friedberg J, Priday L, Baker BR, Greenberg JL, Hollander E. 2008. An open-label trial of venlafaxine in body dysmorphic disorder. *CNS Spectr.* 13(2):138–144
- American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington
- Anderson SW, Damasio H, Damasio AR (2005) A neural basis for collecting behaviour in humans. *Brain* 128:201–212
- Aouizerate B, Pujol H, Grabot D, Faytout M, Suire K, Braud C, Auriacombe M, Martin D, Baudet J, Tignol J (2003) Body dysmorphic disorder in a sample of cosmetic surgery applicants. *Eur Psychiatry* 18:365–368
- Arnold LM, McElroy SL, Mutasim DF, Dwight MM, Lamerson CL, Morris EM (1998) Characteristics of 34 adults with psychogenic excoriation. *J Clin Psychiatry* 59:509–514
- Atmaca M, Bingol I, Aydin A, Yildirim H, Okur I, Yildirim MA, Mermi O, Gurok MG (2010) Brain morphology of patients with body dysmorphic disorder. *J Affect Disord* 123(1–3): 258–263
- Ayers CR, Saxena S, Golshan S, Wetherell JL (2010) Age at onset and clinical features of late life compulsive hoarding. *Int J Geriatr Psychiatry* 25:142–149
- Ayers CR, Wetherell JL, Schiehser D, Almklov E, Golshan S, Saxena S (2013) Executive functioning in older adults with hoarding disorder. *Int J Geriatr Psychiatry* 28(11):1175–1181
- Banga A, Connor DF (2012) Effectiveness of Naltrexone for treating pathological skin picking behaviour in an adolescent with Prader-Willi syndrome. *J Child Adolesc Psychopharmacol* 22(5):396–398

- Bienvenu OJ, Samuels JF, Riddle MA, Hoehn-Saric R, Liang KY, Cullen BA, Grados MA, Nestadt G (2000) The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. *Biol Psychiatry* 48(4):287–293
- Bohne A, Wilhelm S, Keuthen N, Baer L, Jenike M (2002) Skin picking in German students: prevalence, phenomenology, and associated characteristics. *Behav Modif* 26:320–339
- Bohne A, Keuthen N, Wilhelm S (2005) Pathologic hairpulling, skin picking, and nail biting. *Ann Clin Psychiatry* 17(4):227–232
- Brawman-Mintzer O, Lydiard RB, Phillips KA, Morton A, Czepowicz V, Emmanuel N, Villareal G, Johnson M, Ballenger JC (1995) Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. *Am J Psychiatry* 152:1665–1667
- Buhlmann U, Glaesmer H, Mewes R, Fama JM, Wilhelm S, Brähler E, Rief W (2010) Updates on the prevalence of body dysmorphic disorder: a population-based survey. *Psychiatry Res* 178(1):171–175
- Calikusu C, Yücel B, Polat A, Baykal C (2003) The relation of psychogenic excoriation with psychiatric disorders: a comparative study. *Compr Psychiatry* 44:256–261
- Calikusu C, Kucukgoncu S, Tecer Ö, Bestepe E (2012) Skin picking in Turkish students: prevalence, characteristics, and gender differences. *Behav Modif* 36:49–66
- Carey P, Seedat S, Warwick J, van Heerden B, Stein DJ (2004) SPECT imaging of body dysmorphic disorder. *J NeuroPsychiatry Clin Neurosci* 16(3):357–359
- Castle DJ, Molton M, Hoffman K, Preston NJ, Phillips KA (2004) Correlates of dysmorphic concern in people seeking cosmetic enhancement. *Aust N Z J Psychiatry* 38:439–444
- Chamberlain SR, Menzies L, Sahakian BJ, Fineberg N (2007) Lifting the veil on Trichotillomania. *Treat Psychiatry* 164(4):568–574
- Chamberlain SR, Menzies LA, Fineberg NA, Del Campo N, Suckling J, Craig K, Müller U, Robbins TW, Bullmore ET, Sahakian BJ (2008) Grey matter abnormalities in trichotillomania: morphometric magnetic resonance imaging study. *Bri J Psychiatry* 193(3):216–221
- Chamberlain SR, Hampshire A, Menzies LA, Garyfallidis E, Grant JE, Odlaug BL, Craig K, Fineberg N, Sahakian BJ (2010) Reduced brain white matter integrity in trichotillomania: a diffusion tensor imaging study. *Arch Gen Psychiatry* 67:965–971
- Chosak A, Dougherty DD, Greenberg JL, Jenike E, Marques L, Wilhelm S (2008) Body dysmorphic disorder and obsessive-compulsive disorder: similarities, differences and the classification debate. *Expert Rev Neurother* 8(8):1209–1218
- Christenson GA, Pyle RL, Mitchell JE (1991) Estimated lifetime prevalence of trichotillomania in college students. *J Clin Psychiatry* 52:415–417
- Christenson GA, Chernoff-Clementz E, Clementz BA (1992) Personality and clinical characteristics in patients with trichotillomania. *J Clin Psychiatry* 53(11):407–413
- Christenson GA, MacKenzie TB, Mitchell JE (1994) Adult men and women with trichotillomania: a comparison of male and female characteristics. *Psychosomatics* 35:142–149
- De Sousa A (2008) An open-label pilot study of naltrexone in childhood-onset trichotillomania. *J Child Adolesc Psychopharmacol* 18:30–33
- Diefenbach GJ, Reitman D, Williamson DA (2000) Trichotillomania: a challenge to research and practice. *Clin Psychol Rev* 20:289–309
- Diefenbach GJ, Tolin DF, Crocetto J, Maltby N, Hannan S (2005) Assessment of trichotillomania: a psychometric evaluation of hair-pulling scales. *J Psychopathol Behav Assess* 27:169–178
- Duke DC, Keeley ML, Geffken GR, Storch EA (2010) Trichotillomania: a current review. *Clin Psychol Rev* 30:181–193
- Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA (1998) The brown assessment of beliefs scale: reliability and validity. *Am J Psychiatry* 155:102–108
- Faravelli C, Salvatori S, Galassi F, Aiazzi L, Drei C, Cabras P (1997) Epidemiology of somatoform disorders: a community survey in Florence. *Soc Psychiatry Psychiatr Epidemiol* 32:24–29
- Feusner JD, Moody T, Hembacher E, Townsend J, McKinley M, Moller H, Bookheimer S (2010) Abnormalities of visual processing and frontostriatal systems in body dysmorphic disorder. *Arch Gen Psychiatry* 67(2):197–205

- Flessner CA, Woods DW (2006) Phenomenological characteristics, social problems, and the economic impact associated with chronic skin picking. *Behav Modif* 30:944–963
- Flessner CA, Woods DW, Franklin ME, Keuthen NJ, Piacentini J, Cashin SE, Moore PS (2007) The Milwaukee inventory for styles of trichotillomania-child version (MIST-C): initial development and psychometric properties. *Behav Modif* 31(6):896–918
- Flessner CA, Busch AM, Heideman PW, Woods DW (2008a) Acceptance enhanced behavior therapy (AEBT) for trichotillomania and chronic skin picking: exploring the effects of component sequencing. *Behav Modif* 32:579–594
- Flessner CA, Woods DW, Franklin ME, Keuthen NJ, Piacentini J (2008b) Cross-sectional study of women with trichotillomania: a preliminary examination of pulling styles, severity, phenomenology, and functional impact. *Child Psychiatry Hum Dev* 40:153–167
- Flessner CA, Conelea CA, Woods DW, Franklin ME, Keuthen NJ, Cashin SE (2008c) Styles of pulling in trichotillomania: exploring differences in symptom severity, phenomenology, and functional impact. *Behav Res Ther* 46(3):345–357
- Franklin ME, Tolin DF (2007) Treating trichotillomania: cognitive-behavioral therapy for hairpulling and related problems. Springer Science and Media, LLC., New York
- Franklin ME, Zragrabbe K, Benavides KL (2011) Trichotillomania and its treatment: a review and recommendations. *Expert Rev Neurother* 11(8):1165–1174
- Frost RO (2010) Treatment of hoarding. *Expert Rev Neurotherapeutic* 10(2):251–267
- Frost RO, Gross RC (1993) The hoarding of possessions. *Behav Res Ther* 31:367–381
- Frost RO, Hartl T (1996) A cognitive-behavioral model of compulsive hoarding. *Behav Res Ther* 34:341–350
- Frost RO, Meagher BM, Riskind JH. 2001. Obsessive-compulsive features in pathological lottery and scratch-ticket gamblers. *J Gambl Stud* 17(1):5–19
- Frost RO, Tolin DF (2008) Compulsive hoarding. In: McKay D (ed) *Clinical handbook of obsessive-compulsive disorder and related problems*. Johns Hopkins University Press, Baltimore, pp 76–94
- Frost RO, Steketee G, Williams L (2000) Hoarding: a community health problem. *J Psychopathol Behav Assess* 8:229–234
- Frost RO, Steketee G, Williams L (2002) Compulsive buying, compulsive hoarding, and obsessive-compulsive disorder. *Behav Ther* 33:201–214
- Frost RO, Steketee G, Grisham J (2004) Measurement of compulsive hoarding: saving inventory-revised. *Behav Res Ther* 42:1163–1182
- Frost RO, Steketee G, Tolin D, Renaud S (2008) Development and validation of the clutter image rating. *J Psychopathol Behav Assess* 30:193–203
- Frost RO, Tolin DF, Steketee G, Fitch K, Selbo-Bruns A (2009) Excessive acquisition in hoarding. *J Anxiety Disord* 23:632–639
- Frost RO, Steketee G, Tolin DF (2011a) Comorbidity in hoarding disorder. *Depress Anxiety* 28(10):876–884
- Frost RO, Steketee G, Tolin DF (2011b) Diagnosis and assessment of hoarding disorder. *Annu Rev Clin Psychol* 8(4):4.1–4.24
- Gilliam CM, Tolin DF (2010) Compulsive hoarding. *Bull Menninger Clin* 74(2):93–121
- Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Chamey DS (1989) The Yale-Brown Obsessive Compulsive Scale. *Arch Gen Psychiatry* 46:1006–1011
- Grant JE, Odlaugh BL (2009) Update on pathological skin picking. *Curr Psychiatry Rep* 11:283–288
- Grant JE, Won Kim S, Crow SJ (2001) Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. *J Clin Psychiatry* 62:517–522
- Grant JE, Menard W, Phillips KA (2006) Pathological skin picking in individuals with body dysmorphic disorder. *Gen Hosp Psychiatry* 28(6):487–493
- Grant JE, Odlaug BL, Kim SW (2007) Lamotrigine treatment of pathologic skin picking: an open-label study. *J Clin Psychiatry* 68:1384–1391
- Grant JE, Odlaug BL, Kim SW (2009) N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania. *Arch Gen Psychiatry* 66:756–763

- Grant JE, Odlaug BL, Chamberlain SR, Keuthen NJ, Lochner C, Stein DJ (2012a) Skin picking disorder. *Am J Psychiatry* 169:1143–1149
- Grant JE, Odlaug BL, Hampshire A, Schreiber LRN, Chamberlain SR (2012b) White matter abnormalities in skin picking disorder: a diffusion tensor imaging study. *Neuropsychopharmacology* 38:763–769
- Grisham JR, Norberg MN (2010) Compulsive hoarding: current controversies and new directions. *Clin Res* 12:233–240
- Grisham JR, Frost RO, Steketee G, Kim HJ, Hood S (2006) Age of onset of compulsive hoarding. *J Anxiety Disord* 20:675–686
- Grisham JR, Brown TA, Savage CR, Steketee G, Barlow DH (2007) Neuropsychological impairment associated with compulsive hoarding. *Behav Res Ther* 45:1471–1483
- Gupta R, Huynh M, Ginsburgh HI (2013) Body dysmorphic disorder. *Semin Cutan Med Surg* 32:78–82
- Hartl TL, Frost RO, Allen GJ, Deckersbach T, Steketee G, Duffany SR et al (2004) Actual and perceived memory deficits in individuals with compulsive hoarding. *Depress Anxiety* 20:59–69
- Hayes SL, Storch EA, Berlanga L (2009) Skin picking behaviors: an examination of the prevalence and severity in a community sample. *J Anxiety Disord* 23:314–319
- Hemmings SM, Boardman L, van der Merwe L, Lochner C, Kinnear CJ, Seedat S, Stein DJ, Moolman-Smook JC (2011) Investigating SAPAP3 variants in the etiology of obsessive-compulsive disorder and trichotillomania in the South African white population. *Compr Psychiatry*. 52(2):181–187
- Hlal H, Barrimi M, Kettani N, Rammouz I, Aalouane R (2014) “Factitious disorder and skin picking: Clinical approach”. A case report. *Encephale* 40:197–201, S0013–7006(13)00157–7
- Hollander E, Cohen LJ, Simeon D (1993) Body dysmorphic disorder. *Psychiatr Ann* 23:359–364
- Iervolino AC, Perroud N, Fullana MA, Guipponi M, Cherkas L, Collier DA, Mataix-Cols D (2009) Prevalence and heritability of compulsive hoarding: a twin study. *Am J Psychiatry* 10:1156–1161
- Ishigooka J, Iwao M, Suzuki M, Fukuyama Y, Murasaki M, Miura S (1998) Demographic features of patients seeking cosmetic surgery. *Psychiatry Clin Neurosci* 52:283–287
- Ivanov VZ, Mataix-Cols D, Serlachius E, Lichtenstein P, Anckarsäter H, Chang Z, Gumpert CH, Lundström S, Långström N, Rück C (2013) Prevalence, comorbidity and heritability of hoarding symptoms in adolescence: a population based twin study in 15-year olds. *PLoS One* 8(7):1–7
- Keuthen NJ, O’Sullivan RL, Ricciardi JN, Shera D, Savage CR, Borgmann AS, Baer JMA (1995) The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. Development and factor analyses. *Psychother Psychosom* 64:141–145
- Keuthen NJ, O’Sullivan RL, Hayday CF, Peets KE, Jenike MA, Baer L (1997) The relationship of menstrual cycle and pregnancy to compulsive hair-pulling. *Psychother Psychosom* 66:33–37
- Keuthen NJ, Deckersbach T, Wilhelm S, Hale E, Fraim C, Baer L, O’Sullivan RL, Jenike MA (2000) Repetitive skin-picking in a student population and comparison with a sample of self-injurious skinpickers. *Psychosomatics* 41:210–215
- Keuthen NJ, Koran LM, Aboujaoude E, Large MD, Serpe RT (2010) The prevalence of pathologic skin picking in US adults. *Compr Psychiatry* 51:183–186
- Kim H-J, Frost RO, Steketee G (2001) Hoarding by elderly people. *Health Soc Work* 26:176–184
- King RA, Zohar AH, Ratzoni G, Binder M, Kron S, Dycian A, Cohen DJ, Pauls DL, Apter A (1995) An epidemiological study of trichotillomania in Israeli adolescents. *J Am Acad Child Adolesc Psychiatry* 34:1212–1215
- Koran LM, Aboujaoude E, Large MD, Serpe RT (2008) The prevalence of body dysmorphic disorder in the United States adult population. *CNS Spectr* 13:316–322
- Krain AL, Hefton S, Pine DS, Ernst M, Castellanos FX, Klein RG, Milham MP (2006) An fMRI examination of developmental differences in the neural correlates of uncertainty and decision-making. *J Child Psychol Psychiatry* 47(10):1023–1030
- Labouliere MA, Storch EA (2012) Pediatric trichotillomania: clinical presentation, treatment, and implications for nursing professionals. *J Pediatr Nurs* 27(3):225–232

- Lang R, Didden R, Machalicek W, Rispoli M, Sigafoos J, Lancioni G, Mulloy A, Regester A, Pierce N, Kang S (2010) Behavioral treatment of chronic skin-picking in individuals with developmental disabilities: a systematic review. *Res Dev Disabil* 31:304–315
- Lawrence NS, Wooderson S, Mataix-Cols D, David R, Speckens A, Phillips ML (2006) Decision making and set shifting impairments are associated with distinct symptom dimensions in obsessive-compulsive disorder. *Neuropsychology* 20:409–419
- Lochner C, Stein D (2003) Heterogeneity of obsessive-compulsive disorder: a literature review. *Harv Rev Psychiatry* 11(3):113–132
- Lochner C, Grant JE, Odlaug BL, Stein DJ (2012a) DSM-5 field survey: skin picking disorder. *Ann Clin Psychiatry* 24(4):300–304
- Lochner C, Grant JE, Odlaug BL, Woods DW, Keuthen NJ, Stein DJ (2012b) DSM-5 field survey: hair-pulling disorder (trichotillomania). *Depress Anxiety* 29:1025–1031
- Mansueto CS, Golomb RG, McCombs TA, Stemberger RMT (1999) A comprehensive model for behavioral treatment of trichotillomania. *Cogn Behav Pract* 6:23–43
- Mataix-Cols D, Nakatani E, Micali N, Heyman I (2008) Structure of obsessive-compulsive symptoms in pediatric OCD. *J Am Acad Child Adolesc Psychiatry* 47:773–778
- Mataix-Cols D, Frost RO, Pertusa A, Clark LA, Saxena S, Leckman JF, Stein DJ, Matsunaga H, Wilhelm S (2010) Hoarding disorder: a new diagnosis for DSM-V? *Depress Anxiety* 27:556–572
- Matsunaga H, Hayashida K, Kiriike N, Nagata T, Stein DJ (2010) Clinical features and treatment characteristics of compulsive hoarding in Japanese patients with obsessive-compulsive disorder. *CNS Spectr* 15(4):258–265
- Mayville MA, Katz RC, Gipson MT, Cabral K (1999) Assessing the prevalence of body dysmorphic disorder in an ethnically diverse group of adolescents. *J Child Family Stud* 8(3):357–362
- McKay D, Todaro J, Neziroglu F, Campisi T, Moritz EK, Yaryura-Tobias JA (1997) Body dysmorphic disorder: a preliminary evaluation of treatment and maintenance using exposure with response prevention. *Behav Res Ther* 35(1):67–70
- Moore PS, Franklin ME, Keuthen NJ, Flessner CA, Woods DW, Piacentini JC, Stein DJ, Loew B, TLC-SAB (2009) Family functioning in pediatric trichotillomania. *Child Family Behav Ther* 31:255–269
- Mueller A, Mitchell JE, Crosby RD, Glaesmer H, de Zwaan M (2009) The prevalence of compulsive hoarding and its association with compulsive buying in a German population-based sample. *Behav Res Ther* 47(8):705–709
- Ninan PT, Rothbaum BO, Marsteller FA, Knight BT, Eccard MB (2000) A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. *J Clin Psychiatry* 61:47–50
- Nordsletten AE, Monzani B, Fernandez de la Cruz L, Iervolino AC, Fullana MA, Harris J, Rijdsdijk F, Mataix-Cols D (2013) Overlap and specificity of genetic and environmental influences on excessive acquisition and difficulties discarding possessions: implications for hoarding disorder. *Am J Med Genet B* 162B:380–387
- Novak CE, Keuthen NJ, Stewart ES, Pauls DL (2009) A twin concordance study of trichotillomania. *Am J Med Genet* 150:944–949
- Odlaug BL, Grant JE (2007a) Childhood-onset pathologic skin picking: clinical characteristics and psychiatric comorbidity. *Compr Psychiatry* 48(4):388–393
- Odlaug BL, Grant JE (2007b). N-acetyl cysteine in the treatment of grooming disorders. *J Clin Psychopharmacol* 27:227–229
- Odlaug BL, Grant JE (2012) Pathologic skin picking. In: Grant JE, Stein DJ, Woods DW, Keuthen NJ (eds) *Trichotillomania, skin picking and other body-focused repetitive behaviors*. American Psychiatric Publishing, Inc, Washington DC, pp 21–41
- Oranje AP, Peereboom-Wynia JD, Raeymaecker DM (1986) Trichotillomania in childhood. *J Am Acad Dermatol* 15:614–619
- Otto MW, Wilhelm S, Cohen LS, Harlow BL (2001) Prevalence of body dysmorphic disorder in a community sample of women. *Am J Psychiatry* 158:2061–2063

- Papadopoulos AJ, Janniger CK, Chodynicky MP, Schwartz RA (2003) Trichotillomania. *Int J Dermatol* 42:330–334
- Pertusa A, Fullana MA, Singh S, Alonso P, Menchón JM, Mataix-Cols D (2008) Compulsive hoarding: OCD symptom, distinct clinical syndrome, or both? *Am J Psychiatry* 165: 1289–1298
- Perugi G, Giannotti D, Frare F, Di Vaio S, Valori E, Maggo L, Cassano GB, Souren H (1997) Prevalence, phenomenology and comorbidity of body dysmorphic disorder (dysmorphophobia) in a clinical population. *Int J Psychiatry Clin Pract* 1:77–82
- Phillips KA (2009) *Understanding body dysmorphic disorder: an essential guide*. Oxford University Press, New York
- Phillips KA, Diaz SF (1997) Gender differences in body dysmorphic disorder. *J Nerv Mental Dis* 185:570–577
- Phillips KA, Hollander E (2008) Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. *Body Image* 5(1):13–27
- Phillips KA, Kaye WH (2007) The relationship of body dysmorphic disorder and eating disorders to obsessive-compulsive disorder. *CNS Spectr* 12(5):347–358
- Phillips KA, Rogers J (2011) Cognitive-behavioural therapy for youth with body dysmorphic disorder: current status and future directions. *Child Adolesc Psychiatr Clin North Am* 20(2):287–304
- Phillips KA, Atala KD, Albertini RS (1995) Body dysmorphic disorder in adolescents. *J Am Acad Child Adolesc Psychiatry* 34:1216–1220
- Phillips KA, Nierenberg AA, Brendel G, Fava M (1996) Prevalence and clinical features of body dysmorphic disorder in atypical major depression. *J Nerv Mental Dis* 184:125–129
- Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK (1997) A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. *Psychopharmacol Bull* 33:17–22
- Phillips KA, Dufresne RGJ, Wilkel CS, Vittorio CC (2000) Rate of body dysmorphic disorder in dermatology patients. *J Am Acad Dermatol* 42:436–441
- Phillips KA, Menard W, Fay C, Weisberg R (2005) Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder. *Psychosomatics* 46:317–325
- Phillips KA, Didie ER, Menard W, Pagano ME, Fay C, Weisberg RB (2006a) Clinical features of body dysmorphic disorder in adolescents and adults. *Psychiatry Res* 141(3):305–314
- Phillips KA, Menard W, Fay C, Weisberg R (2006b) Gender similarities and differences in 200 individuals with body dysmorphic disorder. *Compr Psychiatry* 47(2):77–87
- Phillips KA, Wilhelm S, Koran LM, Didie ER, Fallon BA, Feusner J, Stein DJ (2010) Body dysmorphic disorder: some key issues for DSMV. *Depress Anxiety* 27:573–591
- Pinto A, Eisen JL, Mancebo M, Dyck I, Edelen M, Rasmussen S (2007) A 2-year follow-up study of the course of obsessive-compulsive disorder. In: Paper presented at the association of behavioral and cognitive therapies, Philadelphia
- Plimpton E, Frost R, Abbey B, Dorer W (2009) Compulsive hoarding in children: six case studies. *Int J Cogn Ther* 2:88–104
- Pope HG, Phillips KA, Olivardia R (2000) *The Adonis complex: the secret crisis of male body obsession*. Free Press, New York
- Read DE (1981) Solving deductive-reasoning problems after unilateral temporal lobectomy. *Brain Lang* 12(1):116–127
- Reeve EA, Bernstein GA, Christenson GA (1992) Clinical characteristics and psychiatric comorbidity in children with trichotillomania. *J Am Acad Child Adolesc Psychiatry* 31(1): 132–138
- Rief W, Buhlmann U, Wilhelm S, Borkenhagen A, Brahler E (2006) The prevalence of body dysmorphic disorder: a population-based survey. *Psychol Med* 36:877–885
- Roos A, Fouche JP, Stein DJ, Lochner C (2013) White matter integrity in hair-pulling disorder (trichotillomania). *Psychiatry Res* 211(3):246–250

- Rosen JC, Reiter J (1996) Development of the body dysmorphic disorder examination. *Behav Res Ther* 34:755–766
- Sah DE, Koo J, Price VH (2008) Trichotillomania. *Dermatol Ther* 21(1):13–21
- Samuels JF, Bienvenu OJ, Pinto A, Fyer AJ, McCracken JT, Rauch SL, Murphy DL, Grados MA, Greenberg BD, Knowles JA, Piacentini J, Cannistraro PA, Cullen B, Riddle MA, Rasmussen SA, Pauls DL, Willour VL, Shugart YY, Liang KY, Hoehn-Saric R, Nestadt G (2007) Hoarding in obsessive-compulsive disorder: results from the OCD collaborative genetics study. *Behav Res Ther* 45:673–686
- Samuels JF, Bienvenu OJ, Grados MA, Cullen B, Riddle MA, Liang KY, Eaton WW, Nestadt G (2008) Prevalence and correlates of hoarding behavior in a community-based sample. *Behav Res Ther* 46(7):836–844
- Sarwer DB, Wadden TA, Pertschuk MJ, Whitaker LA (1998) Body image dissatisfaction and body dysmorphic disorder in 100 cosmetic surgery patients. *Plast Reconstr Surg* 101:1644–1649
- Saxena A (2011) Pharmacotherapy of compulsive hoarding. *J Clin Psychol* 67(5):477–484
- Saxena S, Maidment KM (2004) Treatment of compulsive hoarding. *J Clin Psychol* 60(11):1143–1154
- Seedat S, Stein DJ (1998) Psychosocial and economic implications of trichotillomania: a pilot study in a South African sample. *CNS Spectr* 3:40–43
- Seedat S, Stein DJ (2002) Hoarding in obsessive-compulsive disorder and related disorders: a preliminary report of 15 cases. *Psychiatry Clin Neurosci* 56:17–23
- Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E (1997) A double-blind trial of fluoxetine in pathologic skin picking. *J Clin Psychiatry* 58:341–347
- Snorrason I, Belleau EL, Woods DW (2012) How related are hair pulling disorder (trichotillomania) and skin picking disorder? A review of evidence for comorbidity, similarities and shared etiology. *Clin Psychol Rev* 32:618–629
- Stanley MA, Borden JW, Bell GE, Wagner AL (1994) Nonclinical hair pulling: phenomenology and related psychopathology. *J Anxiety Disord* 8(2):119–130
- Stanley MA, Breckenridge JK, Snyder AG, Novy DM (1999) Clinician-rated measures of hair-pulling: a preliminary psychometric evaluation. *J Psychopathol Behav Assess* 21:157–170
- Stein DJ, Grant JE, Franklin ME, Keuthen N, Lochner C, Singer HS, Woods DW (2010) Trichotillomania (hair pulling disorder), skin picking disorder, and stereotypic movement disorder: toward DSM-V. *Depress Anxiety* 27(6):611–626
- Steketee G, Frost RO (2003) Compulsive hoarding: current status of the research. *Clin Psychol Rev* 23:905–927
- Steketee G, Frost RO (2007) *Compulsive hoarding and acquiring: therapist guide*. Oxford University Press, New York
- Swedo SE, Rapoport JL (1991) Annotation: trichotillomania. *J Child Psychol Psychiatry* 32:401–409
- Swedo SE, Rapoport JL, Leonard HL, Schapiro MB, Rapoport SI, Grady CL (1992) Regional cerebral glucose metabolism of women with trichotillomania. *Arch Gen Psychiatry* 49:690–694
- Teng EJ, Woods DW, Twohig MP (2006) Habit reversal as a treatment for chronic skin picking: a pilot investigation. *Behav Modif* 30:411–422
- Tolin D, Diefenbach G, Flessner C, Franklin M, Keuthen N, Moore P, Piacentini J, Stein DJ, Woods DW, Trichotillomania Learning Center Scientific Advisory Board (2008a) The trichotillomania scale for children: development and validation. *Child Psychiatry Human Dev* 39:331–349
- Tolin DF, Frost RO, Steketee G, Fitch KE (2008b) Family burden of compulsive hoarding: results of an internet survey. *Behav Res Ther* 46:334–344
- Tolin DF, Kiehl KA, Worhunsky P, Book GA, Maltby N (2009) An exploratory study of the neural mechanisms of decision making in compulsive hoarding. *Psychol Med* 39(2):325–336
- Tolin DF, Fitch KE, Frost RO, Steketee G (2010a) Family informants' perceptions of insight in compulsive hoarding. *Cogn Ther Res* 34:69–81
- Tolin D, Frost R, Steketee G (2010b) A brief interview for assessing compulsive hoarding: the Hoarding Rating Scale-Interview. *Psychiatry Res* 178:147–152

- Tolin DF, Stevens MC, Villavicencio AL, Norberg MM, Calhoun VD, Frost RO, Steketee G, Rauch SL, Pearlson GD (2012) Neural mechanisms of decision making in hoarding disorder. *Arch Gen Psychiatry* 69:832–841
- Tucker BT, Woods DW, Flessner CA, Franklin SA, Franklin ME (2011) The Skin Picking Impact Project: phenomenology, interference, and treatment utilization of pathological skin picking in a population based sample. *J Anxiety Disord* 25:88–95
- Uzun O, Basoglu C, Akar A, Cansever A, Ozşahin A, Cetin M, Ebrinç S (2003) Body dysmorphic disorder in patients with acne. *Compr Psychiatry* 44:415–419
- Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J (2010) A randomized, double blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. *J Clin Psychiatry* 71:1336–1343
- van Veen V, Carter CS (2002) The anterior cingulate as a conflict monitor: fMRI and ERP studies. *Physiol Behav* 77(4–5):477–482
- Vargel S, Ulusahin A (2001) Psychopathology and body image in cosmetic surgery patients. *Aesthetic Plast Surg* 25:474–478
- Vindigni V, Pavan C, Semenzin M, Grana S, Gambaro FM, Marini M, Bassetto F, Mazzoleni F (2002) The importance of recognizing body dysmorphic disorder in cosmetic surgery patients: do our patients need a preoperative psychiatric evaluation? *Eur J Plast Surg* 25:305–308
- Walsh KH, McDougle CJ (2001) Trichotillomania: presentation, etiology, diagnosis, and therapy. *Am J Clin Dermatol* 2:327–333
- Wilhelm S, Keuthen NJ, Deckersbach T, Engelhard IM, Forker AE, Baer L, O’Sullivan RL, Jenike MA (1999) Self-injurious skin picking: clinical characteristics and comorbidity. *J Clin Psychiatry* 60:454–459
- Winchel RM (1992) Trichotillomania: presentation and treatment. *Psychiatr Ann* 22:84–89
- Woods DW, Flessner C, Franklin ME, Wetterneck CT, Walther MR, Anderson ER, Cardona D (2006) Understanding and treating trichotillomania: what we know and what we don’t know. *Psychiatr Clin North Am* 29:487–501
- Zuchner S, Cuccaro ML, Tran-Viet KN, Cope H, Krishnan RR, Pericak-Vance MA et al (2006) SLITRK mutations in trichotillomania. *Mol Sci* 11:887–889
- Zuchner S, Wendland JR, Ashley-Koch AE, Collins AL, Tran-Vet KN, Quinn K, Timpano KC, Cuccaro ML, Pericak-Vance MA, Steffens DC, Krishnan KR, Feng G, Murphy DL (2009) Multiple rare sapap3 missense variants in trichotillomania and OCD. *Mol Psychiatry* 14:6–9

Trauma and Stressor-Related Disorders

Kate Walsh, Jennifer B. Wells, Briana Lurie,
and Karestan C. Koenen

Introduction

This chapter focuses on gender differences in trauma exposure and the development of posttraumatic sequelae over the life course. First, we review the prevalence of trauma exposure and posttraumatic sequelae with particular attention to comorbidity and disability or impairment. Second, we review psychobiological processes that explain risk for various types of posttraumatic sequelae with a focus on gender and comorbidity. Third, we review the DSM-5 diagnostic criteria for various disorders associated with trauma exposure. Fourth, we review the best available instruments designed to assess these disorders. Fifth, we review the current best practices for treatment of these conditions including psychopharmacology, psychotherapy, and combined approaches designed to treat comorbid conditions. We conclude that despite a large body of research documenting gender differences in trauma exposure and trauma-related disorders much work remains to be done in this area.

Epidemiology

Exposures

Potentially traumatic event (PTE) exposure is common with 60–90 % of adults worldwide reporting exposure to at least one PTE during their lifetime (e.g., Bohnert and Breslau 2011; Kessler et al. 1995; Perkonig et al. 2000; Resnick et al. 1993). PTEs include interpersonal traumas such as rape, mugging, and physical assault as well as non-interpersonal traumas such as flood, fire, and motor vehicle accidents.

K. Walsh, PhD (✉) • J.B. Wells, BA • B. Lurie, BA • K.C. Koenen, PhD
Department of Epidemiology, Columbia University, Mailman School of Public Health,
New York, NY, USA
e-mail: klw2153@cumc.columbia.edu

PTEs also include witnessing death and injury to others and learning of the violent death or injury of a loved one. A meta-analysis examining gender differences in trauma exposure and posttraumatic stress disorder (PTSD) found that men are slightly more likely to report exposure to any PTE compared to women (Tolin and Foa 2006). However, exposure to specific types of PTSD varies greatly by gender.

Interpersonal PTEs

Interpersonal violence occurs over the life course, but it is especially common among children, adolescents, and young adults (e.g., Kilpatrick et al. 1992). For example, nearly 1 in 4 children in the United States has experienced physical, sexual, or emotional abuse (Finkelhor and Jones 2006), and comparable rates have been observed globally (Finkelhor 1994). Interpersonal trauma exposure also differs by gender such that girls and women are more likely to experience interpersonal violence such as sexual assault and childhood sexual abuse compared to boys and men (Kessler et al. 1995; Tolin and Foa 2006). For example, two meta-analyses of international studies of child sexual abuse (CSA) suggest that, on average, slightly less than 10 % of men reported CSA while 10–20 % of women reported CSA prior to age 18 (Finkelhor 1994; Pereda et al. 2009). In the United States, 1 in 5 women and 1 in 71 men have experienced a lifetime rape, defined as attempted or completed forced penetration or drug/alcohol facilitated penetration (Black et al. 2011). Approximately 1 in 3 US women and more than 1 in 4 US men (28.2 %) have experienced physical violence by an intimate partner (Black et al. 2011). These rates are consistent with those observed in other US samples (Walsh et al. 2015) and in other developed countries including Australia (Rees et al. 2011); however, the prevalence of violence exposure is considerably higher among women in developing and war-ravaged nations (Heise et al. 1994). For example, World Health Organization data from women aged 15–49 in multiple countries found that 15–71 % of ever-partnered women have experienced rape by an intimate partner and 5–65 % of women reported experiencing physical or sexual violence since age 15 by a non-partner (World Health Organization 2013). Pregnancy is also a period of potentially increased risk for violence exposure among women, with 3–32 % of women worldwide reporting abuse during the peripartum period (Campbell et al. 2004).

Non-interpersonal PTEs

In a nationally representative US survey, the most commonly reported PTEs included non-interpersonal violence such as the unexpected death of a loved one (25 %), serious illness, accident, or injury to a loved one (21 %), and indirect exposure to terrorism (e.g., watching the events of 9/11 unfold on television; 22 %) (Bohnert and Breslau 2011). In the same survey, 17–30 % of trauma-exposed persons reported experiencing a life-threatening accident and 16–25 % reported experiencing a natural disaster (Pietrzak et al. 2011). Numerous studies suggest that men are more likely than women to experience accidents, natural disasters or fires, witnessing death or injury, and combat or war (Kessler et al. 1995; Tolin and Foa 2006).

Outcomes

Posttraumatic Sequelae

Although stress disorder (PTSD) is the most commonly studied outcome of trauma exposure, most persons exposed to PTEs do not develop PTSD (Bonanno 2005). Indeed, despite the fact that nearly everyone will be exposed to at least one PTE during his or her lifetime (e.g., Bohnert and Breslau 2011), estimated lifetime rates of PTSD range from 4 to 14 % in the United States (Breslau 2002; Roberts et al. 2011). Globally, the prevalence of PTSD is relatively consistent, although higher prevalence of PTSD has been observed in countries with greater exposure to war and torture (Steel et al. 2009). Among US women and men, rape and combat exposure, respectively, are the PTEs associated with the highest conditional probability of developing PTSD (Kessler et al. 1995). Despite the fact that men are more likely to experience any PTE, women are more likely to develop PTSD once exposed to a PTE (Breslau 2002; Breslau and Anthony 2007; Tolin and Foa 2006). Indeed, women are twice as likely to develop PTSD when compared to men (Kessler et al. 1995), a finding that may relate to women's increased risk for sexual violence compared to men (Cortina and Kubiak 2006). Among women only, exposure to assaultive violence has been shown to both increase risk for PTSD both immediately as well as when exposed to later non-assaultive violence (Breslau and Anthony 2007).

Comorbidity

Among those persons who meet diagnostic criteria for lifetime PTSD following a PTE, the vast majority have significantly elevated risks for other lifetime disorders (Kessler et al. 1995; for review see Breslau 2002; Koenen et al. 2008a). Trauma-exposed persons with PTSD consistently have been found to have higher risk for suicide as well as anxiety, mood, and substance use disorders compared to those without PTSD (Breslau et al. 1997; Breslau 2002; Blanco et al. 2013; Kessler 2000). Other psychopathologies have been associated with trauma exposure and/or the development of PTSD including major depression (Cuijpers and Smit 2002; Cuijpers et al. 2013), suicidality (van Spijker et al. 2011), personality disorders (Walsh et al. *under review*), and substance use disorders (Rehm et al. 2009). In one study, the risk of suicidal ideation was five times higher for those with PTSD compared to those without (Kessler 2000). While PTSD and disorders like depression may share similar symptoms, PTSD may be a causal factor for other psychiatric and physical disorders, contribute to the severity of the comorbid conditions, or share common antecedents or vulnerabilities with the comorbidities (Breslau 2009; Koenen et al. 2008a; McLeod et al. 2001). Physical conditions associated with PTSD include increased chronic physical pain and somatization, cardiovascular conditions, autoimmune disorders, impaired immunity, and obesity (for review, see Qureshi 2009).

Significant gender differences also exist in patterns of comorbidity. For example, women with PTSD are more likely than men with PTSD to meet criteria for another anxiety disorder like Panic Disorder (e.g., 12.6 % versus 7.3 %; Kessler et al. 1995), while men with PTSD are more likely than women with PTSD to meet criteria for a substance use disorder (51.9 % vs. 27.9 % for AUD; 34.5 % vs. 26.9 % for drug use disorder) and

conduct disorder (43.3 % vs. 15.4 %) (Kessler et al. 1995). In a study of women only, the PTSD comorbidity with the highest lifetime prevalence was major depression, although women who developed PTSD were at increased risk for both major depression and AUD (Breslau et al. 1997).

Disability and Impairment

Beyond the development of psychiatric conditions, trauma exposure and PTSD also have been associated with significant functional impairment related to physical and psychiatric comorbidities as well as the chronicity of PTSD symptoms. Adverse consequences throughout the life course include increased risk for poor school performance, work impairment such as absenteeism (estimated at over 3.5 days of work missed per month due to PTSD), and unemployment (Kessler 2000). Other psychosocial impacts include marital instability and parenting challenges (Rodriguez et al. 2012; Kessler 2000). Given that PTSD has been found to persist beyond 2 years in about one-third of cases, the disease burden should not be neglected (Breslau 2009; Kessler et al. 1995). Female gender is a risk factor for chronicity of PTSD (Breslau and Davis 1992). Further, in estimating disease burden, resilience theories may be useful for public health planning and treatment. Studies of symptom trajectories following trauma exposure indicate that persons may experience varying levels of symptom severity over time in patterns that indicate, for example, recovery, chronic dysfunction, or relapsing/remitting (Norris et al. 2009). While a single disorder is associated with substantial functional impairment, comorbidity is associated with even greater costs to the individual and society. Thus, understanding how trauma exposure may give rise to or complicate this host of negative outcomes can improve existing prevention and intervention programs and potentially ameliorate the heavy social and economic burden of trauma exposure and related sequelae.

Psychobiology

A number of psychobiological factors may be important to consider the relationship between trauma exposure and posttraumatic sequelae including genetics, neural circuitry, and psychological phenomena.

Genetics

Genetic factors influence who is trauma exposed (e.g., Sartor et al. 2012) and who develops posttraumatic sequelae (e.g., Sartor et al. 2011). For example, twin studies suggest that 47–60 % of the variance in trauma exposure can be attributed to additive genetic factors (Lyons et al. 1993; Sartor et al. 2012), while 30–70 % of the variance in PTSD can be accounted for by genetic factors (Bailey et al. 2010; Sartor et al. 2011; Stein et al. 2002a; True et al. 1993). Heritability estimates for MDD range from 27 to 40 % (Kendler et al. 2006; Lyons et al. 1998; True et al. 1993; Sartor et al. 2012) while heritability estimates for alcohol dependence range from

55 to 71 % (Young-Wolff et al. 2012; Sartor et al. 2011; Ystrom et al. 2011). The genetic correlation between PTSD and MDD ranges from .77 (Koenen et al. 2008a) to 1.0 in one recent sample (Sartor et al. 2012) while the genetic correlation between PTSD and alcohol dependence has been estimated to be as high as .54 (Sartor et al. 2011). Overall, findings suggest that genetic heritability plays an important role in a range of common outcomes associated with PTE exposure, and some of the heritable influences on trauma exposure and related disorders may be shared.

Gene by environment ($G \times E$) studies provide important information about the specific genetic variants that are associated with PTSD, MDD, suicidality, and substance use disorders. $G \times E$ studies are particularly well-suited to address genetic questions about PTSD as it is a phenotype that requires exposure to an environmental stressor (Koenen et al. 2009; Koenen et al. 2008b). Recent reviews of the $G \times E$ literature relating to PTSD have highlighted interactions between trauma exposure, particularly childhood abuse, and genes involved in the dopaminergic, serotonergic, and neuroendocrine systems (Cornelis et al. 2010; Nugent et al. 2008; Skelton et al. 2012) including the dopamine receptor (D2) and the dopamine transporter (DAT) (e.g., Drury et al. 2009; Segman et al. 2002), the 5-HTTLPR polymorphism in the promoter region of the serotonin transporter gene (*SLC6A4*) (e.g., Wang et al. 2011; Xie et al. 2009), and *FKBP5*, a regulator of glucocorticoid receptor sensitivity that is involved in HPA axis stress reactivity (Binder et al. 2008; Mehta et al. 2012; Sarapas et al. 2011; for review see Yehuda et al. 2011; Xie et al. 2010). Many of the same genes have been shown to interact with trauma exposure to predict MDD, suicidality, and substance use disorders. For example, polymorphisms in 5-HTTLPR (Grabe et al. 2012), brain-derived neurotrophic factor (BDNF; Tsai et al. 2003), and proinflammatory cytokine interleukin-18 (IL-18; Haastrup et al. 2012) have been linked to the development of MDD. Similarly, *D2*, *DAT*, and 5-HTTLPR have been associated with alcohol dependence (for review see Dick et al. 2003), and 5-HTTLPR has been associated with risk for suicide (Roy et al. 2010). In addition to these associations, sex-specific differences have been noted in a $G \times E$ association between *GABRA2* genotype and environmental stressors on alcohol dependence such that men with the risk genotype who had more positive life events were less susceptible to alcohol dependence (Perry et al. 2013).

In addition to family/twin and candidate gene studies, other genetic methods are increasingly being used to study associations between genetics and the development of psychopathology among trauma victims. Genome-wide association studies (GWAS) have been employed to compare DNA markers on the genome in diseased persons as compared to persons free of symptoms of that disorder. Positive results have included an association between PTSD and the retinoid-related orphan receptor alpha (RORA) gene (Logue et al. 2013) and the Toll-like 1 gene (*TLL1*; Xie et al. 2013). Furthermore, in women, a novel positive association has been observed between PTSD and the RNA gene, lincRNA *AC068718.1* (Guffanti et al. 2013) as well as the pituitary adenylate cyclase-activating polypeptide (PACAP) and PAC1 receptor, which broadly regulate the cellular stress response (Ressler et al. 2011). Although some studies have failed to support the PACAP finding (Chang et al. 2011), other replications have garnered support for this association (Uddin et al. 2013). With

regard to substance use disorders, GWAS studies have confirmed associations between alcohol dependence and *ADH1B* and *ADH1C*, while identifying novel risk loci on chromosomes 4 and 2 and population-specific markers on chromosomes 5, 9, and 19 (Gelernter et al. 2014).

Epigenetic mechanisms, which are heritable changes in gene expression or functionality that do not involve changes to the underlying DNA sequence, also may partially explain the development of negative sequelae among trauma-exposed persons. DNA methylation, which involves the addition of a methyl group to the 5 position of the cytosine pyrimidine ring or the number 6 nitrogen of the adenine purine ring, has been the most widely studied with regard to trauma exposure and posttraumatic sequelae. For example, animals exposed to a psychosocial stressor evidence increased DNA methylation in the hippocampus (Chertkow-Deutscher et al. 2010; Roth et al. 2011; Zhang et al. 2010), and there is evidence that these epigenetic modifications can be passed to offspring (e.g., Franklin et al. 2010). Human studies suggest that childhood trauma exposure is associated with methylation in specific genes, including the promoter region of the serotonin transporter (Beach et al. 2010, 2011; Smith et al. 2011) and the glucocorticoid receptor (McGowan et al. 2009). Microarray methylation studies have identified differences in methylation patterns for persons with and without PTSD and MDD (Fuchikami et al. 2011; Smith et al. 2011; Uddin et al. 2010, 2011). Finally, studies that integrate gene expression and methylation data have found evidence of different psychobiological pathways for PTSD among those with and without histories of childhood trauma (Mehta et al. 2013). A recent review of sex differences in DNA methylation associated with PTSD and depression suggests that neurodevelopmental changes in methylation may lay the groundwork for stress differences in reactions to stress that give rise to gender differences in the prevalence of stress-related disorders (Uddin et al. 2013). Specifically, in rodent models, sex-specific methylation at CpG sites in the estrogen receptor interacts with neonatal hormone exposure during sensitive periods to differentially effect brain development that could, in part, explain females' increased susceptibility to psychopathology in adulthood (Kurian et al. 2010; Schwarz et al. 2010).

Neural Circuitry

Trauma exposure also may influence the development of negative sequelae through structural or functional changes in the brain. A meta-analysis of brain imaging studies suggests that trauma exposure is associated with reduced volume in the hippocampus, a brain region implicated in episodic memory, relative to non-trauma exposed controls, and trauma victims with PTSD evidence even greater reductions in hippocampal volume compared to trauma victims without PTSD (Woon et al. 2010). Most brain imaging studies are cross-sectional, which limits conclusions about whether trauma exposure and PTSD decrease hippocampal volume or predispose persons to develop PTSD when exposed to a PTE. However, at least one study using monozygotic twins discordant for trauma exposure indicated that reduced

hippocampal volume is a preexisting risk factor for PTSD when exposed to PTEs, not an outcome of exposure to trauma (Gilbertson et al. 2002). Persons with PTSD and depression also show similar reductions in prefrontal cortex volume when compared to trauma-exposed healthy controls (Kroes et al. 2011). There is evidence of gender differences in brain development among children with and without child maltreatment histories and PTSD such that maltreated boys with PTSD evidence diminished volume in the corpus callosum and cerebrum and increased lateral ventricular volume relative to maltreated girls with PTSD and health controls (De Bellis and Keshavan 2003).

Neuroendocrine Pathways

Alterations in the hypothalamic-pituitary-adrenal (HPA) axis, the primary system involved in the physiological stress response (Sapolsky et al. 2000), have been observed among child abuse victims (e.g., Cicchetti et al. 2010; Shea et al. 2005; Trickett et al. 2010), sexual assault victims (e.g., Resnick et al. 1995; Yehuda and Bierer 2009), combat veterans (e.g., Boscarino, 1996), and motor vehicle accident survivors (Delahanty et al. 2000). In general, trauma victims evidence hypocortisolism, although one study found heightened daily cortisol among women with sexual abuse histories (Lemieux and Coe 1995). Blunted HPA axis responsivity also has been associated with the development and chronicity of PTSD among trauma victims (e.g., Bremner et al. 2003; Walsh et al. 2014; Yehuda et al. 1990). However, heightened cortisol responsivity has been observed among trauma victims with depression when exposed to psychosocial stressors (Burke et al. 2005). Thus, despite clear indications that trauma exposure is associated with HPA axis dysregulation, associations between common trauma-related sequelae like PTSD and depression and HPA axis functioning remain less clear. One study has suggested that prolonged childhood abuse, rather than the development of PTSD, MDD, or even BPD symptoms was associated with hyperresponsivity in the HPA axis (Rinne et al. 2002).

Psychological Factors

Trauma exposure may also influence the development of negative outcomes through cognitive and/or behavioral processes including shame, self-blame, cognitive distortions, and dysregulation in emotion regulation or coping. Developed to explain the negative sequelae of childhood sexual abuse, Finkelhor and Browne's (1985) traumagenic dynamics theory suggests that early life abuse can negatively shape a child's perception of his/herself, his/her behavior, and his/her interpersonal relationships, through four psychological processes that include traumatic sexualization, betrayal, shame/guilt, and powerlessness. These dynamics in turn have been associated with increased distress including PTSD, depression, and substance use disorders among victims of violence (Canton-Cortes et al. 2012; Walsh et al. 2014). Cognitive distortions including self-blame, hopelessness, and

preoccupation with danger also have been associated with more severe PTSD and with brain activation in regions that have previously been implicated in visual processing and autobiographic memory recall (Daniels et al. 2011). Cognitive distortions are also common among women dually diagnosed with PTSD and substance use disorders (Najavits et al. 2004).

Emotional dysregulation, which reflects difficulties identifying, modulating, and expressing emotions (Gratz and Roemer 2004; Gross 1998), is another domain of functioning that may be disrupted among victims of sexual violence. For example, families in which violence is occurring may provide few opportunities for children to observe and model emotion regulation abilities that allow for effective modulation of chronic negative affect. To cope, they may become emotionally or experientially avoidant, and when avoidance does not ameliorate distress, they may develop psychopathology (e.g., PTSD, MDD) and engage in external coping mechanisms including substance abuse and risky sexual behavior (Polusny and Follette 1995).

Support for emotion regulation and maladaptive coping or self-medication as explanatory mechanisms in the link between trauma exposure and negative sequelae stems from research documenting that emotion dysregulation underlies PTSD and MDD (e.g., Tull et al. 2007), and those with trauma histories report greater use of substances to reduce both negative affect (Grayson and Nolen-Hoeksema 2005) and PTSD symptoms (Miranda et al. 2002; Ullman et al. 2005). Hyperarousal symptoms, in particular, are associated with increased alcohol and drug use and dependence (e.g., Reed et al. 2007), and victims who report drinking to cope with distress or to reduce tension are more likely to develop problem drinking behaviors including alcohol abuse/dependence, blackouts, and increased tolerance (Ullman et al. 2005).

Diagnosis

Posttraumatic Stress Disorder

The most commonly assessed and diagnosed condition among trauma victims is posttraumatic stress disorder (PTSD). PTSD as defined in DSM-5 requires: (A) exposure to a PTE; (B) at least one of five possible reexperiencing symptoms (e.g., distressing thoughts/dreams, intense physiological/psychological responses to reminders of the trauma); (C) one of two possible avoidance symptoms (e.g., avoiding internal thoughts or feelings or external reminders of the trauma); (D) two of seven cognitive or mood-related symptoms (dissociative amnesia, persistent self-blame, persistent negative beliefs or emotions, constricted affect, anhedonia, or feelings of alienation); and (E) two of six arousal symptoms (e.g., sleep problems, irritability, heightened startle response, self-destructive behaviors, irritability/aggressiveness). Symptoms must be experienced with at least moderate frequency and severity in the previous month, and they must be associated with some degree of social or occupational functional impairment to yield a diagnosis.

Developmental Considerations

The DSM-5 also includes a developmental subtype of PTSD for children younger than 6 years old. Children younger than age 6 may lack the vocabulary and meta-awareness to describe their symptoms; therefore, DSM-5 criteria for preschool PTSD are more behaviorally grounded. With regard to reexperiencing symptoms, children do not always display overt distress when recollecting PTEs; therefore, no affect or excitement that accompanies a PTE recollection could qualify as a reexperiencing symptom. Only one symptom in the avoidance or negative alterations in cognitions and mood is necessary as these are the least frequent PTSD symptoms (Scheeringa et al. 2006). The wording of the symptoms “diminished interest in significant activities” and “feelings of detachment or estrangement” were changed to “constricted play” and “social withdrawal” for children under age 6. The arousal symptoms are already conducive to behavioral assessment; therefore, only the irritability symptom was changed to “extreme temper tantrums.”

Depression

Frequently comorbid with PTSD (Nixon et al. 2004; Stein and Kennedy 2001), a diagnosis of depression requires depressed mood or anhedonia most days for the previous 2 weeks. It can also include significant changes in weight, appetite, or sleep, fatigue, guilt or feelings of worthlessness, problems with concentration, and suicidal ideation.

Other Anxiety Disorders

Approximately 70 % of trauma-exposed treatment-seeking patients report panic attack symptoms (Falsetti and Resnick 1997). Panic attack symptoms include heart palpitations, sweating, trembling/shaking, shortness of breath, a choking feeling, chest pain, nausea, feeling dizzy/lightheaded, derealization/depersonalization feelings, fear of losing control/going crazy, fear of dying, numbness/tingling, and chills/hot flashes. A panic attack is defined as experiencing four or more of these symptoms without warning or provocation; panic disorder refers to recurrent, unexpected panic attacks. Panic disorder cannot be diagnosed if the attacks only occur when exposed to a traumatic reminder.

Substance Use and Disorders

Trauma exposure has been associated with elevated risk for substance use disorders (Fetzner et al. 2011; Mills et al. 2006; Rees et al. 2011; Walsh et al. 2014); however, some research suggests that it is the development of PTSD, and not trauma exposure itself, that accounts for heightened risk for substance use and disorders (for review see

Breslau 2002). According to the self-medication model of substance use, trauma-exposed persons who develop PTSD, other anxiety symptoms, or depression may use substances to cope with these distressing symptoms (Khantzian 1997).

Evaluation

Clinical Interviews

Psychiatric conditions associated with PTE exposure have been assessed using various tools. The gold standard clinical interview for diagnosing PTSD is the Clinician Administered PTSD Scale (CAPS), which takes approximately 1 h to administer and includes a thorough evaluation of lifetime PTE exposure and the 17 PTSD items identified in the DSM-IV. Respondents are asked to separately rate the frequency and severity of each symptom in the preceding 2 weeks. The CAPS has been shown to have excellent reliability and validity, and consistent scores have been observed across items, raters, and testing occasions (Weathers et al. 2001). With regard to substance use, the Timeline Follow-back interview (Sobell and Sobell 1996) is a validated method to gather data on the patterns and frequency of substance use using a calendar method. The Structured Clinical Interview for DSM-IV also has been used extensively to diagnose PTSD, depression, other anxiety disorders, substance use disorders, and personality disorders.

Self-Report Measures

Although no substitute for diagnostic clinical interviews, a number of self-report measures with excellent reliability have been developed and validated against the gold standard clinical interviews. The PTSD Checklist (PCL; Weathers et al. 1999) has been developed in three formats – Civilian, Military, and Specific. Each version contains the 17 PTSD items from the DSM-IV and requires participants to rate their symptoms on a 0–4 severity scale. The Modified PTSD Symptom Scale-Self-Report (PSS-SR; Foa et al. 1993) is another 17-item measure of PTSD as assessed in the DSM-IV. Each symptom criterion is rated in terms of frequency of symptoms within the past 2 weeks on a scale of 0=*not at all or only one time* to 3=*almost always or five or more times per week*. Total scores range from 0 to 51. The PSS-SR has been shown to correlate highly with interview-based measures of PTSD (Foa et al. 1993) and has been used in numerous longitudinal studies assessing PTSD symptoms over time (e.g., Dunmore et al. 2001; Mayou et al. 2002). Measures such as the Davidson Trauma Scale, a self-report that separately assesses the frequency and severity of each DSM-IV symptom in the previous week on a scale from 0 to 4, also have been used to assess PTSD symptoms, particularly in SSRI trials (Davidson et al. 1997; 2002). Normative scores have been computed for comparison to the general population (Davidson et al. 2002).

Validated self-report measures for depression include the 21-item Beck Depression Inventory (BDI; Beck et al. 1988) and BDI-II (Dozois et al. 1998; Steer et al. 1997). The World Health Organization also has developed the Composite International Diagnostic Interview (CIDI; Wittchen 1994) that has been used in a number of epidemiologic studies (Kessler and Üstün 2004). Validated self-report measures for substance use and disorders include the Alcohol Use Disorders Identification Test (AUDIT; Saunders et al. 1993), a 10-item self-report measure of alcohol use and related problems, and the Drug Abuse Screening Test (DAST-10, Skinner 1982), a 10-item self-report measure of drug use and related problems.

Assessments for Children

The Child Behavior Checklist (CBCL; Achenbach et al. 2002) is a parent/teacher rated scale that measures broad aspects of internalizing and externalizing pathology including anxiety, depression, and anger; however, the CBCL does not capture aspects of functioning that may be particularly related to trauma exposure including intrusions, avoidance, and arousal. The Trauma symptom Checklist for Young Children is a 90-item caretaker completed checklist that assesses eight clinical scales including PTSD Intrusions (PTS-I), Avoidance (PTS-AV), Arousal (PTS-AR), and Total symptoms (PTS-TOT) as well as Sexual Concerns (SC), Dissociation (DIS), Anxiety (ANX), Depression (DEP), and Anger/Aggression (ANG) (Briere et al. 2001). The UCLA PTSD Index (Decker and Pynoos 2004) contains a thorough assessment of trauma exposure as well as the 17 items of PTSD in the DSM-IV. The Children's Depression Inventory (CDI) is a 27-item self-report scale appropriate for children age 7 to 17 that has good reliability and validity with normative scores to facilitate age comparisons (Kovacs 2004).

Pharmacotherapy

Numerous medications have been shown to effectively treat PTSD including tricyclic antidepressants, monoamine oxidase inhibitors, and serotonin reuptake inhibitors (SSRIs); however, SSRIs show the greatest efficacy with the fewest side effects (Albucher and Liberzon 2002). SSRIs such as sertraline, paroxetine, and fluoxetine are commonly prescribed to treat the symptoms of PTSD (Asnis et al. 2004), with sertraline and paroxetine producing reductions in PTSD symptoms in randomized controlled trials (Brady et al. 2000), and receiving FDA approval for the treatment of PTSD in adults. Some sex differences have been found with regard to treatment response to SSRIs. Specifically, women show a more positive treatment response to SSRIs compared to men (Khan et al. 2005; Young et al. 2009). For example, in depressed outpatients, women had a more positive response to the SSRI sertraline compared to the tricyclic imipramine, and men showed a stronger response to imipramine compared to sertraline (Kornstein et al. 2000). Sex hormones appeared to

play a role in treatment response as premenopausal women responded better to sertraline compared to imipramine, while postmenopausal women responded equally well to both medications (Kornstein et al. 2000). To date, no medications have been approved for use in children (Drury and Henry 2012). In PTSD patients with limited responsivity to SSRI treatment, augmentation with an atypical antipsychotic, Olanzapine, has been shown to produce better outcomes (Stein et al. 2002b). While psychopharmacologic interventions can be part of effective treatment for PTSD, findings are limited by high dropout rates in clinical trials, and negative side effects of these medications may explain poor retention in clinical trials (Albucher and Liberzon 2002).

Psychotherapy

A number of exposure-based treatments have been shown to be effective for the treatment of PTSD. For example, Prolonged Exposure (PE), which requires participants to use imaginal exercises to expose themselves to the memory of their PTE and the physical sensations and thoughts that arose during the PTE (Foa et al. 2007), has evidenced large effect sizes for the treatment of PTSD (Powers et al. 2010). PE was originally designed to treat PTSD associated with sexual violence (Foa et al. 1991), but has successfully been extended to other populations including combat veterans and adolescents (Gilboa-Schechtman et al. 2010).

Cognitive Processing Therapy (CPT), which exposes patients to the thoughts and emotions associated with their PTE through a combination of writing and thought challenging exercises, also has been shown to be effective in reducing PTSD symptoms (Resick et al. 2002). However, CPT contains modules that specifically address guilt, shame, and interpersonal difficulties, and thus yields greater reductions in guilt when compared to PE (Resick et al. 2002). Furthermore, dismantling studies have shown that the cognitive component alone has a stronger effect on reducing symptoms compared to the writing component alone (Resick et al. 2008).

Eye Movement Desensitization and Reprocessing (EMDR), which involves imaginal exposure while receiving bilateral sensory input that encourages eye movements, is another form of exposure treatment that shows similar reductions to those found with PE and greater reductions in symptoms relative to a wait-list control (Rothbaum et al. 2005). Meta-analyses support these findings by showing that EMDR is equally efficacious relative to trauma-focused cognitive behavioral therapy such as PE and CPT (Seidler and Wagner 2006).

Stress Inoculation Training (SIT), which involves psychoeducation and coping skills to increase resilience to stress (Meichenbaum 1974), has been applied to trauma victims (Veronen and Kilpatrick 1989). At posttreatment, SIT has been shown to be more effective at reducing PTSD symptoms than supportive counseling or a wait-list control (Foa et al. 1991); SIT and PE were associated with comparable posttreatment reductions in PTSD, although PE was associated with further reductions in PTSD at 3 months follow-up (Foa et al. 1991). In a follow-up study, PE was associated with greater posttreatment reductions in anxiety, social adjustment, and

PTSD severity when compared to SIT, SIT plus PE (SITPE), or a wait-list control (Foa et al. 1999). In a separate investigation comparing EMDR to SITPE, EMDR was associated with greater reductions in reexperiencing symptoms relative to SITPE (Lee et al. 2002).

Psychotherapies for Children

Trauma-focused cognitive behavioral therapy is a developmentally appropriate evidence-based treatment for trauma symptoms among trauma-exposed children (Cohen et al. 2004; Deblinger et al. 2006, 2011). TF-CBT involves the child and non-offending caregiver and includes psychoeducation, coping skills, and in vivo exposure through the construction of a trauma narrative that can be completed in a developmentally appropriate manner. TF-CBT has been shown to improve trauma symptoms, parenting skills, and child personal safety skills (Deblinger et al. 2011).

Treatments for Comorbid Conditions

As noted previously, PTSD and SUDs are frequently comorbid. However, conventional wisdom has often suggested that treating PTSD using difficult exposure techniques in a person with an active SUD may exacerbate the SUD. Consequently, many PTSD treatment programs require patients to receive SUD treatment prior to beginning PTSD treatment. However, patients are often disconnected from services when transitioning from one provider to another, suggesting that evidence-based treatments targeting multiple conditions are much needed. During the past decade, several studies have begun to highlight promising results for the simultaneous treatment of comorbid conditions. For instance, cognitive behavioral treatment for women with PTSD and SUD has been shown to reduce PTSD and SUD symptoms at 3 months follow-up compared to women in a wait-list control group (Cohen and Hien 2006). PE for women with comorbid PTSD and SUD has been shown to reduce PTSD symptoms without increasing SUD symptoms (Mills et al. 2012). CPT also is effective at reducing PTSD symptoms among veterans with comorbid PTSD and AUD (Kaysen et al. 2013). Women with comorbid PTSD and SUD who were randomized to trauma-focused therapy versus a health education program evidenced greater reductions in PTSD symptoms and those who maintained these reductions were more likely show substance use improvement (Hien et al. 2010). Imaginal and in vivo exposure therapy for PTSD plus cognitive behavioral treatment for cocaine dependence was associated with significant pre-post reductions PTSD symptoms and cocaine use (Brady et al. 2001); however, a high degree of dropout was noted. Finally, a recent study examining combined PE and naltrexone for the treatment of comorbid PTSD and AUD found that the combined approach was associated with greater reductions in drinking days relative to either of the individual approaches (Foa et al. 2013).

PTSD is also highly comorbid with mood and other anxiety disorders and symptoms including depression and panic attacks. Given its focus on changing cognitive distortions that may be shared by both PTSD and MDD, CPT has been shown to result in concurrent changes in PTSD and depression symptoms (Liverant et al. 2012). Multiple channel exposure therapy, an evidence-based treatment that includes exposure to panic symptoms as well as imaginal exposure to the PTE, has been shown to effectively reduce comorbid PTSD and panic attacks (Falsetti et al. 2005, 2008). Other comorbid problems like affect dysregulation or interpersonal difficulties that are frequently present among trauma-exposed persons with PTSD may be targeted through treatments like Skills Training in Affective and Interpersonal Regulation (STAIR) followed by exposure therapy. Adult women with child sexual abuse histories who participate in STAIR evidence reductions in PTSD symptoms as well as affect dysregulation and interpersonal problems compared to wait-list controls (Cloitre et al. 2002).

Conclusions

Trauma exposure is prevalent and associated with a wide range of mental health and substance use disorders. Although men are slightly more likely to be exposed to any PTE, women are twice as likely to develop PTSD when exposed. The etiology of gender differences in posttraumatic sequelae may have yet to be elucidated, but may include genetic, neural circuitry, and psychological phenomena. Valid and reliable interviews and self-report measures are available for the assessment of trauma-related conditions. Changes have been made to the criteria for PTSD in DSM-5. Comorbidity is the rule rather than the exception among trauma-exposed persons; however, only in the last decade have treatment outcome studies shown that multiple co-occurring outcomes can be targeted simultaneously. Whether there are gender differences in treatment, response or treatment matching deserves further examination. Despite a large body of work on gender, trauma exposure, and trauma-related disorders, more research is needed to identify the mechanisms by which gender shapes response to PTEs and treatment for posttraumatic sequelae.

References

- Achenbach TM, Dumenci L, Rescorla LA (2002) Ten-year comparisons of problems and competencies for national samples of youth self, parent, and teacher reports. *J Emot Behav Disord* 10(4):194–203
- Albucher RC, Liberzon I (2002) Psychopharmacological treatment in PTSD: a critical review. *J Psychiatr Res* 36(6):355–367
- Asnis GM, Kohn SR, Henderson M, Brown NL (2004) SSRIs versus non-SSRIs in post-traumatic stress disorder. *Drugs* 64(4):383–404
- Bailey JN, Goenjian AK, Noble EP, Walling DP, Ritchie T, Goenjian HA (2010) PTSD and dopaminergic genes, DRD2 and DAT, in multigenerational families exposed to the Spitak earthquake. *Psychiatry Res* 178(3):507–510
- Beach SR, Brody GH, Todorov AA, Gunter TD, Philibert RA (2010) Methylation at SLC6A4 is linked to family history of child abuse: an examination of the Iowa Adoptee sample. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 153(2):710–713

- Beach SR, Brody GH, Todorov AA, Gunter TD, Philibert RA (2011) Methylation at 5HTT mediates the impact of child sex abuse on women's antisocial behavior: an examination of the Iowa adoptee sample. *Psychosomatic medicine* 73(1):83
- Beck AT, Steer RA, Carbin MG (1988) Psychometric properties of the beck depression inventory: twenty-five years of evaluation. *Clin Psychol Rev* 8(1):77-100
- Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Ressler KJ (2008) Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. *Jama* 299(11):1291-1305
- Black MC, Basile KC, Breiding MJ, Smith SG, Walters ML, Merrick MT, Chen J, Stevens MR (2011) National intimate partner and sexual violence survey. Centers for Disease Control and Prevention, Atlanta
- Blanco C, Xu Y, Brady K, Pérez-Fuentes G, Okuda M, Wang S (2013) Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: results from National Epidemiological Survey on Alcohol and Related Conditions. *Drug Alcohol Depend* 132(3):630-638
- Bohnert KM, Breslau N (2011) Assessing the performance of the short screening scale for posttraumatic stress disorder in a large nationally-representative survey. *Int J Methods Psychiatr Res* 20(1):e1-e5
- Bonanno GA (2005) Resilience in the face of potential trauma. *Curr Dir Psychol Sci* 14(3):135-138
- Boscarino JA (1996) Posttraumatic stress disorder, exposure to combat, and lower plasma cortisol among Vietnam veterans: findings and clinical implications. *Journal of Consulting and Clinical Psychology* 64(1):191
- Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM (2000) Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. *JAMA* 283(14):1837-1844
- Brady KT, Dansky BS, Back SE, Foa EB, Carroll KM (2001) Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: preliminary findings. *J Subst Abuse Treat* 21(1):47-54
- Bremner JD, Vythilingam M, Vermetten E, Adil J, Khan S, Nazeer A, Afzal N, McGlashan T, Elzinga B, Anderson GM, Heninger G, Southwick SM, Charney DS (2003) Cortisol response to a cognitive stress challenge in posttraumatic stress disorder (PTSD) related to childhood abuse. *Psychoneuroendocrinology* 28(6):733-750
- Breslau N (2002) In review. *Can J Psychiatry* 47:923-929
- Breslau N (2009) The epidemiology of trauma, PTSD, and other posttrauma disorders. *Trauma Violence Abuse* 10(3):198-210
- Breslau N, Anthony JC (2007) Gender differences in the sensitivity to posttraumatic stress disorder: an epidemiological study of urban young adults. *J Abnorm Psychol* 116(3):607
- Breslau N, Davis GC (1992) Posttraumatic stress disorder in an urban population of young adults: risk factors for chronicity. *Am J Psychiatry* 149:671-675
- Breslau N, Davis GC, Peterson EL, Schultz L (1997) Psychiatric sequelae of posttraumatic stress disorder in women. *Arch Gen Psychiatry* 54(1):583-584
- Briere J, Johnson K, Bissada A, Damon L, Crouch J, Gil E, Ernst V (2001) The trauma symptom checklist for young children (TSCYC): reliability and association with abuse exposure in a multi-site study. *Child Abuse Negl* 25(8):1001-1014
- Burke HM, Davis MC, Otte C, Mohr DC (2005) Depression and cortisol responses to psychological stress: a meta-analysis. *Psychoneuroendocrinology* 30(9):846-856
- Campbell J, Garcia-Moreno C, Sharps P (2004) Abuse during pregnancy in industrialized and developing countries. *Violence Against Women* 10(7):770-789
- Canton-Cortes D, Cortés MR, Canton J (2012) The role of traumatic dynamics on the psychological adjustment of survivors of child sexual abuse. *Eur J Dev Psychol* 9(6):665-680
- Chang SC, Xie P, Anton RF, De Vivo I, Farrer LA, Kranzler HR, Oslin D, Purcell SM, Roberts AL, Smoller JW, Uddin M, Gelernter J, Koenen KC (2011) No association between ADCYAP1R1 and post-traumatic stress disorder in two independent samples. *Mol Psychiatry* 17(3):239-241

- Chertkow-Deutsher Y, Cohen H, Klein E, Ben-Shachar D (2010) DNA methylation in vulnerability to post-traumatic stress in rats: evidence for the role of the post-synaptic density protein Dlgap2. *Int J Neuropsychopharmacol* 13(03):347–359
- Cicchetti D, Rogosch FA, Gunnar MR, Toth SL (2010) The differential impacts of early physical and sexual abuse and internalizing problems on daytime cortisol rhythm in school-aged children. *Child Dev* 81(1):252–269
- Cloitre M, Koenen KC, Cohen LR, Han H (2002) Skills training in affective and interpersonal regulation followed by exposure: a phase-based treatment for PTSD related to childhood abuse. *J Consult Clin Psychol* 70(5):1067
- Cohen LR, Hien DA (2006) Treatment outcomes for women with substance abuse and PTSD who have experienced complex trauma. *Psychiatr Serv* 57(1):100–106
- Cohen JA, Deblinger E, Mannarino AP (2004) Trauma focused cognitive behavioral therapy for sexually abused children. *Psychiatr Times* 21(10):109–121
- Cornelis MC, Nugent NR, Amstadter AB, Koenen KC (2010) Genetics of post-traumatic stress disorder: review and recommendations for genome-wide association studies. *Curr Psychiatry Rep* 12(4):313–326
- Cortina LM, Kubiak SP (2006) Gender and posttraumatic stress: sexual violence as an explanation for women's increased risk. *J Abnorm Psychol* 115(4):753
- Cuijpers P, Smit F (2002) Excess mortality in depression: a meta-analysis of community studies. *J Affect Disord* 72(3):227–236
- Cuijpers P, Vogelzangs N, Twisk J, Kleiboer A, Li J, Penninx BW (2013) Differential mortality rates in major and subthreshold depression: meta-analysis of studies that measured both. *Br J Psychiatry* 202(1):22–27
- Daniels JK, Hegadoren K, Coupland NJ, Rowe BH, Neufeld RW, Lanius RA (2011) Cognitive distortions in an acutely traumatized sample: an investigation of predictive power and neural correlates. *Psychol Med* 41(10):2149–2157
- Davidson JR, Book SW, Colket JT, Tupler LA, Roth S, David D, Feldman ME (1997) Assessment of a new self-rating scale for post-traumatic stress disorder. *Psychol Med* 27(1):153–160
- Davidson JR, Tharwani HM, Connor KM (2002) Davidson trauma scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials. *Depress Anxiety* 15(2):75–78
- De Bellis MD, Keshavan MS (2003) Sex differences in brain maturation in maltreatment-related pediatric posttraumatic stress disorder. *Neurosci Biobehav Rev* 27(1):103–117
- Deblinger E, Mannarino AP, Cohen JA, Steer RA (2006) A follow-up study of a multisite, randomized, controlled trial for children with sexual abuse-related PTSD symptoms. *J Am Acad Child Adolesc Psychiatry* 45(12):1474–1484
- Deblinger E, Mannarino AP, Cohen JA, Runyon MK, Steer RA (2011) Trauma-focused cognitive behavioral therapy for children: impact of the trauma narrative and treatment length. *Depress Anxiety* 28(1):67–75
- Decker KB, Pynoos RS (2004) The University of California at Los Angeles post-traumatic stress disorder reaction index. *Curr Psychiatry Rep* 6(2):96–100
- Delahanty DL, Raimonde AJ, Spoonster E (2000) Initial posttraumatic urinary cortisol levels predict subsequent PTSD symptoms in motor vehicle accident victims. *Biol Psychiatry* 48(9):940–947
- Dick DM, Foroud T (2003) Candidate genes for alcohol dependence: a review of genetic evidence from human studies. *Alcoholism: Clinical and Experimental Research* 27(5):868–879
- Dozois DJ, Dobson KS, Ahnberg JL (1998) A psychometric evaluation of the Beck Depression Inventory–II. *Psychol Assess* 10(2):83
- Drury SS, Henry C (2012) Evidenced-based treatment of PTSD in children and adolescents: where does psychopharmacology fit? *Child Adolesc Psychopharmacol News* 17(3):1–8
- Drury SS, Theall KP, Keats BJ, Scheeringa M (2009) The role of the dopamine transporter (DAT) in the development of PTSD in preschool children. *J Trauma Stress* 22(6):534–539
- Dunmore E, Clark DM, Ehlers A (2001) A prospective investigation of the role of cognitive factors in persistent posttraumatic stress disorder (PTSD) after physical or sexual assault. *Behav Res Ther* 39(9):1063–1084

- Falsetti SA, Resnick HS, Davis J (2005) Multiple channel exposure therapy combining cognitive-behavioral therapies for the treatment of posttraumatic stress disorder with panic attacks. *Behav Modif* 29(1):70–94
- Falsetti SA, Resnick HS, Davis JL (2008) Multiple channel exposure therapy for women with PTSD and comorbid panic attacks. *Cogn Behav Ther* 37(2):117–130
- Fetzner MG, McMillan KA, Sareen J, Asmundson GJ (2011) What is the association between traumatic life events and alcohol abuse/dependence in people with and without PTSD? Findings from a nationally representative sample. *Depress Anxiety* 28(8):632–638
- Finkelhor D (1994) The international epidemiology of child sexual abuse. *Child Abuse Negl* 18(5):409–417
- Finkelhor D, Browne A (1985) The traumatic impact of child sexual abuse: a conceptualization. *Am J Orthopsychiatry* 55(4):530
- Finkelhor D, Jones L (2006) Why have child maltreatment and child victimization declined? *J Soc Issues* 62(4):685–716
- Foa EB, Rothbaum BO, Riggs DS, Murdock TB (1991) Treatment of posttraumatic stress disorder in rape victims: a comparison between cognitive-behavioral procedures and counseling. *J Consult Clin Psychol* 59(5):715
- Foa EB, Riggs DS, Dancu CV, Rothbaum BO (1993) Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. *J Trauma Stress* 6(4):459–473
- Foa EB, Dancu CV, Hembree EA, Jaycox LH, Meadows EA, Street GP (1999) A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victims. *J Consult Clin Psychol* 67(2):194
- Foa E, Hembree E, Rothbaum BO (2007) Prolonged exposure therapy for PTSD: emotional processing of traumatic experiences therapist guide. Oxford University Press, Oxford, UK
- Foa EB, Yusko DA, McLean CP, Suvak MK, Bux DA, Oslin D, Volpicelli J (2013) Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. *JAMA* 310(5):488–495
- Franklin TB, Russig H, Weiss IC, Gräff J, Linder N, Michalon A, Vizi S, Mansuy IM (2010) Epigenetic transmission of the impact of early stress across generations. *Biol Psychiatry* 68(5):408–415
- Fuchikami M, Morinobu S, Segawa M, Okamoto Y, Yamawaki S, Ozaki N, Inoue T, Kusumi I, Koyama T, Tsuchiyama K, Terao T (2011) DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. *PLoS One* 6(8):e23881
- World Health Organization (2013) Global and regional estimates of violence against women: prevalence and health effects of intimate partner violence and non-partner sexual violence. World Health Organization
- Gelernter J, Kranzler HR, Sherva R, Almasy L, Koesterer R, Smith AH, Farrer LA (2014) Genome-wide association study of alcohol dependence: significant findings in African-and European-Americans including novel risk loci. *Mol Psychiatry* 19:41–49
- Gilbertson MW, Shenton ME, Ciszewski A, Kasai K, Lasko NB, Orr SP, Pitman RK (2002) Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. *Nat Neurosci* 5(11):1242–1247
- Gilboa-Schechtman E, Foa EB, Shafran N, Aderka IM, Powers MB, Rachamim L, Apter A (2010) Prolonged exposure versus dynamic therapy for adolescent PTSD: a pilot randomized controlled trial. *J Am Acad Child Adolesc Psychiatry* 49(10):1034–1042
- Grabe HJ, Schwahn C, Mahler J, Appel K, Schulz A, Spitzer C, Fenske K, Barnow S, Freyberger HJ, Teumer A, Petersmann A, Biffar R, Roskopf D, John U, Völzke H (2012) Genetic epistasis between the brain-derived neurotrophic factor Val66Met polymorphism and the 5-HTT promoter polymorphism moderates the susceptibility to depressive disorders after childhood abuse. *Prog NeuroPsychopharmacol Biol Psychiatry* 36(2):264–270
- Gratz KL, Roemer L (2004) Multidimensional assessment of emotion regulation and dysregulation: development, factor structure, and initial validation of the difficulties in emotion regulation scale. *J Psychopathol Behav Assess* 26(1):41–54

- Grayson CE, Nolen-Hoeksema S (2005) Motives to drink as mediators between childhood sexual assault and alcohol problems in adult women. *J Trauma Stress* 18(2):137–145
- Gross JJ (1998) The emerging field of emotion regulation: an integrative review. *Rev Gen Psychol* 2(3):271
- Guffanti G, Galea S, Yan L, Roberts AL, Solovieff N, Aiello AE, Koenen KC (2013) Genome-wide association study implicates a novel RNA gene, the lincRNA, AC068718, as a risk factor for post-traumatic stress disorder in women. *Psychoneuroendocrinology* 38(12):3029–3038
- Haastруп E, Bukh JD, Bock C, Vinberg M, Thøerner LW, Hansen T, Werge T, Kessing LV, Ullum H (2012) Promoter variants in *IL18* are associated with onset of depression in patients previously exposed to stressful-life events. *J Affect Disord* 136(1):134–138
- Heise LL, Raikes A, Watts CH, Zwi AB (1994) Violence against women: a neglected public health issue in less developed countries. *Soc Sci Med* 39(9):1165–1179
- Hien DA, Jiang H, Campbell AN, Hu MC, Miele GM, Cohen LR, Nunes EV (2010) Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network. *Am J Psychiatry* 167(1):95
- Kaysen D, Lindgren K, Zangana GAS, Murray L, Bass J, Bolton P (2013) Adaptation of cognitive processing therapy for treatment of torture victims: experience in Kurdistan, Iraq. *Psychol Trauma: Theory Res Pract Policy* 5(2):184
- Kessler KS, Gatz M, Gardner CO, Pedersen NL (2006) A Swedish national twin study of lifetime major depression. *Am J Psychiatry* 163(1):109–114
- Kessler RC (2000) Posttraumatic stress disorder: the burden to the individual and to society. *J Clin Psychiatry* 61:4–12
- Kessler RC, Üstün TB (2004) The world mental health (WMH) survey initiative version of the world health organization (WHO) composite international diagnostic interview (CIDI). *Int J Methods Psychiatr Res* 13(2):93–121
- Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995) Posttraumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry* 52(12):1048
- Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA (2005) Sex differences in antidepressant response in recent antidepressant clinical trials. *J Clin Psychopharmacol* 25(4):318–324
- Khantzian EJ (1997) The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. *Harv Rev Psychiatry* 4(5):231–244
- Kilpatrick DG, Edmunds CN, Seymour AK (1992) Rape in America: a report to the nation. National Victim Center & The Crime Victims Center, Charleston
- Koenen KC, Fu QJ, Ertel K, Lyons MJ, Eisen SA, True WR, Goldberg J, Tsuang MT (2008a) Common genetic liability to major depression and posttraumatic stress disorder in men. *J Affect Disord* 105(1):109–115
- Koenen KC, Nugent NR, Amstadter AB (2008b) Gene-environment interaction in posttraumatic stress disorder. *Eur Arch Psychiatry Clin Neurosci* 258(2):82–96
- Koenen KC, Amstadter AB, Nugent NR (2009) Gene-environment interaction in posttraumatic stress disorder: an update. *J Trauma Stress* 22(5):416–426
- Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB (2000) Gender differences in treatment response to sertraline versus imipramine in chronic depression. *Am J Psychiatry* 157(9):1445–1452
- Kovacs M (2004) Children's depression inventory (CDI). Multi-Health Systems, Toronto
- Kroes MC, Rugg MD, Whalley MG, Brewin CR (2011) Structural brain abnormalities common to posttraumatic stress disorder and depression. *J Psychiatry Neurosci* 36(4):256
- Kurian JR, Olesen KM, Auger AP (2010) Sex differences in epigenetic regulation of the estrogen receptor- α promoter within the developing preoptic area. *Endocrinology* 151(5):2297–2305
- Lee C, Gavriel H, Drummond P, Richards J, Greenwald R (2002) Treatment of PTSD: stress inoculation training with prolonged exposure compared to EMDR. *J Clin Psychol* 58(9):1071–1089
- Lemieux AM, Coe CL (1995) Abuse-related posttraumatic stress disorder: evidence for chronic neuroendocrine activation in women. *Psychosom Med* 57(2):105–115
- Liverant GI, Suvak MK, Pineles SL, Resick PA (2012) Changes in posttraumatic stress disorder and depressive symptoms during cognitive processing therapy: evidence for concurrent change. *J Consult Clin Psychol* 80(6):957

- Logue MW, Baldwin C, Guffanti G, Melista E, Wolf EJ, Reardon AF, Uddin M, Wildman D, Galea S, Koenen KC, Miller MW (2013) A genome-wide association study of post-traumatic stress disorder identifies the retinoid-related orphan receptor alpha (RORA) gene as a significant risk locus. *Mol Psychiatry* 18:937–942
- Lyons MJ, Goldberg J, Eisen SA, True W, Tsuang MT, Meyer JM, Henderson WG (1993) Do genes influence exposure to trauma? A twin study of combat. *Am J Med Genet* 48(1):22–27
- Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, Meyer JM, Toomey R, Faraone SV, Merlano-Ramos M, Tsuang MT (1998) A registry-based twin study of depression in men. *Arch Gen Psychiatry* 55(5):468–472
- Mayou RA, Ehlers A, Bryant B (2002) Posttraumatic stress disorder after motor vehicle accidents: 3-year follow-up of a prospective longitudinal study. *Behav Res Ther* 40(6):665–675
- McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonté B, Szyf M, Meaney MJ (2009) Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat Neurosci* 12(3):342–348
- McLeod DS, Koenen KC, Meyer JM, Lyons MJ, Eisen S, True W, Goldberg J (2001) Genetic and environmental influences on the relationship among combat exposure, posttraumatic stress disorder symptoms, and alcohol use. *J Trauma Stress* 14:259–275
- Mehta D, Binder EB (2012) Genex environment vulnerability factors for PTSD: The HPA-axis. *Neuropharmacology* 62(2):654–662
- Mehta D, Klengel T, Conneely KN, Smith AK, Altmann A, Pace TW, Binder EB (2013) Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder. *Proc Natl Acad Sci* 110(20):8302–8307
- Meichenbaum D (1974) *Cognitive behavior modification*. General Learning Press, Morristown
- Mills K, Teesson M, Ross J, Peters L (2006) Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of Mental Health and Well-Being. *Am J Psychiatry* 163(4):652–658
- Mills KL, Teesson M, Back SE, Brady KT, Baker AL, Hopwood S, Sannibale C, Barrett EL, Merz S, Rosenfeld J, Ewer PL (2012) Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trial. *JAMA* 308(7):690–699
- Miranda R, Meyerson LA, Long PJ, Marx BP, Simpson SM (2002) Sexual assault and alcohol use: exploring the self-medication hypothesis. *Violence Vict* 17(2):205–217
- Najavits LM, Gotthardt S, Weiss RD, Epstein M (2004) Cognitive distortions in the dual diagnosis of PTSD and substance use disorder. *Cogn Ther Res* 28(2):159–172
- Nixon RD, Resick PA, Nishith P (2004) An exploration of comorbid depression among female victims of intimate partner violence with posttraumatic stress disorder. *J Affect Disord* 82(2):315–320
- Norris FH, Tracy M, Galea S (2009) Looking for resilience: understanding the longitudinal trajectories of responses to stress. *Soc Sci Med* 68(12):2190–2198
- Nugent NR, Amstadter AB, Koenen KC (2008) Genetics of post-traumatic stress disorder: informing clinical conceptualizations and promoting future research. *Am J Med Genet C: Sem Med Genet* 148(2):127–132
- Pereda N, Guilera G, Forns M, Gómez-Benito J (2009) The prevalence of child sexual abuse in community and student samples: a meta-analysis. *Clin Psychol Rev* 29(4):328–338
- Perkonig A, Kessler RC, Storz S, Wittchen HU (2000) Traumatic events and post-traumatic stress disorder in the community: prevalence, risk factors and comorbidity. *Acta Psychiatr Scand* 101(1):46–59
- Perry BL, Pescosolido BA, Bucholz K, Edenberg H, Kramer J, Kuperman S, Schuckit MA, Nurnberger JI Jr (2013) Gender-specific gene–environment interaction in alcohol dependence: the impact of daily life events and GABRA2. *Behav Genet* 43(5):402–414
- Pietrzak RH, Goldstein RB, Southwick SM, Grant BF (2011) Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *J Anxiety Disord* 25(3):456–465

- Polusny MA, Follette VM (1995) Long-term correlates of child sexual abuse: theory and review of the empirical literature. *Appl Prev Psychol* 4(3):143–166
- Powers MB, Halpern JM, Ferenschak MP, Gillihan SJ, Foa EB (2010) A meta-analytic review of prolonged exposure for posttraumatic stress disorder. *Clin Psychol Rev* 30(6):635–641
- Qureshi SU, Pyne JM, Magruder KM, Schulz PE, Kunik ME (2009) The link between post-traumatic stress disorder and physical comorbidities: a systematic review. *Psychiatric quarterly*, 80(2), 87–97
- Reed PL, Anthony JC, Breslau N (2007) Incidence of drug problems in young adults exposed to trauma and posttraumatic stress disorder: do early life experiences and predispositions matter? *Arch Gen Psychiatry* 64(12):1435–1442
- Rees S, Silove D, Chey T, Ivancic L, Steel Z, Creamer M, Forbes D (2011) Lifetime prevalence of gender-based violence in women and the relationship with mental disorders and psychosocial function. *JAMA* 306(5):513–521
- Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J (2009) Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. *Lancet* 373(9682):2223–2233
- Resick PA, Nishith P, Weaver TL, Astin MC, Feuer CA (2002) A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. *J Consult Clin Psychol* 70(4):867
- Resick PA, Galovski TE, Uhlmansiek MOB, Scher CD, Clum GA, Young-Xu Y (2008) A randomized clinical trial to dismantle components of cognitive processing therapy for posttraumatic stress disorder in female victims of interpersonal violence. *J Consult Clin Psychol* 76(2):243
- Resnick HS, Kilpatrick DG, Dansky BS, Saunders BE, Best CL (1993) Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. *J Consult Clin Psychol* 61(6):984
- Resnick HS, Yehuda R, Pitman RK, Foy DW (1995) Effect of previous trauma on acute plasma cortisol level following rape. *Am J Psychiatry* 152(11):1675–1677
- Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, May V (2011) Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. *Nature* 470(7335):492–497
- Rinne T, De Kloet ER, Wouters L, Goekoop JG, DeRijk RH, van den Brink W (2002) Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. *Biol Psychiatry* 52(11):1102–1112
- Roberts AL, Gilman SE, Breslau J, Breslau N, Koenen KC (2011) Race/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States. *Psychol Med* 41(1):71–83
- Rodriguez P, Holowka DW, Marx BP (2012). Assessment of posttraumatic stress disorder-related functional impairment: a review. *J Rehabil Res Dev* 49(5):649–666
- Roth TL, Zoladz PR, Sweatt JD, Diamond DM (2011) Epigenetic modification of hippocampal Bdnf DNA in adult rats in an animal model of post-traumatic stress disorder. *J Psychiatr Res* 45(7):919–926
- Rothbaum BO, Astin MC, Marsteller F (2005) Prolonged exposure versus eye movement desensitization and reprocessing (EMDR) for PTSD rape victims. *J Trauma Stress* 18(6):607–616
- Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA (2010) Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. *Neuropsychopharmacology* 35(8):1674–1683
- Sapolsky RM, Romero LM, Munck AU (2000) How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions 1. *Endocr Rev* 21(1):55–89
- Sarapas C, Cai G, Bierer LM, Golier JA, Galea S, Ising M, Yehuda R (2011) Genetic markers for PTSD risk and resilience among survivors of the World Trade Center attacks. *Disease markers* 30(2–3):101–110
- Sartor CE, McCutcheon VV, Pommer NE, Nelson EC, Grant JD, Duncan AE, Heath AC (2011) Common genetic and environmental contributions to post-traumatic stress disorder and alcohol dependence in young women. *Psychol Med* 41(07):1497–1505

- Sartor CE, Grant JD, Lynskey MT, McCutcheon VV, Waldron M, Statham DJ, Bucholz KK, Madden PA, Heath AC, Martin NG, Nelson EC (2012) Common heritable contributions to low-risk trauma, high-risk trauma, posttraumatic stress disorder, and major depression. *Arch Gen Psychiatry* 69(3):293
- Saunders JB, Aasland OG, Babor TF, Grant M (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. *Addiction* 88(6):791–804
- Scheeringa M, Wright M, Hunt J, Zeanah C (2006) Factors affecting the diagnosis and prediction of PTSD symptomatology in children and adolescents. *American Journal of Psychiatry* 163(4):644–651
- Schwarz JM, Nugent BM, McCarthy MM (2010) Developmental and hormone-induced epigenetic changes to estrogen and progesterone receptor genes in brain are dynamic across the life span. *Endocrinology* 151(10):4871–4881
- Segman RH, Cooper-Kazaz R, Macciardi F, Golster T, Halfon Y, Dobroborski T, Shalev AY (2002) Association between the dopamine transporter gene and posttraumatic stress disorder. *Mol Psychiatry* 7(8):903–907
- Seidler GH, Wagner FE (2006) Comparing the efficacy of EMDR and trauma-focused cognitive-behavioral therapy in the treatment of PTSD: a meta-analytic study. *Psychol Med* 36(11):1515–1522
- Shea A, Walsh C, MacMillan H, Steiner M (2005) Child maltreatment and HPA axis dysregulation: relationship to major depressive disorder and post traumatic stress disorder in females. *Psychoneuroendocrinology* 30(2):162–178
- Skelton K, Ressler KJ, Norrholm SD, Jovanovic T, Bradley-Davino B (2012) PTSD and gene variants: new pathways and new thinking. *Neuropharmacology* 62(2):628–637
- Skinner HA (1982) The drug abuse screening test. *Addict Behav* 7(4):363–371
- Smith AK, Conneely KN, Kilaru V, Mercer KB, Weiss TE, Bradley B, Tang Y, Gillespie CF, Cubells JF, Ressler KJ (2011) Differential immune system DNA methylation and cytokine regulation in post-traumatic stress disorder. *Am J Med Genet B Neuropsychiatr Genet* 156(6):700–708
- Sobell LC, Sobell MB (1996) *Timeline followback user's guide: a calendar method for assessing alcohol and drug use*. Addiction Research Foundation, Toronto
- Steel Z, Chey T, Silove D, Marnane C, Bryant RA, Van Ommeren M (2009) Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis. *JAMA* 302(5):537–549
- Steer RA, Ball R, Raneeri WF, Beck AT (1997) Further evidence for the construct validity of the Beck Depression Inventory-II with psychiatric outpatients. *Psychol Rep* 80(2):443–446
- Stein MB, Kennedy C (2001) Major depressive and post-traumatic stress disorder comorbidity in female victims of intimate partner violence. *J Affect Disord* 66(2):133–138
- Stein MB, Jang KL, Taylor S, Vernon PA, Livesley WJ (2002a) Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: a twin study. *Am J Psychiatry* 159(10):1675–1681
- Stein MB, Kline NA, Matloff JL (2002b) Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. *Am J Psychiatry* 159(10):1777–1779
- Tolin DF, Foa EB (2006) Sex differences in trauma and posttraumatic stress disorder: a quantitative review of 25 years of research. *Psychol Bull* 132(6):959
- Trickett PK, Noll JG, Susman EJ, Shenk CE, Putnam FW (2010) Attenuation of cortisol across development for victims of sexual abuse. *Dev Psychopathol* 22(01):165–175
- True WR, Rice J, Eisen SA, Heath AC, Goldberg J, Lyons MJ, Nowak J (1993) A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms. *Arch Gen Psychiatry* 50(4):257–264
- Tsai SJ, Cheng CY, Yu YWY, Chen TJ, Hong CJ (2003) Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. *Am J Med Genet B Neuropsychiatr Genet* 123(1):19–22

- Tull MT, Barrett HM, McMillan ES, Roemer L (2007) A preliminary investigation of the relationship between emotion regulation difficulties and posttraumatic stress symptoms. *Behav Ther* 38(3):303–313
- Uddin M, Aiello AE, Wildman DE, Koenen KC, Pawelec G, de Los Santos R, Galea S (2010) Epigenetic and immune function profiles associated with posttraumatic stress disorder. *Proceedings of the National Academy of Sciences* 107(20):9470–9475
- Uddin M, Koenen KC, Aiello AE, Wildman DE, de Los Santos R, Galea S (2011) Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. *Psychological medicine* 41(05):997–1007
- Uddin M, Chang SC, Zhang C, Ressler K, Mercer KB, Galea S, Koenen KC (2013) Adcyap1r1 genotype, posttraumatic stress disorder, and depression among women exposed to childhood maltreatment. *Depress Anxiety* 30(3):251–258
- Ullman SE, Filipas HH, Townsend SM, Starzynski LL (2005) Trauma exposure, posttraumatic stress disorder and problem drinking in sexual assault survivors. *J Stud Alcohol Drugs* 66(5):610
- van Spijker BA, van Straten A, Kerkhof AJ, Hoeymans N, Smit F (2011) Disability weights for suicidal thoughts and non-fatal suicide attempts. *J Affect Disord* 134(1):341–347
- Veronen LJ, Kilpatrick DG (1989) Stress management for rape victims. In: *Stress reduction and prevention*. Springer, New York, NY, pp 341–374
- Walsh K, Latzman NE, Latzman RD (2014) Pathway from child sexual and physical abuse to risky sex among emerging adults: the role of trauma-related intrusions and alcohol problems. *J Adolesc Health* 54:442–448
- Walsh K, Keyes KM, Koenen KC, Hasin D (2015) Lifetime prevalence of gender-based violence in US women: associations with mood/anxiety and substance use disorders. *J Psychiatr Res* 62:7–13
- Walsh K, Hasin DS, Keyes KM, Koenen KC (under revision). Associations between gender-based violence and personality disorders in US women. *Personality Disorders: Theory, Research, and Treatment*
- Wang Z, Baker DG, Harrer J, Hamner M, Price M, Amstadter A (2011) The relationship between combat-related posttraumatic stress disorder and the 5-HTTLPR/rs25531 polymorphism. *Depression and anxiety* 28(12):1067–1073
- Weathers FW, Ruscio AM, Keane TM (1999) Psychometric properties of nine scoring rules for the Clinician-Administered Posttraumatic Stress Disorder Scale. *Psychological Assessment* 11(2):124
- Weathers FW, Keane TM, Davidson JR (2001) Clinician-Administered PTSD Scale: A review of the first ten years of research. *Depression and anxiety* 13(3):132–156
- Wittchen HU (1994) Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): a critical review. *J Psychiatr Res* 28(1):57–84
- Woon FL, Sood S, Hedges DW (2010) Hippocampal volume deficits associated with exposure to psychological trauma and posttraumatic stress disorder in adults: a meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry* 34(7):1181–1188
- Xie P, Kranzler HR, Poling J, Stein MB, Anton RF, Brady K, Gelernter J (2009) Interactive effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. *Archives of general psychiatry* 66(11):1201–1209
- Xie P, Kranzler HR, Poling J, Stein MB, Anton RF, Farrer LA, Gelernter J (2010) Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. *Neuropsychopharmacology* 35(8):1684–1692
- Xie P, Kranzler HR, Yang C, Zhao H, Farrer LA, Gelernter J (2013) Genome-wide association study identifies new susceptibility loci for posttraumatic stress disorder. *Biol Psychiatry* 74:656–663
- Yehuda R, Bierer LM (2009) The relevance of epigenetics to PTSD: Implications for the DSM-V. *J Trauma Stress* 22(5):427–434
- Yehuda R, Southwick SM, Nussbaum G, Wahby V, Giller EL Jr, Mason JW (1990) Low urinary cortisol excretion in patients with posttraumatic stress disorder. *J Nerv Ment Dis* 178(6):366–369

- Yehuda R, Koenen KC, Galea S, Flory JD (2011) The role of genes in defining a molecular biology of PTSD. *Dis Markers* 30(2):67–76
- Young EA, Kornstein SG, Marcus SM, Harvey AT, Warden D, Wisniewski SR, John Rush A (2009) Sex differences in response to citalopram: a STAR* D report. *J Psychiatr Res* 43(5): 503–511
- Young-Wolff KC, Chereji E, Prescott CA (2012) Heritability of alcohol dependence is similar in women and men. *Evid Based Ment Health* 15(3):57
- Ystrom E, Reichborn-Kjennerud T, Aggen SH, Kendler KS (2011) Alcohol dependence in men: reliability and heritability. *Alcohol Clin Exp Res* 35(9):1716–1722
- Zhang TY, Hellstrom IC, Bagot RC, Wen X, Diorio J, Meaney MJ (2010) Maternal care and DNA methylation of a glutamic acid decarboxylase 1 promoter in rat hippocampus. *J Neurosci* 30(39):13130–13137

Anxiety and Related Disorders in Women

Katherine Sevar, Bavi Vythilingum, and David Castle

*Anxiety does not empty tomorrow of its sorrows, but only
empties today of its strength (Charles Spurgeon)*

Anxiety disorders are highly prevalent and persist across the life course. As documented in earlier chapters of this volume, women are particularly prone to anxiety disorders, with around a third meeting diagnostic criteria over the course of a lifetime (Alexander et al. 2007). In this chapter, we will summarize some key points pertaining to the epidemiology, clinical presentation, and treatment of anxiety disorders in women. We will also address the comorbidity between physical illness and anxiety disorders in women. Finally, we will examine the specific challenges faced in treating women with anxiety disorders during pregnancy and lactation.

Epidemiology

Kessler et al. (2012) found the prevalence of anxiety disorders in women in the USA were as follows: specific phobia 12.1 %; social phobia 7.4 %; post-traumatic stress disorder 3.7 %; generalized anxiety disorder 2.0 %; separation anxiety disorder 1.2 %; panic disorder 2.4 %; agoraphobia 1.7 %; obsessive-compulsive disorder (OCD) 1.2 % (Kessler et al. 2012). In an Australian study, Williams et al. (2010) used the Structured Clinical Interview for DSM-IV TR Axis-I Disorders, non-patient edition (SCID-I/NP) to report the prevalence of anxiety and mood disorders, in an age-stratified representative sample of women aged 20 years and older (Williams et al. 2010). The median age of onset of anxiety disorders was 18.5 years and the prevalence of anxiety disorders in women across the life course was 13.5 % with panic disorder (5.5 %) and specific phobias (3.5 %) being the most common.

K. Sevar, MBChB, DCH, MPM, FRANZCP (✉) • D. Castle, MD, FRCPsych, FRANZCP
Department of Psychiatry, University of Melbourne, Parkville, Australia

Department of Psychiatry, St Vincent's Hospital Melbourne, Fitzroy, Australia
e-mail: katherine.sevar@svhm.org.au

B. Vythilingum, FCPsych
Department of Psychiatry, UCT, Rondebosch, Cape Town, South Africa

The preponderance of these conditions in women is not well understood. In a prospective, longitudinal, population-based study of 643 women, psychosocial variables were examined to evaluate whether it was possible to predict the onset of a new anxiety disorder or the recurrence of an existing disorder. The presence of anxiety disorders was assessed every 6 months over a 3-year period, using the Structured Clinical Interview for the Diagnosis of Axis I Disorders (SCID-I). It was found that focusing on negative life events was not a predictor of the onset of anxiety either alone or in interaction with other variables. Significant predictors of anxiety included a history of anxiety, increased anxiety sensitivity (i.e., fear of anxiety-related sensations), and increased neuroticism (Calkins et al. 2009).

The complex interplay between genetic risk factors and environmental influences was studied by Hettema and colleagues (2005) who reported that there were no differences between the sexes with regard to the vulnerability to develop anxiety disorders. However, these authors suggested that the development of anxiety disorders could be split across the both sexes: firstly, “panic-generalized-agoraphobic anxiety” and secondly, the “specific phobias.” They suggested that the underlying etiology of both of these groups is best explained by the presence of two genetic factors which are additive and common across the disorders, with one genetic factor contributing a more causative role to the first subset of “panic-generalized-agoraphobic anxiety” and a second genetic factor contributing to the second subset of “specific phobias.” Social anxiety disorder (SAD) was influenced by both genetic factors (Hettema et al. 2005).

Social Anxiety Disorder (SAD)

Social anxiety disorder (SAD) affects men and women almost equally with approximately 15 % of women and 11 % of men affected across the life course (Kessler et al. 2005). SAD usually begins in childhood or early adolescence and maintains a chronic course throughout adulthood. The clinical features include experiencing extreme anxiety in social scenarios due to a fear of embarrassment or ridicule. Sufferers often manifest physical signs such as blushing and stuttering if asked to speak in public. People with social phobia may become avoidant of social situations and there is some difference between sexes with women stating that they have more distress when speaking in public or meeting strangers (Turk et al. 1998).

Treatment

Psychological therapies for SAD focus on assertiveness training, cognitive behavioral therapy (CBT) and graded exposure to overcome avoidance behavior (Rodebaugh et al. 2004). Meta-analyses have suggested that individual and group CBT may work equally well for individuals with SAD (Rodebaugh et al. 2004; Liber et al. 2008), and that women and men respond equally well to CBT (Canton et al. 2012).

Panic Disorder

Estimates suggest 1–2 % of the adult population suffer panic disorder (Yates 2009). Common risk factors for the development of panic disorder include female gender, low socioeconomic status, and an anxious temperament in childhood. Panic disorder is associated with an elevated risk of suicide as well as all-cause mortality and cardiovascular disease. It ranks highest among the anxiety disorders in terms of disease burden. There has been interest in the conceptualization of anxiety disorders as resulting from psychopathology during childhood, in particular in relation to the presence of separation anxiety disorder in childhood. A meta-analysis of 20 studies indicated that children with separation anxiety disorder were more likely to develop panic disorder in adulthood (odds ratio (OR)=3.45; 95 % confidence interval [CI]=2.37–5.03). Additionally, five studies suggested that a childhood diagnosis of separation anxiety disorder increased the overall risk of the development of future anxiety disorders in adulthood (OR=2.19; 95 % CI=1.40–3.42) (Kossowsky et al. 2013).

Recent research has focussed on the gene encoding monoamine oxidase A (MAOA) in women. This has been of particular interest given the effectiveness of MAO inhibitors in the treatment of panic disorder and previous studies of MAO inhibitors in animal models of panic disorder. A meta-analysis of four studies reported a significant female-specific association when calculating an allelic model in panic disorder, leading the authors to suggest that “this sex-specific effect might be explained by a gene-dose effect causing higher MAOA expression in females.” Furthermore, they hypothesized that high-expression MAOA-uVNTR alleles significantly increase the risk of developing panic disorder in women. This finding will require further replication in larger samples, but may be a lead in the understanding of female vulnerability to the development of panic disorder (Reif et al. 2012).

Panic disorder has been reported as having a prevalence of between 1.3 and 2.0 % in pregnancy (Sholomskas et al. 1993). While in the postpartum period both an increased risk of relapse as well as increased risk of new onset panic disorder has been reported, the risk in pregnancy per se is not known (Sholomskas et al. 1993). There are conflicting data about the course of panic disorder in pregnancy. Some studies report improvement of symptoms (Wisner et al. 1996; Cohen et al. 1994); such improvements have been linked to physiologic changes in hormonal milieu and progesterone metabolites, as well as attenuation of the noradrenergic response to stress (Majewska et al. 1986; Barron et al. 1986). Other studies have reported either no change or worsening of symptoms. It may be that the best predictor of symptom change is pregravid symptom severity, with greater severity predicting a worse course (Ross and McLean 2006). Chen et al. (2001) found that in women with panic disorder who actually experienced panic attacks during pregnancy, there was an increased risk of having small-for-gestational-age infants and the adjusted odds ratio for having a preterm delivery was 2.54 (95 % CI=1.09–5.93).

Treatment

Cognitive behavioral therapy (CBT) is again the first-line psychotherapy treatment for panic disorder. Pharmacotherapy, particularly selective serotonin reuptake inhibitors (SSRIs) are also a first-line option (Mitte et al. 2005). A recent review (Stein et al. 2010) also suggested efficacy when combining SSRIs with CBT. (See chapter “Anxiety and related disorders in men” for greater detail).

Generalized Anxiety Disorder

Women with generalized anxiety disorder (GAD) report intrusive, pervasive worries that affect their function and quality of life across many domains (Grant et al. 2005). GAD usually has an onset prior to 25 years old and most often has a chronic course throughout adulthood (Stein et al. 2005). In the USA, generalized anxiety disorder was second only to substance abuse in terms of population prevalence (Fricchione 2004). Individuals with generalized anxiety disorder have a significantly increased risk of developing subsequent depression (Hettema et al. 2006) with up to 75 % developing a major depressive episode in their lifetime. The risk factors for the development of generalized anxiety disorder include a family history of the disorder or stress and trauma. Individuals with comorbid generalized anxiety disorder and depression are more disabled than those with either disorder alone (Grant et al. 2005).

A neurobiological model of generalized anxiety disorder suggests that the early life experience of an increased circulation of adrenaline and cortisol, as a result of exposure to stressful situations, may lead to increased upregulation, and hypersensitivity, of the HPA axis in adulthood. The role of the transgenerational transmission of generalized anxiety disorder is worth considering in this context given that the infants of women with anxiety disorders in pregnancy are more likely to be exposed to greater circulating levels of adrenaline in utero, meaning that they are more vulnerable to developing anxiety disorders in childhood if exposed to early life trauma.

There is little data on the epidemiology of GAD in pregnancy. One study found a rate of 8.5 % in the third trimester (Shear and Oommen 1995). There are few data on the course of pre-existing GAD in pregnancy. Diagnosing GAD poses special challenges in pregnancy – it is normal to have degree of worry and anxiety in pregnancy. DiPietro et al. (2002) developed the Pregnancy Experiences Scale which in addition to measuring worry also measures uplifts (the positive emotional experiences of pregnancy) (DiPietro et al. 2002). In a sample of well pregnant women the majority endorsed both worries and uplifts, and thoughts about normality of baby endorsed by over 80 % of the sample (DiPietro et al. 2002).

Treatment

The psychotherapy treatment of choice for generalized anxiety disorder is cognitive behavioral therapy with women and men both responding in equal measure (Yonkers et al. 2003). There has been some recent evidence suggesting that applied relaxation

techniques could be as useful as cognitive behavioral therapy (Cujipers 2014). Pharmacotherapy in generalized anxiety disorder has an effect size of 0.6 (Gould et al. 1997), and SSRIs would be considered the first-line treatment.

Specific Phobias

Specific phobias are lasting or unreasonable fears of specific objects or situations which often pose little or no real danger. If an individual is exposed to this situation, they experience severe anxiety symptoms and therefore seek to avoid situations of exposure which may lead to significant functional impairment and limitations.

Specific phobias are usually characterized by early age of onset and high rates of comorbidity. A 17-month prospective study from Germany found that women with a specific phobia were twice as likely to develop another anxiety disorder, in particular, generalized anxiety disorder and somatoform disorder when followed over a 17-month period (Trumpf et al. 2010). The same group of researchers also investigated the predictors of specific phobias in women and found that high levels of pre-existing psychopathology, a lack of coping skills, and a negative cognitive style were all associated with increased incidence of specific phobias. They suggest that identifying these risk factors may aid in identifying individuals who are at increased risk of the development of specific phobias and may lead to an improvement in the prevention of these conditions (Trumpf et al. 2010).

Treatment

Psychological therapy, namely, exposure therapy as part of CBT, is the first-line treatment for specific phobias although only a small minority of individuals seek treatment, as low as 8 % (Stinson et al. 2007). A meta-analysis conducted in 2008 (Wolitzky-Taylor et al. 2008) found that exposure-based psychological treatments were effective in the treatment of specific phobias.

Obsessive-Compulsive Disorder

Obsessive-compulsive disorder (OCD) is estimated to have been the fifth leading cause of disability for women aged 15–44 years in developed countries (Murray and Lopez 1996), and epidemiological surveys suggest that the condition afflicts women more frequently than men (Bebbington 1990) although clinical studies show a less marked female excess, which may reflect differences in help-seeking behavior and a more severe illness course in men (Castle et al. 1995; Lensi et al. 1996; Noshirvani et al. 1991). Additionally, men tend to have an earlier onset of OCD than their female counterparts (Castle et al. 1995; Lensi et al. 1996; Lochner et al. 2004).

There are also sex differences between the type of symptoms manifested in OCD with women more likely to manifest contamination fears and cleaning rituals and

men more prone to aggressive and sexual obsessions, and symmetry concerns (Lensi et al. 1996; Bogetto et al. 1999).

Women with obsessive-compulsive disorder (OCD) sometimes report that symptoms first appear or exacerbate during reproductive cycle events and there has been recent research which has demonstrated the relationship between OCD and the reproductive cycle in women. A meta-analysis revealed that the prevalence of OCD increased during pregnancy (mean=2.07 %) and even more so in the postpartum period (mean=2.43 %) compared with the general population (mean=1.08 %). Additionally, both pregnant (mean=1.45) and postpartum (mean=2.38) women were at greater risk of experiencing OCD compared to the general female population, with an aggregate risk ratio of 1.79 (Russell et al. 2013).

Further research has focussed on OCD across the reproductive cycle including at menarche, premenstruum, pregnancy, postpartum, and at menopause. In a survey of 542 women (United States, $n=352$; Dutch, $n=190$) using a self-report questionnaire of symptoms across time, a significant relationship between exacerbations of OCD and various phases of the reproductive cycle was found. OCD onset occurred within 12 months after menarche in 13.0 % of participants; during pregnancy in 5.1 %; postpartum in 4.7 %; and at menopause in 3.7 %. It was evident that worsening of pre-existing OCD occurred at reproductive cycle events with 37.6 % of women reporting worsening of symptoms at premenstruum, 33.0 % during pregnancy, 46.6 % in postpartum period, and 32.7 % at menopause. Furthermore, a first pregnancy was significantly associated with exacerbation in second pregnancy (OR=10.82, 95 % CI = 4.48–26.16); similarly, postpartum exacerbation in a first pregnancy was associated with an elevated risk in ensuing pregnancies (OR=6.86, 95 % CI = 3.27–14.36). These findings reinforce the importance of clinical vigilance during these phases of the reproductive cycle (Guglielmi et al. 2014).

Treatment

The main psychological therapy in the treatment of OCD is exposure and response prevention (ERP) (Abramowitz 1997) and this is often used in combination with SSRI medications.

Physical Illness and Anxiety Disorders in Women

There is an increased prevalence of anxiety disorders in the presence of chronic physical illness when compared to the prevalence of anxiety disorders in individuals without chronic physical illness. These disorders include chronic fatigue syndrome, fibromyalgia, gastrointestinal conditions, and bronchitis. Anxiety disorders which are comorbid with physical illness have also been significantly associated with short-term disability, requiring help with instrumental daily activities, and suicidal ideation (Gadalla 2008). These findings highlight the importance of screening for the presence of anxiety disorders in women with chronic physical illnesses given

the potential for detrimental impact on their quality of life and level of disability associated with their chronic physical illness.

The relationship between anxiety disorders and physical illness appears bidirectional as the incidence of certain medical conditions appears to be higher in patients with anxiety disorders. A study conducted over 10 years in Canada (Bowen et al. 2000) showed that individuals with anxiety disorders, in comparison to those without, had a significantly higher relative risk of developing medical diseases. The highest hazard ratio was for cerebrovascular disease (hazard ratio = 2.0, 95 % CI = 1.09–3.65); hazard ratios were also significant for ischemic heart, gastrointestinal, respiratory diseases as well as hypertension (Bowen et al. 2000).

Heart Disease

Anxiety has been associated with the development and recurrence of coronary heart disease. Tordaro et al. (2007) reviewed the prevalence of anxiety disorders in men and women with established coronary heart disease and reported that 36.0 % ($n=54$) met the diagnostic criteria for a current anxiety disorder, while 45.3 % ($n=68$) had a past history of an anxiety disorder. Female cardiac patients had significantly higher current (women=58.3 % vs. men = 25.5 %, $p<0.001$) and lifetime (women=70.8 % vs. men=33.3 %, $p<0.001$) rates of anxiety disorders compared with male participants (Tordaro et al. 2007). Special efforts are needed to screen patients for anxiety disorders when attending outpatient cardiology or cardiac rehabilitation.

Cancer

There has been a considerable amount of research into the prevalence of anxiety disorders in women with cancer. A meta-analysis conducted in 3,469 Chinese adults with all types of cancer found the prevalence of anxiety disorders was 49.69 % versus 18.37 % in control subjects (OR=6.46, 95 % CI=4.36–9.55, $p=0.000$) (Yang et al. 2013).

In women, there have been several studies concentrating on breast or gynecological cancers. A prospective study of a hospitalized sample of 167 women examined the prevalence of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS-A) and Centre for Epidemiological Studies Depression Scale (CES-D) at diagnosis and again every 8 weeks for 56 weeks. Rates of anxiety (17.7 %), depression (32.5 %) and combined anxiety and depression (35 %) symptoms were highest at diagnosis but dissipated over time and overall rates of anxiety, depression, and combined symptoms were 7.5 %, 23.4 %, and 24.1 %, respectively, at study end, with most improvement having occurred by 24 weeks. Furthermore, using the cut-off for referral to mental health services as ≥ 11 and ≥ 16 on the HADS-A and CES-D, respectively, there were 54 % of women who met criteria. Half of these women declined referral, a quarter accepted and a further quarter were already receiving

treatment. This meant that 30 % of women in the study were receiving treatment for a mental health condition and that women were most vulnerable to psychological morbidity at the time of cancer diagnosis (Stafford et al. 2013).

Wurtzen et al. (2013) conducted a randomized controlled trial of an 8-week mindfulness-based group therapy intervention targeting anxiety and depressive symptoms in 336 women with breast cancer. Symptoms were assessed immediately preceding and following the intervention and at 6- and 12-month intervals following thereafter. Intention-to-treat analyses showed differences between groups in levels of anxiety ($p=0.0002$) and depression (SCL-90r, $p<0.0001$; CES-D, $p=0.0367$) after 12 months (Wurtzen et al. 2013).

Gastrointestinal Disorders

Irritable bowel syndrome (IBS) is often associated with anxiety and depression. A sample of 1,077 women found that current diagnosis of irritable bowel syndrome was associated with an increased likelihood of current mood or anxiety disorders with OR=2.62, 95 % CI = 1.49–4.60. Additionally, half of those participants diagnosed with irritable bowel syndrome IBS had also previously been diagnosed with a mood or anxiety disorder (Mykletun et al. 2010).

Anxiety Across the Life Course in Women

The prevalence of anxiety disorders in women across menstrual cycle, pregnancy, and menopause has been extensively investigated with research revealing rates of some anxiety disorders being higher in postpartum women than in the general population (Ross and McLean 2006). The relationship between the menstrual cycle, menopause, and anxiety disorders has also been considered with links established between hormonal phases of the menstrual cycle and the worsening of anxiety disorders.

Premenstrual Dysphoric Disorder (PMDD)

Premenstrual dysphoric disorder (PMDD) is a mood disorder with onset of functionally impairing or distressing mood symptoms in the late luteal phase of the menstrual cycle. It is classified as a depressive disorder but there are studies which have identified anxiety as a key component (Stein et al. 1989); in particular, the frequency of panic attacks can increase in PMDD (Facchinetti et al. 1992).

Recent research has attempted to interrogate state versus trait symptoms in PMDD and explore the relationship between physiological findings and psychological symptoms. Poromaa (2014) found that in individuals with PMDD, “state” symptoms occur in the luteal phase, suggesting that women with PMDD have altered luteal phase emotion processing and lower pre-pulse inhibition in the late luteal phase, which could reflect

ovarian steroid-influenced altered serotonergic neurotransmission. They suggested that “trait” findings in these women occur in the asymptomatic phases of the menstrual cycle and physiologically exhibited trait vulnerability markers include diminished cardiovascular stress responses, lower P300 amplitude, and lower heart rate variability reflecting increased vagal tone. These findings suggest that women with PMDD share physiological correlates with women with anxiety and depression (Poromaa 2014).

Menopause

A recent systematic review examining 19 studies conducted between 1960 and 2011 (Bryant et al. 2012) evaluated the prevalence of anxiety disorders during the menopausal transition to ascertain whether there was any utility in the diagnosis of “menopausal anxiety” as a discrete category. The review examined the relationship between the vasomotor symptoms of menopause (e.g., “hot flashes”), and anxiety states. Findings suggest that there is no current evidence to suggest that there is an increased prevalence of anxiety disorders during the menopause, nor the emergence of an anxiety disorder specifically determined by the menopause.

Anxiety Disorders During Pregnancy and Postnatally

It has often been considered that pregnancy is a time of low risk for the new onset or exacerbation of an anxiety disorder. However, there is growing evidence that many women suffer from either new onset or worsening of their anxiety disorders during pregnancy. The occurrence of an anxiety disorder in pregnancy has important consequences – it not only impacts on the woman’s mental health, but also is a risk for postnatal disorders, as well as having possible effects on the unborn child. Studies of anxiety in a pregnancy show that a not insubstantial proportion of women is affected. For example, Heron et al. (2004) in a large community sample of pregnant women found that 21 % had clinically significant anxiety, and of these 64 % continued to have anxiety postnatally.

Perinatal Post-traumatic Stress Disorder (PTSD)

Perinatal post-traumatic stress disorder (PTSD), that is, PTSD related to medical procedures, childbirth, or other obstetric events, has been reported (Beck 2004). One study found that 20 % of women reported traumatic pregnancy-related procedures, and of these 6 % met criteria for PTSD (Menage 1993). Controversy exists as to whether medical procedures during pregnancy and/or childbirth meet DSM criteria for a traumatic event. While pregnancy and childbirth are not considered to be an event outside the range of normal human experience, the DSM V stressor criterion requires that the person must be exposed to a death, threatened death, actual or threatened serious injury; it is generally acknowledged that traumatic reactions may occur when neither resistance nor escape is possible and helplessness and loss of control are experienced. Childbirth could certainly pose a risk of death and/or serious

injury. Risk factors for perinatal PTSD include previous adverse reproductive events such as ectopic pregnancy, miscarriage, stillbirth, unwanted pregnancy, and abortion; history of sexual trauma (Beck 2004), past traumatic experience (Beck 2004; Menage 1993), prior psychiatric history (Menage 1993), obstetric interventions or complications (Beck 2004; Menage 1993) and poor social support (Beck 2004).

The clinical features of anxiety disorders in pregnancy are similar to those in nonpregnant women. However, concerns over the pregnancy and fetus may present as the predominant feature. For example, in panic disorder, women may interpret panic attacks as something being wrong with the fetus (Weisberg et al. 2002).

Perinatal OCD is classically described as involving obsessive concerns of harming child, together with checking and cleaning compulsions (Abramowitz et al. 2003). It is important to differentiate this from homicidal impulses toward the child (e.g., as part of a psychotic disorder) – in OCD these thoughts are experienced as intrusive and the mother has no wish of harming her child. It has been postulated that these features may be an exacerbation of the normal vigilance toward the child that is characteristic of pregnancy and the postpartum period (Stein and Bouwer 1997).

Women with anxiety disorders also commonly present with numerous physical complaints. Studies of health in pregnancy in women with psychiatric disorders showed an increased frequency of nausea and vomiting (adjusted OR = 2.04, 95 % CI = 1.40–2.98), disability days (OR = 2.10, 95 % CI = 1.49–3.00), and physician visits (OR = 1.52, 95 % CI = 1.10–2.12) in women with anxiety and/or mood disorders (Andersson et al. 2003). Indeed, frequent physical complaints with no discernable physical cause should prompt the clinician to screen for an anxiety disorder.

Risk of Anxiety Disorders in Pregnancy

Maternal Risks

The majority of anxiety disorders in pregnancy have a continued postnatal course. Further, several prospective studies have shown that a prenatal anxiety disorder is one of the strongest risk factors for developing postnatal depression (Milgrom et al. 2008; Sutter-Dallay et al. 2004). An anxiety disorder in pregnancy is thus associated with significant potential maternal morbidity.

Fetal Effects of Maternal Anxiety

Both animal and human studies suggest that antenatal stress/anxiety can cause poorer obstetric outcomes and a range of neurobehavioral problems in exposed infants (Schneider et al. 2002; Bergman et al. 2007). In animals, prenatal stress has been reported to be associated with spontaneous abortion, delays in the birth process, smaller litter size and animals with lower birth weight, compromised physical growth and an increased incidence of malformations (Huizink et al. 2004). Similarly in humans, women reporting high levels of subjective stress have been found to be at doubled risk for delivering preterm or growth-restricted baby (Wadhwa et al.

2002). Antenatal anxiety or stress has been linked with physical defects in the child (Hansen et al. 2000) and low birth weight (Hedegaard et al. 1993). More worryingly, prenatal maternal anxiety has been linked with persisting neurobehavioral problems, including poorer performance on tests of neurodevelopment, increased fearfulness (Bergman et al. 2007) and conduct problems (Huizink et al 2004).

Screening for Anxiety Disorders in Pregnancy

There are no specific screening programs for anxiety disorders in pregnancy. Screening for depression in pregnancy, however, has been well validated and several established screening programs exist (Buist et al. 2002; Austin and Lumley 2003). A strong case can be made to extend these to detect anxiety in pregnancy as well. This is particularly relevant given the rate of women reporting clinically significant anxiety in pregnancy (Heron et al. 2004) and the morbidity that may be associated with the offspring of such women (Glover and O'Connor 2002). In addition, successful management of symptoms present during pregnancy is likely to aid in the reduction of postnatal psychological mood and anxiety disorder (Buist et al. 2002).

The most commonly used screening tool for postnatal depression is the Edinburgh Postnatal Depression Scale (EPDS), referred to as the Edinburgh Depression Scale (EDS) when used during pregnancy (Matthey 2007). It is probable that the EDS also identifies a number of women with anxiety disorders (Matthey 2007). It has been recommended that use of the EDS in combination with a risk questionnaire (assessing alcohol and drug use, partner and social support, and domestic violence) is a good model for screening for both anxiety and depression in pregnancy (Buist et al. 2002; Matthey 2007).

Management of Anxiety Disorders in Pregnancy

Preconceptual Counselling

Ideally, all women known to have an anxiety disorder should have preconception psychoeducation. This should include discussing the risk of relapse during pregnancy and the postnatal period, the risks versus benefits of medications if she were to become pregnant and/or breastfeed as well as a discussion around partner and psychosocial support during pregnancy once baby is born. Asking about the contraception women are using is essential.

Psychotherapy

Psychotherapy is considered first choice for treating mild to moderate anxiety in women who are pregnant. It poses minimal risk to the fetus. While there are no studies addressing the efficacy of psychotherapy in pregnancy, studies in nonpregnant women show efficacy in both interpersonal and cognitive behavioral therapy (CBT).

Relaxation therapy also has shown efficacy in treating anxiety disorders. In a randomized controlled trial of 110 pregnant women with high-level anxiety, 7 weeks of applied relaxation training sessions was associated with significant reductions in low-weight births, cesarean sections, and instrumental extractions (Bastani et al. 2006). Supportive therapy has also been shown to be useful in terms of improving maternal mood and ameliorating anxiety (Fricchione 2004).

Pharmacotherapy

When considering medication in pregnancy, one needs to consider possible effects on the fetus. Two main classes of medication are commonly used to treat anxiety, namely, antidepressants and benzodiazepines.

Selective serotonin reuptake inhibitors (SSRIs) are a first-line pharmacological treatment for anxiety disorders. Large population-based studies have found no increase in the rates of major congenital malformations in infants exposed to SSRIs, with the exception of paroxetine, which has been associated with an increased risk for fetal ventricular and/or atrial septal defects with first-trimester exposure. Paroxetine is consequently best avoided during pregnancy (Källén and Otterblad Olausson 2007).

A concern around SSRI use in pregnancy is the possible increased risk of persistent pulmonary hypertension of the newborn (PPHN), which occurs in 1–2 infants per 1,000 live births. Grigoriadis and colleagues (2014) in a meta-analysis of published studies found that while exposure to SSRIs in early pregnancy was not associated with an increased risk of PPHN (OR = 1.23, 95 % CI = 0.58–2.60; $p=0.58$), exposure in late pregnancy was (OR = 2.50, 95 % CI = 1.32–4.73; $p=0.005$). One of the strengths of this meta-analysis was the examination of moderator variables which included study design, congenital malformations, and meconium aspiration. The authors were, however, unfortunately not able to assess for the effect of cesarean section, body mass index, or preterm delivery – which are known risk factors for PPHN. It must be noted that even though SSRI exposure in late pregnancy does pose a statistically increased risk of PPHN, the clinical risk remains low, with an estimated 286–351 women needing to be treated to result in an average of one additional case.

It is currently unclear whether SSRI (and other antidepressants) use during pregnancy is associated with an increased risk of autism spectrum disorders. The two largest population-based studies have shown conflicting results (Rai et al. 2013; Hviid et al. 2013). However, both these studies point out multiple confounding factors including the possible effect of depression itself on risk for autism spectrum disorders. Furthermore, Rai et al. (2013) point out that the increased risk of autism spectrum disorders found in their study was very small and must be balanced against the risks of untreated depression.

Infants of women who need to take SSRIs just before delivery can develop toxicity or withdrawal syndromes. Occurrence of either syndrome depends on SSRI half-life, serum concentration, and the pharmacodynamics of other medications given during pregnancy and labor (Sanz et al. 2005). Discontinuation syndromes can

occur within a few hours or days after birth and last up to a month after delivery, depending on the infant's susceptibility. Most suspected SSRI-induced neonatal withdrawal syndromes have been associated with paroxetine, although all SSRIs appear to confer some risk (Sanz et al. 2005). Affected infants are tremulous, jittery, irritable, have poor sucking, high-pitched cries, and sleep and gastrointestinal disturbances.

Tapering and stopping SSRIs prior to the third trimester is an option that would serve to prevent these syndromes and also potentially decrease the risk for PPHN. However, this strategy must be weighed against the risk of relapse if medication is stopped. Benzodiazepine cover may be useful during this period. The antidepressant should be started immediately postdelivery to decrease risk of postpartum relapse. If a withdrawal syndrome is present, breastfeeding may help ameliorate this, by providing smaller regular exposures to SSRIs.

Of the *tricyclic antidepressants (TCAs)*, clomipramine and imipramine are the most commonly used in the management of anxiety. No increased teratogenic risk has been found with these agents (Nulman et al. 2002). However, due to their adverse side effect profile, particularly postural hypotension, which can be a significant problem in a pregnant patient, and lethality in overdose, they are generally used as second-line agents.

There is little data available on the safety of other antidepressants in pregnancy. A few small studies suggest a slight increased risk of malformations with venlafaxine (Polen et al. 2013) and duloxetine (Hoog et al. 2013), but given the paucity of data non-SSRI antidepressants are probably best used as second- or third-line agents.

There is little data about dosing of antidepressant drugs during pregnancy and the early postpartum period. Some physiologic changes of pregnancy that may lead to altered dose requirements include steroid hormone effects on cytochrome activities (Tanaka 1999); plasma volume expansion; reduction in plasma protein (albumin) levels that leads to decreased drug binding; diminished hepatic blood flow (Stika et al. 2001; Kalra et al. 2005); and increased glomerular filtration rate and renal excretion (Keller et al. 2001; Weinstein 1980). In addition, increases in plasma volume and total body water may increase the volume of distribution and thereby increase the dose requirements that are necessary to sustain therapeutic drug levels (Little 1999).

Heikkinen and colleagues (2002) showed decreasing plasma citalopram concentration after 20 weeks gestation. Sit et al. (2008) replicated this and, in addition, showed this for escitalopram and sertraline, with drug levels decreasing by up to 40 % in some women. Their study also linked decreased plasma levels to changes in mood. The authors suggest that in women whose symptoms recur or worsen a dose increase should be considered.

Benzodiazepines may provide immediate symptomatic relief for anxiety symptoms and can be used alone or in conjunction with an antidepressant for long-term treatment, though the risk of dependence must be considered. Benzodiazepine teratogenicity remains controversial (Levey et al. 2004); some – but not all – data suggest a small but significant increased risk for major malformations/oral cleft malformations with first-trimester benzodiazepine exposure.

Benzodiazepines use close to term can also have fetal effects. Neonatal toxicity (“floppy infant syndrome”) – characterized by hypothermia, lethargy, poor respiratory effort, and feeding difficulties – occurs after maternal benzodiazepine use just before delivery (Levey et al. 2004). Neonatal withdrawal may be caused by very late, third-trimester exposure to benzodiazepines. Symptoms – which can persist up to 3 months after delivery – include restlessness, irritability, abnormal sleep patterns, suckling difficulties, growth retardation, hypertonia, hyperreflexia, tremulousness, apnea, diarrhea, and vomiting (Levey et al. 2004; Iqbal et al. 2002). It is not clear though whether this is entirely due to withdrawal per se or whether ongoing exposure via breastmilk plays a role in these symptoms.

When possible, benzodiazepines should be avoided in the first trimester because of possible teratogenicity and then again late in the third trimester before delivery because of neonatal withdrawal syndromes. To minimize neonatal withdrawal, gradually taper the mother’s benzodiazepine before delivery (Iqbal et al. 2002). Because the baby’s due date is often imprecise, it is sensible to begin this taper 3–4 weeks before the due date and discontinue at least a week before delivery. If benzodiazepines cannot be tapered, it is best to use a short acting agent and to advise the mother to discontinue benzodiazepine use as soon as she thinks she is going into labor. Breastfeeding while taking benzodiazepines is not recommended because of the risk of over-sedating the infant.

Conclusions

Anxiety disorders occur commonly in women. There are differences in the epidemiology, clinical presentation, and etiology between men and women. However, these differences are not yet fully elucidated. In particular, further work is required on how these differences impact on management.

References

- Abramowitz JS (1997) Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. *J Consult Clin Psychol* 65(1):44–52
- Abramowitz JS, Schwartz SA, Moore KM et al (2003) Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature. *J Anxiety Disord* 17:461–478
- Alexander JL, Dennerstein L, Kotz K, Richardson G (2007) Women, anxiety and mood: a review of nomenclature, comorbidity and epidemiology. *Expert Rev Neurother* 7(11 Suppl):S45–S58
- Andersson L, Sundstrom-Poromaa I, Bixo M, Wulff M, Bondestam K, Astrom M (2003) Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. *Am J Obstet Gynecol* 189:148–154
- Austin MP, Lumley J (2003) Antenatal screening for postnatal depression: a systematic review. *Acta Psychiatr Scand* 107(1):10–17
- Bebbington PE (1990) Population surveys of psychiatric disorder and the need for treatment. *Soc Psychiatry Psychiatr Epidemiol* 25(1):33–40. Review
- Barron WM, Mujais SK, Zinaman M, Bravo EL, Lindheimer MD (1986) Plasma catecholamine responses to physiologic stimuli in normal human pregnancy. *Am J Obstet Gynecol* 154(1):80–84
- Bastani F, Hidarnia A, Montgomery KS et al (2006) Does relaxation education in anxious primigravid Iranian women influence adverse pregnancy outcomes? A randomized controlled trial. *J Perinat Neonatal Nurs* 20(2):138–146

- Beck CT (2004) Post-traumatic stress disorder due to childbirth: the aftermath. *Nurs Res* 53:216–224
- Bergman K, Sarkar P, O'Connor TG, Modi N, Glover V (2007) Maternal stress during pregnancy predicts cognitive ability and fearfulness in infancy. *J Am Acad Child Adolesc Psychiatry* 46(11):1454–1463
- Bogetto F, Venturello S, Albert U et al (1999) Gender-related clinical differences in obsessive-compulsive disorder. *Eur Psychiatry* 14(8):434–441
- Bowen RC, Senthilselvan A, Barale A (2000) Physical illness as an outcome of chronic anxiety disorders. *Can J Psychiatry* 45(5):459–464
- Bryant C, Judd FK, Hickey M (2012) Anxiety during the menopausal transition: a systematic review. *J Affect Disord* 139(2):141–148. doi:[10.1016/j.jad.2011.06.055](https://doi.org/10.1016/j.jad.2011.06.055)
- Buist AE, Barnett BE, Milgrom J, Pope S, Condon JT, Ellwood DA, Boyce PM, Austin MP, Hayes BA (2002) To screen or not to screen—that is the question in perinatal depression. *Med J Aust* 177(Suppl):S101–S105
- Calkins AW, Otto MW, Cohen LS, Soares CN, Vitonis AF, Hearon BA, Harlow BL (2009) Psychosocial predictors of the onset of anxiety disorders in women: results from a prospective 3-year longitudinal study. *J Anxiety Disord* 23(8):1165–1169. doi:[10.1016/j.janxdis.2009.07.022](https://doi.org/10.1016/j.janxdis.2009.07.022)
- Canton J, Scott KM, Glue P (2012) Optimal treatment of social phobia: systematic review and meta-analysis. *Neuropsychiatr Dis Treat* 8:203–215. doi:[10.2147/NDT.S23317](https://doi.org/10.2147/NDT.S23317), Epub 2012 May 3
- Castle DJ, Deale A, Marks IM (1995) Gender differences in obsessive compulsive disorder. *Aust N Z J Psychiatry* 29(1):114–117
- Chen YH, Lin HC, Lee HC (2010) Pregnancy outcomes among women with panic disorder – do panic attacks during pregnancy matter? *J Affect Disord* 120(1–3):258–262. doi:[10.1016/j.jad.2009.04.025](https://doi.org/10.1016/j.jad.2009.04.025)
- Cohen LS, Sichel DA, Dimmock JA et al (1994) Impact of pregnancy on panic disorder: a case series. *J Clin Psychiatry* 55:284–288
- Cuijpers P, Sijbrandij M, Koole S et al (2014) Psychological treatment of generalized anxiety disorder: a meta-analysis. *Clin Psychol Rev* 34(2):130–140. doi:[10.1016/j.cpr.2014.01.002](https://doi.org/10.1016/j.cpr.2014.01.002), Epub 2014 Jan 10
- DiPietro J, Ghera M, Costigan K et al (2002) Measuring the ups and downs of pregnancy stress. *J Psychosom Obstet Gynecol* 25:189–201
- Facchinetti F, Romano G, Fava M, Genazzani AR (1992) Lactate infusion induces panic attacks in patients with premenstrual syndrome. *Psychosom Med* 54(3):288–296
- Fricchione G (2004) Clinical practice. Generalized anxiety disorder. *N Engl J Med* 351(7):675–682. doi:[10.1056/NEJMc022342](https://doi.org/10.1056/NEJMc022342)
- Gadalla TM (2008) Disability associated with comorbid anxiety disorders in women with chronic physical illness in Ontario, Canada. *Women Health* 48(1):1–20. doi:[10.1080/03630240802131965](https://doi.org/10.1080/03630240802131965)
- Glover V, O'Connor TG (2002) Effects of antenatal stress and anxiety: implications for development and psychiatry. *Br J Psychiatry* 180:389–391
- Gould RA et al (1997) Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. *Behav Ther* 28(2):285–305
- Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Huang B (2005) Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychol Med* 35(12):1747–1759. doi:[10.1017/S0033291705006069](https://doi.org/10.1017/S0033291705006069)
- Grigoriadis S, Vonderporten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE (2014) Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. *BMJ* 348:f6932
- Guglielmi V, Vulink NC, Denys D, Wang Y, Samuels JF, Nestadt G (2014) Obsessive-compulsive disorder and female reproductive cycle events: results from the OCD and reproduction collaborative study. *Depress Anxiety*. doi:[10.1002/da.22234](https://doi.org/10.1002/da.22234)
- Hansen D, Lou HC, Olsen J (2000) Serious life events and congenital malformations: a national study with complete follow-up. *Lancet* 356(9233):875–880
- Hedegaard M, Henriksen TB, Sabroe S, Secher NJ (1993) Psychological distress in pregnancy and preterm delivery. *BMJ* 307(6898):234–239

- Heikkinen T, Ekblad U, Kero P et al (2002) Citalopram in pregnancy and lactation. *Clin Pharmacol Ther* 72:184–191
- Heron J, O'Connor T, Evans J et al (2004) The course of anxiety and depression through pregnancy and the postpartum in a community sample. *J Affect Disord* 80(1):65–73
- Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS (2005) The structure of genetic and environmental risk factors for anxiety disorders in men and women. *Arch Gen Psychiatry* 62(2):182–189
- Hettema JM, Kuhn JW, Prescott CA, Kendler KS (2006) The impact of generalized anxiety disorder and stressful life events on risk for major depressive episodes. *Psychol Med* 36(6):789–795. doi:[10.1017/S0033291706007367](https://doi.org/10.1017/S0033291706007367)
- Hoog S, Cheng Y, Elpers J et al (2013) Duloxetine and pregnancy outcomes: safety surveillance findings. *Int J Med Sci* 10(4):413–419. doi:[10.7150/ijms.5213](https://doi.org/10.7150/ijms.5213), Epub 2013 Feb 28
- Huizink AC, Mulder EJ, Buitelaar JK (2004) Prenatal stress and risk for psychopathology: specific effects or induction of general susceptibility? *Psychol Bull* 130:115–142
- Hviid A, Melbye M, Pasternak B (2013) Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. *N Engl J Med* 369(25):2406–2415
- Iqbal MM, Sobhan T, Ryals T (2002) Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. *Psychiatr Serv* 53(1):39–49
- Källén BA, Otterblad Olausson P (2007) Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. *Birth Defects Res A Clin Mol Teratol* 79(4):301–308
- Kalra S, Born L, Sarkar M et al (2005) The safety of antidepressant use in pregnancy. *Expert Opin Drug Saf* 4:273–284
- Keller F, Griesshammer M, Haussler U et al (2001) Pregnancy and renal failure: the case for application of dosage guidelines. *Drugs* 61:1901–1920
- Kessler RC, Demler O, Frank RG et al (2005) Prevalence and treatment of mental disorders, 1990 to 2003. *N Engl J Med* 352(24):2515–2523
- Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *Int J Methods Psychiatr Res* 21(3):169–184. doi:[10.1002/mpr.1359](https://doi.org/10.1002/mpr.1359)
- Kossowsky J, Pfaltz MC, Schneider S, Taeymans J, Locher C, Gaab J (2013) The separation anxiety hypothesis of panic disorder revisited: a meta-analysis. *Am J Psychiatry* 170(7):768–781. doi:[10.1176/appi.ajp.2012.12070893](https://doi.org/10.1176/appi.ajp.2012.12070893)
- Lensi P, Cassano GB, Correddu G et al (1996) Obsessive-compulsive disorder. Familial-developmental history, symptomatology, comorbidity and course with special reference to gender-related differences. *Br J Psychiatry* 169(1):101–107
- Levey L, Ragan K, Hower-Hartley A et al (2004) Psychiatric disorders in pregnancy. *Neurol Clin* 22(4):863–893
- Liber JM, Van Widenfelt BM, Utens EM et al (2008) No differences between group versus individual treatment of childhood anxiety disorders in a randomised clinical trial. *J Child Psychol Psychiatry* 49(8):886–893. doi:[10.1111/j.1469-7610.2008.01877.x](https://doi.org/10.1111/j.1469-7610.2008.01877.x), Epub 2008 Mar 10
- Little B (1999) Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. *Obstet Gynecol* 93:858–868
- Lochner C, Hemmings SM, Kinnear CJ et al (2004) Gender in obsessive-compulsive disorder: clinical and genetic findings. *Eur Neuropsychopharmacol* 14(2):105–113
- Matthey S (2007) Using the Edinburgh postnatal depression scale to screen for anxiety disorders. *Depress Anxiety* 25(11):926–931
- Menage J (1993) Post-traumatic stress disorders in women who have undergone obstetric and/or gynaecological procedures. *J Reprod Infant Psychol* 11:221–228
- Milgrom J, Gemmill AW, Bilszta JL, Hayes B, Barnett B, Brooks J, Erickson J, Ellwood D, Buist A (2008) Antenatal risk factors for postnatal depression: a large prospective study. *J Affect Disord* 108(1–2):147–157
- Mitte K (2005) A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. *J Affect Disord* 88(1):27–45

- Murray CJL, Lopez AD (1996) The global burden of disease and injury series, volume 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard School of Public Health, Cambridge, MA
- Mykletun A, Jacka F, Williams L, Pasco J, Henry M, Nicholson GC, Kotowicz MA, Berk M (2010) Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome (IBS). An epidemiological population based study of women. *BMC Gastroenterol* 10:88. doi:[10.1186/1471-230X-10-88](https://doi.org/10.1186/1471-230X-10-88)
- Noshirvani HF, Kasvikis Y, Marks IM et al (1991) Gender-divergent aetiological factors in obsessive-compulsive disorder. *Br J Psychiatry* 158:260–263
- Nulman I, Rovet J, Stewart DE et al (2002) Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. *Am J Psychiatry* 159(11):1889–1895
- Poromaa IS (2014) Physiological Correlates of Premenstrual Dysphoric Disorder (PMDD). *Curr Top Behav Neurosci*. doi:[10.1007/7854_2014_296](https://doi.org/10.1007/7854_2014_296)
- Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C (2013) Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case–control study. *BMJ* 346:f2059
- Reif A, Weber H, Domschke K, Klauke B, Baumann C, Jacob CP, Deckert J (2012) Meta-analysis argues for a female-specific role of MAOA-uVNTR in panic disorder in four European populations. *Am J Med Genet B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet* 159B(7):786–793. doi:[10.1002/ajmg.b.32085](https://doi.org/10.1002/ajmg.b.32085)
- Rodebaugh TL, Holaway RM, Heimberg RG (2004) The treatment of social anxiety disorder. *Clin Psychol Rev* 24(7):883–908
- Ross LE, McLean LM (2006) Anxiety disorders during pregnancy and the postpartum period: a systematic review. *J Clin Psychiatry* 67(8):1285–1298
- Russell EJ, Fawcett JM, Mazmanian D (2013) Risk of obsessive-compulsive disorder in pregnant and postpartum women: a meta-analysis. *J Clin Psychiatry* 74(4):377–385. doi:[10.4088/JCP.12r07917](https://doi.org/10.4088/JCP.12r07917)
- Polen K, Rasmussen SA, Riehle-Colarusso T et al (2013) Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997–2007. *Birth Defects Res A Clin Mol Teratol* 97(1):28–35. doi:[10.1002/bdra.23096](https://doi.org/10.1002/bdra.23096), Epub 2012 Dec 26
- Sanz EJ, De-las-Cuevas C, Kiuru A et al (2005) Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. *Lancet* 365(9458):482–487
- Schneider ML, Moore CF, Kraemer GW, Roberts AD, DeJesus OT (2002) The impact of prenatal stress, fetal alcohol exposure, or both on development: perspectives from a primate model. *Psychoneuroendocrinology* 27:285–298
- Sit DK, Perel JM, Helsel JC et al (2008) Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. *J Clin Psychiatry* 69(4):652–658
- Shear KM, Oommen M (1995) Anxiety disorders in pregnant and postpartum women. *Psychopharmacol Bull* 31(4):693–703
- Sholomskas DE, Wickamaratne PJ, Dogolo L et al (1993) Postpartum onset of panic disorder: a coincidental event? *J Clin Psychiatry* 54:476–480
- Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M (2013) Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months. *Psychooncology* 22(9):2071–2078. doi:[10.1002/pon.3253](https://doi.org/10.1002/pon.3253)
- Stein DJ, Bouwer C (1997) A neuro-evolutionary approach to the anxiety disorders. *J Anxiety Disord* 11(4):409–429
- Stein MB, Schmidt PJ, Rubinow DR, Uhde TW (1989) Panic disorder and the menstrual cycle: panic disorder patients, healthy control subjects, and patients with premenstrual syndrome. *Am J Psychiatry* 146(10):1299–1303
- Stein MB, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Pyne JM, Sherbourne CD (2005) Functional impact and health utility of anxiety disorders in primary care outpatients. *Med Care* 43(12):1164–1170
- Stika C, Frederiksen M (2001) Drug therapy in pregnant and nursing women. In: Atkinson AJ Jr, Daniels CE, Dedrick RL et al (eds) *Principles of clinical pharmacology*. Academic, New York, pp 277–291.17

- Stinson F, Dawson DA et al (2007) The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychol Med* 37(7):1047–1059. Epub 2007 Mar 5
- Sutter-Dallay AL, Giaconne-Marcasche V, Glatigny-Dallay E, Verdoux H (2004) Women with anxiety disorders during pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the MATQUID cohort. *Eur Psychiatry* 19(8):459–463
- Tanaka E (1999) Gender-related differences in pharmacokinetics and their clinical significance. *J Clin Pharm Ther* 24:339–346
- Todaro JF, Shen BJ, Raffa SD, Tilkemeier PL, Niaura R (2007) Prevalence of anxiety disorders in men and women with established coronary heart disease. *J Cardiopulm Rehabil Prev* 27(2): 86–91. doi:[10.1097/01.HCR.0000265036.24157.e7](https://doi.org/10.1097/01.HCR.0000265036.24157.e7)
- Trumpf J, Margraf J, Vriends N, Meyer AH, Becker ES (2010) Specific phobia predicts psychopathology in young women. *Soc Psychiatry Psychiatr Epidemiol* 45(12):1161–1166. doi:[10.1007/s00127-009-0159-5](https://doi.org/10.1007/s00127-009-0159-5)
- Turk CL, Heimberg RG, Orsillo SM et al (1998) An investigation of gender differences in social phobia. *J Anxiety Disord* 12(3):209–223
- Wadhwa PD, Glynn L, Hobel CJ, Garite TJ, Porto M, Chicx-DeMet A, Wigglesworth AK, Sandman CA (2002) Behavioral perinatology: biobehavioral processes in human fetal development. *Regul Pept* 108(2–3):149–157
- Weinstein M (1980) Lithium treatment of women during pregnancy and in the post-delivery period. MTP Press, Lancaster
- Weisberg RB, Paquette JA (2002) Screening and treatment of anxiety disorders in pregnant and lactating women. *Womens Health Issues* 12(1):32–36
- Williams L, Jacka F, Pasco J, Henry M, Dodd S, Nicholson G, Berk M (2010) The prevalence of mood and anxiety disorders in Australian women. *Australas Psychiatry Bull R Aust N Z Coll Psychiatrists* 18(3):250–255. doi:[10.3109/10398561003731155](https://doi.org/10.3109/10398561003731155)
- Wisner KL, Peindl KS, Hanusa BH (1996) Effects of childbearing on the natural history of panic disorder with comorbid mood disorder. *J Affect Disord* 41:173–180
- Wolitzky-Taylor KB, Horowitz JD et al (2008) Psychological approaches in the treatment of specific phobias: a meta-analysis. *Clin Psychol Rev* 28(6):1021–1037. doi:[10.1016/j.cpr.2008.02.007](https://doi.org/10.1016/j.cpr.2008.02.007), Epub 2008 Mar 7
- Würtzen H, Dalton SO, Andersen KK et al (2013) Who participates in a randomized trial of mindfulness-based stress reduction (MBSR) after breast cancer? A study of factors associated with enrollment among Danish breast cancer patients. *Psychooncology* 22(5):1180–1185. doi:[10.1002/pon.3094](https://doi.org/10.1002/pon.3094), Epub 2012 May 16
- Yang YL, Liu L, Wang Y, Wu H, Yang XS, Wang JN, Wang L (2013) The prevalence of depression and anxiety among Chinese adults with cancer: a systematic review and meta-analysis. *BMC Cancer* 13:393. doi:[10.1186/1471-2407-13-393](https://doi.org/10.1186/1471-2407-13-393)
- Yates WR (2009) Phenomenology and epidemiology of panic disorder. *Ann Clin Psychiatry* 21(2):95–102
- Yonkers KA, Bruce SE, Dyck IR, Keller MB (2003) Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. *Depress Anxiety* 17(3):173–179

Anxiety and Related Disorders in Men

Jon E. Grant and Brian L. Odlaug

Introduction

Anxiety disorders are among the most common of all psychiatric disorders. The global current prevalence for anxiety disorders is 7.3 %, suggesting that 1 in 14 people around the world at any given time has an anxiety disorder and 1 in 9 (11.6 %) will experience an anxiety disorder in a given year (Baxter et al. 2013). Per year, the estimated cost (directly and indirectly) of anxiety disorders in the United States alone is over \$42 billion (Greenberg et al. 1999). More than 50 % of these expenses are due to clinical care stemming from misdiagnosis, inadequate treatment, and emergency care (including psychiatric and nonpsychiatric hospitalization), the net effect of which is reduced productivity and absenteeism from the workplace (Lepine 2002).

Anxiety disorders have a substantial, negative impact on individuals. Effects are seen not only in emotional and physical health but also through impairments in educational, social, and occupational functioning as well as in overall quality of life (Olatunji et al. 2007). A review of over 1,000 subjects aged 16–25 with anxiety disorders found that those with anxiety disorders had a 5.85 times higher rate of suicide attempts (Boden et al. 2007) than those without an anxiety disorder. There are numerous risk factors implicated in the development of anxiety disorders, including low self-esteem, family history of depression, female sex, childhood sexual abuse, White race, years of education, number of traumatic experiences, and disturbed family environment (Blanco et al. 2014).

J.E. Grant, MD, JD, MPH (✉)

Department of Psychiatry and Behavioral Neuroscience, University of Chicago,
Chicago, IL, USA

e-mail: jongrant@uchicago.edu

B.L. Odlaug, PhD, MPH

Department of Public Health, Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark

Anxiety disorders are characterized by excessive fear and the associated behavioral disturbances. Although the experience of some degree of anxiety is normal in life, anxiety *disorders* are defined by both the severity and duration of symptoms. In anxiety disorders, the fear is excessive and, in general, lasts for 6 months or longer (APA 2013).

The National Comorbidity Survey found that lifetime prevalence rates for each anxiety disorder were lower in males compared to females: panic disorder (PD) (2.0 % in males vs. 5.0 % females), specific phobia (6.7 % vs. 15.7 %), social anxiety disorder (SAD) (11.1 % vs. 15.5 %), and generalized anxiety disorder (GAD) (3.6 % vs. 6.6 %) (McLean et al. 2011). Because each of the anxiety disorders occur approximately half as commonly in men (APA 2013; Blanco et al. 2014; Mondin et al. 2013; Kessler et al. 2005a), and because the anxiety disorders may differentially impact men (Grant and Potenza 2007), the goal of this chapter is to discuss the role of gender in our understanding and treating of anxiety disorders. Specifically, we will be discussing the impact of gender on social anxiety disorder, panic disorder, generalized anxiety disorder, and phobias, with particular emphasis on their epidemiology, etiology, clinical presentation, current treatment guidelines, and future directions for research.

Social Anxiety Disorder

Social anxiety disorder (SAD), also referred as social phobia, is the fourth most commonly diagnosed psychiatric disorder with lifetime and current prevalence rates of 12.1 % and 6.8 %, respectively, in the general population (Magee et al. 1996; Kessler et al. 2005a, b). SAD appears to be less common in men (11.1 %) than women (15.5 %) (Kessler et al. 1994, 1998). Generally, SAD begins in the early teen years and maintains a chronic course (Bruce et al. 2005; Wittchen and Beloch 1996). Because individuals with SAD experience anxiety and fear in social situations, many also report reduced quality of life in personal and professional areas (Wittchen et al. 1999).

Although the symptoms of SAD do not appear to differ based on gender, the contexts that elicit anxiety may. Men with SAD, for example, tend to have less severe symptoms than women (Turk et al. 1998) and tend to report less distress from public speaking, talking to strangers, and meeting new people (Turk et al. 1998). In addition, and while depression, alcohol dependence, and other anxiety disorders have been documented in people with SAD (Bruce et al. 2005; Grant et al. 2005; Lecrubier and Weiller 1997), the type of psychiatric comorbidity may differ based upon gender (Grant et al. 2005). Studies of adults have found that males with social phobia are less likely to endorse drug use (Buckner et al. 2008; Magee et al. 1996). Among adolescent boys with social phobia, however, the use of nicotine and drugs are more likely (Wu et al. 2010). These findings suggest that the nature of social phobia's relationship with gender and drug use may change during the transition from adolescence to adulthood.

Overall, there is accumulating evidence that abnormal conditioning (e.g., stimulus overgeneralization) and/or extinction failure may contribute to the genesis of social phobias in humans. Abnormalities in conditioning and extinction processes suggest dysfunction within cortico-limbic circuits (Davidson et al. 2000). For example, there is pathophysiological evidence of delayed extinction of the conditioned response in SAD patients relative to controls, supporting the concept that extinction failure could contribute to the maintenance of social fears in SAD patients (Hermann et al. 2002). Based on this hypothesized etiology, why this problem should be less pronounced in males is not yet clear although many hypotheses have been suggested (for a review, see Bekker and van Mens-Verhulst 2007).

Treatment

Psychological Treatments

Cognitive behavioral therapy (CBT) is an evidence-based psychotherapy for individuals with anxiety disorders (Hoffman and Smits 2008; Acarturk et al. 2008) and in particular, SAD (Rodebaugh et al. 2004). CBT involves strategically and repeatedly practicing changing maladaptive behaviors and thoughts by using graded exposure to feared situations, applied relaxation (AR), cognitive restructuring, and learning social skills. Research has demonstrated that CBT is effective in reducing SAD symptomology and may be associated with lower relapse rates (17 %) than pharmacotherapy alone, which has demonstrated relapse rates of 30–60 % in a number of studies (Rodebaugh et al. 2004; Liebowitz 1999). In addition, meta-analyses have suggested that group CBT and individual CBT yield similar treatment results (Rodebaugh et al. 2004; Manassis et al. 2002; Liber et al. 2008) (but see Canton et al. 2012; Mortberg et al. 2007; Stanger et al. 2003). The available data suggest that men and women are equally likely to seek treatment for SAD (Iza et al. 2013) and appear to respond equally well to CBT (Canton et al. 2012).

Pharmacological Treatment

Convincing anxious individuals to consider treatment with psychotropic medications is often quite challenging and may be at least partially responsible for the chronicity of SAD. It requires significant discussions regarding medication-related side effects such as sexual dysfunction, weight gain, and suicidal thinking (McLeod et al. 2004). Pharmacotherapy for SAD includes a variety of medication classes such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), anticonvulsants, benzodiazepines, and beta-blockers (for a review, see Ipser et al. 2008).

SSRI medications such as sertraline and paroxetine are Food and Drug Administration (FDA)-approved treatments for SAD, as is the SNRI, venlafaxine, and are considered the first-line medication treatments for SAD (Schneier 2006).

Several randomized, controlled studies have been conducting and reporting the efficacy of these medications (including other SSRIs) for SAD (Wagner et al. 2004; Lader et al. 2004). In general, an adequate clinical trial (8–12 weeks) should be conducted before considering switching to other medications in the same class. Following stabilization, medications should generally be maintained for 12–18 months prior to discontinuation or dose tapering (Schneier 2006). In addition, due to their potential for abuse, benzodiazepines should be prescribed with caution to those with histories of substance abuse. MAOI drugs should be considered as third-line agents for SAD, but may be limited in their acceptability because of the restrictions of the low-tyramine diet. Studies that have examined the differential response to these medications based on gender have found that men and women respond equally well to medications (Van Ameringen et al. 2004).

Panic Disorder

Epidemiological data suggest that panic disorder (PD) has lifetime rates of 3.5–4.7 % and current rates of 2.2–2.7 % in the general population (Kessler et al. 2005a, b; Grant et al. 2005). Men are two times less likely to be diagnosed with PD compared to women (Eaton et al. 1994), but men and women with PD are equally likely to seek treatment (Mackenzie et al. 2012). Both men and women with PD often are usually seen in medical settings prior to seeking psychiatric care and have more frequent visits to emergency rooms compared to patients with other anxiety disorders (Deacon et al. 2008). Complaints of general fatigue, low productivity, and pain are often associated with PD, subsequently masking the disorder, and often result in underdiagnosis by treating physicians (Zastrow et al. 2008). Men with PD are less likely to have respiratory symptoms and faintness during panic attacks (Weissman, 1993).

Co-occurring psychiatric conditions are extremely common in individuals with PD. Studies have found high rates of comorbid anxiety (66–93.6 %), mood (50–73.3 %), impulse control (47–59.5 %), nicotine dependence, and other substance use (27–37.3 %) disorders in patients diagnosed with PD (Kessler et al. 2006; Goodwin et al. 2012). Men with panic disorder, however, may be at lower risk of having a pattern of binge drinking than women (Chou et al. 2011). The poor quality of life secondary to PD is comparable to that reported by patients with major depressive disorder (Candilis et al. 1999), and panic symptoms increase the likelihood of both suicidal ideation and suicide attempts independent of gender (Katz et al. 2011).

Two possible genetic variables associated with PD involve brain-derived neurotrophic factor (BDNF), a protein hypothesized to limit or repair the damage caused by stress, and catechol-*O*-methyltransferase (COMT) (Domschke et al. 2007), both of which has been investigated as the typical gene polymorphisms related to PD. These genetic variables may differ based on gender. One study reported that in male subjects, BDNF Val/Val homozygotes showed a greater increase in salivary cortisol than Val/Met heterozygotes, but in female subjects, the opposite trend was observed (Shalev et al. 2009). Other research suggests

that gender plays a role in the relationship between the COMT gene and anxiety phenotypes (Harrison and Tunbridge 2008). Thus, there is the possibility of BDNF–COMT–gender involvement in anxiety traits and PD. Gender differences may interact with the effects of BDNF and COMT genes on anxiety sensitivity and related personality characteristics in the pathogenesis of this disorder through the monoamine system comprised of serotonergic, norepinephrine, and dopaminergic systems (Konishi et al. 2014).

Treatment

Psychological Treatment

Cognitive behavioral therapy (CBT), which involves psychoeducation, skills for coping with and monitoring panic attacks, cognitive restructuring, and in vivo exposure, has been shown to be an effective treatment for PD. Both individual and group CBT have been demonstrated as useful in reducing the symptoms of PD (El Alaoui et al. 2013). Using meta-analytic techniques on 124 articles, Mitte (2005) examined the efficacy of CBT treatment for subjects with PD with and without agoraphobia, finding an effect size of 0.87 for CBT compared to wait list on measures of anxiety. Other studies have further supported the efficacy of CBT, and found that briefer versions of CBT or CBT with minimal therapist involvement have also been effective (Roberge et al. 2008; Choi et al. 2005). For a recent review of psychosocial treatments for PD, see Otte (2011). There is currently no data to support the view that gender plays a role in response to CBT.

Pharmacotherapy

Two SSRIs, paroxetine and sertraline, have been approved by the FDA to treat PD; however, case studies have shown that other SSRIs may also be beneficial (Goddard and Charney 1998; Sheehan 1999). Other medications to consider are SNRIs (venlafaxine) (Sheehan 2002), tricyclic antidepressants (TCAs) (Zitrin et al. 1983; Andersch et al. 1991; Schweizer et al. 1993), or benzodiazepines (alone or in conjunction with antidepressants or CBT) (Nardi et al. 2013). In addition, the combination of an SSRI or imipramine with CBT (Barlow et al. 2000; Coupland 2008; Marchand et al. 2008; Furukawa et al. 2006), TCAs with CBT (Furukawa et al. 2006), SSRI or SNRI medications with CBT (Craske et al. 2005; Roy-Byrne et al. 2005), and benzodiazepines with exposure therapy (Marks et al. 1993; Cottraux et al. 1995) have all been shown to be beneficial for PD subjects in reducing anxiety and fear associated with the disorder (for a recent review, see Stein et al. 2010). Although early research suggested that men experienced a slightly lower level of response to pharmacotherapy (Yonkers et al. 1998), pooled data analyses have not supported that finding (Pollack et al. 2000; Roy-Byrne et al. 2003).

Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is a syndrome characterized by excessive and constant worry over different life areas (APA 2013). The 1-year prevalence rate among the general population is approximately 1.6–3 % with a lifetime prevalence of 5.1–6 % (Kessler et al. 2005a). Even though the mean age onset of GAD is in the mid-30s, it is a condition that affects all age groups (Kessler et al. 2001). GAD is about half as common in men compared to women (Vesga-López et al. 2008) with 12-month prevalence rates of 2.4 % for men and 5 % for women (Wittchen et al. 1994).

A majority of individuals with GAD do not seek treatment from a psychiatrist, but instead are seen by primary care physicians (Bélanger et al. 2005), cardiologists, and pulmonologists due to the physical symptoms often associated with the disorder. In fact, men with GAD are less likely to seek treatment for the disorder compared to women (Brawman-Mintzer et al. 1993). GAD is associated with considerable health care costs, lower work productivity, and high utilization of medical resources (Roy-Byrne et al. 2008; Hoffman et al. 2008). Men with GAD, however, report less functional impairment than women (Yonkers et al. 1996). Men with GAD also have a later onset of the disorder, generally have milder symptom presentation, and are at a lower risk of suicide (Steiner et al. 2005; Bruce et al. 2005; Yonkers et al. 1996). Men are also more likely to have comorbid alcohol or drug use disorders, including nicotine dependence while women are more likely to have co-occurring mood or anxiety disorders and having a family history of depression (Vesga-López et al. 2008).

There are several different biological models, which have been implicated in the pathogenesis of GAD. One proposed theory is the behavioral inhibition model (Gray 1988), which involves the septohippocampal area, locus ceruleus, and median raphe nuclei in the brain. This model asserts that during acute stress and fear states, the hippocampus is placed on “high alert” by neurochemicals like norepinephrine and serotonin. Researchers have found that repeated activation of this area leads to hypervigilance and a chronic state of fear in the animals (Vianna et al. 2004). Other proposed models such as the developmental vulnerability model hypothesize that the neurobiological impact of early life stressors may lead to the upregulation of CRF and the HPA axis (Nemeroff 2004). Abnormal noradrenergic, serotonergic, and GABAergic functioning occurs in patients with GAD (Jetty et al. 2001). Another model suggests that vasopressin also plays a role in anxiety and affective disorders, and that antagonism of vasopressin reduces anxiety symptoms (Surget and Belzung 2008).

Functional MRI studies have shown that individuals with GAD demonstrate differential activation patterns in the regions of the amygdala, ventrolateral prefrontal cortex, and anterior cingulate cortex in response to anxiety-inducing negative images compared with healthy controls, and volumetric studies have reported that individuals with GAD show a significant increase in gray matter volumes of the amygdala and dorsomedial prefrontal cortex compared with healthy controls (Monk et al. 2008; McClure et al. 2011; Schienle et al. 2011). More recently, a study showed that men with GAD exhibited a significant decrease in the volume of the dorsolateral prefrontal cortex relative to women (Moon et al. 2014).

Treatment

Psychotherapy

Psychotherapy, such as CBT and applied relaxation (AR) therapy, has a strong evidence base for the treatment of GAD (Gorman 2003; Canadian Psychiatric Association 2006; Hunot et al. 2007; Cuijpers et al. 2014). One meta-analysis (Hunot et al. 2007) examined 13 studies comparing CBT to treatment as usual/wait list (TAU/WT) and found that a significantly higher percentage (47 % vs. 13 %) of subjects in the CBT group responded to treatment. In addition, applied relaxation (AR) is another form of therapy that has shown benefit in the treatment of GAD (Cuijpers et al. 2014). In AR, patients learn progressive relaxation techniques, how to identify feared situations and utilize relaxation skills in stressful situations (Arntz 2003). Studies that have compared CBT to AR have found that both treatments are comparable in decreasing anxiety and depression (Ost and Breitholtz 2000; Borkovec and Costello 1993). There is no evidence that men respond differently to CBT or AR compared to women.

Pharmacotherapy

To date, there have been eight different medications that have been approved by the FDA for the treatment of GAD, including SSRIs (paroxetine, escitalopram), SNRIs (duloxetine, venlafaxine), benzodiazepines (diazepam, lorazepam, alprazolam), and azapirone (buspirone). A meta-analysis of 39 pharmacotherapy interventions revealed an overall effect size of 0.60 for medication treatment of GAD (Gould et al. 1997). SSRIs are widely considered to be the first-line treatments for GAD (Pollack et al. 2001; Davidson et al. 2004). In terms of a differential response based on gender, the limited research suggests that men may be less likely to respond to venlafaxine, more likely to respond to fluoxetine, and equally likely to respond to sertraline compared to women (Pollack et al. 2003; Steiner et al. 2006; Simon et al. 2006).

Specific Phobias

Specific phobias are characterized by fear or anxiety that is circumscribed to the presence of a particular situation or object and the response is not the same as a normal, transient fear that may commonly occur in the population. The fear must be intense or severe (APA 2013). Specific phobias may encompass a range of objects or situations that induce fear—high places (e.g., acrophobia), certain animals (e.g., spiders), and health-related issues (e.g., blood, needles).

Specific phobia is one of the most common mental health disorders with a lifetime prevalence of 9.4–12.5 % and a 12-month prevalence of 7.1–8.7 % (Kessler et al. 2005a; Stinson et al. 2007). Men have half the lifetime risk for specific phobia compared to women (12 % vs. 26 %) (Fredrickson et al. 1996). The mean age at

onset of specific phobia is generally 9–10 years, with a mean duration of 20 years (Stinson et al. 2007). Among adolescents, however, this gender discrepancy appears to apply only to those who are affected with a greater number of phobia types (Burstein et al. 2012).

In terms of clinical presentation, men are less likely to report situational or animal phobias and are less likely to have multiple phobias (Fredrickson et al. 1996). Women with specific phobia appear to be at increased risk (twofold increase) of developing other anxiety disorders, depression, and somatoform disorders (Trumpf et al. 2010).

Twin studies suggest a genetic influence in the development of specific phobias. Situational and medical phobias may have a lower heritability among men but animal phobias appear equally heritable by men and women (Kendler et al. 2002).

A recent review found that functional neuroimaging, mostly using symptom provocation paradigms, has demonstrated abnormal activations in brain areas involved in emotional perception and early amplification, mainly the amygdala, anterior cingulate cortex, thalamus, and insula. The insula, thalamus, and other limbic/paralimbic structures are particularly involved in specific phobias with prominent autonomic arousal. Emotional modulation is also impaired after exposure to phobic stimuli, with abnormal activations reported for prefrontal, orbitofrontal, and visual cortices (Del Casale et al. 2012).

Treatment

Psychotherapy

Although only 8.0 % of individuals with specific phobia report receiving treatment (Stinson et al. 2007), an analysis of psychotherapy research supports the use of CBT, specifically involving exposure therapy. In fact, *in vivo* exposure therapy for most of the specific phobia types has a response rate of 80–90 % (Choy et al. 2007). In addition, long-term follow-up studies of CBT suggest that treatment gains are generally maintained from 6 months to 1 year, and often improved if self-exposure is continued during the follow-up period (Choy et al. 2007). Men appear to respond as well as women to CBT. A meta-analysis of 33 randomized treatment studies for specific phobias found that exposure-based treatments were effective in reducing symptoms (Wolitzky-Taylor et al. 2008).

Pharmacotherapy

There are limited data regarding effective pharmacotherapy options for specific phobias. One study of paroxetine, an SSRI, showed significant superiority to placebo (Benjamin et al. 2000). Two benzodiazepine studies suggest limited acute use for either flying phobia (Wilhelm and Roth 1997) or dental phobia (Jöhren et al. 2000). Due to the limited research, no useful gender comparisons can be made.

Conclusions/Future Directions

The current research indicates that anxiety disorders, as an overall group of disorders, are less common among men. Etiological factors have been explored in anxiety disorders, yet despite the high occurrence of anxiety disorders globally, the data are currently too limited to determine if men and women with anxiety disorders have different etiologies. In addition, little is known about whether men and women respond differently to available treatment options. Further research is needed to examine if and how gender influences response to treatment. Areas such as neuroimaging (SPECT or fMRI) (Roth 2008), molecular psychiatry, animal models (including translational research) (Glasgow et al. 2005; Roth 2008), innovative clinical trials (Tunis et al. 2003), pharmacogenetics (Broich and Möller 2008), and refining different modes of psychotherapy and combining them with pharmacological interventions (Hyland 1991; Foa et al. 2002) are all beneficial in learning more about the role of gender in these disorders.

References

- Acarturk C, Cuijpers P, van Straten A et al (2008) Psychological treatment of social anxiety disorder: a meta-analysis. *Psychol Med* 28:1–14
- American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Washington, DC
- Andersch S, Rosenberg NK, Kullingsjö H et al (1991) Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. *Acta Psychiatr Scand Suppl* 365:18–27
- Arntz A (2003) Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder. *Behav Res Ther* 41:633–646
- Barlow DH, Gorman JM, Shear K et al (2000) Cognitive behavior therapy, imipramine or their combination for panic disorder. *JAMA* 283:2529–2536
- Baxter AJ, Scott KM, Vos T, Whiteford HA (2013) Global prevalence of anxiety disorders: a systematic review and meta-regression. *Psychol Med* 43(5):897–910
- Bekker MH, van Mens-Verhulst J (2007) Anxiety disorders: sex differences in prevalence, degree and background but gender neutral treatment. *Gend Med* 4 Suppl B:S178–S193
- Bélanger L, Ladouceur R, Morin CM (2005) Generalized anxiety disorder and health care use. *Can Fam Physician* 51:1362–1363
- Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P (2000) Double-blind placebo-controlled pilot study of paroxetine for specific phobia. *Psychopharmacology (Berl)* 149(2):194–196
- Blanco C, Rubio J, Wall M, Wang S, Jiu CJ, Kendler KS (2014) Risk factors for anxiety disorders: common and specific effects in a national sample. *Depress Anxiety* 31(9):756–764. doi:10.1002/da.22247
- Boden JM, Fergusson DM, Horwood LJ (2007) Anxiety disorders and suicidal behaviours in adolescence and young adulthood: findings from a longitudinal study. *Psychol Med* 37(3):431–440
- Borkovec TD, Costello E (1993) Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. *J Consult Clin Psychol* 61:611–619
- Brawman-Mintzer O, Lydiard RB, Emmanuel N, Payeur R, Johnson M, Roberts J, Jarrell MP, Ballenger JC (1993) Psychiatric comorbidity in patients with generalized anxiety disorder. *Am J Psychiatry* 150(8):1216–1218
- Broich K, Möller HJ (2008) Pharmacogenetics, pharmacogenomics and personalized psychiatry: are we there yet? *Eur Arch Psychiatry Clin Neurosci* 258(Suppl 1):1–2

- Bruce SE, Yonkers KA, Otto MW et al (2005) Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. *Am J Psychiatry* 162(6):1179–1187
- Buckner JD, Timpano KR, Zvolensky MJ et al (2008) Implications of comorbid alcohol dependence among individuals with social anxiety disorder. *Depress Anxiety* 25(12):1028–1037
- Burstein M, Georgiades K, He JP, Schmitz A, Feig E, Khazanov GK, Merikangas K (2012) Specific phobia among U.S. adolescents: phenomenology and typology. *Depress Anxiety* 29(12):1072–1082
- Canadian Psychiatric Association (2006) Clinical practice guidelines: management of anxiety disorders. *Can J Psychiatry* 51(8 Suppl 2):9S–91S
- Candilis PJ, Mclean RY, Otto MW et al (1999) Quality of life in patients with panic disorder. *J Nerv Ment Dis* 187(7):429–434
- Canton J, Scott KM, Glue P (2012) Optimal treatment of social phobia: systematic review and meta-analysis. *Neuropsychiatr Dis Treat* 8:203–215
- Choi YH, Vincelli F, Riva G et al (2005) Effects of group experiential cognitive therapy for the treatment of panic disorder with agoraphobia. *Cyberpsychol Behav* 8:387–393
- Chou KL, Liang K, Mackenzie CS (2011) Binge drinking and Axis I psychiatric disorders in community-dwelling middle-aged and older adults: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry* 72(5):640–647
- Choy Y, Fyer AJ, Lipsitz JD (2007) Treatment of specific phobia in adults. *Clin Psychol Rev* 27(3):266–286
- Cottraux J, Note ID, Cungi C et al (1995) A controlled study of cognitive behavior therapy with buspirone or placebo in panic disorder with agoraphobia. *Br J Psychiatry* 167:635–641
- Coupland N (2008) Combined antidepressants and CBT for panic disorder with agoraphobia. *J Psychiatry Neurosci* 33:E1
- Craske MG, Golinelli D, Stein MB et al (2005) Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting. *Psychol Med* 35:1645–1654
- Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G (2014) Psychological treatment of generalized anxiety disorder: a meta-analysis. *Clin Psychol Rev* 34(2):130–140
- Davidson RJ, Marshall JR, Tomarken AJ et al (2000) While a phobic waits: regional brain electrical and autonomic activity in social phobics during anticipation of public speaking. *Biol Psychiatry* 47(2):85–95
- Davidson JR, Bose A, Korotzer A et al (2004) Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. *Depress Anxiety* 19(4):234–240
- Deacon B, Lickel J, Abramowitz JS (2008) Medical utilization across the anxiety disorders. *J Anxiety Disord* 22(2):344–350
- Del Casale A, Ferracuti S, Rapinesi C, Serata D, Piccirilli M, Savoia V, Kotzalidis GD, Manfredi G, Angeletti G, Tatarelli R, Girardi P (2012) Functional neuroimaging in specific phobia. *Psychiatry Res* 202(3):181–197
- Domschke K, Deckert J, O'donovan MC, Glatt SJ (2007) Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. *Am J Med Genet B Neuropsychiatr Genet* 144B(5):667–673
- Eaton WW, Kessler RC, Wittchen HU et al (1994) Panic and panic disorder in the United States. *Am J Psychiatry* 151:413–420
- El Alaoui S, Hedman E, Ljótsson B, Bergström J, Andersson E, Rück C, Andersson G, Lindfors N (2013) Predictors and moderators of internet- and group-based cognitive behaviour therapy for panic disorder. *PLoS One* 8(11):e79024
- Foa EB, Franklin ME, Moser J (2002) Context in the clinic: how well cognitive behavioral therapies and medications work in combination? *Biol Psychiatry* 52(10):987–997
- Fredrickson M, Annas P, Hakan F, et al (1996) Gender differences in the prevalence of specific fears and phobias. *Behav Res* 34:33–39
- Furukawa TA, Watanabe N, Churchill R (2006) Psychotherapy plus antidepressant for panic disorder with or without agoraphobia. *Br J Psychiatry* 188:305–312

- Glasgow RE, Magid DJ, Beck A et al (2005) Practical clinical trials for translating research to practice: design and measurement recommendations. *Med Care* 43(96):551–557
- Goddard AW, Charney DS (1998) SSRIs in the treatment of panic disorder. *Depress Anxiety* 8 Suppl 1:114–120
- Goodwin RD, Zvolensky MJ, Keyes KM, Hasin DS (2012) Mental disorders and cigarette use among adults in the United States. *Am J Addict* 21(5):416–423
- Gorman JM (2003) Treating generalized anxiety disorder. *J Clin Psychiatry* 64(Suppl 2):24–29
- Gould RA, Otto MW, Pollack MH et al (1997) Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. *Behav Ther* 28:285–305
- Grant JE, Potenza MN (2007) Textbook of men's mental health. American Psychiatric Association, Washington, DC
- Grant BF, Hasin DS, Blanco C et al (2005) The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 66(11):1351–1361
- Gray JA (1988) The neuropsychological basis of anxiety. In: Last GC (ed) *Handbook of anxiety disorders*. Pergamon, New York
- Greenberg PE, Sisitsky T, Kessler RC et al (1999) The economic burden of anxiety disorders in the 1990s. *J Clin Psychiatry* 60(7):427–435
- Harrison PJ, Tunbridge EM (2008) Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. *Neuropsychopharmacology* 33(13):3037–3045
- Hermann C, Ziegler S, Birbaumer N et al (2002) Psychophysiological and subjective indicators of aversive pavlovian conditioning in generalized social phobia. *Biol Psychiatry* 52(4):328–337
- Hoffman SG, Smits JA (2008) Cognitive-Behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. *J Clin Psychiatry* 69(4):621–632
- Hoffman DL, Dukes EM, Wittchen HU (2008) Human and economic burden of generalized anxiety disorder. *Depress Anxiety* 25(1):72–80
- Hunot V, Churchill R, Teixeira V et al (2007) Psychological therapies for generalised anxiety disorder. *Cochrane Database Syst Rev* (1):CD001848
- Hyland JM (1991) Integrating psychotherapy and pharmacotherapy. *Bull Menninger Clin* 55(2):205–215
- Ipsen JC, Kariuki CM, Stein DJ (2008) Pharmacotherapy for social anxiety disorder: a systematic review. *Expert Rev Neurother* 8(2):235–257
- Iza M, Olfson M, Vermes D, Hoffer M, Wang S, Blanco C (2013) Probability and predictors of first treatment contact for anxiety disorders in the United States: analysis of data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry* 74(11):1093–1100
- Jetty PV, Charney DS, Goddard AW (2001) Neurobiology of generalized anxiety disorder. *Psychiatr Clin North Am* 24(1):75–97
- Jöhren P, Jackowski J, Gängler P, Sartory G, Thom A (2000) Fear reduction in patients with dental treatment phobia. *Br J Oral Maxillofac Surg* 38(6):612–616
- Katz C, Yaseen ZS, Mojtabai R, Cohen LJ, Galynker II (2011) Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry* 72(12):1628–1635
- Kendler KS, Jacobson KC, Myers J, Prescott CA (2002) Sex differences in genetic and environmental risk factors for irrational fears and phobias. *Psychol Med* 32(2):209–217
- Kessler RC, McGonagle KA, Zhao S et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry* 51(1):8–19
- Kessler RC, Stein MB, Berglund P et al (1998) Social phobia subtypes in the national comorbidity survey. *Am J Psychiatry* 155(5):613–619
- Kessler RC, Keller MB, Wittchen HU (2001) The epidemiology of generalized anxiety disorder. *Psychiatr Clin North Am* 24(1):19–39
- Kessler RC, Berglund P, Demler O et al (2005a) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 62(6):593–602

- Kessler RC, Chiu WT, Demler O et al (2005b) Prevalence, severity, and comorbidity of 12 month DSM-IV disorders in the national comorbidity survey replication. *Arch Gen Psychiatry* 62(6):617–627
- Kessler RC, Chiu WT, Jin R et al (2006) The epidemiology of panic attacks, panic disorder, and agoraphobia in the national comorbidity survey replication. *Arch Gen Psychiatry* 63:415–424
- Konishi Y, Tani H, Otowa T, Sasaki T, Tochigi M, Umekage T, Motomura E, Shiroyama T, Kaiya H, Okazaki Y, Okada M (2014) Gene \times gene \times gender interaction of BDNF and COMT genotypes associated with panic disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 51C:119–125
- Lader M, Stender K, Bürger V et al (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. *Depress Anxiety* 19(4):241–248
- Leclerubier Y, Weiller E (1997) Comorbidities in social phobia. *Int Clin Psychopharmacol* 12(Suppl 6):S17–S21
- Lepine JP (2002) The epidemiology of anxiety disorders: prevalence and societal cost. *J Clin Psychiatry* 63(Suppl 14):4–8
- Liber JM, van Widenfelt BM, Uten EMWJ et al (2008) No differences between group versus individual treatment of childhood anxiety disorders in a randomized clinical trial. *J Child Psychol Psychiatry* 49:886–893
- Liebowitz MR (1999) Update on the diagnosis and treatment of social anxiety disorder. *J Clin Psychiatry* 60 Suppl 18:22–26
- Mackenzie CS, Reynolds K, Cairney J, Streiner DL, Sareen J (2012) Disorder-specific mental health service use for mood and anxiety disorders: associations with age, sex, and psychiatric comorbidity. *Depress Anxiety* 29(3):234–242
- Magee WJ, Eaton WW, Wittchen HU et al (1996) Agoraphobia, simple phobia and social phobia in the national comorbidity survey. *Arch Gen Psychiatry* 53(2):159–168
- Manassis K, Mendlowitz SL, Scapillato D et al (2002) Group and individual cognitive-behavioral therapy for childhood anxiety disorders: a randomized trial. *J Am Acad Child Adolesc Psychiatry* 41(12):1423–1430
- Marchand A, Coutu MF, Dupuis G et al (2008) Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. *Cogn Behav Ther* 37(3):146–159
- Marks IM, Swinson RP, Basoglu M et al (1993) Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. *Br J Psychiatry* 162:776–787
- McClure EB, Monk CS, Nelson EE, Parrish JM, Adler A, Blair RJ et al (2011) Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. *Arch Gen Psychiatry* 64:97–106
- McLean CP, Asnaani A, Litz BT, Hofmann SG (2011) Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. *J Psychiatr Res* 45(8):1027–1035
- McLeod JD, Pescosolido BA, Takeuchi DT et al (2004) Public attitudes towards the use of psychiatric medications for children. *J Health Soc Behav* 45(1):53–67
- Mitte K (2005) A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. *J Affect Disord* 88:27–45
- Mondin TC, Konradt CE, Cardoso Tde A, Quevedo Lde A, Jansen K, de Mattos LD, Pinheiro RT, da Silva RA (2013) Anxiety disorders in young people: a population-based study. *Rev Bras Psiquiatr* 35(4):347–352
- Monk CS, Telzer EH, Mogg K et al (2008) Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder. *Arch Gen Psychiatry* 65(5):568–576
- Moon CM, Kim GW, Jeong GW (2014) Whole-brain gray matter volume abnormalities in patients with generalized anxiety disorder: voxel-based morphometry. *Neuroreport* 25(3):184–189

- Mortberg E, Clark DM, Sundin O et al (2007) Intensive group cognitive therapy treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial. *Acta Psychiatrica Scand* 115:142–154
- Nardi AE, Machado S, Almada LF et al (2013) Clonazepam for the treatment of panic disorder. *Curr Drug Targets* 14(3):353–364
- Nemeroff CB (2004) Early life adversity, CRF dysregulation and vulnerability to mood and vulnerability to mood and anxiety disorders. *Psychopharmacol Bull* 38 Suppl 1:14–20
- Olatunji BO, Cisler JM, Tolin DF (2007) Quality of life in the anxiety disorders: a meta-analytic review. *Clin Psychol Rev* 27(5):572–581
- Ost LG, Breitholtz E (2000) Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. *Behav Res Ther* 38:777–790
- Otte C (2011) Cognitive behavioral therapy in anxiety disorders: current state of the evidence. *Dialogues Clin Neurosci* 13(4):413–421
- Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R. (2000) Sertraline treatment of panic disorder: response in patients at risk for poor outcome. *J Clin Psychiatry* 61(12):922–927
- Pollack MH, Zaninelli R, Goddard AW et al (2001) Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. *J Clin Psychiatry* 62(5):350–357
- Pollack MH, Meoni P, Otto MW, Simon N, Hackett D (2003) Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. *J Clin Psychopharmacol* 23(3):250–259
- Roberge P, Marchand A, Reinharz D et al (2008) Cognitive-behavioral treatment for panic disorder. *Behav Modif* 32:333–351
- Rodebaugh TL, Holaway RM, Heimberg RG (2004) The treatment of social anxiety disorder. *Clin Psychol Rev* 24:883–908
- Roth WT (2008) Translational research for panic disorder. *Am J Psychiatry* 165(7):796–798
- Roy-Byrne PP, Russo J, Cowley DS, Katon WJ (2003) Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. *J Clin Psychiatry* 64(4):383–389
- Roy-Byrne PP, Craske MG, Stein MB et al (2005) A randomized effectiveness trial of CBT and medication for primary care panic disorder. *Arch Gen Psychiatry* 62(3):290–298
- Roy-Byrne PP, Davidson KW, Kessler RC et al (2008) Anxiety disorders and comorbid illness. *Gen Hosp Psychiatry* 30(3):208–225
- Schienze A, Ebner F, Schäfer A (2011) Localized gray matter volume abnormalities in generalized anxiety disorder. *Eur Arch Psychiatry Clin Neurosci* 261:303–307
- Schneier FR (2006) Clinical Practice. Social anxiety disorder. *N Engl J Med* 355(10):1029–1036
- Schweizer E, Rickels K, Weiss S et al (1993) Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. *Arch Gen Psychiatry* 50(1):51–60
- Shalev I, Lerer E, Israel S, Uzefovsky F, Gritsenko I, Mankuta D, Ebstein RP, Kaitz M (2009) BDNF Val66Met polymorphism is associated with HPA axis reactivity to psychological stress characterized by genotype and gender interactions. *Psychoneuroendocrinology* 34(3):382–388
- Sheehan DV (1999) Current concepts in the treatment of panic disorder. *J Clin Psychiatry* 60 Suppl 18:16–21
- Sheehan DV (2002) The management of panic disorder. *J Clin Psychiatry* 63 Suppl 14:17–21
- Simon NM, Zalta AK, Worthington JJ 3rd, Hoge EA, Christian KM, Stevens JC, Pollack MH (2006) Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. *Depress Anxiety* 23(6):373–376
- Stanger U, Heidenreich T, Peitz M et al (2003) Cognitive therapy for social phobia: individual versus group treatment. *Behav Res Ther* 41:991–1007
- Stein M, Steckler T, Lightfoot JD, Hay E, Goddard AW (2010) Pharmacologic treatment of panic disorder. *Curr Top Behav Neurosci* 2:469–485

- Steiner M, Allgulander C, Ravindran A, Kosar H, Burt T, Austin C (2005) Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder. *Hum Psychopharmacol* 20(1):3–13
- Steiner M, Pearlstein T, Cohen LS et al (2006) Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. *J Womens Health (Larchmt)* 15(1):57–69
- Stinson FS, Dawson DA, Patricia Chou S, Smith S, Goldstein RB, June Ruan W, Grant BF (2007) The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychol Med* 37(7):1047–1059
- Surget A, Belzung C (2008) Involvement of vasopressin in affective disorders. *Eur J Pharmacol* 583(2–3):340–349
- Trumpf J, Margraf J, Vriends N, Meyer AH, Becker ES (2010) Specific phobia predicts psychopathology in young women. *Soc Psychiatry Psychiatr Epidemiol* 45(12):1161–1166
- Tunis SR, Stryer DB, Clancy CM (2003) Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. *JAMA* 290(12):1624–1632
- Turk CL, Heimberg RG, Orsillo SM, et al (1998) An investigation of gender differences in social phobia. *J Anxiety Disord* 12(3):209–223
- Van Ameringen M, Oakman J, Mancini C, Pipe B, Chung H (2004) Predictors of response in generalized social phobia: effect of age of onset. *J Clin Psychopharmacol* 24(1):42–44
- Vesga-López O, Schneier FR, Wang S, Heimberg RG, Liu SM, Hasin DS, Blanco C (2008) Gender differences in generalized anxiety disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry* 69(10):1606–1616
- Vianna MR, Coitinho AS, Izquierdo I (2004) Role of the hippocampus and amygdala in the extinction of fear-motivated learning. *Curr Neurovasc Res* 1(1):55–60
- Wagner KD, Berard R, Stein MB et al (2004) A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. *Arch Gen Psychiatry* 61(11):1153–1162
- Weissman MM (1993) Family genetic studies of panic disorder. *J Psychiatr Res* 27(Suppl. 1):69–78
- Wilhelm FH, Roth WT (1997) Acute and delayed effects of alprazolam on flight phobics during exposure. *Behav Res Ther* 35(9):831–841
- Wittchen HU, Beloch E (1996) The impact of social phobia and the quality of life. *Int Clin Psychopharmacol* 11(Suppl 3):15–23
- Wittchen HU, Zhao S, Kessler RC et al (1994) DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. *Arch Gen Psychiatry* 51(5):355–364
- Wittchen HU, Fuetsch M, Sonntag H et al (1999) Disability and quality of life in pure and comorbid social phobia—findings from a controlled study. *Eur Psychiatry* 14(3):118–131
- Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ (2008) Psychological approaches in the treatment of specific phobias: a meta-analysis. *Clin Psychol Rev* 28(6):1021–1037
- Wu P, Goodwin RD, Fuller C, Liu X, Comer JS, Cohen P, Hoven CW (2010) The relationship between anxiety disorders and substance use among adolescents in the community: specificity and gender differences. *J Youth Adolesc* 39(2):177–188
- Yonkers KA, Warshaw MG, Massion AO, Keller MB (1996) Phenomenology and course of generalised anxiety disorder. *Br J Psychiatry* 168(3):308–313
- Yonkers KA, Zlotnick C, Allsworth J, Warshaw M, Shea T, Keller MB (1998) Is the course of panic disorder the same in women and men? *Am J Psychiatry* 155(5):596–602
- Zastrow A, Faude V, Seyboth F et al (2008) Risk factors of symptom underestimation by physicians. *J Psychosom Res* 64(5):543–551
- Zitrin CM, Klein DF, Woerner MG et al (1983) Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. *Arch Gen Psychiatry* 40(2):125–138